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Abstract
Exogenous zinc has been shown to alter the cellular response to inflammatory 
conditions. Both common zinc salt and novel zinc compounds have been shown 
to be therapeutic in various disease states. However, little is known about their 
action on immune cells in these conditions. This thesis aims to investigate the 
effectiveness of zinc monoglycerolate (ZMG), a novel zinc compound, in 
providing bioavailable zinc. This study also aims to examine the effect of zinc on 
the inflammatory responses of immune and gastric cells.
Using cell culture techniques, fluorescence microscopy and inductively coupled 
plasma mass spectroscopy (ICP-MS), comparison was made of zinc 
bioavailability from ZMG, zinc oxide and zinc sulphate. The cellular protein 
interactions of the zinc provided by these compounds was investigated by 
autoradiography, Western blot analysis and cytokine assay. As a result of the 
biological study, chemical analyses were carried out on ZMG using high 
performance liquid chromatography (HPLC), inductively coupled plasma atomic 
emission spectroscopy (ICP-AES) and matrix assisted laser desorption ionisation 
time of flight (MALDI-ToF).
The result of the cell culture study indicated that ZMG and zinc oxide provided 
significantly more bioavailable zinc than zinc sulphate. Furthermore, these 
results showed that the different cell lines examined treated the zinc in distinctly 
different manners. The studies on direct zinc-protein interactions did not 
conclusively determine whether such interactions occurred between cytoplasmic 
proteins and exogenous zinc. However, zinc was shown to modulate cytokine 
secretions in vitro in cultured cell lines. The chemical analyses provided novel 
observations about the polymeric structure of ZMG and its solubility profile.
In conclusion the results showed that ZMG is a highly effective source of 
bioavailable zinc and that exogenous zinc can modulate the immune response of 
cultured cell lines to external stimuli.
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A brief history of zinc and its uses in medicine
Zinc has been used since Roman times for metal working where, as a 
contaminant of copper compounds, it was a constituent of brass alloys however it 
was not known as a metal in its own right. It appears possible that metallurgists 
in India, around the 13th century, may have developed metal purification methods 
that allowed the isolation of the metal itself and it is thought that the knowledge of 
metal work came from India, via China, to Europe (Encyclopaedia Britannica). 
Certainly, zinc does not seem to have been known as a specific metal in Europe 
until it was separated from zinc rich slag metal, a by product of the silver smelting 
industry, by Erasmus Ebener of Nurnberg in 1509 (Encyclopaedia Britannica). 
Around the same time, Paracelsus (original name - Theophrastus Bombastus Von 
Hohenheim) a Swiss physician and alchemist, first used the recorded name of 
zinken, for a metal which he thought was a contaminated form of copper. 
Paracelsus turned his knowledge of chemicals to the treatment of his patients and 
he first described the usage of zinc compounds in texts on pharmaceutical 
preparations (Hoogenraad, 1998). However, it was not until the eighteenth 
century that zinc was purified and described as a separate element, probably by 
Johan Friedrich Henckel or Andreas Sigismund Marggraf (Colliers 
Encyclopaedia). Shortly after the isolation and description of this ‘newly’ isolated 
element, a paper was written in 1771 by Gaubius, a Professor of medicine and 
chemistry in the University of Leiden, which described the effect of zinc oxide in 
curing convulsions in a child (Hoogenraad, 1998). By the eighteen hundreds, 
high concentrations of zinc were being used as an anti-epileptic and emetic. 
Gradually the use of zinc oxide as an anti-epileptic was reduced leaving zinc 
being used pharmaceutically mainly for emetic purposes (Hoogenraad, 1998).
Interest in zinc revived as in 1869 Raulin showed that zinc was essential for the 
growth of the fungus Aspergillus Niger (Reviewed Prasad, 1991). This was 
shown to be true also for higher plants in 1926 by Sommer and Lipman, for rats in 
1934 by Todd et al. and in 1958 zinc was also shown to be essential for growth in 
chickens by O’Dell et al. (Prasad, 1991).
It was not until relatively recently that zinc was discovered to effectively and 
consistently treat a specific disease state in humans and the first of these was
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Wilson’s disease. In 1961 Schouwink showed that oral zinc was able to reverse 
the effects of this genetic defect in copper metabolism (Grungreiff and Reinhold,
1997). Wilson’s disease results in a toxic build up of copper in the patients and it 
was later shown that zinc administration caused the appearance of large amounts 
of copper in the faeces indicating a direct cause and effect between zinc 
administration and excess copper excretion (Grungreiff and Reinhold, 1997).
Around the same time, in 1963, Prasad and co-workers first described the 
symptoms of zinc deficiency and attributed them to lack of zinc as opposed to, for 
example, parasitic infection (Prasad, 1991). They focussed on populations where 
growth retardation was prevalent, particularly in Egypt, and showed that the 
general failure to thrive in the patients was due to zinc deficiency as a result of 
dietary insufficiency. The diet was low in animal protein and high in cereals. 
Previously O’Dell and Savage (1960) had shown that phytate (inositol 
hexaphosphate), a constituent of cereal grains, was able to inhibit the absorption 
of zinc. Supplementation of the diet with zinc reversed many of the symptoms of 
growth retardation in the Egyptian patients (Prasad, 1991). And so began the 
study of zinc as an essential micronutrient for humans.
As it was realised that zinc was an integral requirement for nutrition the study of 
zinc biology expanded enormously. Zinc was found to be associated with an 
increasing number of biological molecules involved in metabolism. From 1940 
and for approximately the following twenty years, only five biological molecules 
containing zinc were identified (Prasad, 1991). The first of these was carbonic 
anhydrase which Keilin and Mann showed contained zinc, and who further 
showed that the zinc was essential for the enzymatic function of the molecule 
(Prasad, 1991). It would now be difficult to put a precise figure on the number of 
metalloproteins that require zinc for structure and function as new molecules are 
still being identified and with the publication of the human genome, it is likely that 
even more zinc binding proteins will be identified. For enzymatic reactions alone 
there are now known to be over 300 molecules requiring zinc for function (Kruse- 
Jarres, 1997).
However, not all protein bound zinc is equal, it was realised that the role of zinc 
atoms in metalloenzymes could be divided into three general areas, catalytic zinc,
co-catalytic zinc and structural zinc (Vallee and l-alchuK, iyy3). uataiytic zinc 
was shown to have a direct role in the enzyme function and was essential for that 
function, where zinc was able to enhance or diminish enzymatic activity but was 
not absolutely required, it was defined as co-catalytic zinc. Structural zinc atoms 
played no part in the enzymatic reaction itself but were required for structural 
stability of the enzyme (Vallee and Falchuk, 1993).
In general zinc is found co-ordinated in these metalloenzymes by a few specific 
ligands. Cysteine and histidine are the two main peptide ligands in zinc 
metalloenzymes and, in molecules where zinc is catalytic, a water molecule is 
often bound to the zinc atom.
Molecules other than enzymes bind zinc. Metallothionein, a cysteine rich protein, 
was identified as a cadmium and zinc-binding molecule in 1957 (Vallee and 
Falchuk, 1993). The functions and zinc binding activity of the molecule are 
discussed later in this chapter. Whilst metallothioneins are the main storage 
molecules for intracellular zinc there is another class of zinc molecule that was 
only discovered in approximately the last fifteen years. The zinc finger proteins 
were first proposed by Klug in 1985 as DNA binding molecules that controlled 
transcription and that required zinc atoms for binding co-ordination (Rhodes and 
Klug, 1993). The first of these, Transcription Factor III A (TFIIIA), was discovered 
during a search to understand how a relatively small protein could be associated 
with a particularly long piece of DNA as it appeared to have a rather large binding 
site on the DNA strand (Rhodes and Klug, 1993). It was shown that the zinc 
fingers fitted into the grooves of the DNA double helix and the flexibility of the zinc 
finger transcription factors allowed them to stretch along the DNA strand with 
successive zinc fingers making contact along it (Rhodes and Klug, 1993). This 
was an unknown ability for transcription factors, which had previously been 
thought to have only one DNA binding site per molecule.
The breadth of action of zinc fingers, and other related zinc co-ordinated peptide 
structures such as clusters and rings has grown to encompass protein-protein 
binding in addition to DNA binding. LIM domain proteins contain zinc-binding 
sequences that can mediate protein complex formation. Schmeichel and 
Beckerle (1994) showed that the three LIM domains in the cytoskeletal protein
zyxin were required to bind another cytoskeletal protein cysteine-rich protein 
(CRP). The protein binding and DNA binding activities of zinc fingers are neatly 
brought together in the form of the oestrogen receptor molecule. It was shown 
that the receptor binds DNA as a receptor dimer and that both the DNA binding 
and the stability of the dimer structure were determined by zinc finger interactions 
with the DNA and between the two receptor molecules (Rhodes and Klug, 1993).
The ubiquitous activities of both enzymes, transcription factor and signal 
transduction molecules indicate the importance of zinc in metabolism in particular 
and in organism survival in general. As the knowledge of the physiology of zinc 
is understood it is clear that zinc is essential for all aspects of homeostasis. For 
example any mechanism requiring cells to proliferate, such as tissue growth and 
repair, T-cell expansion as a result of immune challenge or just about any aspect 
of the reproductive cycle will require zinc for proper function. Due to its universal 
use around the body it has been increasingly apparent that even small changes in 
zinc levels that do not result in gross symptoms can have measurable and 
important effects (Sullivan and Cousins, 1997).
Zinc therapy for zinc deficiency and also for various disease states has taken 
great strides since its importance was realised. Many zinc compounds in which 
zinc is the active component have been developed, each with different properties, 
often improving zinc availability to the body by novel mechanisms (Fairlie et al., 
1992, Rainsford and Whitehouse, 1992) or adding some additional properties to 
those of zinc alone (Navarro et al., 1988).
Prevention of zinc deficiency, understanding the role of zinc in health and disease 
states and designing therapeutic zinc compounds depend heavily on 
understanding how zinc is taken into the body. This chapter aims to examine and 
discuss the literature describing zinc uptake by the body, by various tissues and 
by individual cells. The therapeutic use of zinc in the disease state is then 
looked at in detail followed by an examination of zinc function in the immune 
system as it related to the thesis as a whole.
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Absorption and biodisposition of zinc
Little was known about the mechanism of zinc transport at the cellular level until 
quite recently which might seem unusual as both the dietary and therapeutic value 
of the element have been known experimentally and clinically for decades. 
Perhaps the sudden interest and intense investigation of cellular zinc uptake has 
been driven simply by the massive expansion of known involvement of zinc with 
protein components of so many biological systems or because of the ability shown 
for zinc to modulate other mediators of these systems. Another factor could be 
the increased number of therapeutic applications of zinc and the development of 
new zinc bearing drugs. It has also relatively recently been understood that both 
moderate to marginal chronic deficiencies of zinc are widespread in the 
industrialised countries (Mares-Perlman, 1995) and not only to countries 
traditionally associated with poor diet in third world countries (Prasad, 1961, 
Halsted, 1972). This has quite recently increased interest in understanding the 
biology of nutritional zinc. It should be pointed out that until recently, methods for 
determination of zinc deficiency were limited to clinical determination which was 
really only effective in moderate to severe disease and only relatively recent 
developments have allowed determination of marginal deficiency (King, 1990, 
Sullivan and Cousins, 1997). Whatever the reasons behind the increased study 
of zinc transport at the cellular and membrane level, it has led to a greater variety 
and increased sensitivity of zinc specific detection and labelling techniques.
Vital to the understanding of the functions and mechanics of both dietary and 
pharmacological zinc is knowledge of how zinc enters the body. The exact 
mechanism has not been described to date but several possibilities exist and are 
described in the following section.
Kinetic Studies
Kinetic studies of zinc uptake using radiolabelled zinc (^Zn) have been carried 
out for several decades and have looked at in vivo, ex vivo and in vitro 
preparations. These studies almost exclusively have described different kinetics 
or transport velocities with each method and preparation. They have also shown
that zinc uptake by the gastrointestinal tract is site specific. There is also dispute 
as to the site of greatest zinc absorption, although there is general consensus that 
the duodenum, jejunum and ileum absorb more zinc than the colon. This has 
been backed up by more recent studies of expression patterns for zinc binding 
molecules such as metallothionein and CRIP (cysteine-rich intestinal protein) in 
animals consuming zinc deficient and zinc adequate diets.
The majority of the work on zinc kinetics has been carried out on rats, either 
whole animal or tissue preparations as described in this following section. The 
kinetic studies have also shown that there are the characteristics of both 
facilitated (readily saturable) and non-mediated (not readily saturable) 
components of zinc uptake in the gastrointestinal tract (Davies, 1980, reviewed 
Albergoni, 1998). Methfessel and Spencer (1973) carried out studies on intact 
rats and ligated sections of rat intestine to look at both the kinetics of uptake and 
the sites of uptake. The animals received food and water ad libitum before and 
throughout the experiment, a factor that should be noted and will be discussed 
later. Rats were given a dose of 65ZnCI2 by intubation. They were then 
maintained in a metabolic cage, to allow collection of urine and faeces, for varying 
times before sacrificing and removal of portions of the gastrointestinal tract. In 
the ligated intestinal sections, the dose of 65Zn was placed directly into the sacs. 
The rats were anaesthetized in all in vivo experiments currently discussed. With 
the in vivo ligation the gastric blood supply was uninterrupted by the ligatures, so 
molecular transfer from gastric lumen via mucosal cytosol to the general 
circulation was unhindered. Tissue was measured for 65Zn uptake by radioassay 
by gamma-scintillation counter, the samples included liver, heart, lungs, spleen, 
kidneys, femur, muscle and whole blood sample as well as the gastrointestinal 
sections. The results indicated that the stomach did not retain label for very long, 
8% total 65Zn after 4 hours. Very little zinc absorbed during this time was found 
as label in any of the major organs tested when compared to zinc absorbed by 
other ligated sections in the small intestine. A similar observation was made after 
zinc was introduced into the ligated colonic sacs. Although in the whole animal 
experiment zinc was present far longer in this organ than in either stomach or 
small intestine, only trace amounts of label was found in either blood or plasma or 
any of the major organs tested. However in the small intestine, 33% of total 65Zn 
was found after 15 minutes, increasing to a maximal 65% within an hour. In
addition to this, the ligated sacs of duodenum, mid-jejunum and ileum provided 
the majority of the percentage total label found in blood, plasma or other organs 
when compared to the uptake from the other gastrointestinal section. The 
duodenum provided the greatest percentage of labeled zinc to all organs 
compared to the mid-jejunum or ileum. What is particularly of note in this study is 
that non-fasted animals were studied and that the zinc absorption reached a 
plateau at 30 minutes and was maintained at this level (-25% total ^Zn) for the 
following 7.5 hours. The fasted and non-fasted state takes on greater importance 
with later studies showing both kinetic and intestinal protein differences between 
these two experimental conditions.
Seven years later the next oft quoted study was performed, which described 
similar site-specific uptake of isotopic zinc and went on further to describe two 
distinct phases of zinc uptake (Davies, 1980). In this study, Davies described 
experiments similar to those described previously by Methfessel and Spencer 
(1973), but they altered conditions to account for the passage of digesta and 
consequently zinc binding ligands and dietary zinc. It should be noted that in 
their study, Methfessel and Spencer (1973) acknowledge this factor. They point 
out that in the ligated small intestinal segments there were similar amounts of 
digesta and therefore similar amounts of dietary zinc (and, it may be expected, 
similar amounts of binding ligands) and that this should not be a variable factor in 
their uptake observations. Again, all rats were anaesthetised for all procedures.
The first major difference between the two studies is that Davies fasted the test 
animals 18 hours before the experiment and that additionally they were fed a zinc 
deficient diet two days prior to surgery, in order to prevent a high dietary zinc 
concentration from affecting the 65Zn uptake. During surgery, the rats were 
opened up and 65ZnCI2 in saline solution was injected directly into the lumen of 
the duodenum, jejunum, ileum or caecum. The labelled zinc was also injected 
intramuscularly. The wounds were then sown up and the animals placed back 
into clean cages with free access to water and food after total body gamma 
counting. The total body measurement was carried out on successive days until 
the end of the experiment. This method allowed the measurement of relative 
absorption of radiolabel and successive subtraction of initial body count allowed 
calculation of uptake by the various segments injected with label. Further
experiments used modified forms of the ligated intestinal loops described in the 
previous study. In the first of these, in situ ligated loops were injected with 
various concentrations of zinc sulphate containing 65ZnS04 and incubated for 
increasing times before having the contents washed out. The loop was excised 
and the loop, the loop contents and the whole body were separately measured for 
levels of radioactivity. The second experiment looked at absorption, during the 
first 15 minutes (a period of rapid uptake), of varying concentrations of labelled 
zinc sulphate into the duodenal mucosa. In situ ligated duodenal loops were 
cannulated at either end. Radiolabelled zinc sulphate was introduced into the 
loop and incubated for fifteen minutes before the loop was flushed with saline. 
This was followed by varying incubation periods before the animals were killed 
and the loop contents and tissue assayed for presence of label. This is really an 
extension of the previous experiment to allow more detailed kinetic study of zinc 
absorption in this particular site.
Results for the intact rat studies indicated that, as was shown by Methfessel and 
Spencer (1973) that the duodenum provided the highest levels of retained label 
when the whole body was analysed over time. After eight days the levels of 
radioactivity were still distinctly higher than those of any of the other intestinal 
sites. The order of decreasing uptake was the duodenum (57.9% total zinc) 
followed by the ileum (30.1%), the jejunum (8.9%) and the colon with the caecum 
(3.0%) providing virtually no bioavailable zinc after eight days. Intramuscular 
injection of the radiolabelled zinc chloride in the whole animal study showed the 
highest levels of retained zinc after eight days. This was an indication perhaps 
that bypassing the gastrointestinal regulatory barrier for zinc uptake allows 
greater incorporation of zinc, however this may only reflect the fact that the zinc is 
readily bound by muscle tissue. Thus the label was not available to the 
circulating zinc ligands that are part of the regulatory mechanism for excretion, 
and the radiolabel retention may not reflect total incorporated zinc. Due to this, 
the study would not seem to be a useful comparison for the intestinal absorption 
and retention of zinc. However, as the rate of elimination of radiolabelled zinc 
from all sites, including the intramuscular injection, was very similar (as 
determined by regression analyses) there may be a comparison made in the 
manner of handling the zinc whether administered intestinally or intramuscularly. 
Billiary secretions had no effect on duodenal uptake as shown by uptake
measurements in duodenally administered 65Zn with or without ligating the bile 
duct.
That the labelled zinc introduced into the caecum was very poorly absorbed was 
an observation interesting in the light of later studies that showed the importance 
of fermenting digesta in the rat caecum for optimal absorption of zinc at that site 
(Seal and Mathers, 1989). A further observation from this study noted that the 
caecum increased in size in rats fed a high fibre diet in the form of increased 
pectin content. These studies also showed that, in comparison to other studies, 
the colon did indeed absorb dietarily important amounts of zinc although less than 
duodenum and ileum and that dietary fibre content which increased size of colon 
especially at the caecum might therefore increase zinc absorption. The fact is 
pointed out that as digesta are held for longer in the colon, this may compensate 
for the lower absorption rates (Seal and Mathers, 1989). It has also been 
observed that caecal tissue in rats and humans has a high cell proliferation rate 
(Hall et al., 1992), which might be expected to reduce mucosal zinc transport as 
zinc absorbing cells would be rapidly sloughed before absorption could occur. 
Therefore prolonged exposure of that portion of the intestine to readily 
fermentable digesta containing zinc ligands could enhance the otherwise poor 
caecal zinc uptake. Indeed the mass of the caecal and other gastric tissue is 
significantly increased from normal in the presence of fermentable digesta in rat 
(Seal and Mathers, 1989), pig (Jorgensen et al., 1996a) and chicken (Jorgensen 
et al., 1996b). This indicates that cell proliferation occurs faster than cell loss, 
which would aid zinc absorption across the mucosa. This possibility is supported 
by the fact that most cells, including gastric cells, require zinc to proliferate, zinc 
being required especially for nucleic acid replication and translation (Albergoni,
1998) and higher rates of proliferation therefore require more zinc. However 
studies have not shown a high level of zinc transfer from colon or caecum 
specifically to the circulation or body in general. Zinc absorbed by the caecum 
could thus play a localised role in the absorption or metabolism of some other 
nutrients, but studies have yet to look at this. It is clear that the importance of the 
caecum and the effect of fermenting digesta on zinc uptake cannot be dismissed 
for animal studies, and the large proportional difference in size of caecum 
between human and rodent must be considered when comparing studies.
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Davies (1980) further showed that in ligated loops of duodenum, absorption of 
zinc showed rapid onset, defined as greater than 1% uptake one minute after 
dosing. This may effectively be due to binding to the mucous layer at this point 
rather than absorption into the cells, which one might expect to take a little longer, 
as the dose penetrates or saturates the potential zinc ligands in the mucus. 
Binding to mucus in effect could not be considered absorption, instead it would be 
surface retention, and indeed 2 minutes after dosing, the rate of apparent zinc 
absorption increased rapidly as, it could be suggested, the true mucosal 
absorption began. Davies (1980) then made the observation that has directed 
research into zinc uptake right up to date. Zinc is absorbed over sixty minutes in 
a curvilinear pattern, but if this is divided into the first fifteen minutes and the 
following 45 minutes, two distinct patterns emerge. The first is a saturable phase 
characterised by a linear relationship for dose versus absorption when plotted as 
double reciprocals (Lineweaver Burk graph). The second uptake phase 
increases linearly with time and is not saturable within normal physiological limits 
for zinc concentration. Davies (1980) concluded that zinc is initially absorbed in 
the rapid uptake phase by an enzyme or carrier-mediated process that is 
predominant with lower zinc concentrations. However, at higher concentrations 
of luminal zinc (50pg and above) a non-specific binding and uptake mechanism 
predominates. A specific uptake process was consistent with observations of 
competitive inhibition of copper uptake by zinc (Brewer et al, 1979) which it 
appeared must share at least one specific uptake mechanism.
It should be noted when considering these two studies that neither used any more 
than descriptive statistics, mean and standard error and that the conclusions, 
especially about sites of greatest absorption, were not specifically stated as being 
statistically significant. In addition, both studies use measures of integrity for the 
mucosal barrier to ensure that tissue degradation did not account for zinc efflux 
from the lumen.
These two studies, amongst the earliest of the comprehensive studies looking at 
absorptive differences along the gastrointestinal tract headed a series of studies 
examining this in more detail. As mentioned in association with the two previous 
studies there are distinct differences in absorption of zinc associated with dietary 
zinc status. Jackson et al. (1981) carried out a series of experiments that
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described this dietary modulation of zinc uptake in rats. The experiments carried 
out in this study were similar to the whole animal preparations of the previous 
studies. They showed that zinc depleted diets could cause an increase in zinc 
absorption when radiolabelled zinc was administered acutely, compared to 
animals fed zinc adequate diets. They also differentiated zinc bound to the 
mucosa and zinc taken up into the whole body. They showed that the levels of 
zinc bound to the intestinal wall did not change in acute administration to either 
zinc-adequate or zinc-deficient rats, even though total body zinc was significantly 
higher in the zinc deficient rats. This observation would, at first sight, seem to 
argue against dietary modulation of a proposed regulatory zinc binding molecule 
in the mucosa, in turn being the cause of the dietary regulation of zinc uptake and 
this is what Jackson et al. (1981) proposed. However as all the rats were fasted 
24 hours prior to the experiment, this may easily have had a large influence on 
expression of such a regulatory protein, so such a conclusion is not entirely valid.
Whilst examination of zinc uptake over isolated portions of the intestine can 
produce a great deal of information it has been argued that this does not provide 
a complete or even accurate picture of actual zinc uptake from the gastrointestinal 
tract (House and Wastney, 1997). This is because the exact sites of specific zinc 
uptake or even the sites of variations in non-specific uptake are simply not known 
with any certainty. Further studies were carried out, under varying conditions, 
that analysed zinc transport over the whole intestine (House and Wastney, 1997, 
Steel and Cousins, 1985, Gisbert-Gonzalez and Torres-Molinas, 1996) and as a 
result distinctly different results were obtained from them, all claiming to be an 
accurate picture of zinc uptake in the gastrointestinal tract.
The major site of zinc uptake in the gastrointestinal tract was and still is a matter 
for great debate. Logic would decree that if a positive result is obtained in a well 
controlled study, then it should have practical predominance over a negative 
result in an equally well controlled study. Thus, as has been proposed (Steel and 
Cousins, 1985), probably all parts of the intestine participate in absorption of zinc, 
despite observations of no uptake from various gastrointestinal sites. The 
occurrence and the extent of this activity is dependant on luminal, dietary and 
physiological conditions (Gisbert-Gonzales and Torres-Molinas, 1996, House and 
Wastney, 1997). A comparison of the three whole intestine studies is again
12
difficult, as one uses a modelling system based on intravenous administration of 
radiolabelled zinc chloride from which tissular zinc uptake and transfer between 
organs is determined (House and Wastney 1997). In this study uptake from the 
gastric lumen can only be calculated indirectly, as zinc is not taken directly from 
the gut, instead transport is inferred from calculation of tissue zinc transfer over 
time. In this study, House and Wastney (1997) make the claim that zinc 
transferred from the gastrointestinal tissue to the plasma is greatest from the 
caecum followed by the jejunum and colon with very minimal transfer from the 
duodenum. Another group, Gisbert-Gonzales and Torres-Molina (1996), looked 
at zinc uptake and secretion in whole animals but used zinc acexamate 
(Esplugues et al., 1985) as the zinc source and as representative of zinc. 
However, zinc acexamate has been shown to have properties quite distinct from 
simple zinc salts and whilst it may prove an indication of true zinc uptake kinetics, 
it is difficult to claim it as a definitive study. This study concluded that zinc is 
absorbed most rapidly from the jejunum closely followed by the ileum and colon 
absorbing at approximately the same rate and finally the duodenum with a rate of 
absorbance roughly three fifths that of the jejunum. The third study (Steel and 
Cousins, 1985) examined the whole intestine and set out to look at the effect of 
dietary zinc status on zinc uptake after acute zinc administration and not 
specifically to identify the sites of zinc uptake. They used whole perfused 
intestine to look at zinc uptake kinetics in zinc-adequate and zinc-deficient rats 
from perfused lumen to perfused vasculature, vascular perfusate contained 
albumin as a major circulating zinc-binding ligand, to better simulate the normal 
vascular compartment. Their results backed up those of Davies (1980) who 
showed an uptake profile for zinc in ligated intestinal sacs that was biphasic, 
expressing saturable and effectively non-saturable kinetics. Steel and Cousins 
(1985) measured both absorbed radiolabelled zinc in the vascular perfusate and 
mucosally bound zinc in the gut. They showed that not only was zinc bound 
within the whole mucosal cytosol in greater concentration in zinc-deficient rats 
compared with zinc-adequate rats (control), but that after an hour there was a five 
fold increase in zinc concentration in the deficient rats’ vascular perfusate 
fractions compared to that of the zinc adequate rats. However both groups of 
rats displayed the biphasic uptake profile although the control intestines saturated 
at around 100pM zinc whereas the deficient rat intestines were not saturated at 
the concentrations used in the experiment. Assuming that non-specific sites were
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not increased in number, which would be difficult unless the intestine grew 
substantially in area, the study’s claim is that there is an upregulation of the 
specific component of zinc uptake in zinc deficient rats allowing them to maintain 
normal zinc levels with less available dietary zinc.
It seems therefore that only limited consensus exists over the exact site of zinc 
uptake, but what is generally agreed is that dietary constituents within the lumen 
may play an important role in zinc uptake. These include specific ligands which 
may aid or prevent zinc uptake, anion coupling which may also affect absorption 
and other divalent ions which may compete with zinc for uptake pathways.
Factors effecting zinc uptake mechanisms 
Luminal ligands
Ligands for zinc within the lumen can be divided conveniently into two major 
groups. Dietary ligands found to varying degrees in different foods (Peres et al., 
1998, Hansen et al., 1997, Lonnerdal, 1988), and secreted endogenous ligands 
(Prasad and Oberleas, 1970, Seal and Heaton, 1983).
Dietary ligands are often the major dietary sources of zinc but may also act as 
inhibitors of uptake (Reviewed Lonnerdal, 1997) where the ligand is part of an 
indigestible food source (Lonnerdal, 1997). As discussed previously zinc in 
humans is obtained proportionally in the main from red meat and to a lesser 
extent from other animal sources such as milk and fish (Lonnerdal, 1997, Mares- 
Perlman, et al 1995).
Zinc is bound very well by several small peptides (Prasad and Oberleas, 1970, 
Seal and Heaton, 1983) and by combinations of peptides (Prasad and Oberleas, 
1970). In vitro studies have shown that histidine binds zinc with greatest affinity, 
with glutamine, threonine, cysteine and lysine also markedly binding zinc (Seal 
and Heaton, 1983). Histidine and 2-picolinic acid have been shown to increase 
zinc absorption in vivo but not tryptophan (picolinic acid progenitor) or cysteine (a 
major intracellular zinc binding ligand) (Seal and Heaton, 1983). Milk proteins, 
casein, albumin, lactoferrin, and metallothionein in human breast milk have also
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been shown to bind zinc (Michalke et al, 1991) and cow milk equivalents have 
been proposed as supplements to increase zinc absorption in food rich in natural 
zinc chelators (Lonnerdal et al, 1984). In addition, milk proteins casein and alpha 
lactalbumin have been proposed to affect zinc absorption in vitro and in vivo. 
Casein specifically has been described as the major individual binding ligand for 
zinc in cows’ milk with the rest being found in the whey fraction by HPLC analysis 
(Kincaid and Cronrath, 1992). Another study quantified the zinc binding 
capabilities of whole bovine and human casein (Singh et al., 1989). It 
approximated 5-8 Zn atoms/mol but showed competition for the binding sites from 
calcium atoms. Additionally they described the other proposed zinc binding 
constituents, bovine whey proteins, beta-lactoglobulin, alpha-lactalbumin and 
lactotransferrin, as having minimal capacity for binding zinc. Interestingly this 
study also showed that casein binds less zinc with increasing ionic strength, the 
implication possibly being that in the acidic milieu of the stomach it may release 
much of the bound zinc, although this was not directly examined in this study. 
Casein has also been shown to improve zinc absorption in rat intestinal perfused 
loops (Peres et al., 1998) and in human volunteers casein phosphopeptides 
increased zinc absorption from rice based meals (Hansen et al., 1997). In 
primate studies casein and whey hydrolysate based diets increased both zinc and 
calcium bioavailability when compared to soya based diets (Rudloff and 
Lonnerdal, 1992).
In the gastric milieu there is also a large bacterial population and many bacterial 
proteins have been shown to bind zinc or contain it as an active or structural 
component. These include superantigenic (immune cell activating) proteins 
which require zinc to bind to the major histocompatibility protein (MHC) on cells, 
complement, which is part of the non-specific defence mechanism, and several 
inflammatory modulators (Papageorgiou et al., 1999, Al-Daccak et al., 1998). It 
might be interesting to look at the contribution of these interactions. These must 
occur quite regularly on zinc uptake in the intestine, due to the certain ubiquitous 
presence of antigens and superantigens and the expression of MHC on almost all 
cells, however no study has yet covered this.
The effect of dietary or gastric secreted ligands for zinc was investigated with 
several small molecules being proposed as major transport facilitators for the zinc
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ion (Jackson et al., 1981). Jackson et al. (1981) carried out one experiment in 
which the luminal contents of zinc deficient rats were dosed with radiolabelled 
zinc and replaced in the lumen of zinc-adequate rats to see if the increased 
absorption was due to an endogenously secreted factor. No increase in 
absorption was seen compared with that of normal rats. Neither was there a 
decrease in absorption of labelled zinc when luminal contents of zinc-adequate 
rats were placed in the lumen of zinc-deficient rats. These results appeared to 
indicate that secreted inhibitors or enhancers of absorption did not affect zinc 
absorption. This disagreed with other groups (Seal and Heaton, 1983) and did 
not at least take into account the effect of secreted endogenous zinc on 
exogenous zinc uptake. Jackson et al. (1981) were however careful not to 
exclude the possibility of specific ligands in the diet and specifically proposed 
mucosally bound ligands as one possible uptake mechanism. They examined a 
proposed ligand from the literature, picolinic acid, which was shown not to 
significantly affect zinc uptake, but another ligand, citrate, did increase the 
transfer rate of zinc from lumen to carcass.
Seal and Heaton (1983) amongst others (Lonnerdal et al., 1980, Evans and 
Johnson, 1980) also looked at the effect of anions and organic ligands such as 
picolinic acid and citrate on zinc uptake. It should be noted that while Jackson et 
al. (1981) used fasted animals, Seal and Heaton (1983) did not fast the animals 
used. Thus the two studies may not be directly comparable. Seal and Heaton 
(1983) used everted intestinal sacs, intestinal loop sections or everted gastric 
sacs that allowed greater control of zinc uptake conditions. Everted tissue, in this 
case gastrointestinal tissue, is turned inside out so that the mucosal surface is on 
the exterior, thus allowing transport of material through the mucosa to be 
examined at constant or specific concentrations. Using these preparations, Seal 
and Heaton (1983) found that zinc acetate was more effective than zinc chloride 
at zinc absorption and zinc citrate less so. The latter observation disagreed with 
the previously discussed study (Jackson et al., 1981) which showed increased 
zinc uptake with citrate, however this increase, whilst significant was very small 
and a corresponding loss of mucosally bound zinc makes the effect of citrate 
appear real. Seal and Heaton (1983) also looked at different anionic partners for 
zinc and concluded that zinc sulphate was absorbed better than the other anionic 
forms in the order of zinc sulphate > zinc chloride > zinc phosphate. These
16
observations make it even more difficult to compare studies that have used two 
different anions, normally chloride and sulphate but also citrate, to examine zinc 
uptake. However when radiolabelled zinc sulphate or chloride are used to 
determine uptake profiles they tend to be used at such low concentration within a 
larger amount of cold zinc that they are unlikely to affect the overall uptake. 
Despite this fact and with the additional observation that zinc chloride uptake is 
dependant on pH of the medium it is incubated in (Seal and Heaton, 1983), the 
differences in ionic form of zinc used in higher concentrations in an experiment 
must affect interpretation of uptake results. In this study picolinic acid (a 
metabolite of tryptophan) was shown to vary in aiding zinc uptake. This 
depended on isoform, 2-picolinic acid greatly increasing uptake and 4-picolinic 
acid reducing it. This supported a possible role of picolinic acid in one isoform 
aiding zinc uptake as proposed in another study (Evans and Johnson, 1981).
Other than protein, many other substances will chelate zinc and many will reduce 
its uptake from the lumen. In 1961, Ananda Prasad first observed zinc deficiency 
in a young male population in Iran where geophagia, consumption of earth, was 
practised (Prasad et al., 1961). Iron supplementation was used but subsequent 
studies indicated that zinc deficiency was the prevalent problem in malnourished 
individuals (Halsted et al., 1972) in this area. Comparison of zinc 
supplementation with iron supplementation in similar cases in Egypt indicated that 
it may have been trace zinc in the iron supplement that reversed the symptoms 
(Prasad, 1963). It was discovered in the course of these studies that the low 
endogenous zinc levels were causing physical symptoms that were readily 
reversed by zinc supplementation and cessation of geophagia. It appeared that 
the clay in the earth was chelating the zinc and was subsequently being excreted 
with minimal absorption. Also, a study carried out on anorexic patients showed 
that vegetarian anorexics took in significantly lower levels of zinc than non­
vegetarian anorexics (Bakan et al., 1993). However these extreme cases are 
examples of reduced zinc uptake due to diet. More commonly, if dietary zinc 
concentrations are adequate then reduced zinc absorption may be due to high 
fibre content and more specifically the presence of high phytate levels in the diet. 
Phytate (inositol hexaphosphate) is a highly negatively charged molecule that will 
bind strongly with divalent cations such as zinc (Lonnerdal, 1997). It is not 
absorbed by the body (Lonnerdal et al., 1988) and so, like the clay in the previous
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case, chelates zinc and prevents its uptake in the gut. Phytate, along with fibre, 
is found in large amounts in unrefined flour, especially wheat flour and has been 
shown in vivo to significantly reduce absorption of zinc in rats (Levrat-Vernay et 
al., 1999). Often marginal and pronounced zinc deficiency may be due to socio­
economic conditions where reduced red meat consumption is combined with 
higher vegetable consumption or simply lower overall consumption of food 
(Mares-Perlman et al., 1995). Two groups where marginal zinc deficiency may 
result in marked symptoms are the elderly and the very young. In the former 
case reduced overall food intake may contribute to significantly lower zinc levels 
than the normal population, in the latter case reduced overall consumption may be 
a factor, but also infant formula with high concentrations of phytate, soya based, 
can chelate significant amounts of zinc. Soya based phytate may be indicated as 
contributing to the reduced absorption of zinc in animal models (Lonnerdal et al., 
1988, Rudloff and Lonnerdal, 1992, Momcilovic et al., 1976), in human infant 
studies (Chan et al., -1987, Shinwell and Gorodischer, 1982) and in adults 
exclusively fed infant formula (Lonnerdal et al., 1984). However it is noted in one 
of the human infant studies that general nutrition was low and this may be a 
contributing factor. It is interesting to compare this with the in vivo studies of zinc 
uptake in rats fed zinc deficient diets in which they adapted to the low zinc 
availability by increasing uptake capacity. In these in vivo experiments, the 
kinetics of uptake changed over time to maintain adequate levels of zinc (Davies, 
1980). This observation may indicate that dietary zinc-binding constituents 
themselves could be more important in modulating human zinc deficiency than 
any effect of dietary composition or metabolic imbalance on the specific and non­
specific zinc uptake sites in the gut. It is even possible that the rat model for zinc 
uptake is not a very good one for drawing conclusions about human zinc 
deficiency. It is most likely that dietary ligand binding of zinc is both directly and 
indirectly contributory, but a study that would conclusively compare these two 
factors is not present in the available literature. Additionally in relation to the 
infant studies, little is known in general about zinc absorption kinetics in very 
young children and these may well be distinct from adult absorption kinetics, even 
in healthy zinc adequate infants, as it is known that at least one proposed major 
gastric mucosal cytosolic zinc, ligand, CRIP, is developmentally regulated 
(Levenson et al., 1993).
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In vivo studies have also shown directly that plant products in various forms may 
modulate zinc absorption (Seal and Mathers, 1989), with good evidence that 
phytate contributes greatly to decrease in zinc absorption (O’Dell and Savage, 
1960, House et al., 1982). However Seal and Mathers (1989) carried out studies 
in everted gut-sac preparations as described previously and showed that dietary 
fibre, and especially pectin, fermented to a great degree in the caecum, increased 
size and reduced pH of the large intestine. The high fibre diet also increased 
zinc intake. Rats absorbed zinc most rapidly from fibre preparations particularly 
high in pectin, followed by high bran preparations, when compared to normal diets 
(Seal and Mathers, 1989). The pectin fed rats however grew least of all so it 
seems the high levels of pectin may have been interfering with other nutritional 
pathways.
It seems therefore that in general, animal derived ligands tend to increase zinc 
absorption and plant derived ligands tend to decrease zinc absorption. However, 
the available evidence indicates that this is not a hard and fast rule. Whilst 
dietary ligands obviously play an important role in modulation of zinc uptake, 
endogenous secreted ligands may also be equally important.
Gastrointestinal Mucus
One proposed substance with ligand properties and which is ubiquitous 
throughout the gastrointestinal tract is the mucus coating the gut wall. In porcine 
gut mucosa it varies in strength and morphology throughout the gastrointestinal 
tract, with stronger mechanical characteristics in the stomach, duodenum and 
colon and thinner, weaker mucus in the small intestine typified by a high level of 
insoluble non-mucus glycoprotein which is removable by centrifugation (Sellers, et 
al., 1987). Obviously differences in the structure and integrity of a physical 
barrier could affect passage of material through that barrier. Electron probe 
microanalysis studies of rat duodenum has shown that zinc is evenly distributed 
throughout the mucus of that part of the gut in contrast to calcium which is bound 
unevenly (Coleman and Young, 1979). Oddly, cadmium distribution resembled 
more the calcium distribution which is unexpected as cadmium is generally a 
strong competitor for zinc binding ligands (Jaeger, 1990, Khoo and Cousins, 
1994) and it should be expected to have a similar distribution to zinc, rather than
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calcium, in the mucus. One of the first studies to show zinc binding capacity of 
the gut mucus layer as distinct from zinc binding by the mucosal cells also 
showed mucin, the major glycoprotein in mucus, to have a capacity for binding 
divalent ions including zinc (Coleman and Young, 1979). In agreement with an 
active zinc-binding role for secreted mucus are results that show a very rapid 
sequestration of zinc to the gastric wall of rinsed tissue, after just one minute 
(Davies, 1980). This is unlikely to be due only to cellular uptake, simply because 
the mucus layer itself must be crossed to reach the gastric epithelium. The mucus 
is thus probably retaining the zinc to some extent.
Of course the mucus also functions as a matrix within which any of the small 
amino acids or zinc binding proteins, such as albumin or transferrin which have 
been secreted by mucosal cells (Larhed, et al., 1998, Alvarez-Hernandez et al., 
1998, Marriott, 1989) could be retained. Reabsorption of these molecules could 
conceivably contribute to zinc uptake. The nature of the zinc binding capacity of 
mucus and its contents remains to be fully determined.
Copper
Zinc uptake is also affected by competition with other ions (Reviewed Folwaczny, 
1997); the best characterised competition coming from ionic copper. Although 
the specific pathways that copper and zinc share have not been completely 
described, various points on the pathways are known to coincide and there are 
several studies looking at the competitive uptake kinetics of zinc and copper and 
which are examined below. Although there appears to be a divalent ion 
transporter that may be involved in zinc and copper uptake (Gunshin et al., 1997), 
it is certain that the two ions will compete for binding to metallothionein in 
enterocytes (Hall et al., 1979). Thus excess of one ion will prevent binding and 
hence cellular sequestration of the other ion. However the interaction is more 
complex as described elsewhere, in that zinc will induce metallothionein 
production. This will itself increase copper binding (Brewer et al., 1990). It 
should be noted that the role of metallothionein in mucosal to serosal transport of 
ions, particularly zinc, is still a matter for debate and is examined later in this 
chapter (p.29). The relationship between zinc, copper and metallothionein is
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more complex than simple competition for binding sites. In treatment of Wilson’s 
disease (Reviewed Ferenci, 1997) which is a congenital inability to excrete 
copper, zinc has been proposed as a preventative treatment (Brewer, et al.,
1990). The complexity arises in that administration of zinc in pharmacological 
dosage for Wilson’s disease increases production of metallothionein itself over a 
period of days, so that more copper is bound and held in the enterocyte which is 
lost by desquamation along with its load of copper. It is difficult to reconcile the 
theory behind this treatment with the proposals of metallothionein as both a 
transferable storage molecule for zinc and a cytosolic transport molecule for zinc 
(Reviewed Albergoni and Piccinni, 1998). The reason for this difficulty is that 
acting as a storage or transport molecule, metallothionein would represent a 
highly exchangeable pool of either zinc or copper. Therefore, increasing 
metallothionein levels may actually increase the availability of copper for uptake 
into the body rather than locking it into the mucosal cells for excretion. However 
the answer to this problem may be that concentration and effect over time are 
decisive factors for determining the fate of excess copper bound in mucosal cells 
by the upregulated metallothionein. The certainty is that at this point in the 
absorption process there is both direct and indirect interaction and competition for 
binding by copper and zinc. In addition, copper has been shown in vitro to 
modulate metallothionein, by competing with zinc for binding to the metal 
responsive element (MRE) for a transcription factor which in turn activates 
transcription of metallothionein (Czupryn et al., 1992). However another study 
indicated that in vitro only zinc activates metallothionein via the MRE and other 
heavy metals did not (Koizumi et al., 1992, Murata et al., 1999). It should, 
however, be pointed out that one particular isoform of metallothionein (MT-IIA) 
was used for the investigation and the results indicate an even greater complexity 
of interaction between zinc and copper and putative zinc transport molecules.
Iron
Iron has also been proposed as a competitive inhibitor for zinc uptake in vivo 
however those experiments were carried out under controlled conditions with zinc 
in aqueous solution and iron at pharmacological concentrations (Craig et al., 
1984). Subsequent studies in infant (Fairweather-Tait et al., 1995) and adult 
(Davidsson et al., 1995, Lonnerdal et al 1984) humans showed that in fact under
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normal dietary conditions iron in food has minimal, if any, effect on the uptake of 
zinc, although if administered simultaneously there may be some limited 
interaction.
Cadmium
Cadmium is another metal that shares protein binding affinities with zinc, however 
unlike copper, cadmium is rarely found in levels great enough to cause zinc 
imbalance. Under conditions of dietary restriction with increased cadmium 
content, which is mainly ingested from vegetable sources (McKenna and Chaney,
1995), the effects of cadmium may be seen in zinc deficiency when its competitive 
effects are exaggerated (Nath et al., 1984). In vitro, the saturable uptake 
mechanism for zinc is inhibited competitively by cadmium in porcine brush border 
membrane vesicles, where cuprous ferric and ferrous ions had no effect 
(Blakeborough and Salter, 1987). Again the effect of cadmium on zinc uptake 
may be more complex than simple competitive inhibition but the concentrations of 
cadmium make it unlikely to have much effect under normal dietary 
circumstances.
Calcium
Interactions between zinc and calcium have been mentioned previously in relation 
to casein and phytate binding from dietary sources (pp 14-19). The mechanisms 
of uptake control shared by these two ions are more complex than simple 
competition for ligand binding with interactions between the ions and transport 
molecules such as calmodulin (Mills and Johnson, 1985) and lactalbumin 
(Murakami and Berliner, 1983) being described in detail. The concept of some 
mutual regulation was proposed over a decade ago (Brewer et al., 1979). 
Calmodulin is one of the major binding and transport molecules for calcium and 
has both functional and structural roles (Brewer et al., 1979). Zinc, along with 
other divalent ions, has been shown to bind to calmodulin (Milos et al., 1989) in a 
non-competitive fashion (Mills and Johnson, 1985) with binding sites that become 
available only when calcium is bound to its calmodulin binding sites (Mills and 
Johnson, 1985). As calmodulin has been proposed as a transport molecule for 
zinc in spermatozoa (Silvestroni et al., 1989), shown by inhibition of zinc uptake
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by calmodulin inhibitors, this molecule may act as a transporter for zinc in other 
cells as it is present in most tissues. In particular, calmodulin inhibitors have 
been shown to decrease calcium uptake in duodenal segments of rat intestine 
indicating a role for calmodulin in gastric absorption of calcium (Pento et al.,
1991). It is therefore reasonable to deduce that zinc may also be absorbed to 
some degree whilst bound to calmodulin in the intestine. Calcium ion permeable 
kainate channels in cultured cortical neurones have also been shown to facilitate 
transport of zinc (Sensi et al., 1999) after exposure to kainate. In addition to this, 
patch clamp analysis of nuclear membrane in hepatocytes has shown zinc and 
calcium transport through ion channels, with characteristics so similar that it was 
proposed that they are using the same channel (Longin et al., 1997). Zinc has 
also been shown to be taken up by submandibular cells via ATP (adenosine 
triphosphate) sensitive purinergic receptors (Dehaye, 1995). The uptake is 
inhibited by calcium, nickel and lanthanum (Dehaye, 1995). However of these 
ions calcium is probably the most dietarily relevant ion due to its widespread 
availability. The presence of zinc permeable calcium ion channels in salivary 
gland cells (Dehaye, 1995) and hepatic cell lines (Longin et al., 1997) provide 
another mechanism whereby zinc uptake may be regulated by calcium. Studies 
of zinc intake in elderly humans with high calcium diets, either as milk or calcium 
phosphate supplements, have shown that zinc absorption is reduced (Wood and 
Zheng, 1997). In another study by the same group adults were subject to whole- 
gut lavage followed by test meals containing normal or supplemented zinc 
content, which was challenged by acute treatment with high dose calcium 
carbonate (Wood and Zheng, 1997). Results indicated 50% reduction in zinc 
absorption when calcium was administered at the same time as the meal. The 
inhibitory effect was itself partially reversed by co-administration of the higher zinc 
dosage with the calcium carbonate bolus. It would seem then that whatever the 
molecular interactions between zinc and calcium at the cellular level, the net 
absorption of zinc from a meal can be inhibited by dietary calcium.
Zinc uptake at the cellular level
Zinc transport at the level of the mucosal cell itself has been only recently looked 
at in any detail with the advent of molecular techniques. These have facilitated 
the identification of several zinc specific ion channels (Palmiterand Findley, 1995,
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Palmiter et al., 1996, Wenzel et al., 1997, Huang and Gitschier, 1997) and at least 
one non specific divalent ion channel able to transport zinc (Gunshin et al., 1997). 
In addition to these channels there is the possibility of zinc uptake by ion 
channels such as those for calcium discussed previously. Other studies have 
suggested that zinc uptake may be related to an endocytic mechanism (Fleet et 
al., 1993, Grider and Vasquez., 1996) which may in turn be related to soluble or 
membrane-bound zinc ligand uptake (Bax and Bloxam, 1995). These various 
transport routes are discussed below.
Non-specific divalent ion channel - DCT-1
Very recently a gene was cloned that coded for membrane bound protein, 
divalent-cation transporter 1 (DCT1). It was ubiquitously expressed in rat tissue, 
particularly highly in the duodenum, jejunum and kidney, with very little expression 
in the ileum or the colon and virtually none in the stomach (Gunshin et al., 1997). 
DCT1 was shown by in situ hybridisation to be highly expressed in enterocytes 
lining the villus, particularly the crypts and lower portions of the villi. In the same 
study oocytes expressing DCT1 large inward currents were recorded for zinc, 
manganese, copper and cadmium ions, with uptake for iron shown to be linked to 
co-influx of H+ ions. This allows for a direct uptake mechanism of zinc by cells 
and interestingly, as calcium showed a weak outward current different from the 
other ions, it was proposed be part of the zinc-calcium uptake regulation 
mechanism as suggested by previous studies in brush border membrane vesicles 
(Gunshin et al., 1997).
Zinc specific ion channels
Zinc Transporter -1  (ZNT-1)
Four zinc specific ion channels have been cloned and characterised to date, and 
have been placed in a newly emerging class of ion channels called cation 
diffusion facilitators (Reviewed in Paulsen and Saier, 1997). The first of the zinc 
transporters to be identified was as recently as 1995. Palmiter and Findley 
(1995) used a complex method, involving deletion of function by mutagenesis of 
baby hamster kidney (BHK) cells, to produce mutant cells which did not have the
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resistance to accumulated intracellular zinc that the wild type BHK cells had. 
They then screened an expression library of rat DNA, transfected into and 
expressed by the mutated BHK cells, for the gene that conferred resistance to 
excess zinc. Transfected cells that contained rat DNA coding for this gene 
recovered the ability to tolerate excess zinc. This was successful to varying 
degrees in different clones. They then extracted the DNA from the successful 
clones and sequenced the library fragments that contained the gene conferring 
zinc resistance. The sequences from the DNA library that, when expressed in the 
zinc sensitive mutant BHK cells, made them zinc resistant if grown in high zinc 
medium, were identified as coding for a protein of 507 amino acids long 
designated ZNT-1. They were also identified as being homologous with two 
yeast genes, one that conferred resistance to zinc (Kamizono et al., 1989) and 
another identified as a cobalt transporter (Conklin et al., 1992). These two yeast 
proteins and the newly sequenced mammalian protein from the BHK study were 
determined, by hydrophobicity plot, to have six membrane spanning regions with 
both N- and C- terminals intracellular. In addition all three proteins had identical 
amino acids in position 121 with general similarity being highest in, or adjacent to, 
the membrane-spanning domains. All had a large intracellular histidine-rich loop 
between domains IV and V spanning the membrane and finally a long intracellular 
C-terminal tail. Once the mammalian ZNT1 gene was cloned it was engineered 
to contain a marker gene at the C- terminal, coding for green fluorescent protein 
(GFP). It was then transfected back into BHK cells and expression of the ZNT1 
protein linked to the fluorescent GFP protein was examined. In the BHK cells 
ZNT1 was localised to the plasma membrane by fluorescence that was not 
present in untransfected cells. Additionally, another engineered gene with a 
different marker, pGeo, on the C-terminus showed that the C-terminal 
fluorescence was situated in an organelle-rich compartment, supporting the 
results of the hydrophobicity plot that indicated that the C-terminal end was in the 
cytoplasmic compartment. These results were modified by later studies 
(McMahon and Cousins, 1998). Those studies showed a definite localisation of 
the ZNT-1 protein at the basolateral membrane of the enterocyte cells lining the 
villi rather than the luminal membrane. This meant that the channel could not be 
involved in uptake of zinc from the gastrointestinal lumen, but rather affected 
mainly efflux of zinc from and to the serosa and microcirculation.
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Zinc influx was greater than efflux in the transfected BHK cells compared to the 
wild type (original) cells (Palmiter and Findley, 1995). However, this could have 
been a function of the cell growth, as the influx was measured by intake of radio­
zinc. This could thus be affected by higher cell proliferation, as zinc is essential 
for adequate cell growth and thus higher intake would itself increase cell growth. 
The interesting point about this observation is that the transfected cells regulated 
intracellular zinc levels by increasing zinc efflux under conditions of increased 
zinc concentration, whilst untransfected, wild type cells modulated cellular zinc by 
reducing influx of zinc. ZNT-1 mRNA expression was increased (50%) in the rat 
intestinal but not hepatic tissue by dietary zinc supplement (McMahon and 
Cousins, 1998). However the ZNT-1 protein level increased only 10% in the 
intestinal tissue with the same dietary supplement. Acute administration of zinc 
increased intestinal mRNA 8-fold but had no effect on the protein. In the liver the 
acute dose of zinc had no effect on the mRNA expression but caused a 5-fold 
increase in the protein.
Zinc Transporter-2 (ZNT-2)
As a continuation of the study that described ZNT-1 further clones, coding for 
different proteins were identified, that also protected cells against high zinc 
concentrations. These were examined using the same process as used for ZNT- 
1 and a second zinc resistance gene was identified that coded for another 
membrane bound protein with similar characteristics to ZNT-1 (Palmiter et al.,
1996). This study showed that ZNT-2 has only a 26% amino acid similarity to 
ZNT-1 but in structure is rather similar with six presumed membrane spanning 
domains, a large intracellular histidine-rich loop and a long C-terminal tail. Using 
zinquin, a zinc specific fluorophore, it was shown that ZNT-2 facilitates zinc 
uptake into intracellular vesicles and again, use of a GFP fusion protein system 
showed that the expressed ZNT-2 protein was localised to the membrane of these 
intracellular vesicles. Mainly, the channel facilitated uptake into the vesicles, 
however a little zinc appeared to leak back into the cytoplasm from the vesicles. 
The significance of this vesicular sequestration was emphasised by the fact that 
only the highest zinc concentrations allowed optimal influx of zinc into the 
vesicles. Expression of either ZNT-1, the cellular efflux channel, or 
metallothionein, the major cellular zinc storage/binding protein, suppressed this
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vesicular sequestration activity. This would seem to indicate a lower affinity for 
zinc by ZNT-2 and subsequently a role perhaps only in preventing toxicity of zinc 
in the cell, rather than as a major zinc regulatory metabolic pathway. The low 
level of leakage back into the cytoplasm could also indicate that ZNT-2 allows 
these vesicles to act as cellular reservoirs for zinc. ZNT-2 mRNA in rat tissue 
was expressed clearly in kidney, intestine, seminal vesicles and testes as shown 
by reverse transcription polymerase chain reaction (RT-PCR). The authors did 
point out that as the transfected gene was expressed very highly using a strong 
transcriptional CMV promoter in the BHK cells, which they assumed would not 
normally express the protein, the expression may have been directed to 
inappropriate cellular compartments. Thus cellular location of normal ZNT-2 
would differ from just that of the vesicles. Currently only this one original 
publication exists describing ZNT-2 so a more specific understanding of its role in 
regulation of intracellular zinc is as yet unknown.
Zinc Transporter-3 (ZNT-3) and Zinc Transporter-4 (ZNT-4)
With continuing study of the ZNT-2 gene a murine homologous gene, ZNT-3, was 
identified and cloned. This had a 53% homology with murine ZNT-2 and coded 
for another protein with six membrane-spanning domains (Palmiter et al., 1996). 
Whilst neither ZNT-3 nor ZNT-4 are expressed in the gastrointestinal tract a brief 
description of their identification and function are included at this point. The 
murine ZNT-3 was shown to have 86% homology with the amino acid sequences 
for human ZNT-3 that was also cloned in this study. In order to identify and 
describe ZNT-3, antibodies were raised to the protein, which were then used for 
immunocytochemistry to examine localisation of the protein. In situ hybridisation 
was used to examine the corresponding expression of ZNT-3 mRNA in the tissue 
and in the same manner as used for ZNT-2, GFP fusion proteins were produced 
to look at the expression of transfected ZNT-3 DNA. Results of the sequencing 
showed that ZNT-3 lacked the distinctive large intracellular histidine rich loop of 
ZNT-1 and ZNT-2. ZNT-3 mRNA was identified by RT-PCR only in the brain and 
testes and localised by in situ hybridisation to the hippocampus and the cortex. 
Antibody staining indicated that immunoreactive ZNT-3 protein was spread in 
granule cell neurones in a pattern that was very similar to that of histochemically 
reactive zinc. This pattern was examined further (Wenzel et al., 1997) and ZNT-
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3 was found to be localised in the plasma membrane of small, clear, synaptic 
vesicles, 60-80% of which contained histochemically reactive zinc. Unlike ZNT-2, 
ZNT-3 did not facilitate uptake of zinc into vesicles when expressed in BHK, cells 
so it was proposed that other proteins aid ZNT-3 in its function. However, 
targeted disruption of the ZNT-3 gene in mice produced animals with total zinc 
levels reduced by 20% in the hippocampus and cortex. Specifically, the 
disruption abolished the histochemically reactive zinc normally found in the 
synaptic vesicles to which ZNT-3 was found to be localised (Cole et al., 1999). 
Disruption of only one allele for ZNT-3 led to less ZNT-3 protein being identified 
on the synaptic vesicles and a corresponding reduction in amount of zinc being 
found in the vesicles.
ZNT-4, the most recent mammalian zinc transporter in this series cloned to date 
(Huang and Gitschier, 1997) was shown to be expressed in mammary glands and 
coded for a protein homologous to ZNT-2 and ZNT-3. This protein also 
facilitated sequestration of zinc into endosomal/lysosomal compartments and also 
synaptic vesicles.
Despite their localisation in regions other than the gut, discussion of the ZNT-3 
and ZNT-4 studies has been added for completeness but since the recent 
identification of ZNT-1 in 1995 the even more recent cloning of subsequent 
receptors does leave the possibility that other channels remain to be identified. 
Additionally, clearer understanding of the cellular localisation of ZNT-2 may 
further elucidate its role in gastrointestinal tissue.
Vesicular transport
There are a few publications recently that have suggested that zinc may be 
transported in association with vesicular activity, endocytosis, or more specifically 
‘potocytosis’ of caveolae (Chang et al., 1998, Grider and Vasquez, 1996). 
Caveolae are non-clathrin coated, vesicle forming, pits on the surface of cell 
membranes. These membrane structures have been identified by a resistance to 
solubilization by Triton X-100 at 4°C, by a light buoyant density and by a richness 
in glycosphingolipids, cholesterol and lipid anchored membrane proteins 
(Reviewed by Anderson, 1998). Initially discovered to transport folate into cells,
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the transport of a large number of molecules has been shown to be associated 
with caveolae (Anderson, 1998). Potocytosis is the endocytic mechanism by 
which the caveolae transport a variety of molecules into the cytoplasm and target 
them to specific compartments within the cell (Anderson, 1998). Zinc, bound to a 
variety of anions, has been proposed to be transported along with these ions via a 
mammalian ion transporter mechanism (Vasquez and Grider, 1995). This 
transport was shown to be inhibited by an inhibitor of folate transport, probenecid 
(Chang et al., 1998) and by nystatin an antibiotic and inhibitor of caveolae 
formation (Grider and Vasquez 1996). These observations indicated that zinc 
uptake into cells can occur through a potocytic mechanism. However the 
probenecid study used both healthy fibroblastic cells and acrodermatitis 
enteropathica fibroblasts and showed activity of a secondary uptake mechanism. 
Acrodermatitis enteropathica is a genetic disorder that prevents zinc absorption 
and manifests as acute and severe zinc deficiency in infancy, it is completely 
treatable by zinc supplementation. Probenecid did not inhibit the uptake of zinc 
by the acrodermatitis enteropathica cells, which under normal conditions have 
only a low level of zinc uptake. This observation suggested that there was a 
secondary uptake mechanism unrelated to the potocytic mechanism and 
additionally that it indicated the deficiency in the acrodermatitis enteropathica 
fibroblasts might be that of the potocytic mechanism. The exact mechanism by 
which zinc is transported via the caveolae system has yet to be described in the 
literature.
Intracellular ligands involved in zinc uptake - Metallothionein and Cysteine- 
Rich Intestinal Protein (CRIP)
Whatever the mechanism by which ionic zinc or loosely ligand-bound zinc enters 
the cell and specifically the gastrointestinal cell, there exist two major zinc binding 
molecules that have variously been proposed as initial intracellular storage and 
transport facilitators for zinc. These are metallothionein and the more recently 
characterised CRIP.
Metallothionein was first characterised in 1957 as a cadmium binding protein 
(Margoshes and Vallee, 1957) and shown to be a low molecular weight zinc 
binding ligand implicated in the homeostasis of zinc and inducible by zinc (Pulido
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et al., 1966). Metallothionein has been very well described and a wide range of 
publications exists on the topic (Albergoni and Piccinni, 1998, Vallee and Falchuk,
1994) so only the area relating to zinc absorption will be considered in this part of 
the chapter. The role of metallothionein in zinc absorption is still debatable, 
although its involvement in the process is certain. However, whether it acts as a 
storage molecule for zinc (Olafson, 1983), a rescue molecule protecting against 
excess zinc or a zinc transfer molecule (Kruse-Jarres, 1997) has not been 
decisively determined. In vitro studies have shown metallothionein synthesis is 
directly proportional to zinc concentration in the human gastric cell line CACO 
(Rafaniaello, 1991). In fact the metallothionein genes have a transcriptional 
promoter that is activated by levels of various metals, mainly zinc, cadmium and 
copper, and these sequences are called metal responsive elements (MRE’s) 
(Murata, 1999). Metallothionein has a number of isoforms some of which are 
tissue specific and some that are more ubiquitous (Albergoni and Piccinni, 1998). 
Some isoforms respond to different stimuli (Huber 1993).
Both the hepatic and intestinal metallothioneins are inducible by zinc, although 
this seems to depend on species and experimental condition. There appears to 
be a differential response to dietary zinc in various parts of the murine intestine 
with endogenous metallothionein concentrations decreasing from the stomach 
down the gastrointestinal tract (Tran et al., 1998). In this recent study a high 
(400mg/kg food) dietary zinc concentration increased metallothionein levels most 
in the duodenum, then the jejunum and finally the ileum with no increase in the 
stomach, caecum or colon. In another study examining mouse intestine, oral zinc 
doses caused no increase in duodenal metallothionein but did increase hepatic 
metallothionein indicating that the zinc was being absorbed (Olafson, 1983). 
However duodenal metallothionein was induced by dietary zinc at exceedingly 
high dietary concentration (300ppm) and with repetitive dosing (Olafson, 1983) 
although the biological relevance of this zinc concentration is questionable. 
Further work has shown intestinal metallothionein to be readily induced, by orally 
administered zinc, in the jejunum (Ouellette et al., 1982) and gastric mucosa 
(Starcher et al., 1980). In the latter case, the mice were first injected intra- 
peritoneally with zinc and then the absorption of radiozinc was examined. This 
indicated that a high injected concentration of zinc increased metallothionein
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levels but decreased intestinal zinc uptake, whilst a ten fold decrease in 
concentration of the injected dose caused an increase in zinc uptake.
In zinc depleted rats it seems that dietary zinc will increase expression of 
intestinal metallothionein mRNA and production of protein (Menard et al., 1981). 
However, in one study (Blalock et al., 1988) a very high zinc dosage was required 
to stimulate intestinal metallothionein production, whilst stimulation of kidney 
metallothionein from animals in the same study occurred at lower zinc 
concentrations. More drastic differences were seen in another study with zinc 
deficient rats expressing 76% reduction in ileal metallothionein mRNA compared 
to controls and rats fed a zinc supplement expressing 80% higher levels of 
metallothionein mRNA than control animals (Levenson et al., 1994). In addition 
induction of metallothionein in rat intestine by zinc was investigated for its effect 
on cadmium uptake and increased metallothionein was shown by 
immunohistochemical staining techniques (Ohta and Cherian, 1991).
As was pointed out in the discussion of zinc uptake kinetics, it is reasonable to 
say that the studies in rat and mouse varied greatly in protocol and methodology 
and that these differences in either animal treatment or zinc administration for 
example could lead to the variation of results. However a general observation 
can be made that zinc at pharmacological doses seems to induce intestinal 
metallothionein mRNA and probably protein to some level and that dietary zinc 
levels may induce metallothionein.
In humans the study of zinc induction of intestinal metallothionein is more difficult. 
It is not easy to get healthy people to undergo gastroscopic biopsy for the sake of 
science. However several disease states have been studied where analysis of 
gastrointestinal tissue is necessary and metallothionein has been looked at. In 
Wilson’s disease, for example, copper is not excreted adequately and eventually 
becomes toxic. Zinc therapy has been used to inhibit the copper uptake 
(Yuzbasiyan-Gurkan et al., 1992) and does this by increasing metallothionein 
levels in the gut as calculated from analyses of intestinal biopsies. In this study 
metallothionein levels in the gut correlated directly with levels of zinc excreted in 
the urine, a measure of zinc status. In another study, duodenal biopsy
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metallothionein levels were increased 1500% from untreated control patients after 
oral therapy with zinc sulphate (Sturniolo et al., 1999).
It is clear from all these studies that zinc and metallothionein have a direct and 
specifically controlled relationship in intestinal processing of zinc, however in 
1990 the identification of CRIP (Liebhaber et al., 1990) began to change the 
understanding of intestinal zinc transport and the function of metallothionein. A 
subsequent paper showed tissue specificity of CRIP in rat intestinal mucosa and 
not liver or pancreas and described saturation kinetics for zinc binding to the 
molecule (Hempe and Cousins, 1991). CRIP was shown not to be directly 
induced by dietary zinc supplementation and ileal CRIP mRNA was reduced by 
only 19% in rats fed a zinc deficient diet as opposed to metallothionein in the 
same study which was highly regulated (Levenson et al., 1994) by dietary zinc. A 
competitive interaction was suggested for CRIP and metallothionein as radio-zinc 
was preferentially bound to CRIP in isolated intestinal loops from rats fed low zinc 
diets whilst in rats fed high zinc diet the proportion of CRIP bound radio-zinc 
reduced and metallothionein bound zinc proportion increased. Additionally, as 
luminal zinc concentration increased, CRIP-bound zinc gradually decreased 
(Hempe and Cousins, 1992). The transport of zinc in these loops was inhibited 
as metallothionein levels increased. These results suggest a co-operative 
modulation of zinc transport by CRIP and metallothionein in which high zinc level 
lead to saturated CRIP zinc binding and consequently greater zinc binding by 
metallothionein which seems to point to a protective role for metallothionein in 
preventing toxic levels of cytoplasmic free zinc. In partial disagreement with this 
theory Fleet et al. (1993) showed that increased metallothionein and reduced 
CRIP mRNA, in monolayer cultured CACO cells occurred with increased zinc 
transport across the monolayer. However they went on to show that zinc 
transport was inhibited by a lysosome disrupting agent in this model and 
proposed a zinc transport mechanism involving lysosomal sequestration and 
transport, with metallothionein in a protective role as described above.
The role of CRIP has also yet to be fully understood. Currently two functional 
roles have been proposed, the first being the involvement of CRIP in zinc 
transport and the second being a role for CRIP in modulation of immune function 
and inflammatory response (Halquist et al., 1996, Khoo et al.,1996). CRIP was
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shown to be expressed in immune mononuclear cells and macrophages and also 
in thymus, spleen and plasma to a lesser extent. Furthermore, the levels of CRIP 
were increased in peritoneal macrophages and mononuclear cells by the 
presence of lipopolysaccharide (LPS) (Halquist et al., 1996). An inflammatory 
model of carbon tetrachloride-induced intestinal and liver damage in rats, showed 
that CRIP mRNA levels were increased in the intestinal and liver tissue but not in 
immune cells. This suggests differential control of CRIP induction depending on 
stimulus and tissue type. The common factor between the two studies is the 
increase of CRIP mRNA levels with cell proliferation, either as immune response 
or for purposes of tissue repair. In fact recent immunohistochemical studies on 
the localisation of CRIP in rat intestine indicate a role other than transmucosal 
zinc trafficking for the molecule (Fernandes et al., 1997). CRIP was highly 
expressed in the cytoplasmic granules of Paneth cells in rat duodenal sections 
and to a far lesser extent in the tips of the villi. Paneth cells are derived from 
pluripotent stem cells, share many features with leukocytes (Bry et al., 1994) and 
have been shown to contain zinc rich granules (Dinsdale and Biles, 1986). 
These cells have also been implicated in antimicrobial activity in the intestine 
(Ouellette et al., 1992). This further reinforces a role for CRIP specifically in the 
defensive and reparative functions in the intestine, and by association with 
macrophage and mononuclear cells, in the whole of the body. This does not 
preclude a subsidiary role in zinc transport for CRIP but certainly brings it into 
question.
Zinc binding molecule in the circulation
Whether by ion channel activity, vesicular sequestration or transfer by specific 
cytoplasmic ligand the collection of zinc into the plasma is the final step for 
absorption of either dietary or pharmacological zinc and its distribution to the 
tissues. By far the ‘most important zinc binding plasma component is albumin 
with most of the circulating zinc (around 80%) loosely bound to the molecule. 
Around 15% of the plasma zinc is tightly bound to a2-macroglobulin, with the 
remainder bound to diverse small molecules, mainly amino acids and circulating 
metallothioneins (Reviewed by Albergoni, 1998). In addition to soluble plasma 
components circulating erythrocytes absorb zinc (Schmetterer, 1978) and
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presumably participate in the circulation of zinc. However, a study of zinc 
supplementation in inflammatory rheumatic disease showed no change in 
erythrocyte zinc content (Peretz et al., 1993). Thus if erythrocytes are involved in 
zinc transport, they are unlikely to be part of any response to acute changes in 
zinc levels. By in vitro analyses of serum components stable zinc content was 
identified mainly in fractions containing albumin but also in those of gamma, beta 
and alpha globulins. However a distinction was made between exogenous and 
endogenous zinc (Prasad and Oberleas, 1970). Dialysed serum when incubated 
with zinc, representing exogenous zinc, showed ready binding to albumin, 
haptoglobin, ceruloplasmin, a2-macroglobulin, transferrin and IgG. Amino acids 
were shown to compete for zinc bound to albumin, haptoglobin, transferrin and 
IgG, but not ceruloplasmin or a2-macroglobulin (Prasad and Oberleas, 1970). In 
perfused rat intestine albumin was shown to be the major circulatory binding 
molecule for zinc absorbed from intestinal mucosal cells (Smith et al., 1979). This 
agrees with the zinc binding molecules in porcine plasma, in which again, albumin 
and a2-macroglobulin were shown to be the major zinc binding proteins, whilst 
transferrin, proposed as an important serum zinc binding molecule (Harris and 
Keen, 1989), appeared to bind zinc but was described as being in too insignificant 
quantities to affect proportions of bound plasma zinc (Chesters and Will, 1981). 
In human studies, mainly of disease states with healthy controls, albumin is also 
shown to be the major zinc-binding molecule in serum (Kiilerich and Christiansen, 
1986, Boosalis et al., 1988, Failla et al., 1982). a2-Macroglobulin was the next 
major binding protein, although with only 5-6% of the total serum zinc in one study 
(Kiilerich and Christiansen, 1986).
Final destination of absorbed zinc
Zinc from the circulation may be taken anywhere in the body, but certain organs 
are particularly rich in zinc. In one whole body analysis of rats, the tissue with 
the highest concentration of zinc was bone with 217±3 pg/g dry weight, followed 
by the testes (165±4pg/g), with spleen, gut, liver, kidney and skeletal muscle 
having about half that concentration and plasma having the lowest concentration 
(1.69±0.03pg/g) (House and Wastney 1997). In terms of percentage body zinc, 
bone was still highest as it is a large volume of tissue with a high zinc
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concentration, roughly twice as much as any other tissue. Testes tissue was 
lowest, reflecting tissue volume. The plasma and gut percentage was not 
determined. The same study indicated that the transfer of zinc from plasma to 
liver was over twice that of any other tissue transfer of zinc indicating its 
importance in zinc homeostasis. Presence of a large amount of metallothionein 
in the liver allows sequestration of a large amount of zinc.
Summary of zinc uptake
The studies described in this section show that zinc absorption is similar but not 
identical between species and that it is a highly complex mechanism with a variety 
of possible pathways. Zinc in dietary or pharmacological form appears to interact 
with dietary or endogenous ligands on the mucosal surface, in various ways 
depending on the precise site within the intestine. A practically saturable 
mechanism at low zinc concentrations and a non-specific mechanism at higher 
concentrations then moderate the transport of zinc into the mucosa. These 
mechanisms may involve specific and non-specific zinc ion channels, ligand or 
cation transport channels or vesicular sequestration, followed by either vesicular 
transport across the mucosa or transport bound to a cytoplasmic carrier. 
Transfer from mucosal tissue to circulation may involve further zinc ion channel 
activity and vesicular exocytosis and collection of absorbed zinc in the plasma is 
mainly by albumin, which then transports the ion around the body.
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Zinc Pharmacology - Zinc and the Disease State
The role of zinc in disease and treatment of disease is a very broad subject and 
has been reviewed extensively in the literature, the scope of this section will cover 
zinc in disease as it relates to pathological inflammatory and immune conditions 
with particular reference to ulcerative disease. As zinc is intimately and vitally 
involved in cell proliferation, any condition that requires a rapid cellular response 
such as defense or repair will require either increased mobilization of zinc or 
increased cellular concentration of zinc, most probably both of these. Generally, 
pathological states may be divided into those that are caused by zinc deficiency, 
those that have zinc deficiency as a side effect from some other causative agent 
and those that respond to zinc treatment in a specific manner. This is an 
arbitrary division in that zinc deficiency has been observed and zinc 
supplementation has been indicated as therapeutic to varying extents in all of 
these conditions. In some of these disease states, zinc is the primary treatment 
and in others, zinc is very much a secondary treatment. Ulcerative disease, 
especially in the Gl tract, is an area where zinc salts and novel zinc compounds 
are being found highly effective in treatment of the condition.
Zinc Deficiency
Zinc deficiency can arise due to dietary reasons as described previously where 
either dietary zinc is in insufficient quantities or it is prevented from being 
absorbed by other dietary constituents. Disease is the other main reason for zinc 
deficiency, where zinc is either prevented from uptake or is used up and excreted 
excessively. These cases are discussed in the following sections. Zinc 
deficiency in any form has several common aspects, including impaired taste and 
smell, height and growth retardation, immune dysfunction, flattening of affect, 
flattening of emotions and other neuropsychiatric symptoms, visual impairment, 
weight loss, alopecia, dermatitis and delayed sexual development (Agget, 1997). 
Often mild to moderate deficiency may manifest itself only in a very limited 
fashion, but improved direct (Hsiung et al., 1997, Wastney et al., 1996) and 
indirect (Sullivan and Cousins, 1997) detection techniques for variations in zinc
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levels have led to increased diagnosis of the condition. Deficiency caused by 
dietary insufficiency has been observed in several distinct groups including 
infants, the elderly, strict vegetarians, patients on total parenteral nutrition (TPN) 
and those with habitually poor diet for socioeconomic reasons.
The effect of the ingredients in infant formula on zinc absorption in young rodents 
(Momcilovic et al., 1976) and human infants (Cooke and Nichoalds, 1986) has 
been discussed previously. In practice, deficiency is readily preventable by 
addition to the formula of ingredients that increase zinc uptake, or reducing the 
ingredients that are inhibiting the zinc uptake. In breast-fed infants, zinc 
deficiency, may be due to decreases in zinc levels in the milk and by inference 
low absorption by the mother (Atkinson et al., 1989). Although this is rare under 
normal circumstances of nutrition, in areas of poor nutrition breast milk may not 
contain enough to supply adequate zinc, but infants have been shown to recover 
readily after weaning away from the breast milk (Bhaskaram and Hemalatha,
1995).
Zinc deficiency in the elderly is most probably due to reduced consumption 
(Mares-Perlman et al., 1995, Fabris, 1997), but zinc absorption kinetics change 
with age, so this may be a function of homeostatic changes and can be prevented 
by zinc supplementation to the normal recommended daily allowance (RDA) 
(Turnland et al., 1986). One major area of research relating to zinc and aging is 
the role of zinc in the immune systems of the elderly and has produced conflicting 
results. Zinc has been documented in vitro as having immune modulating effects 
(See p68 for discussion on zinc immunology). In vivo, under some 
circumstances, the in vitro effects can be related to in vivo immune function. 
Thus the efficacy of zinc treatment in a population such as the elderly with, for 
many reasons, a reduced immune function, has been studied and the treatment 
shown effective (Prasad et al., 1993, Boukaiba et al., 1993, Bodgen et al., 1990, 
Girodon et al., 1999) with particular benefit to the humoral immune response 
(Girodon et al., 1999) and response to some (Girodon et al., 1999) but not all 
(Johnson and Porter, 1997) infections. In disagreement with this are studies that 
showed mixed effect, no effect or solely negative effects, of zinc supplementation 
on immune system function, or hypersensitivity response (Remarque et al., 1993, 
Bogden et al., 1988, Bogden et al., 1990).
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Vegetarians also run the risk of zinc deficiency and it is distinctly due to dietary 
restriction (Bhattacharya et al., 1985). By definition vegetarians consume larger 
than normal amounts of plant material which will chelate and remove zinc from the 
gut without allowing absorption. They also consume fewer foods such as meat, 
which can contain adequate levels of zinc to compensate for the reduced 
absorption. Vegetarian infants are particularly at risk of zinc deficiency (Shinwell 
and Gorodischer, 1982) however, this is treatable with zinc supplementation 
(Golden and Golden, 1981).
Zinc deficiency in patients undergoing total parenteral nutrition (TPN) has been 
identified (Chen etal., 1991, Tagaki etal., 1986) but was marginal and completely 
reversible by zinc supplementation (Chen et al., 1991). However, in post surgical 
or otherwise recovering patients, even marginal zinc deficiency could be 
deleterious, as repair mechanisms require amounts of zinc and zinc 
supplementation has been advised (Alfieri et al., 1998, Younoszai, 1983). In at 
least one study of TPN usage for children undergoing treatment for severe burns, 
increased excretion of zinc in the urine (hyperzincuria) and reduced plasma zinc 
concentration was observed, despite rather high concentrations of zinc being 
administered (Cunningham, et al., 1991). Close monitoring of zinc metabolism is 
thus indicated in cases of TPN during recovery, despite zinc supplementation. 
As there is an increase in urinary protein excretion (proteinuria), including the 
major zinc binding molecule albumin, in burns patients (Lindquist et al., 1984, 
Shakespeare et al., 1981) this might account for hyperzincuria in the study by 
Cunningham et al. (1991).
In general, zinc deficiency as a primary cause of illness is readily treatable by zinc 
supplementation and normal sources of nutrition and adequate consumption of 
these sources are enough to compensate and prevent deficiency. However, 
certain particularly susceptible groups may require additional pharmacological 
supplementation and monitoring.
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Zinc and ulcer
In order to better understand the actions of zinc in and on gastrointestinal 
ulceration, where zinc therapy has been shown to be effective, a very brief 
description of the structure of the gastric tissue and ulcerative process is 
presented below. A more detailed discussion of gastrointestinal physiology is 
beyond the scope of this thesis except where it involves zinc.
Gastrointestinal mucosal structure and causes of experimental ulcer
The gastrointestinal tract consists of a series of four major layers, each layer is 
composed of a mixture of thinner layered tissue and cell types with one 
predominant one that characterizes that layer. The inner layer, the mucosa (Fox, 
1987), is exposed to the digesta, gastrointestinal secretions and the various flora 
and fauna of the gut. It is itself coated with various amounts of mucus secreted 
by goblet cells on the mucosal surface, the strength and coverage area of which 
varies with position along the gastrointestinal tract (Jentjens and Strous, 1985). 
The mucosa, the absorptive and major secretory layer, is mainly comprised of 
columnar epithelium and contains various specialized secretory cells (Beinborn et 
al., 1993). It is supported by connective tissue, the lamina propria, within which 
there are lymph nodes. Surrounding the lamina propria are thin layers of muscle, 
the muscularis mucosa, which create the distinctive mucosal folds increasing the 
absorptive area of the gut. The folds are named villi and the troughs between 
these folds are called the Crypts of Lieberkuhn. The troughs also contain various 
gland ducts which cross through the muscularis mucosa into the second major 
layer of gut tissue, the submucosa. The submucosa contains a large number of 
blood vessels, branches of which extend from the submucosa to the mucosa and 
along the villi, and act to receive material absorbed through the epithelium and 
lamina propria from the lumen of the gut and also to transport endogenous 
molecules from the circulation back to the gastric mucosa. The submucosa itself 
is innervated by autonomic nerves in the form of the submucosal plexus. 
Surrounding the submucosa is the major musculature of the gut, the muscularis, 
which provides motility to the gastrointestinal tract, it is innervated by nerves in 
the myenteric plexus. The outer layer of the gastrointestinal tract, the serosa, is
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a protective coat of connective tissue, covered in simple squamous epithelium 
(Fox, 1987).
The stomach has a very similar structure to the rest of the intestine but has some 
specialized cells distinguish it from the rest of the intestine. The ‘villi’ of the 
stomach are modified with the villus epithelium consisting mainly of mucous cells 
that secrete dense protective mucus. The troughs between these microscopic 
folds in the stomach are called gastric pits. The lower portions of those are 
comprised of chief cells secreting pepsinogen and parietal cells secreting 
hydrochloric acid, also argentaffin cells secreting 5-HT and histamine and G cells 
secreting the hormone gastrin. The folds and troughs and the associated cells 
comprise as a whole, the gastric gland. The cells themselves form ‘tight 
junctions’ with adjoining cells, thus minimizing leakage of material from the lumen 
around the cells (Iwata et al., 1998). The structure of the stomach in particular is 
designed to maintain integrity and prevent back-diffusion of gastric acid that 
would damage the stomach itself. Ulcer preventions and cures, including zinc, 
have utilized most of these structures and secretagogues (D’Souza and Dhume,
1991).
Peptic ulcers can occur in the stomach or duodenum and occur when some 
causative agent weakens the factors, such as the mucus, that protect the mucosa. 
This may happen through a number of mechanisms. The main ones include 
nonsteroidal anti-inflammatory (NSAID) usage such as aspirin and indomethacin 
acting via a number of mechanisms (Navarro et al., 1994), stress causing 
increased gastric acid release mediated by the vagal nerve (Cho and Ogle, 1977) 
and Helicobacter pylori, a bacterium resident in the digestive system of about 50% 
of the population (Chan et al., 1991). H. pylori has been closely associated with 
peptic ulcer formation (Chan et al., 1991) and stomach cancer incidence 
(Yoshimura et al., 2000). The basis for zinc therapy in ulcer treatment is twofold. 
First, significant changes in endogenous tissue zinc occur in ulcerative disease 
(Troskot et al., 1996) and zinc deficiency has been shown to be associated with 
impaired gastric ulcer healing (Watanabe et al., 1995). Secondly zinc treatment, 
if effective, is well tolerated and has few side effects except in overdose.
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Within the mucosa, endogenous zinc is associated either structurally or 
catalytically with a number of important enzymes. These include carbonic 
anhydrase which regulates secretion of bicarbonate ions that protect the mucosa 
by neutralizing gastric acid, and also superoxide dismutase a well characterized 
copper/zinc enzyme which is a scavenger of superoxide (Vallee and Falchuk, 
1994). Also associated with zinc are thymidine kinase synthesis, important for 
nucleic acid synthesis, alcohol dehydrogenase and a large number of enzymes 
(Kruse-Jarres, 1997) and DNA binding zinc finger transcription factors (Vallee and 
Falchuk, 1994) that are vital to cell control and proliferation.
Ulcers can form as a result of disruption of pathways involving any of these zinc 
requiring proteins. Ulcer formation and treatment is well documented by in vivo 
studies and several mechanisms have been used to induce experimental 
ulceration, each with a specific aetiology, and therapeutic compounds may display 
different actions on disease modification depending on the model (Cho and Ogle, 
1992). Methods for induction of experimental ulceration in vivo include application 
of cold restraint, ethanol (alcohol), exogenous acid, reserpine, cysteamine, NSAID 
and Helicobacter pylori or secreted components of Helicobacter pylori as 
discussed below. In addition other agents may be used such as platelet 
aggregating factor (PAF) (Esco|ar and Bulbena, 1989) when a specific mechanism 
is being examined. Occasionally induction methods are used in conjunction with 
other factors likely to speed formation or increase duration of ulcers (Desai and 
Parmar, 1994).
Cold restraint ulceration is induced by immobilizing the animal in a restrictive cage 
and reducing the temperature (Alarcon de la Lastra, 1996). Tissue damage by 
hydroxyl radicals after inactivation of gastric peroxidase appears to be involved in 
cold stress-induced ulceration (Das et al., 1998). Ulceration by this method has 
been prevented experimentally by the calcium antagonist Verapamil (Koo et al.,
1986) which may inhibit histamine production and therefore acid secretion. Also 
by Cisapride a prokinetic agent that stimulates gut motility (Alarcon de la Lastra,
1996) the involvement in ulceration of which has not been clearly described. 
Finally, zinc compounds have also been shown effective in ulcer prevention 
(Escolar et al., 1987). Prostaglandin administration, particularly PGE2l has been 
shown to be effective against some ulcerogenic agents but may not be so
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effective against cold stress induced ulcer. However, diets that increased PGE2 
release into the lumen did show a reduction in stress induced mucosal lesions 
(Schepp etal., 1988).
Ethanol is a well known ulcerogenic agent however the exact mechanism of the 
ulcerative process involved is not entirely clear with possible underlying cellular 
mechanisms still being elucidated (Hiraishi et al., 1999). It is has been shown 
however that there is a reduction in mucus secretion in rats treated with 40%, 
50% and 80% alcohol (Wong et al., 1986). Divalent ions including zinc have 
been shown to dose-dependently reduce ethanol-induced gastric ulceration 
(Bandyopadhyay and Bandyopadhyay, 1997, Dupuy and Szabo, 1986) partially by 
reduction in acid secretion but mainly by stabilizing sulphadryl residues in 
mucosal proteins (Dupuy and Szabo, 1986) indicating the involvement of these 
two processes in ulceration. Another action of ethanol in ulceration has recently 
been suggested to involve oxygen radical production (Hiraishi et al., 1999).
Exogenous acid-induced ulceration simply enhances the endogenous acid effect 
of gastric erosion. Increases in endogenous acid secretion can lead to tissue 
erosion and ulcer when stimulated by a variety of agents for example 
(Kang and Wee, 1991) or cysteamine (Groves et al., 1974).
Reserpine induced ulceration is thought to involve stimulation of mast cell 
degranulation which releases histamine and other ulcerogenic agents (Ogle and 
Cho, 1978). It has been shown that increasing or depleting mast cell populations 
in the mucosa respectively intensify or prevent ulcerative responses to reserpine 
(Ogle and Cho, 1978, Rasanen and Taskinen, 1967).
Cysteamine-induced ulcer does not seem to have one major ulcerative action but 
has a wide range. Those include increased histamine secretion (Man et al., 
1990), increased gastrin secretion, increased acid secretion (Kirkegaard et al., 
1980), a reduction in the protective PGE2 (Pugh, 1991) and copper/zinc 
superoxide dismutase levels (Chen et al., 1994) and also alkaline phosphatase 
(Japundzic et al., 1991). A difference in the ulcerative process has been 
observed when cysteamine has been injected submucosally or applied topically to 
the mucosa. These account for a paradoxical damaging and protective effect for
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cysteamine on mucosal injury (Abdel-Salam et al., 1996). Subcutaneous 
injection of the compound decreased mucosal blood flow and inhibited gastric 
acid secretion. However, cysteamine applied topically to the serosa increased 
blood flow (Abdel-Salam et al., 1996). The clinical relevance of this is unclear 
but certainly indicates that cysteamine has a complex effect on gastric tissue 
function.
NSAID-induced ulceration is probably the most relevant model for clinical 
application and testing of drugs, as it is probably the most common cause of 
gastro-duodenal ulceration in the western population. As with ethanol and cold 
restraint, NSAID induced ulceration has been used commonly in investigations of 
zinc therapy in ulcerative disease (Bandyopadhyay and Bandyopadhyay, 1997, 
Rainsford and Whitehouse, 1992). Bolus administration of NSAID in tablet form 
but not suspension or solution has been shown to produce distinctive ulceration 
on point of contact with the mucosa (Rainsford, 1978) indicating definite 
physiochemical differences in the manner of administration for NSAID-induced 
ulceration. Two NSAIDs commonly used in experimental models are 
indomethacin (McCafferty et al., 1995, Kasuya et al., 1978) and aspirin (Kasuya et 
al., 1978, Desai and Parmar, 1994). The major and recently described factor in 
NSAID induced ulceration is the non-selective inhibition of both cyclooxygenase 
(COX) isoforms COX-1 and COX-2 (Kawai, 1998). NSAID-induced ulceration 
occurs mainly by reduction in protective prostaglandin biosynthesis (Vane, 1971). 
Selectivity in NSAID inhibition of COX isoforms has been suggested to reduce 
ulcerative effects of the drugs, COX-1 is constitutively expressed in many cells 
whilst COX-2 is inducible and is expressed especially at sites of inflammation 
(Warner et al., 1999), so it would seem that drugs that selectively inhibit COX-2 
would be preferable. Aspirin and indomethacin have been shown in vitro to be 
COX-1-selective but with COX-2 inhibitory activity (Kawai, 1998) and thus the 
ulcerative activity they display may be associated with this observation.
H. pylori-associated ulceration is still relatively uncharacterized at the molecular 
and cellular level in ulcer, with much of the work investigating gastric cancer 
rather than ulcer, but its association with ulcer as a probable causative agent is 
undoubted and has been well described (Yamaoka et al., 1999).
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Role of zinc in recovery and treatment of gastric and duodenal ulcerative 
disease
Healthy endogenous zinc levels are vital to both prevention of ulceration and 
recovery from either external ulceration such as venous leg ulcer (Wissing et al.,
1997) or internal, duodenal and gastric ulceration (Troskot et al., 1996). This has 
been indicated by studies that showed initially reduced serum zinc concentration 
after experimental induction of ulceration. This was followed by increased tissue 
zinc concentration in the ulcerous area and subsequent reversal of this process, 
and the reduction of tissue zinc which correlated over time with ulcer healing 
(Troskot et al., 1996). Therapeutic treatment of ulcer with zinc has also indicated 
a positive effect for the ion on healing of the lesion, in fact this is a very well 
documented action of zinc as discussed below.
The localization of endogenous zinc in rat gastric and duodenal ulcerous tissue 
has only fairly recently been studied with only one paper specifically dealing with 
endogenous tissue zinc levels in ulceration (Troskot et al., 1996). Ulceration 
does not appear to lead to increased secretion of zinc into the gastric fluid as 
shown by lack of significant differences in metal content of gastric juice between 
healthy and peptic ulcer patients (Powell et al., 1992), so the localization of zinc in 
ulcer would seem to be limited to local tissue activity as opposed to increased 
secretion. Much of this activity could be associated with the repair process, 
particularly increased cellular proliferation as the ulcer heals. This is indicated 
by a study in which zinc deficiency reduced cell proliferation rates (Watanabe et 
al., 1995). Studies of the effect of zinc deficiency on rat models of ulcer have 
shown that zinc deficiency produces or aggravates gastric ulceration (Cho et al., 
1987). However another study showed that rats that were fed zinc-deficient diets 
to produce systemic deficiency, then subjected to acid-induced ulceration, had no 
increased incidence of ulceration but did display a slower healing rate and a lower 
cell proliferation rate by four days after ulcer induction (Watanabe et al., 1995). 
The effect of experimental zinc deficiency on the stomach has been observed to 
produce a significant increase in gastric volume, in acid and in pepsin (Cho et al.,
1987). In addition there was a decrease in mast cell count which may adversely
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effect ulcer formation (Cho et al., 1987) as mast cells are involved in ulcer 
formation (Santos et al., 1998) and zinc therapy has been shown to inhibit mast 
cell degranulation which releases histamine and other ulcer promoting soluble 
mediators (Ogle and Cho, 1978).
Although simple zinc salts have been shown to be effective in a variety of 
ulcerative conditions, there are a number of problems associated with their usage. 
Ionic zinc compounds may not be very well absorbed in the gastric milieu and can 
have emetic actions, probably due to gastric irritancy (Reviewed Rainsford and 
Zeitlin, 1998). A number of zinc compounds have been developed to counteract 
these problems and are discussed individually below. Two of these, zinc 
acexamate and zinc carnosine (polaprezinc), have been tested experimentally 
and clinically in ulcerative disease. Several other zinc complexes, zinc 
monoglycerolate (ZMG), zinc-cimetadine, zinc-aspartate, zinc-glycinate, zinc- 
indomethacin and zinc-aspirin have been tested variously in vivo and in vitro. The 
latter two zinc NSAID complexes were designed specifically to reduce the 
ulcerative side effects of the NSAIDs but have also been proposed by the authors 
as making the zinc bioavailable whilst reducing the irritancy of the zinc ion (Singla 
and Wadhwa, 1994, Singla and Wadhwa, 1995).
Zinc acexamate
Zinc acexamate has been widely described in a number of experimental models 
and clinical trials (Rainsford and Zeitlin, 1998). Zinc acexamate has been 
developed now for over thirteen years (Alcala and Santaella, 1985).
Zinc acexamate appears to act at several levels with protective effects on all 
ulcerative models tested. In cold restraint-induced ulceration, zinc acexamate 
exhibited dose dependant reduction of ulcerative lesions (Navarro et al., 1988, 
Pfeiffer et al., 1987, Navarro et al., 1990). In this model mucus secretion and 
prostaglandin production were increased after zinc acexamate treatment (Navarro 
et al., 1988), the effects of which were reduced by preadministration of the NSAID, 
indomethacin. After application of zinc acexamate, with cold restraint-induced 
ulceration, zinc levels in the tissue corresponded with ulcer healing, however 
there was no such correlation with serum level of zinc (Navarro et al., 1990).
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Mucosal mast cell count (300mg/kg zinc acexamate) and related ulceration by 
reserpine administration (75-400 mg/kg zinc acexamate) was dose dependently 
inhibited by zinc acexamate pretreatment. These results were related to 
reduction in membrane permeability as indicated by dose dependant inhibitory 
effects on leakage of hepatic lysosomes induced by Triton X-100 (0.1 - 2x104M 
zinc acexamate) (Pfeiffer et al., 1987).
Acetic acid-induced ulceration was inhibited by zinc acexamate (200mg/kg) and 
ranitidine (30mg/kg), with lesions statistically smaller in the zinc acexamate 
treated animals (Navarro et al., 1990). Other chemical induced ulcerative lesions 
examined included those caused by platelet aggregation factor (PAF) (Escolar et 
al., 1989). PAF binding to its receptor is dose dependently inhibited by zinc 
(Nunez et al., 1989) and the widespread aggressive ulceration induced by PAF in 
the gastric mucosa was prevented by zinc acexamate by an action that included 
inhibition of mast cell degranulation (Escolar et al., 1989).
Acetyl salicylic acid (100 mg/kg ASA) induced ulceration was inhibited by zinc 
acexamate, which increased protective mucus production and PGE2, levels 
(Bravo et al., 1992). However, the zinc acexamate (100mg/kg zinc acexamate) 
did not interfere with the anti-inflammatory properties of aspirin in carrageenin 
induced oedema (Bravo et al., 1990). Zinc acexamate administration over three 
days (50-150mg/kg/day), also significantly reversed, to varying degrees, PGE2 
inhibition by indomethacin, naproxen and piroxicam, but not diclofenac or 
ketoprofen. Moreover zinc acexamate significantly raised PGE2 levels from 
control animals without NSAID pretreatment (Navarro et al., 1994). Zinc 
acexamate in the same study significantly prevented ulcerative lesions induced by 
ketoprofen, naproxen and piroxicam but not diclofenac and indomethacin 
(Navarro et al., 1994). The most recent study has described a novel action of 
zinc acexamate, as an antioxidant, utilizing an in vitro superoxide radical- 
dependant fluorescence technique on rat neutrophil and guinea pig macrophages 
(Tsutsui et al., 1999). In vivo administration of 30mg/kg zinc acexamate 
significantly inhibited alcohol/acid produced radicals in homogenate preparations 
of gastric mucosa (Tsutsui et al., 1999), both observations which suggest another 
level of gastric protection by zinc acexamate.
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There have been at least six recent publications on clinical observations of zinc 
acexamate, however two of the most recent are non-English publications (Guilarte 
Lopez-Manas et al., 1998, Garcia-Plaza et al., 1996). By 1992 there had been 
eighteen clinical trials, a meta analysis of which was carried out (Jiminez et al., 
1992). This study examined thirteen randomized clinical trials with a sum of 757 
patients in total, with placebo control treatments and proton pump antagonist 
comparison treatments, with zinc acexamate treatments of 300, 900 and 1200 
mg/day for 3-6 weeks, concentrations and time period which differed between 
original studies (Jiminez et al 1992). It might be a consideration when comparing 
experimental effect and clinical effects that the experimental concentrations were 
far higher with between 50-200 mg/kg in rats as opposed to 300-1200 mg in 
patients, assuming body weights around 60-90 kg. This is approximately ten 
times lower than the experimental concentrations that did not always give 
complete protection from ulcer. Although the actual clinical effectiveness of zinc 
acexamate is undoubted, it does make it difficult to draw definite conclusions on 
the clinical mechanism of action of zinc acexamate. However, the meta study still 
indicated that the anti-ulcer activity of zinc acexamate was significantly better than 
placebo, but was not different from the proton receptor antagonists (Jiminez et al., 
1992). In the meta study there was a low frequency of reported side effects (less 
than 3%) and these included nausea, vomiting, constipation, somnolescence, 
headache and dry mouth (Escolar and Bulbena, 1989).
Therckas been an acute allergic reaction observed for zinc acexamate taken as an 
anti-ulcerative and published as a case study (Galindo et al., 1998). This was 
not seen in the large meta study, however it does indicate a possibly serious 
reaction based on patch tests representing all the constituents of the proprietary 
zinc acexamate preparation. The perfume, flavouring and matrix were reactive 
and so was a 5% solution of zinc acexamate alone indicating a general allergic 
response to all the constituents of the proprietary compound as well as the other 
ingredients (Galindo et al., 1998). The importance of this adverse reaction to the 
wider population is unlikely to be known until wider commercial usage of the 
product is examined.
It may also be noted that acexamic acid (also called 6-aminocaproic acid and 6- 
acetamidohexanoic acid) has a pharmacological action of its own including
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modulation of the coagulation cascade (Green et al., 1986). In many of the 
functional in vitro and in vivo studies, it should be noted that there is no control for 
acexamic acid itself, although it is possible that these controls were examined in 
earlier studies published by these authors in Spanish. It would have seemed 
appropriate to have included acexamic acid alone in the later in vivo and in vitro 
studies due to its above mentioned properties.
Zinc camosine
The second novel zinc delivery compound developed that has been extensively 
studied in vitro (Furuta et al., 1994), in vivo (Yoshikawa et al., 1991a) and in 
clinical trial (Kashimura et al., 1999) is zinc carnosine (also called polaprezinc 
and Z-103).
Zinc carnosine transport has been found to follow Michaelis-Menten kinetics in 
everted gut sac preparations, with transport inhibited by ouabain and low 
temperatures, indicating a carrier mediated active uptake process (Furuta et al., 
1994). Uptake of zinc carnosine in acetic acid-induced ulcer was greater than 
either zinc sulphate or L-carnosine alone and was localized in higher 
concentration at the site of lesion (Furuta et al., 1995a). In addition, it was shown 
that zinc carnosine dissociated in the gastrointestinal tract as a function of time, 
being found as a complex after 0.5 hours with dissociation occurring by 1 hour 
(Furuta et al., 1995b). The binding of zinc carnosine to gastric mucosa was 
increased in the presence of the anti-ulcer drug cimetidine (Furuta et al., 1995b).
In acetic acid-induced ulceration, post treatment with zinc carnosine, 3 and 10 
mg/kg two times daily for 14 days, reduced size and depth of ulcerous lesion and 
promoted mucosal regeneration (Ito et al., 1990). In the same study, a relapse 
model of ulcer was induced by hydrocortisone administration. Zinc carnosine 
with the above regime for 20 days, prevented mucosal exfoliation in the 
regenerated tissue (Ito et al., 1990). These observations indicate the in vivo 
efficacy of zinc carnosine in prophylaxis and therapy of a recurring ulcer model.
Ischaemia and reperfusion injury was used in vivo to examine the actions of zinc 
carnosine on gastric lesions (Yoshikawa et al., 1991a) by application of a clamp to
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the celiac artery supplying blood to the stomach. Zinc carnosine significantly 
inhibited erosion of gastric mucosa produced in this model without affecting blood 
flow in the blood restricted areas. The mechanism of action in this model 
appears to include significant inhibition of the lipid peroxide increase in the 
affected areas of mucosa (Yoshikawa et al., 1991a). Further study of this 
antioxidant action of zinc carnosine was carried out, comparing it with zinc 
sulphate and L-carnosine (Yoshikawa et al., 1991b). Both zinc carnosine and 
zinc sulphate, but not L-carnosine, inhibited superoxide generation from 
stimulated polymorphonuclear leukocytes. They also inhibited increase of lipid 
peroxides produced by rat brain homogenates and liver microsomes (Yoshikawa 
et al., 1991b). The inhibitory effect of zinc carnosine on lipid peroxidation, which 
occurs with free radical damage of tissue, is proposed in both studies as a major 
mechanism of the compound in its therapeutic action on gastric mucosal damage 
(Yoshikawa et al., 1991a. Yoshikawa et al. 1991b). Oxidative damage of gastric 
mucosal cultured monolayers by hydrogen peroxide was measured by radio­
chromium release in a further study. It was shown to be dose-dependently 
reduced by zinc carnosine by shifting to the right of dose-response curves for the 
hydrogen peroxide induced chromium release (Hiraishi et al., 1999).
The effect of zinc carnosine on models of gastric ulceration caused by 
monochloramine was examined in vivo. The drug dose-dependently inhibited the 
ulceration but the healing mechanism was suggested to be different from the anti- 
ulcerative mechanism of PGE2 (Nishiwaki et al., 1997, Kato et al., 1997).
In clinical trials, zinc carnosine has been shown to be effective against \MpyM  in 
combination therapy (Kashimura et al., 1999). A group of 66 patients was divided 
into two groups, one of 31 received lanzoprazol, amoxycillin and clarithromycin. 
The other group of 35 received the same drug treatment in addition to zinc 
carnosine, 150mg twice daily, for one week. Including drop out patients the, 
patients taking zinc carnosine with combination therapy had a significantly higher 
percentage recovery, 94%, than those without zinc carnosine, 77% (p<0.05) 
(Kashimura et al., 1999).
The efficacy of zinc carnosine appears good in the models of ulcer tested but this 
has not been as complete as those for zinc acexamate, although all appropriate
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controls appear to be included in the in vitro experiments that have been carried 
out. Again, as with zinc acexamate, some of the studies have been published in 
foreign language journals and may contain information that would further 
elucidate the actions of zinc carnosine. Certainly, the clinical improvement of 
zinc carnosine-treated patients infected with added to the improvement,
seen in vivo, of ulcer models, is an indication that this therapy may prove valuable 
in the clinical treatment of ulcer. However a clinical study of this has not yet been 
published.
Zinc monoglycerolate
Zinc monoglycerolate has been studied in vivo in models of inflammation and 
ulceration (Whitehouse etal., 1990, Rainsford, 1992, Rainsford and Whitehouse,
1992). It has been shown to be a slow release source of zinc having anti-arthritic 
properties in vivo given parenterally but not orally (Whitehouse et al., 1990) and 
subsequently shown to have significant antiulcerative properties in vivo compared 
to zinc salts and comparable to traditional antiulcer drugs when taken orally 
(Rainsford, 1992). Models of ulceration in rats using orally or parenteral 
administered NSAIDs, aspirin or indomethacin, in animals pre-sensitized by 
arthritis, were used to examine the anti ulcerative effects of zinc monoglycerolate 
compared to zinc sulphate as determined by lesion size (Rainsford and 
Whitehouse, 1992). ZMG was very similar to zinc sulphate in its ability to reduce 
lesion size at doses from 5mg/kg up to 23 mg/kg, showing significant reduction in 
both aspirin and indomethacin induced ulceration, but the ZMG displayed none of 
the mucosal irritancy seen with the zinc sulphate (Rainsford and Whitehouse
1992). In arthritic rats using this same model, ZMG was compared with zinc 
sulphate and zinc acexamate and showed similar antiulcerative activity in the 100 
pmol/kg range for both aspirin and indomethacin induced lesions (Rainsford and 
Whitehouse, 1992). Effect of ZMG (100mg/kg) on ulceration induced by a variety 
of NSAIDs and cold stress indicated that ZMG caused reduction in lesion size for 
indomethacin, piroxicam, diclophenac, phenylbutazone, meclofenamic acid, 
isoxicam and aspirin, with results similar to cimetadine. ZMG did not seem to 
provide protection from ulceration by the propionic acid series of NSAIDs in 
general (Rainsford and Whitehouse, 1992).
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In ulcers induced by ethanol with HCI in cold stressed normal or arthritic rats, 
pretreatment with ZMG was comparable to both zinc sulphate and zinc acexamate 
in ability to significantly reduce ulceration in the 100-500 pmol/kg range 
(Rainsford and Whitehouse, 1992). Orally pre-administered ZMG was also 
effective in significantly reducing reserpine-induced ulceration in rats (Rainsford 
and Whitehouse, 1992). Of importance in possible clinical usage of ZMG, it was 
shown to have antiulcerative effects without compromising the anti-inflammatory 
actions of the NSAID aspirin in rats challenged with cold stress to induce 
ulceration and subplantar carrageenan induced paw inflammation (Rainsford and 
Whitehouse, 1992).
Further investigation into the mechanism of ZMG antiulcerative activity was 
carried out focussing on aspirin and indomethacin-induced ulcer-related 
biochemical changes and actual ulceration in rats and mice (Rainsford, 1992). 
ZMG, 50mg/kg, inhibited an aspirin induced increase in mucosal 5-HETE, a 
component of the 5-lipoxygenase pathway which induces vasoconstriction and 
contributes to inflammatory damage (Rainsford, 1992). Paradoxically in relation 
to the antiulcerative actions of ZMG, it was also observed that under the same 
conditions of aspirin and ZMG as above the aspirin-induced reduction in PGE2 
levels was significantly increased by the ZMG treatment (Rainsford, 1992). In the 
same study ZMG in single dose, 100mg/kg, and three consecutive four hourly 
doses of 50mg/kg, were shown to significantly reduce lesion size and number 
however a single dose of 50mg/kg had no significant effect on lesion size or 
number (Rainsford, 1992).
In addition to the directly antiulcerative actions of zinc monoglycerolate, this 
compound has recently been shown to inhibit growth and reduce viability of &  
p jk t  when administered as a mixture with (3-cyclodextrin in vitro, with more 
pronounced effects seen in a growth medium of pH5.0 as opposed to pH7.2 
(Rainsford et al., 1997). The inhibition of growth by ZMG (Rainsford et
al., 1997) is likely to be effective in treating ulcer in a similar manner to zinc 
carnosine (Kashimura et al., 1999).
Zinc-cimett dine
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Zinc-cimetidine has been shown to have ulcer-healing effects in acetic acid- 
induced ulcers in rats (Ito et al., 1995). The model described involved injection 
of 0.05ml 20% acetic acid into the submucosal layer at the junction between the 
fundus and antrum and the test compounds were given orally twice daily for 14 
days, after which measurements of the ulcer size and other parameters were 
taken. A dose-related reduction (range 15 mg/kg - 60mg/kg p.o.) in ulcer index 
was observed with zinc cimetidine but not with the molar equivalent of zinc as zinc 
chloride (Ito et al., 1995). The index of mucosal regeneration was increased with 
both the complex and the mixture of cimetidine and zinc. The ulcer-healing effect 
of zinc cimetidine preceded an increase in thiobarbituric acid reactants, 
suggesting that an anti-oxidant effect of the complex was responsible for this ulcer 
healing activity. Oddly, the zinc-cimetidine complex did not inhibit acid secretion 
even though cimetidine did, so it is puzzling to understand why this complex was 
developed in the first place. This is especially so as the anti-secretory effect of 
cimetidine would have been expected to have a specific advantage in being 
incorporated in the complex.
Zinc-indomethacin and zinc-aspirin
Briefly, neither of these can strictly be classed as compounds inhibiting or treating 
ulcer as both NSAID groups may actively induce ulcer. However, for this reason 
and as these NSAID groups are such widely used medications in the non-zinc 
form, the complexing of zinc to the drugs may be seen to create, in practical 
terms, antiulcer therapeutic agents (Singla and Wadhwa, 1994a, Singla and 
Wadhwa, 1994b).
Zinc-aspartate and zinc-glycinate
The zinc-amino acid complexes, zinc-aspartate and zinc-glycinate, given 
intraperitoneally reduced the incidence, number and severity of reserpine-induced 
ulcers in rats (Barbarino et al., 1988). This was paralleled by histochemically- 
observed increases in PAS+ve mucosubstances in the outer mucous cells, 
decrease in RNA in chief cells, and increased periglandular capillary ATPase the 
latter being interpreted as reflecting improved gastric mucosal microcirculation 
(Barbarino et al., 1988). These observations may reflect the actions of
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endogenous zinc-aminoacid complexes from following the oral administration of 
zinc compounds.
Inflammatory Bowel diseases
The role of zinc in inflammatory bowel diseases such as Crohn’s disease and 
ulcerative colitis is not entirely clear. It seems certain that a level of zinc 
depletion occurs with these conditions, but clinical symptoms of zinc deficiency 
appear rare in the studies described below. Additionally, disruption of zinc 
absorption by the diseased gastric mucosa has been proposed to cause the 
deficiency rather than the zinc deficiency being a causative factor in the bowel 
disease (Reviewed Thompson, 1997). As early as 1977, zinc deficiency was 
observed in patients with Crohn’s disease where hair samples contained 
significantly low zinc levels and significantly low plasma zinc correlated directly 
with low plasma albumin levels (Solomons et al., 1977). It had been shown in 
several further studies of inflammatory bowel diseases, such as Crohn’s disease, 
that plasma zinc levels were significantly reduced compared to healthy controls, 
p<0.05, (Sjogren et al., 1988) and colitis, where serum zinc was highly 
significantly reduced compared to healthy controls, p<0.0007 (Fernandez- 
Banarez et al., 1990).
In a study of Crohn’s disease and colitis patients superoxide dismutase (SOD) 
and metallothionein (zinc proteins with involvement in free radical scavenging) 
levels were measured in inflamed and non-inflamed Crohn’s and colitis patients’ 
tWffnal mucosa and compared to control mucosa from colorectal cancer patients 
(Mulder et al., 1991). No difference in SOD levels compared to controls was 
seen in non-inflamed tissue from inflammatory bowel disease patients. However 
there was a significant reduction in SOD compared to controls, p<0.005, in 
inflamed areas of tissue (Mulder et al., 1991). In both inflamed and non-inflamed 
tissue, metallothionein levels were significantly reduced compared to controls, in 
samples from the inflammatory bowel disease patients, p<0.001 and p<0.02 
respectively (Mulder et al., 1991).
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Although zinc uptake and levels in various body compartments appear to be 
altered, records of overt clinical symptoms of zinc deficiency do not seem to 
appear often in the literature for inflammatory bowel disease. One such case 
study describes acrodermatitis enteropathica occurring in conjunction with 
Crohn’s disease whilst on parenteral nutrition, which was subsequently alleviated 
by intravenous zinc supplementation (Myung et al., 1998). However, as 
discussed previously parenteral nutrition alone may be a cause of zinc deficiency. 
Certainly therapy of inflammatory bowel diseases with zinc compounds has not 
been greatly studied in clinical trial, probably for the very fact that the imbalances 
of zinc in the body do not seem to lead to zinc deficiency and other specific 
treatments are available for these disease states (Reviewed Thompson, 1997).
Inflammatory disease - particular reference to rheumatic disease
As previously discussed, several inflammatory mechanisms are zinc dependant, 
due either to zinc atoms integral to the structure of inflammatory mediators, zinc 
ions vital to enzyme function and possibly zinc as an inflammatory mediator itself. 
Thus, it would seem from the physiological role for zinc that a pharmacological 
role for zinc therapy would be indicated for chronic inflammatory diseases, but the 
experimental and clinical literature does not consistently support this idea. One 
such example of this is rheumatoid arthritis, in which the involvement of zinc 
metalloproteins in the degradation of cartilage (Gunther et al., 1994), the high 
cellular infiltration of the synovium by T-cells, macrophage and activation of 
articular chondrocytes and subsequent cytokine induction has been described 
(Bondeson et al., 1999, Gunther et al., 1994). Additionally, in vivo experimental 
data has shown efficacy for zinc for treatment of inflammatory joint models 
(Whitehouse et al., 1990). It should also be noted, that fluctuation of zinc status 
in inflammatory disease, including rheumatoid arthritis, has been documented 
(Svenson et al., 1985, Simkin, 1981). However, clinical evidence for the use of 
zinc therapy for rheumatoid arthritis is at best unclear with few clinical studies 
having been carried out.
In rats, zinc plasma levels are reduced and hepatic metallothionein levels are 
increased in acute experimental inflammatory conditions such as adjuvant (heat 
killed M. tuberculosis) induced arthritis (Rofe et al., 1992). The peak
metallothionein levels corresponding with the lowest plasma zinc concentrations 
at 16 hrs after adjuvant injection and subsequent induction of inflammation. After 
a recovery of both zinc and metallothionein levels to near normal, zinc levels 
subsequently fall and metallothionein concentration increases a second time 
between 8 and 14 days after adjuvant injection (Rofe et al., 1992). Studies of 
patients with inflammatory diseases, especially arthritis, indicate a significant 
reduction for mean patient values of plasma zinc compared to healthy controls, 
p<0.001 (Svenson et al., 1985). This phenomenon has long been recognized 
and as early as 1981, Simkin (1981) reviewed published reports in which serum 
zinc concentrations had been determined in patients with rheumatoid arthritis 
compared with those in control subjects. There was marked geographical 
variation, with the differences in zinc levels between patients with rheumatoid 
arthritis and controls appearing greatest in the data derived from studies in India, 
New Zealand and two locations in southern USA, whereas they were less so in 
data from Glasgow and Omaha, and not significantly different in groups from 
Seattle, Rochester and Parma (Simkin, 1981). In addition, there was no 
consensus on the effect of zinc treatment for rheumatoid arthritis, with some 
studies showing great improvement with supplementation and some showing no 
improvement. It was hypothesised that, when it occurred, the improvement of 
disease parameters was due to a general zinc deficiency as indicated by the 
serum zinc levels (Simkin, 1981). It is difficult to draw definitive conclusions from 
the various studies as differences in zinc measurement and sampling and 
differences in patient profile and the lack of case-matching in some studies, 
provides an area of great variability. However there would seem to be a trend to 
lower serum zinc in patients with rheumatoid arthritis that agrees with more recent 
studies.
Frigo et al. (1989) reported plasma concentrations of zinc determined by atomic 
absorption spectroscopy to be reduced in patients with rheumatoid- but not osteo­
arthritis compared with controls. In addition, the plasma zinc status was found to 
be correlated with duration of illness, number of swollen joints, ESR and a2- 
globulins (Frigo et al. 1989). Urinary elimination of zinc over a 24 hr period was 
not shown to be reduced in patients with rheumatoid arthritis. This was also 
confirmed in later studies (Dore-Duffy et al., 1990).
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Possible differences between the earlier studies, many of which were from assays 
of serum samples compared with those observations in plasma samples, could be 
related to the fact that serum samples are often obtained under variable 
conditions of collection and the red blood cells can serve as a source of zinc 
sequestered during formation of serum. Furthermore, plasma zinc levels 
correlate with albumin (Dore-Duffy et al., 1990) which is the principal ligand for 
zinc in the circulation. Since plasma albumin is often reduced in rheumatoid 
arthritis it is important to establish if the reduction in plasma zinc is related to the 
reduced mass of circulating albumin. Thus, in their carefully-controlled analysis 
of zinc profiles in blood components in patients with rheumatoid compared with 
osteoarthritis, Dore-Duffy and co-workers (1990) showed that the statistically 
significant reduction in both plasma and serum zinc concentrations in the former 
but not the latter patients was also observed in the fraction of albumin binding 
zinc (g Zn albumin/g albumin), as well as in the plasma protein fraction. This 
suggests that either zinc affinity for albumin is somehow reduced in rheumatoid 
arthritis or that zinc levels are lower than a saturation concentration for albumin. 
No such changes were reflected in the patients with osteoarthritis. Furthermore, 
no changes were observed in the zinc concentrations in red blood cells or in white 
blood cells (Dore-Duffy et al., 1990). In contrast to the Dore-Duffy group which 
analysed zinc levels by atomic absorption spectroscopy, Svenson and co-workers 
(1985) utilised X-ray emission nuclear microprobe and, in contrast to Dore-Duffy 
et al. (1990), were able to show marked reductions in zinc concentrations in the 
granulocyte, platelets and erythrocytes of patients with rheumatoid arthritis, 
seronegative spondylo-arthropathies and scleroderma. Thus, the more sensitive 
and specific nuclear microprobe technique probably accounts for the differences 
observed in the studies by Svenson et al. (1985) compared with those from the 
studies by Dore-Duffy et al. (1990). The former authors also confirmed the 
reduction in plasma zinc concentrations in patients with rheumatoid arthritis, again 
using the more sensitive methodology of X-ray fluorescence spectrophotometry. 
Negative correlation of plasma zinc concentrations with disease activity (ESR, 
serum arosomucoid and other biochemical parameters) was again observed 
(Svenson et al. 1985). This feature has been observed by others in serum 
samples in rheumatoid arthritis patients assayed by atomic absorption 
spectroscopy (Mussalo-Rauhamaa et al., 1988) as well as in plasma samples 
from patients with psoriatic arthritis analysed by this technique (Frigo et al., 1989).
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In contrast to the observed reduction in zinc in plasma and blood leukocytes there 
is an apparent increase in zinc concentration in the synovial tissues of patients 
with rheumatoid arthritis (Simkin, 1981). This could be expected from the 
observations that the reduced levels of zinc in serum and plasma are not 
necessarily predictive of zinc deficiency but instead may be indicative of zinc 
redistribution related to the inflammatory disease progression. Furthermore the 
disappearance of zinc from this compartment could be related to a redistribution 
of high zinc bearing cells, especially immune cells, to the inflamed synovium and 
can also be directly correlated with metallothionein induction in the liver (Rofe et 
al., 1992). The role of metallothioneins in inflammation has not been distinctly 
explained, possibly because of the complex induction mechanisms of 
metallothionein which include the metals it binds, zinc and copper (Blalock et al., 
1988), glucocorticoid hormones and cytokines (Hempe et al., 1991), all of which 
are possible components of the inflammatory process itself. It seems clear 
therefore that zinc is involved in mechanisms active during acute inflammatory 
insult, as shown particularly with the adjuvant arthritis studies but also in chronic 
inflammatory states such as rheumatoid arthritis, and further that low plasma and 
serum levels correlate to disease severity.
It is with the background of these observations that zinc therapy for inflammatory 
conditions such as rheumatoid arthritis was investigated.
Simkin (1981) was the first to report studies of zinc supplementation on the 
progress of pctrents with rheumatoid arthritis. It was reasoned that since leg 
ulcers are a manifestation of rheumatoid disease, a trial of oral zinc for this 
complication seemed appropriate after the efficacy of oral zinc sulphate in 
treatment of leg ulcers had been observed in an unrelated study (Serjeant et al., 
1970). Furthermore, the apparent zinc deficiency in this disease was another 
reason to study the effects of zinc treatment. Thus, the study involved observing 
the effects of 250 mg zinc sulphate hepfahydrate (50 mg elemental zinc) in 
capsule form given three times daily with meals for 12 weeks under double-blind 
cross-over (to placebo) in 24 patients. Evaluations included grip strength, time to 
walk 50 ft, sum of points for swelling and tenderness in 68 joints patients' "global" 
assessment of their conditions, severity of morning stiffness, Westergren
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sedimentation rate, and various laboratory parameters determined initially then at 
2 and 4 week intervals. All the clinical parameters improved in the ZnS04 treated 
groups and the mean serum zinc levels rose from 84 pg/dl to 116 pg/dl whilst the 
serum histidine concentration declined from 1.57 to 1.36 mg/dl. Upon cessation 
of therapy most patients qualitatively considered the disease had worsened 
without zinc and improved upon reinstitution of zinc therapy. While no patients 
were cured by zinc supplementation in this study and some did not show any 
beneficial effects at all, there was a number who did see an improvement in the 
disease state when taking zinc.
Despite the reported effects from the Simkin study, subsequent studies have 
shown no beneficial effect for oral supplement zinc in rheumatoid arthritis (Job et 
al., 1980, Rasker and Kardaun, 1982, Mattingly and Mowat, 1982). One study 
appears to have directly repeated the Simpkin study (Menkes et al., 1981). 
Although not published in English and with no translation available, the abstract 
reports a regime of zinc sulphate 600 mg/day split into three doses given to 35 
patients over a period of months which is close to the conditions used by Simkin. 
This study showed no improvement of rheumatoid arthritis in either clinical or 
laboratory indices.
Although the efficacy of zinc as a specific treatment for inflammatory conditions 
was shown in gastric lesions and external ulcer and wounding, it seems that for 
internal inflammatory diseases, zinc is generally not effective in reducing 
symptoms other than to return plasma and serum zinc levels to normal. It could 
be argued that this is expected to happen as ingestion and excretion of zinc is 
tightly regulated as previously discussed. Therefore pharmacological doses of 
zinc taken orally do not result in greater than normal plasma or serum levels of 
zinc. Consequently localised areas of inflammation at organs or joints do not 
receive the high concentrations of zinc that are seen to be present at external 
wounds or ulcers treated with topical zinc. Even zinc concentrations in the 
gastrointestinal tract after swallowing a pharmacological dose of zinc would be 
generally much higher than normal, with dilution gradually occurring with passage 
of the bolus through the gut. This could explain the disparity between the positive 
clinical effects of zinc in inflammatory conditions such as peptic ulcer and 
epidermal lesion and the lack of effect of zinc treatment in ‘internal’ inflammatory
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conditions such as rheumatoid arthritis. This would suggest that if local zinc 
levels at inflamed joints for example, could be increased to above normal 
concentration, then the therapeutic properties of zinc could be seen, but zinc salts 
are water soluble and the skin acts as a very effective barrier to them. Topically- 
applied drugs have the additional advantage in reducing the burden of toxic 
effects on the gastrointestinal tract, as might happen if taken orally, or on 
metabolism by the liver. Furthermore, topical application of drugs has the 
advantage in being a controllable means of drug delivery and this is particularly 
the case for lipophilic metal complexes (Fairlie and Whitehouse, 1991). Fairlie 
and Whitehouse (1991) have considered the theoretical and practical issues of a 
number of metal complexes applied in transdermal systems in animal model 
systems and achieved significant success with ZMG. In fact, a search of the 
literature reveals no other studies into the efficacy of topically applied zinc in 
models of arthritis.
ZMG, when applied to the skin has been found effective in controlling polyarthritis 
in rodent models of arthritis. The preparation, physical properties and crystalline 
morphology of ZMG have been previously described (Whitehouse et al., 1990, 
Hambley and Snow, 1983, Radoslovich et al., 1970). This lipophilic, highly 
lubricious, polymeric slow-releasing zinc complex has been found to be highly 
effective when applied topically or subcutaneously in, e.g. DMSO/glycerol 
mixtures, or rubbed on the skin as the powder in the therapeutic or prophylactic 
models of treatment for controlling fore- and hind-paw swelling of adjuvant- 
polyarthritic rats (Fairlie et al., 1992). Topically applied ZMG was found to be 
non-irritant to the skin and indeed when administered subcutaneously (in 
DMSO/glycerol) does not elicit inflammatory responses even though there is a 
localised encapsulation at the injection site (Fairlie et al., 1992). When injected 
subcutaneously in the polyarthritic rat model, ZMG dispersed in saline acted dose 
dependently to reduce hind- and fore-paw inflammation which reappeared after 
cessation of the treatment. ZMG was ineffective in controlling this chronic 
inflammatory disease model when given orally and also in carrageenan induced 
rat paw oedema models of acute inflammation when injected subcutaneously 
(Fairlie et al., 1992).
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The latter observation may seem contradictory to other studies in which 
intraperitoneal zinc chloride (in saline) has been found to reduce the 
carrageenan-induced pleurisy in rats as evidenced by reduction in pleural 
exudation and neutrophil accumulation (Yatsuyanagi et al., 1987). In contrast, 
the lack of effect of ZMG on the hind-paw inflammation induced by carrageenan 
(Fairlie et al., 1992) may be due to insufficient zinc ions reaching the inflamed site 
in the short time period of 1-3hrs used. In the studies by Yatsuyanagi et al. 
(1987) the injection of zinc into the peritoneal cavity would presumably have 
enabled this ion to move rapidly into the pleural cavity where the inflammation 
was induced. This twin-compartment model of inflammation, separated by the 
well vascularized smooth muscle of the diaphragm, is a useful means of 
examining the direct functions of zinc, and indeed other agents, in vivo without the 
confounding problem of the putative anti-inflammatory agent coming into direct 
contact with the inflammogen. Other investigations by Yatsuyanagi et al. (1987) 
showed that i.p. zinc chloride (16.4mg Zn/kg) markedly reduced neutrophil 
chemotaxis, phagocytosis and superoxide production in the pleural inflammation 
model in vivo; these effects being corroborated from studies in vitro in which these 
neutrophil (rat) responses where shown to be significantly inhibited by 100-300pM 
zinc (Yatsuyanagi et al., 1987). Thus control of both the vascular permeability 
and neutrophil accumulation/activation by zinc may account in part for the acute 
anti-inflammatory properties of this metal ion.
Zinc and liver disease
Zinc deficiency has long been linked to liver disease, as long ago as 1956 
hypozincaemia was described, by Valee et al., (1956) in patients with alcoholic 
hepatic cirrhosis (Valee et al., 1956). Subsequently it has been shown that the 
observed hypozincaemia is not dependant on cause of cirrhosis with hepatitis B 
patients also displaying reduced serum zinc in addition to increased urinary zinc 
(zinc excretion) (Gusau et al., 1990). In addition to this, the course of 
experimental liver disease in rats has been shown to affect (Khan and Ozeran, 
1957) and be affected by (Anttinen et al., 1984) zinc status. Both observations 
are mutually compatible and led to studies about the effect of zinc
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supplementation on both liver tissue and serum zinc status in liver disease 
patients and also of the effect of the supplementation on disease state.
Zinc has been implicated in the modulation of hepatic nitrogen metabolism with an 
inverse relationship between serum zinc and ammonia being observed in cirrhotic 
patients (Grungreiff et al., 1988). Investigations using experimental liver damage 
in rats have reinforced this observation, with zinc supplementation reducing the 
plasma ammonia levels to near normal in cirrhotic rats when compared to healthy 
animals (Riggio et al., 1992). This was accompanied by an increase in the mean 
ornithine transcarbamylase (OTC) concentration of the livers of cirrhotic animals 
that had been treated with zinc compared to untreated cirrhotic animals (Riggio et 
al., 1992). OTC is a component of the body’s ammonia detoxification process 
and improvement of this aspect of liver disease may indicate a role for zinc 
treatment cirrhosis.
Studies of zinc levels, zinc supplementation and liver diseases have indicated 
more general aspects of the disease that are affected. Collagen accumulation 
may occur in areas of tissue inflammation and the carbon tetrachloride (CCL) 
model of liver damage in rats displays such accumulation (Anttinen et al., 1984). 
In this study, oral zinc supplementation inhibited CCL-induced collagen 
accumulation, although this was not disease or tissue specific as collagen levels 
were also lower in liver and skin of healthy animals given zinc (Anttinen et al., 
1984).
Zinc has also been shown to be involved in apoptosis (programmed cell death) in 
liver tissue and cultured liver cells to varying effects. In vivo studies using the 
CCL induced rat liver damage model have shown that a zinc supplemented diet 
produces an inhibition of DNA fragmentation (an accepted measure of apoptosis) 
which was proportional to the amount of zinc in the tissue, when compared to 
diseased controls (Cabre et al., 1999). However it should be noted that various 
studies from another laboratory using in vitro culture of human hepatoma cell line 
HuH-7, have indicated that zinc induction of the c-myc gene leads to cell death 
(Xu et al., 1996). This cell death appears apoptotic under light, fluorescent and 
electron microscopic observation, but does not have the characteristic DNA 
fragmentation normally displayed during apoptosis (Xu et al., 1996). The cell
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death resulting from zinc induction of c-myc also appeared to be related to 
increased intracellular hydrogen peroxide (H20 2) levels and reduced intracellular 
glutathione (a free radical scavenger) levels (Xu et al., 1997).
It would seem that zinc therapy could be effective in liver disease, in preventing 
liver tissue damage and liver cell apoptosis, and it seems certain that 
maintenance of normal zinc levels would be beneficial. However further 
research, both clinical and experimental, needs to be carried out to determine the 
therapeutic actions of zinc in this disease state.
Zinc and Bacterial Infection
The effects of zinc on infection have been discussed previously with
antibacterial activity being seen for certain zinc compounds, however zinc therapy 
has been studied for a number of other bacterial infections.
Studies on the effect of zinc and bacterial infections appear to divide generally 
into several distinct groups, the effect of bacterial infection on zinc metabolism, 
the effect of zinc administration on bacterial infection, the effect of zinc on oral 
bacteria (especially in studies on dental protection) and the effect of zinc on 
wound infection, this last being dealt with in a separate section discussing zinc 
and wound healing.
The effect of bacterial infection on circulating zinc levels is to reduce the 
concentration in either plasma or serum as indicated in both animal (Tufft et al., 
1988, Erskine and Bartlett, 1993, Barton and Embury, 1987) and human (Heese 
et al., 1985, Taneja, 1990, Ray et al., 1998) studies. As the zinc levels are 
reduced it appears that the zinc is being redistributed around the body with 
corresponding increases in splenic and hepatic zinc levels after infection, as 
indicated in at least one poultry study (Tufft et al., 1988) but which is consistent 
with many studies of serum zinc in disease states some of which have been 
discussed previously (Svenson et al., 1985). A two year randomized, double­
blind, placebo controlled trial investigating the effect of mineral (zinc and 
selenium) and vitamin supplementation on incidence of respiratory and urogenital 
infection in institutionalized elderly individuals was carried out (Johnson and
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Porter, 1997). A significant reduction in mean number of infections was seen in 
those receiving the minerals (p<0.01) but no significant reduction was observed 
as a result of the vitamin supplementation (Johnson and Porter, 1997). The 
amount of supplements administered was less than twice the recommended daily 
allowance (RDA). This means that the results show the effect of maintaining 
normal body levels of zinc and selenium rather than showing a pharmacological 
effect. Nonetheless, as it is increasingly apparent that modern diets lead to low 
grade mineral deficiencies (Sullivan and Cousins, 1997) and taking into account 
that selenium is required in very minute amounts compared to zinc, it maybe 
understood, from the Johnson and Porter (1997) study, that zinc supplementation 
has an important prophylactic effect for prevention of infections.
More specifically, there are two areas in particular where zinc has been used as 
an antibacterial agent, dental hygiene and prevention of wound infection. Zinc- 
acetate containing preparations have been shown to be effective in inhibiting oral 
bacterial plaque accretion and gingivitis when compared to untreated controls 
(Hefti and Huber, 1987). Zinc preparations generally appear to be simple salts, 
either sulphate or citrate, which are administered in conjunction with mainly 
triclosan, although some research was carried out on plant extracts of 
sanguinaria, a folk remedy containing benzophenanthridine alkaloids. Zinc and 
triclosan mouthwash preparations have been shown to reduce gingivitis 
(Schaeken et al., 1996) and in a double blind parallel group study of 544 
individuals, to reduce the formation of dental calculus (Fairbrother et al., 1997). 
Furthermore the zinc and triclosan preparations have been shown to have 
additive effects on plaque growth inhibition (Cummins, 1991) which may be due to 
the anti bacterial effects of both agents but also to the effect of zinc on triclosan 
clearance. In one study, varying the concentrations of either zinc or triclosan to 
optimize the formulation increased the retention of both agents in the plaque 
(Creeth et al., 1993). This would directly increase antiplaque and antibacterial 
activity over time, zinc levels in particular increased by up to seven fold over 
controls (Creeth et al., 1993).
Other than the zinc triclosan combination, zinc and sanguinaria have been 
investigated as possible co-candidates for oral hygiene products. Whilst several 
studies were carried out in the late 1980s and early 1990s, little work appears to
have been published recently on this preparation. In fact, whilst a review of the 
preparation in 1995 indicated that co-use of zinc and sanguinaria mouthwash and 
toothpastes is widespread in Europe and America (Grenby, 1995). The most 
recent publication looking at its clinical effectiveness indicated that after thorough 
dental cleansing, post use of a sanguinaria/zinc chloride mouthwash gave no 
significant protection against bacterial plaque reoccurrence or gingival bleeding 
(Cullinan etal., 1997).
A potentially interesting action of zinc has also been reported for zinc in dental 
hygiene use and that is the protective action of zinc on the gums which are 
exposed to the irritant sodium lauryl sulphate (sodium dodecyl sulphate) a 
component of many toothpastes (Skaare et al., 1997). However, only this study 
appears to have been published on the subject.
Whilst many studies have been carried out on the antibacterial action of zinc in 
toothpaste others exist that examine the antibacterial action of zinc in other 
hygiene products. It would seem that zinc has antibacterial properties but is most 
effective in combination with a second antibacterial compound. This is another 
area where the novel zinc compounds have not been examined where they may 
prove more effective than the commonly used zinc salts.
Zinc and skin lesions (burns, ulcers and incisions)
It is as a topical treatment for wounds that zinc paste has been used for millennia, 
for example, in calamine paste used during the Egyptian Empire (Lancet editorial, 
1975). The application of topical zinc either in compound preparation or in 
impregnated bandage is still used particularly for burns (Hallmans, 1978) and 
venous ulcer (Mayrovitz et al., 1998) and has been shown effective in incision 
wound healing (Agren et al., 1991b). Certainly endogenous zinc has an integral 
role in epidermal wound healing with zinc concentrations increased at the site of 
an incision wound (Iwata et al., 1999), burn (Berger et al., 1992) and venous ulcer 
(Ackerman et al., 1990) as a result of the lesion itself.
The zinc loss directly from burnt areas has been measured in humans by 
determining the zinc concentration of the burn exudate obtained from the textile
dressing which, in one study of ten people, averaged 14.4mg per day (Berger et 
al., 1992). This loss compares in magnitude with the 15mg zinc required as the 
average daily dietary intake (Vallee and Falchuk, 1994) suggesting that this is a 
major route for zinc loss in burns. In a study of lower limb venous ulcer, zinc 
concentration was found to be raised at the site of ulcer compared to healthy 
tissue in the same leg and also the unaffected leg (p>0.05) (Ackerman et al., 
1990). However the same study indicated significantly raised zinc concentration 
in skin from the arms of the leg ulcer patients when compared to that from the 
arms of the control group (Ackerman et al., 1990). Whilst the first observation 
indicates an accumulation of zinc to the wound site, authors suggest that the 
second observation indicates an imbalance of general zinc distribution in the leg 
ulcer patients (Ackerman et al., 1990). In vivo studies of wound healing in mice 
have shown that zinc localisation and accumulation was an early stage event in 
the healing mechanism of incision wounds and was associated with an increase in 
wound metallothionein concentration which occurred immediately prior to the 
increase in zinc (Iwata et al., 1999). So it is apparent that in all these epidermal 
lesion states zinc may be localised to the wound site in greater than usual 
concentration and that, whilst some of this increase may be due to increased fluid 
loss at the wound site of the epidermis, much of it is localised to the tissue and so 
may be a function of the wound healing process.
Reinforcing this idea, nutritional zinc status has been suggested to affect wound 
healing rates in all three types of epidermal lesion with low serum zinc levels 
observed in a number of studies of venous ulcer (Wissing et al., 1997, Rojas 
1999, Cruse et al., 2000). Similar observations of low serum zinc is observed 
with burns patients especially receiving TPN where zinc excretion is raised and 
the normal uptake of zinc through the gastric system is bypassed by intravenous 
drip (Cunningham et al., 1991). In vivo studies using rodent models of post- 
surgery wound repair, in which animals receive TPN, have further indicated the 
importance of zinc supplementation for improved wound zinc concentration and 
concomitant increase in wound strength (Nezu et al., 1999). These studies 
indicate that zinc supplementation is beneficial both for general nutritional 
reasons alone and also for improvement of the wound lesions. It should be noted 
however that in at least one study looking specifically at burns patients, 
intravenous administration of large doses of trace elements, including two and a
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half times the RDA of zinc, reduced hospitalisation time but had no effect on 
wound severity. It thus appeared to indicate improvement of general well being 
but had no special effect on the specific healing process (Berger et al., 1994). 
This study however used a large dose of copper as part of this supplementation 
and this might have affected zinc uptake into cells altering normal processing of 
zinc. So it seems that a normal level of zinc intake may improve healing rate and 
wound strength and that low body levels of zinc may be a cause of delayed 
healing.
Direct topical application of zinc to incision wounds has been shown to promote 
wound healing in several studies when applied for example as zinc oxide, in vivo 
(Kietzmann, 1999, Agren et al., 1991b) and on human patients as zinc chloride 
spray (Pastorfide et al., 1989). In regular practice, compression bandages 
impregnated with zinc oxide, Unna’s sleeves, are used to treat venous leg ulcers 
and as a supplement to other venous ulcer therapies (McCulloch et al., 1994). 
Additionally, burns requiring graft are often treated with Unna’s paste or graft 
surgery followed by application of an Unna sleeve which aids wound repair and 
improves graft take (Grube et al., 1992).
The action of zinc at the cellular level is complex during the tissue remodelling 
and re-epithelialisation activity of wound repair. In vivo studies showed that 
application of zinc oxide but not zinc sulphate increased re-epithelialisation 
significantly more than controls (p<0.05) in a porcine model of partial thickness 
wounds (Agren et al., 1991a). This exogenous zinc may act at many levels of the 
repair process. Studies in mice have indicated that metallothionein mRNA is 
expressed within 12hrs in the proliferating region of the epidermis surrounding the 
wound and that this is followed by an increase of the zinc content of the wound 
(Iwata et al., 1999). The endogenous zinc absorbed by the epidermal cells within 
the lesion may well act as a source of zinc for the newly formed metalloprotein, 
which itself acts as a storage or sink for zinc exchange with other metalloproteins 
such as zinc finger transcription factors (Kruse-Jarres, 1997). Recently, Huang 
et al. (1999) showed in vitro that endogenous zinc and high concentrations of 
calcium, such as those found in the dermal layer of the skin, act synergistically to 
promote DNA synthesis in fibroblasts (Huang et al., 1999). Studies on
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keratinocytes, the main cells comprising the epidermis, have implicated zinc in a 
rather complex involvement in the mechanisms of wound healing, both alone 
(Tenaud et al., 1999) but also as an active component of various molecules such 
as the matrix metalloproteinase (MMP) enzymes (Pilcher et al., 1997). In vitro, 
zinc gluconate induced the expression of a2, a3, aV and a6 integrins, external 
cellular adhesion proteins responsible for cellular migration and proliferation in 
wound healing (Tenaud et al., 1999). As an integral component of the enzyme 
MMP-1, zinc is vital for another aspect of keratinocyte migration, in this case 
through collagen-i the main structural molecule of the extracellular matrix in the 
dermis (Pilcher et al., 1997). On contact with collagen the keratinocyte is 
induced to produce MMP-1 (Sudbeck et al., 1994), this may occur through 
interaction of the collagen with the a2 integrin (Pilcher et al., 1997). Then after 
synthesis and secretion the MMP-1 cleaves the collagen and the cells are able to 
migrate through the matrix (Pilcher et al., 1997). This mechanism is a good 
example of one in which zinc both modulates and participates leading to possible 
cell progression to the wound site.
In summary, these studies collectively indicate that clinical application of zinc is 
positively therapeutic for dermal incision, burn and ulcer lesions and that at the 
cellular level, exogenous zinc may exert a direct modulatory effect on some 
aspects of cellular motility integral to wound healing. It should be noted that in 
most medical studies, zinc oxide alone was used as a zinc source, none of the 
newer zinc compounds such as ZMG, polarprezinc or zinc acexamate appear to 
have been studied or tested clinically for possible usage in wound healing.
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Zinc immunology
Zinc is involved at almost every level of the immune system however its precise 
role has only begun to be elucidated in the last ten years. Barnes and Moynahan 
(1973) first described genetic zinc deficiency and subsequent investigation of this 
disease indicated that patients displayed immune dysfunction. Immune 
symptoms of zinc deficiency related to T-cell function alone include thymic 
atrophy, alteration in lymphocyte subpopulations, and reduced proliferation and 
differentiation of immature T-cells, reduced thymulin production and reduced 
mitogen responsiveness (Reviewed Fabris, 1997). These symptoms of 
deficiency indicate the importance of zinc to healthy immune function and in fact 
zinc has a very wide role in the function and immune response of other cell types 
such as macrophage, neutrophils and natural killer cells however it is beyond the 
scope of this chapter to discuss all of these. Instead, only aspects of zinc 
modulation of immune cells will be discussed, which relate to the studies in this 
thesis. These include zinc modulation of T-cell maturation and function, 
modulation of macrophage function, effect of zinc on cytokine production and on 
apoptosis.
Zinc modulation of cytokine levels in vivo
Studies of cytokine modulation in vitro, specifically by zinc, have only relatively 
recently been carried out mainly by two or three groups, and so the subject is still 
very much under examination. Analysis of cytokine levels in patients and healthy 
volunteers has been examined more widely. However, in inflammatory and 
immune disease states it may be more difficult to attribute cytokine modulation to 
variations in zinc levels as the diseases tend to involve other factors that may 
affect cytokine production. Marginal zinc deficiency has been shown to be very 
prevalent, as previously discussed, and is also often found in head and neck 
cancer patients (Prasad et al., 1997). In this study Prasad et al. (1997) observed 
cytokine production in three groups, head and neck cancer patient, healthy 
volunteers with mild zinc deficiency and in healthy volunteers with adequate zinc 
levels. The healthy and zinc replete groups had zinc deficiency induced by
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dietary restriction. All groups then received dietary zinc supplementation and the 
cytokine levels were measured again. It was shown that the cytokines secreted 
by TH1 helper T- cells, IL-2 and interferon gamma (IFN-y) were sensitive to zinc 
status and reduced in concentration. In the cancer patients and zinc deficient 
healthy volunteers IL-2 was significantly lower than zinc replete healthy controls, 
p=0.003 and p=0.023 respectively. IFN-y production by PBM cells was found to 
be significantly reduced in zinc deplete healthy volunteers compared to zinc 
replete volunteers, p=0.05. TNF-a and IL-1 p were found to be significantly lower 
in zinc deplete individuals compared to healthy controls, respectively p=0.0001 
and p=0.0056 for cancer patients and p=0.005 and p=0.037 for healthy zinc 
deplete volunteers. The TH2 T-cell cytokines, IL-4, IL-5 and IL-6 appeared 
unaffected by marginal zinc deficiency (Prasad et al., 1997).
In a study of cytokine production from PBM cells from chronic liver disease 
patients the effect of zinc supplementation was observed (Reinhold et al., 1996). 
The investigation was carried out in light of the fact that chronic liver disease 
often gives rise to immune dysfunction, indicated by abnormal circulating cytokine 
levels, and also to reduced serum zinc levels. The effect of zinc supplementation 
was observed in cytokine production of isolated PBM cells after mitogen 
stimulation. At 0.1 mM no effect was seen on cytokine production however at 
0.2mM there was a significant decrease in IL-2, IL-6 and IL-10 production 
compared to controls without zinc (p<0.05 in each case) (Reinhold et al., 1996). 
Although a high zinc concentration, 0.2mM was well below the toxic limit in this 
study where cell viability was shown by trypan blue stain and MTT assay to be 
greater than 90% up to 0.4mM zinc (Reinhold et al., 1996).
In overdose zinc has been shown to affect cytokine levels. Zinc oxide fume 
inhalation which may lead to metal fume fever in high enough dose and which is 
common in welders, was experimentally induced in volunteers (Kuschner et al., 
1997). Level of cytokines were measured in exudate obtained from 
bronchioalveolar lavage before and, over a period of time, after zinc oxide 
inhalation. TNF-a, IL-6 and IL-8 were shown to be increased significantly 
(p=0.02, 0.009 and 0.02 respectively). The TNF-a response occurred before the
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other increases at 3 hrs and ail cytokine changes were dose related to zinc 
concentration inhaled.
It is clear therefore that evidence exists of a role for zinc in the modulation of 
cytokine levels and that supplementation with zinc may in some cases return the 
cytokine levels to normal. Additionally, cytokine levels are altered specifically by 
zinc in overdose. Further studies have investigated the functions of zinc in 
cytokine modulation in vitro.
Zinc modulation o f  cytokine levels in vitro
In vitro studies using enzyme linked immunoassay (ELISA) or whole cell assays 
have allowed the investigation of zinc modulation of cytokines at the cellular level. 
Human peripheral blood leukocytes incubated in whole medium (culture medium 
with foetal calf serum and growth supplements) zinc was shown to stimulate TNF 
and IL-1 p in a concentration dependent manner (Scuderi, 1990). Addition of 
lipopolysaccharide (LPS, a bacterial surface protein), along with zinc, to the cell 
medium, caused a synergistic and concentration dependant increase in TNF 
release (Scuderi, 1990). The action of zinc with LPS is interesting in that LPS 
may be used to induce both inflammation and immune response in vivo. The 
synergistic activity of zinc and LPS was the subject of a later study by one group 
in Germany, who additionally have done most of the work on zinc and cytokine 
stimulation in vitro (Wellinghausen et al., 1996a). They showed that zinc is able 
to potentiate TNF-a and IL-1 p release from PBM cells stimulated with LPS from 
different bacterial sources and that this ability was specific to zinc and not similar 
cations such as cobalt and nickel (Wellinghausen et al., 1996a). Additionally, the 
study indicated that the synergy was a specific action of zinc on the LPS and not 
as a result of action on the target cells. It was shown that zinc altered the 
structural state of the LPS making the structure more fluid when zinc-bound and 
that this enhanced the cytokine stimulation abilities of the LPS molecule 
(Wellinghausen et al., 1996a). The same group showed that zinc stimulation of 
cytokine release in vitro was dose dependent on protein concentration of the 
culture medium. Although zinc alone in LPS and protein free medium stimulated 
IL-1 p release from PBM cells it was shown that proteins such as transferrin and
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albumin greatly potentiated this action in a dose dependant manner although 
maximal cytokine release appeared to be independent of protein type (Driessen et 
al., 1995). From previous discussion of zinc uptake it may be remembered that 
both albumin and transferrin are major transport molecules of zinc. Therefor*, it 
may be that the increased cytokine release seen in this study was due to an 
action of the increased bioavailable zinc bound to the transport proteins and not 
to any action of the proteins themselves (Driessen et al., 1995). The same study 
showed an increase in IFN-y by PBM cells incubated with zinc and also a 
decrease in superantigen induced cytokine production when in the presence of 
zinc (Driessen et al., 1995). It should be noted however that no statistics are 
presented in this study so, although the values appear dramatically different 
between cytokine stimulation by zinc alone and zinc plus protein supplement, 
there is no measure of validity for the results and so they should be accepted with 
caution.
Control pathways for zinc modulation of cytokine stimulation
The mechanism by which zinc alters cytokine levels has not been completely 
described. A number of possible points of control have been described. 
Continuing the studies on modulation of cytokines by zinc, Wellinghausen et al. 
(1996b) showed that zinc added to PBM cell preparations, in serum free and LPS 
free medium, led to an increase in expression of TNF-a and IL-1 p mRNA 
(Wellinghausen et al., 1996b). Interestingly, they reported that IL-1 p mRNA was 
induced by zinc but also by the related cations cobalt, nickel and mercury whilst 
TNF-a mRNA was induced only by zinc (Wellinghausen et al., 1996b). These 
results agreed in part with the earlier study by Scuderi (1990) who also reported 
an increase in TNF mRNA when cells were incubated with zinc in endotoxin 
(including LPS) free culture medium.
The same group further published a report describing the inhibition of zinc 
induced cytokine stimulation by inhibitors of cellular signal transduction 
(Wellinghausen et al., 1996c). Herbimycin A, an inhibitor of the signal 
messenger protein tyrosine kinases, significantly inhibited the secretion of IL-1 
(p=0.005) as did HA 1004, an inhibitor of cAMP and cGMP, also signal
71
messenger (p=0.005) (Wellinghausen et al., 1996c). The authors do not specify 
at what level or manner zinc participates other than it may act synergistically with 
these second messengers of cellular signal transduction. Within the literature 
there appears to be no other studies published on the effect of zinc on the signal 
transduction system during cytokine production so the subject is still very much 
open to investigation.
Whilst a putative link between zinc stimulation of tyrosine kinases, cAMP and 
cGMP may exist, there are more widely studied possible mechanisms for 
intervention by zinc. Zinc, as a constituent of polymerases or zinc finger 
molecules, is vital for transcription of any DNA sequence to RNA and subsequent 
upregulation of release of the final protein however it is beyond the scope of this 
thesis to examine all such zinc finger molecules. Instead, a transcription factor, 
nuclear factor kappa B (NF-kB), common to control of several cytokines, immune 
molecules and inflammatory mediators, will be discussed as it is involved in rapid 
modulation of cytokine production with particular relevance to TNF- production 
(Reviewed Chen et al., 1999). NF-kB and TNF participate in a rather 
complicated control mechanism whereby the nuclear factor is integral to, although 
not solely responsible for, TNF gene transcription (Bergmann et al., 1998, 
Swantek et al., 1999). Conversely, the cytokine can downregulate NF-kB activity 
by inhibiting its release from IkB a control molecule to which it binds in its inactive 
form (Ghosh and Baltimore, 1990). The cytokine modulation of NF-kB may 
occur, in part, via a cytokine responsive kinase IKK (IkB Kinase), that 
phosphorylates IkB thus allowing its degradation and therefor*release of NF-kB 
(DiDonato et al., 1997). The transcription factor is then released to travel from 
cytoplasm to nucleus where it may bind DNA and promote transcription.
Whilst zinc, in the form of zinc finger-bearing signal transduction molecules, 
metalloenzymes, transport molecules or transcription factors other than NF-kB, is 
integral to cytokine production NF-kB links many of the inflammatory molecules 
that are controlled by endogenous administration of zinc. Thus investigation of 
zinc modulation of NF-kB was one of the aims of this thesis. In this regard NF-kB 
is examined further in the Discussion Chapter.
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Zinc and T-cell development and function
Of all cells involved in immune function, T-cells appear most intricately involved 
with zinc, development and maturation of these cells are in fact dependant on zinc 
whilst the T-cell related organ, the thymus relies on adequate zinc levels for 
healthy structure and function.
Zinc has been described as the simplest mitogen; it induces blast cell formation 
and immune cell growth including pre T-cells. T-cells derive from bone marrow 
pluripotent stem cells that mature to lymphoid progenitor cells, which migrate to 
the thymus. The preT-cells then mature in the thymus under control of thymic 
hormones and surface markers are changed as the T-cell differentiate to either 
cytotoxic, helper or supressor T-cell which is then released to circulate until 
required for host defence. The surface markers or surface antigen are 
membrane proteins that both distinguish the type of T-cell and allow its function 
as the particular T-cell subtype. In lymphocytes isolated from zinc deficient 
individuals and compared to those from zinc sufficient individuals, a clear 
difference has been shown in these proteins (Prasad et al., 1997). In this study it 
was shown that zinc deficiency led to a significant reduction in the numbers of 
immature helper T-cells, designated by surface antigen as CD4+ CD45RA+ cells, 
as compared to mature cells of this type CD4+ CD45RO+ cells (p=0.021) (Prasad 
et al., 1997). These helper T-cells are vital to the function of CD8+ T-cells which 
are involved in immune defence from viral attack. The ratio of CD4+/CD8+ was 
seen to decrease and the authors suggest that this was due to the decreased 
numbers of immature CD4+CD45RA+ cells.
There was also a significant decrease seen in the numbers of the CD8+ subset 
CD8+ CD73+ CD11b- cells from zinc deficient patients compared to those from 
zinc sufficient individuals (p=0.0001) (Prasad et al., 1997). This subclass are 
precursors to the cytotoxic T-cells involved in combating viral attack and so it may 
be seen, between maintaining helper T-cell numbers and function and numbers of 
cytotoxic T-cells, that zinc plays an integral role in healthy T-cell mediated host 
defence.
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In partial agreement with these results Oksel and Taneli (1996) looked at T-cell 
levels in children with and without upper respiratory tract infection and in which 
the zinc deficient infected patients received zinc supplement. They showed that 
zinc deficiency in these patients caused a significant decrease (p<0.013) in the 
CD4+/CD8+ ratio but that this was due to an increase in the CD8+ T-cell numbers 
rather than a decrease in any of the CD4+ subsets (Oksel and Taneli, 1996). 
Certainly though, in both cases, zinc supplementation normalised the altered T- 
cell subset levels.
Zinc and T-cell maturation
Changes in plasma zinc levels affect thymic hormone levels such as thymulin, a 
hormone that controls T-cell maturation and which binds one zinc atom per 
molecule (Reviewed Fabris, 1997). Either illness related or artificially induced 
zinc deficiency causes a decrease in active thymulin in humans and animals 
(Brignola et al., 1993, Mocchegiani et al., 1998). Thymulin is required to bind 
zinc in its active form and disease related increase in molecules with high affinity 
for zinc, such as a2 macroglobulin, can compete for zinc binding, thus causing a 
decrease in active thymulin and consequently impairment of immune response 
(Mocchegiani et al., 1999). The authors suggest here that zinc supplementation 
in, for example, cervical carcinoma patients where zinc may be bound by 
increased high affinity zinc binding molecules such as a2 macroglobulin, may 
restore immune activity (Mocchegiani et al., 1999).
Again, as with the cytokine modulation via NF-kB, zinc is involved in a complex 
control mechanism related to T-cell maturation. As has been previously 
mentioned, zinc can modulate IL-1 production and it can stimulate metallothionein 
production via the metal responsive element on the metallothionein gene. In 
thymic epithelial cells IL-1 has been shown to regulate secretion of the zinc 
thymulin complex and additionally, in conjunction with free zinc, to induce 
metallothionein production in this cell line (Coto et al., 1992). It is thought that 
metallothionein is the donor that transfers zinc to the inactive thymulin molecule 
(Savino et al., 1984). So zinc can upregulate IL-1 production that, along with zinc 
can upregulate metallothionein synthesis, promote formation of the zinc thymulin 
complex and therefor&promote T-cell maturation. Coto et al. (1992) also show
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that IL-1 and zinc thymulin, but not IL-1 alone, greatly stimulate protein kinase C 
(PKC) activity. PKC is a second messenger in the cellular signalling cascade 
that leads to IL-2 production and IL-2 is a strong promoter of T-cell proliferation. 
Zinc thereforcappears to be exquisitely bound up with the thymulin based control 
of T-cell maturation.
As was mentioned earlier, zinc status appears to significantly effect IL-2 levels, 
possibly dependant on zinc concentration, zinc lowers IL-2 secretion in both 
deficiency or in high concentration (Prasad et al., 1997, Beck et al., 1997, 
Reinhold et al., 1996). Zinc has also been shown to increase IL-2 receptor (IL- 
2r) synthesis in a dose dependant manner (Driessen et al., 1994). IL-2 is the main 
proliferative stimulus on T-cells at all points in the life time of the immune cell and 
as such, modulation of the cytokine and its receptor would appear to be a highly 
significant control point for zinc on T-cell activity.
There are several zinc finger molecules that are vital specifically to the T-cell 
maturation events, however as zinc finger control in general is not specific to T- 
cell maturation it is not discussed here in detail. Mutations of the 6EF1 gene 
have been shown to specifically and drastically reduce the numbers of mature T- 
cells in a murine model (Higashi et al., 1997). 6EF1 is a transcription factor with 
two zinc fingers and a homeodomain, mutation of the gene causes the thymus, 
medulla and cortex to develop poorly and whilst drastically altering the profile of 
mature T-cells, the mutation has no effect on other cells of the haematopoietic 
lineage (Higashi et al., 1997). Another nuclear transcription factor vital to the 
development of the T-cell lineage, as well as other lymphoid cell types, is the 
early growth response-1 gene product (Egr-1) (Shao et al., 1997). Egr-1, and 
possibly the other members of the Egr family, is involved with the maturation of T- 
cells from the double negative CD4-/CD8- cells to the double positive CD4+/CD8+ 
more mature cells (Miyazaki, 1997). 6EF1 and Egr-1 are examples of just some of 
the many zinc finger transcription factors required for T-cell maturation.
Zinc is also vital to the signalling mechanisms that allow the T-cell to function as 
well as mature. Light chain kinase (Lck, also called p56,ck) is a T-cell specific 
cytoplasmic kinase that is anchored to the inner membrane of the cell (Pernelle et
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al., 1991). Lck is stimulated to autophosphorylation by micromolar amounts of 
zinc and is involved in T-cell activation (Pernelle et al., 1991). As previously 
mentioned, CD4 and CD8 are cell surface markers for T-cells and are required for 
recognition of target cells by the T-cell, binding of Lck to CD4 or CD8 is necessary 
for their function (Lin et al., 1998). Zinc, but not calcium, nickel, iron or copper is 
essential for binding of Lck to CD4 and CD8a (Lin et al., 1998). In CD4 at least, 
binding of the zinc ion has been shown to be co-ordinated by thiol binding of the 
ion by cysteine residues on the cytoplasmic tail of CD4 and the N-terminal region 
of Lck (Huse et al., 1998). Addition of zinc chelators in isolated binding reactions 
disrupts the CD4/Lck or CD8/Lck complexes (Huse et al., 1998, Lin et al., 1998). 
The same was also shown to be true for these same complexes in cells pre­
treated with the chelators (Lin et al., 1998).
In summary, the maturation, proliferation and direct immune function of the T-cell 
lineage is intimately linked to the zinc ion and by extension, general zinc status. 
In light of these relatively recently understood roles for endogenous zinc in T-cell 
activity, examination of the actions of exogenous zinc is an important area for 
research.
Zinc and cells of the monocyte/macrophage lineage
Whilst these cell types are not as intimately bound with zinc for development and 
function as T-cells are, zinc still plays an important role in immune activity 
associated with these lines. Cells of the monocyte/macrophage lineage and 
neutrophils from the granulocyte lineage are phagocytic, they recognise non-self 
material and particles that have been coated with secreted markers such as 
antibody and complement, attach to these particles and engulf them.
As with T-cells, the zinc finger transcription factor Egr-1 is involved in 
macrophage differentiation (Krishnaraju et al., 1995), directing the differentiation 
of some granulocyte/macrophage colony stimulating factor (G/MCSF) stimulated 
cell lines specifically along the macrophage lineage. This example being one of 
the many nuclear factors, including NFkB (Chen et al., 1999), that are involved in 
macrophage activation.
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An important aspect of zinc modulation of macrophage activity has been observed 
in cases of zinc deficiency where cells isolated from deficient individuals have 
reduced phagocytic ability in vitro (Reviewed Shankar and Prasad, 1998). 
Phagocytosis was reconstituted by zinc supplementation in vitro and also in 
macrophages isolated from zinc deficient individuals given dietary zinc 
supplementation. Zinc at higher concentrations has been shown inhibit some 
macrophage functions in vitro (Shankar and Prasad, 1998). Bronchiolar 
macrophages have been shown to secrete high levels of inflammatory cytokines 
in response to excess zinc in cases of metal fume fever (Kuschner et al., 1997).
There is little more general data for the action of exogenous zinc on macrophage 
function in the literature. Much of what has been published in relation to 
macrophage and zinc has looked at zinc metalloprotein function and very little 
work appears to have been carried out on the interaction of macrophage and 
exogenous free zinc.
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Chemical analysis of Zinc Monoglycerolate (ZMG)
Chapter Introduction
In the course of this investigation the nature of ZMG was investigated, both in 
solid form and in preparative solutions. As differences were seen in cellular 
uptake between ZMG in solution and suspension and as the ZMG solution acted 
in a very similar fashion to that of free zinc ion solution, it was thus to determine 
the state of ZMG in the preparations used. However, until recently, there has 
been no published analytical method that has been directly able to examine ZMG 
preparations in media. Described in this chapter is a series of experiments that 
were developed to give an insight into the nature of ZMG in solid form, 
suspension and solution and which add to the published data on ZMG chemistry 
(Fairlie et al., 1992, Tiekink et al., 1996). In addition to analyses of ZMG 
preparations, it was necessary to develop a preparation of ZMG compatible with 
cell culture conditions and non-toxic to the cell lines.
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Background
2.0.1 High Pressure Liquid Chromatography (HPLC)
HPLC is an analytical technique that has been developed for applications across 
the disciplines in the chemical and biological sciences (LKB Handbook, 1982). 
HPLC requires a suitable liquid mobile phase to carry an analyte through a solid 
phase packed in a column varying in length, but normally between 0.75-2.5cm 
wide (LKB Handbook, 1982). The column is the most important functional 
component of the HPLC system. Column packing beads have been developed 
for use with most solvents and the beads may be cross linked to functional groups 
that can ‘add’ an affinity for a specific compound of interest. In this project, size 
exclusion chromatography and metal chelate chromatography are used for 
analysis of glycerol and zinc respectively.
2.0.2 Degradation analysis
The two constituent ingredients of ZMG are zinc and glycerol, both of which have 
well described methods of analysis. It was preferable to have an analytical 
method for study of ZMG that could be applied to both constituents and HPLC 
was selected due to the convenience and adaptability of the technique. It was 
decided to analyse initially aqueous preparations of glycerol, zinc and ZMG for 
the following reasons. For cell culture experimentation the ZMG and other 
compounds would be administered to the cells which are grown in a balanced 
aqueous salt solution. Also in vivo the ZMG, administered orally, would 
encounter first saliva and ultimately gastric juices, both of which are aqueous 
based. In all three media mentioned above there is a significant protein content, 
and it has been shown that ZMG has higher solubility in such biological solutions 
(Fairlie et al., 1992). However, dissolution in these solutions is incomplete and 
other simpler reactions may be assumed to occur between the ZMG and the 
aqueous and salt constituents of these media. However, for construction of an 
HPLC method for ZMG analyses it was preferable initially to keep the system as
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simple as possible. A search of the available literature provided very little on 
methods of glycerol analysis by HPLC other than with a refractive index detector 
(See for example Parpinello and Versari, 2000). At the beginning of the study a 
refractive index detector was not available and a method using UV detection was 
developed.
2.0.3 Determination of zinc in solution by HPLC and Inductively Coupled 
Plasma -  Atomic Emission Spectroscopy (ICP-AES) analyses
Poros MC™ is a chromatographic column packing material with a bimodal pore 
size with large pores (6000-8000 A) smaller pores (800-1500 A)
which allow a high flow rate. It consists of polystyrene/divinylbenzene particles 
(2jnm in diameter) cross-linked by a polyhydroxylated polymer with imidodiacetate 
functional groups, which bind transition metals with varying affinity. The Poros 
MC™ material, used in this study, is suitable for use over pH range, pH 1- 
14. It was developed and is marketed as a protein purification material such that 
transition metals could be preparatively loaded onto the column and metal binding 
proteins run through the column, binding to the metal ions and consequently, the 
column. The commercial protocol suggested that the metals be loaded onto the 
column in weakly acidic conditions, most of the ZMG preparations were either 
neutral or slightly acidic.
All of these properties made Poros™ an ideal material for developing a method 
for analysis of the soluble zinc content of ZMG preparations. The free chelatable 
zinc from the preparations would be bound and other soluble material would pass 
through. There were two possibilities as to the fate of the zinc in the ZMG 
solution; either it will be free ionic zinc and will bind directly to the column or it will 
be zinc in the form of a soluble ZMG fraction. In the latter case it will either pass 
through unbound to the column and be detected in the load eluent fractions or it 
will be bound to the column along with the free zinc. If bound to the column, the 
zinc can then be eluted from the column using a chelator solution as indicated for 
removing metal bound proteins in the original method. It was thought that free 
ionic zinc might be eluted from the column in a fraction different from that of zinc 
in the form of soluble ZMG. Fractions collected from the HPLC were analysed for 
zinc by ICP-AES; copper was also analysed as a reference metal.
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ICP-AES is an analytical technique that allows the detection and measurement of 
several elements at one reading from one specimen. It is very commonly used 
for elemental analysis of biological, environmental and geological materials. The 
method works as a sample aerosol is introduced into a stream of super heated 
gas, normally argon plasma, which is able to vaporise, atomise, excite and ionise 
the sample. In this form the sample constituent elements may be measured by a 
number of detector types including atomic emission spectrometer (AES), mass 
spectrometer (MS) and atomic fluorescence spectrometer (AFS) (Reviewed 
Montaser et al.,1998). In this study an AES detector was used. This utilises a 
photomultiplier array to measure the unique wavelengths of radiation emitted by 
the analyte as it is passed through the argon plasma flame (Montaser et al., 
1998).
It is a relatively rapid technique, with approximately one sample per minute, or 
slightly longer, being processed depending on the number of elements to be 
measured in each sample. A computer attached to the ICP-AES collated results.
2.0.4 ZMG synthesis
Radiolabelled ZMG was required for cell uptake experiments but no data was 
available to compare ZMG synthesis techniques for product recovery and purity of 
recovered product. These experiments were carried out to determine the most 
appropriate method for production of radiolabelled ZMG. In addition to this, 
experiments were undertaken to investigate the possibility of labelling ZMG with 
the fluorescent marker fluorescein isothiocyanate (FITC).
In its most basic form, ZMG is synthesised by heating zinc salt with glycerol to 
between 240°C and 290°C at which point the zinc and glycerol spontaneously 
combine. Above 300°C the ZMG complex begins to degrade. In order to 
examine the uptake pathways of ZMG in cultured cells, ZMG was synthesised with 
a radioactive tracer, 65ZnCI2. This could be detectable by autoradiography. Prior 
to using the radioactive tracer the most efficient method for ZMG synthesis had to 
be developed.
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The choice of zinc compound was arbitrary and the decision was based, in this 
study, on availability, mechanical characteristics and eventual product recovery. 
Initially, zinc oxide was used as it was the first compound available but its lack of 
solubility meant that determining complete reaction was difficult as both zinc oxide 
and ZMG look rather similar when in suspension. In addition to this, zinc oxide, 
even when finely crushed, did not form a very efficient suspension, specifically, as 
the glycerol was heated and its density decreased the zinc oxide powder 
remained resolutely on the base of the reaction vessel.
The next method carried out, utilised zinc chloride. Zinc chloride is water-soluble 
and the solution is miscible with glycerol. This removed the problem of 
differentiating product from source material during the reaction and reduced 
requirement for constant stirring. Zinc chloride was also attractive as a zinc 
source as it matched the radioactive tracer, 65ZnCI2, and so should react exactly 
as the main body of zinc salt. The tracer had very high specific activity and so 
represented an exceedingly small fraction of the total volume. The method 
incorporating zinc chloride was taken from the original paper describing the 
properties of ZMG (Fairlie etal., 1992).
ZMG was also synthesised from zinc acetate. The method was described in a 
personal communication (Personal communication from Dr. Reg Taylor, Adelaide, 
South Australia via Professor Kim Rainsford).
The synthesis of ZMG with an FITC label was a novel concept and whilst the 
results were only preliminary they are included for completeness and for 
reference in future work. It was observed that the structure of the fluorescent 
marker used for cellular endocytosis, FITC-dextran conjugate, was a long chain 
polymer (Sigma Technical Notes for FITC-dextran). From the commercial 
literature it was seen that the FITC fluorescent label on the dextran was attached 
to a hydroxyl residue at random points along the dextran polymer chain. As ZMG 
is theoretically able to present free hydroxyl residues at the end of the ZMG 
polymer it was decided to investigate the possibility of conjugating ZMG with 
FITC. The benefit of this would be the possibility of observing the progress of 
ZMG uptake by cells directly or even observing uptake in conjunction with a zinc
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specific fluorophore. Specifically, FITC fluorescence is pH sensitive with neutral 
pH being the optimum. By co-staining cells with zinquin, a fluorescent ZMG-FITC 
conjugate would allow the tracking of ZMG uptake through acidic or neutral cell 
vesicles. This is discussed further in the following chapter dealing with cellular 
zinc uptake.
2.0.5 ZMG preparations for use in cell culture
Data has been published on the physicochemical properties of ZMG and its 
solubility (Fairlie et al., 1992). However Fairlie et al. (1992) did not especially 
consider preparations for in vitro studies and did not set out to establish a 
particular preparation as preferable. The study only documented a solubility 
profile for ZMG. To enable to the investigation of the effects of ZMG for in vitro 
cell culture systems it was important to prepare the compound so that it was 
compatible with cell culture. The most important consideration was the toxicity of 
the preparation; the pharmacological effects of the vehicle itself must be taken 
into account in order that any overall effect may be attributed directly to the ZMG. 
Ease and rapidity of formulation was also important and, with very little data on 
the effect of ZMG in suspension or solution, it was prudent to keep the 
preparation time as short as possible in order to reduce the probability of 
molecular degradation.
2.0.6 Matrix Associated Laser Desorption/Ionisation -  Time of Flight 
(MALDI-ToF)
MALDI-ToF is a relatively new analytical technique, available to the biochemical 
and pharmaceutical industries for approximately a decade (Reviewed by Cotter, 
1997). The widespread use of this instrument has occurred even more recently 
with the manufacture of bench-top MALDI-ToF analysers. The technique uses a 
target slide, bearing a matrix-coated sample, at which a laser is fired. The laser- 
hit causes desorption of the sample from the target slide and simultaneous 
ionisation of the sample matrix coating the particles. The energy from the laser 
accelerates the sample particles towards the detector array of a mass 
spectrometer. The time-of-flight between target slide and detector is dependent
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on the velocity of the sample particle, which in turn is inversely proportional to the 
square root of the particle mass. A computer attached to the mass spectrometer 
analyses the time-of-flight, relative to an internally calibrated set of masses, and 
produces a mass/charge versus intensity graph of particles detected by the mass 
spectrometer. This method has been used with great success in analysing large 
biological molecules and polymeric compounds (Cotter, 1997). For this reason it 
seemed ideal for analysing the state of ZMG in various preparations.
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Experimental
Reagents
Solvents acetonitrile, methanol and dichloromethane, were all HPLC grade from 
either BDH, Fischer or Fisons. Hydrochloric acid, sodium hydroxide, potassium 
hexacyanoferrate and citric acid monohydrate were Analar grade and obtained 
from BDH. Laboratory grade glycerol, EDTA (Ethylenediamine tetraacetic acid, 
disodium salt) and sodium chloride (NaCI) were also obtained from BDH, as were 
the zinc and copper-standard stock calibration solutions for ICP-AES (ICP 
analytical grade). ZMG was obtained from Glyzinc (Bellara Pharmaceuticals). 
All other zinc compounds, tris-HCI, glycerol (SigmaUltra grade), dimethyl 
sulphoxide (DMSO), 2,5-Dihydroxybenzoic acid, Hydroxypropyl-p-cyclodextrin, 
y-cyclodextrin and fluorescein isothiocyanate (FITC) were obtained from Sigma- 
Aldrich. Ultrafine cobalt metal powder was obtained from Shimadzu. Helium 
and argon, for degassing solutions, were obtained from BOC. Poros™ HPLC 
column packing material was obtained from Boeringer Mannheim. Absolute 
ethanol was obtained from Hayman Ltd. 65ZnCI2 was obtained from Amersham. 
Disposable plasticware was obtained from Falcon or Nunc. Roswell Park 
Memorial Institute (RPMI) cell culture medium and Hank’s Buffered Saline 
Solution (HBSS) were obtained from GIBCO BRL. Bovine Serum Albumin (BSA) 
supplement, PEG300 and Tween 20 were unbranded laboratory reagents. 
Ultrapure deionised water was obtained from Millipore Milli-QPLUS PF water 
system.
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2.1.1 HPLC Analysis of ZMG - Determination of glycerol in solution and 
analyses of ZMG degradation
Equipment
The initial method development experiments were carried out on an integrated 
Waters HPLC system. A Waters 510 HPLC pump was attached to a Waters 717 
plus autosampler, with 20-50pl injection volume, coupled to a Waters 486 
Tuneable Absorbance Detector. The whole system was controlled from a Digital 
Venturis computer, running Waters Millennium Chromatography Manager 
software, which both remotely managed the hardware control and recorded data 
received from the detector. When refractive index detection was carried out, the 
above system was used replacing the Waters 486 Tuneable Absorbance Detector 
with an unbranded refractive index detector.
Due to reallocation of resources, further method development and subsequent 
analyses were carried out on a different system. This consisted of a Gilson 
Model 302 pump attached via a Gilson Model 802 Pressure module to a Waters 
Model 480 Lambda Max LC Spectrophotometer. Manual injection of sample was 
carried out through a Rheodyne switching valve Model 7125 with a 20pl injection 
loop. Data from this second system was recorded on a Western Systems 
computer running DUO interface software.
The HPLC column used for glycerol analysis was a Spherisorb NH2 5pm column 
with length 250mm and diameter 4.6mm, for size exclusion chromatography. The 
column was obtained from Alltech.
ZMG and glycerol analyses were carried out using 80% acetonitrile:water 
degassed under helium or nitrogen. Laboratory grade glycerol was used for 
initial method development experiments and was replaced by SigmaUltra grade 
glycerol for the later analytical experiments. All solutions used were filtered 
through Whatmans filter paper.
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Method
ZMG was initially undetectable by the HPLC methods used and subsequent 
detection problems were encountered with the citric acid Tris buffered 
preparations initially used to dissolve ZMG. It was therefore decided to 
concentrate on glycerol detection alone and then to move on to ZMG analysis. 
This further allowed development of a method for quantification of glycerol release 
from degraded ZMG
Adaptation and validation of HPLC method for glycerol detection
Initial adaptation of the HPLC method was necessary, as a working refractive 
index detector, recommended for glycerol detection, was unavailable. The 
Waters automated system was set up with a UV spectrophotometer detecting at 
210nm.
Dilutions were made of glycerol (2mg/ml) in ultrapure water and injected using the 
Waters autosampler.
It was found that glycerol was not detectable at wavelength 210nm and so 190nm 
was tried instead. Glycerol was diluted in double distilled water to make a 
standard curve, starting with 100mM glycerol which was serially diluted 1 in 2 
down to a concentration of 1.56mM glycerol. A volume of 50 pi from each 
concentration was run at 1ml/min and the results recorded on computer.
Detection of glycerol by HPLC
For the continuation of the study the Gilson/Waters hplc apparatus was used and 
the validation was repeated on this apparatus to determine reproducibility.
Glycerol in aqueous solution was analysed as follows. Dilutions were made of 
glycerol in distilled water, in the concentration range 1mM-800mM. Samples 
were filtered through a 0.22pm syringe tip filter into clean tubes. Samples to be
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loaded onto HPLC were drawn into a polypropylene syringe before injecting into a 
20pl loading coil attached to a Rheodyne™ injection valve. Conditions used on 
all HPLC runs in this method were 1000bar column pressure, 1ml/min flow rate, 
80% acetonitrile/double distilled water mobile phase. The column used for the 
separation was a Spherisorb NH2 affinity chromatography column.
After every third or fourth glycerol injection the system was flushed with dilute 
(0.1 mM) hydrochloric acid as it was found that repeated sample injections caused 
deposition of glycerol and build up of pressure. Following the acid cleaning, the 
system was allowed to flush with mobile phase for approximately 30 mins or until 
the baseline stabilised.
Glycerol, eluted from the column, was measured by a UV spectrophotometer set 
at 190nm wavelength. A computer linked to the spectrophotometer and running 
DUO data recording system recorded absorbance.
Analysis by HPLC of glycerol released from ZMG in suspension
ZMG (1-1.25g) was weighed out into 50ml plastic centrifuge tubes. Ultrapure 
water was added to give a final ZMG concentration of 100mg/ml. Immediately 
after the water was added the tubes were vortexed for 15 seconds and then 
placed on a rotating wheel to incubate at room temperature with continual 
inversion for increasing periods of time. At the end of the incubation period the 
suspension was drawn into a syringe and immediately filtered through a 0.22pm 
syringe tip filter. Samples were then treated as described above for the analysis 
of glycerol.
The filtrate was also stored for increasing periods of time, 18hr, 42hr, 66hr and 1 
week and rerun on the HPLC as described above.
89
2.1.2 HPLC Analysis of ZMG - Determination of zinc in solution and 
analyses of ZMG degradation
Equipment
The HPLC system used in this series of studies was based on the Waters/Gilson 
system used for the glycerol analyses although a WatersTM 510 HPLC pump 
later replaced the Gilson pump, as it required repair. Data was captured as 
before using the DUO software. The analytical column used was 50mm in length 
by 8mm in diameter, packed with Poros MC™ polystyrene-divinylbenzene beads 
with particle diameter 20pm. The beads were coated with a cross-linked 
hydroxypolymer with imidodiacetate functional groups as the immobilised metal 
chelating ligands. The guard column, 30mm in length by 8mm in diameter, was 
packed with Poros MC™ as with the analytical column. Sample injection was 
carried out through an Omnifit valve attached to a 2ml reservoir. Fraction 
collection was carried out manually and fractions were collected into clean 
borosilicate test tubes.
All solutions were tested on ICP-AES for zinc contamination before use and 
subsequently throughout the study periodic analysis of solutions was carried out 
to ensure mobile phase (water) and eluent (EDTArNaCI solution) contained no 
zinc contamination.
Method
Detection of zinc in solution by HPLC and ICP-AES -  Sample preparation 
and separation by HPLC
Zinc released into solution by either zinc salt, dissolved ZMG or ZMG in aqueous 
suspension was analysed by HPLC using a Poros MC™ column. Zinc sulphate in 
aqueous solution was initially used to construct a standard method for extraction 
of zinc from a solution and measurement of zinc in eluted fractions.
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The mobile phase was distilled water filtered through Whatman’s coarse filter 
paper and degassed under helium for a minimum of 15 mins with flow rate 
2.9ml/min (1mM zinc analysis) and 6ml/min (10mM zinc analysis) at room 
temperature. Zinc sulphate was dissolved in distilled water to a final 
concentration of either 1mM or 10mM. ZMG was prepared in citric acid (10mM) 
to the same concentrations of ionic zinc and balanced to a pH of ~6.6 by sodium 
hydroxide. Before loading, the sample was filtered through a 0.22jjwsyringe tip 
filter to remove any particulate matter. The sample loading was timed from the 
instant the flow started and a computer using DUO data capture system monitored 
the whole procedure. The sample was eluted through guard and sample columns 
packed with Poros MC™. Fractions were sometimes collected during the load 
and were started at 1min after loading and subsequently every 30 seconds until 
the baseline returned to normal. The mobile phase was allowed to elute for a 
further 5-10 mins.
Elution was carried out with an aqueous mixture of EDTA (50mM), NaCI (500mM), 
filtered through Whatman’s coarse filter paper and degassed under helium for at 
least 15 mins. Elution was carried out under continuous flow at 2.9ml/min (1mM 
samples) and 6ml/min (10mM samples) at room temperature and was timed from 
the start of eluent flow. For analysis of 1mM zinc, 2.9ml fractions were collected 
from 30 seconds after the start of eluent flow and subsequently for every minute 
during elution. For analysis of 10mM zinc, 2.9ml fractions were collected from 30 
seconds after the start of elution and subsequently every 30 seconds during 
elution. Eluent was allowed to flow for a further 5-10 minutes to completely 
remove trace zinc after which distilled water was run through the system until the 
baseline returned to normal. Fractions collected from both stages were either run 
immediately on the ICP-AES or stored at 4°C until ready for analysis.
Analysis of zinc released from ZMG in suspension by HPLC and ICP-AES
To quantify ZMG degradation in aqueous suspension zinc, a breakdown product 
of ZMG, was measured. Further studies were carried out on the filtrate from 
ZMG suspension. The assay allowed detection of released zinc that either 
bound or did not bind to the Poros MC™ HPLC column packing
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ZMG samples were treated with the same protocol as used for the analysis of 
glycerol released by ZMG suspension.
ZMG (1-1.25g) was weighed out into 50ml plastic centrifuge tubes. Ultrapure 
water was added to give a final ZMG concentration of 100mg/ml. Immediately 
after the water was added the tubes were vortexed for 15 seconds and then 
placed on a rotating wheel to incubate at room temperature with continual 
inversion. At the end of the incubation period the suspension was drawn into a 
syringe and rapidly filtered through a 0.22pm syringe tip filter. The filtrate (2ml) 
was loaded immediately onto the HPLC following the method described for 
analysis of zinc sulphate solution (pp.90-91). Fractions collected from both 
stages were either run immediately on the ICP-AES or stored at 4°C until ready 
for analysis.
Sample analysis by ICP-AES
Samples for ICP-AES analysis were prepared by 1:1 dilution with distilled water to 
give a final volume of 2.9ml. The ICP-AES was calibrated, before every analysis, 
with zinc and copper solutions as follows. Zinc and copper salt stock standard 
solutions (both lOOOppm) were diluted serially to give two standard solutions 
containing 100ppm zinc/copper and 10ppm zinc/copper using zinc free distilled 
water as reference. These solutions were run through the ICP-AES and the 
instrument automatically calibrated for each concentration of metal. Samples 
were then run through the calibrated instrument and the zinc was detected as 
parts per million per fraction (ppm/fraction).
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2.1.3 Analysis of ZMG by Matrix Assisted Laser Desorption/Ionisation Time 
of Flight (MALDI-ToF)
Equipment
MALOI-VoP analyses were carried out on a Laser Tof 1500 (SAI Ltd. Manchester). 
Analysis of ZMG using MALDI-ToF initially followed a protocol using a standard 
matrix and a solution of ZMG. Further analyses included a suspension of ZMG 
and different matrices.
Method
Analysis of ZMG in solution using 2,5-dihydroxybenzoic acid (2,5-DBH) as 
matrix
Initially ZMG was dissolved in 1M hydrochloric acid to a final concentration of 1M 
ZMG. This was then diluted 1:10 in distilled water to give a 0.1M ZMG solution in 
0.1M HCI. Controls used were HCI solutions of 1M and 0.1 M. From each 
preparation or control 10ml was mixed with 10ml of a saturated solution of 2,5- 
DHB in methanol. Approximately 2pl of each prepared sample or control was 
immediately spotted onto a clean, steel MALDI-ToF slide and allowed to 
evaporate at room temperature to complete dryness. The slide was then placed 
into the MALDI-ToF for analyses of the samples. The results were obtained in 
the form of a fragment spectrum given by signal intensity against fragment mass.
Analysis of ZMG in suspension using 2,5-DBH as matrix
The media used for suspension of ZMG were water, glycerol and DMSO. ZMG 
was suspended in distilled water, 100% glycerol or 100% DMSO to a final 
concentration of 100mg/ml ZMG. The DMSO preparation was also further diluted 
with 100% DMSO as required. Each preparation was then mixed 1:1 with 2,5- 
DHB. Approximately 2pl of each prepared sample or control was immediately
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spotted onto a clean, steel MALDI-ToF slide and allowed to evaporate at room 
temperature to complete dryness with the exception of DMSO. The DMSO did 
not dry in air but instead was allowed tosfa^for between 10 and 20 minutes and 
run whilst still wet. The slide was then placed into the MALDI-ToF for analyses of 
the samples. The results were obtained in the form of a fragment spectrum given 
by signal intensity against fragment mass.
Analysis of ZMG in suspension using potassium hexacyanoferrate (II) as 
matrix
Results for each of the previous sample preparations were not, at first, consistent 
and the possibility that the MALDI-ToF matrix, which is acidic, could be degrading 
the ZMG was considered. Most matrices for MALDI-ToF analysis are acids but 
there are some far less commonly used matrices that are not acidic including 
potassium hexacyanoferrate (II) and cobalt. The matrix used in the following 
experiment was potassium hexacyanoferrate (II) and was carried out as described 
in the literature (Zollner et ai., 1997).
A saturated solution of potassium hexacyanoferrate (II) was prepared in methanol 
and glycerol was added to a final concentration of 5% (v/v). This was then mixed 
vigorously by repeated vortex and inversion for 5min and then centrifuged at 
for 1min. A slightly opaque suspension with a large pellet consisting of 
excess compound was produced after centrifugation. The opaque supernatant 
(the matrix) was pipetted into a clean tube and 0.5pl then spotted onto a clean 
target slide where the methanol evaporated rapidly leaving a colourless coating of 
matrix on the target slide. It should be noted that in the published methods 
(Zollner et al., 1997) the matrix is not directly mixed with the sample, instead the 
sample is layered on top of the matrix. For the sample preparation ZMG was 
vigorously suspended, by vortex and manual inversion in 100% DMSO to a final 
concentration of 100mg/ml that was diluted 1:100 to give 1 mg/ml. Approximately 
2pl of each dilution was spotted onto target slides precoated with matrix.
ZMG was also prepared, without DMSO, in potassium hexacyanoferrate (II) 
solution alone as follows. ZMG was mixed with saturated potassium
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hexacyanoferrate (II) solution to a final concentration of 100mg/ml, which was 
diluted further by 1:10 to give 20mg/ml ZMG. From both sample concentrations 
~2pl was spotted onto a clean target slide not pre-coated with matrix.
Analysis of ZMG suspension using cobait matrix
Ultrafine cobalt metal powder was also tested for suitability as a non-acidic matrix 
for ZMG analysis. A suspension of cobalt powder was made in methanol. The 
ZMG sample was prepared as before by suspension in 100% DMSO. The 
sample was then sonicated for 5 minutes with an equal volume of cobalt 
suspension. Sample preparations (~2pl) were then spotted onto the target slide.
As with the potassium hexacyanoferrate (II) matrix, ZMG without DMSO, was also 
mixed directly with the cobalt matrix for analysis. The preparation (~2pl) was 
spotted onto a clean target slide.
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2.1.4 Synthesis of ZMG
Equipment
The glassware and Buchner funnel were washed in 1M HCI, then detergent and 
rinsed thoroughly in tap water and then distilled water both before and after use. 
Polypropylene centrifuge tubes were clean sterile plastic.
Method
ZMG Synthesis using Zinc Oxide
In a round bottomed glass flask zinc oxide (81 mg, 1 mmole) was mixed manually 
with excess glycerol (9.2g, lOOmmoles). The flask was then placed in a heated 
sandbath and stirred continuously for 15 minutes maintained at between 260°C 
and 280°C. At this point the opaque zinc oxide suspension became flocculent 
and the reaction was stopped. A high temperature mercury thermometer placed 
directly into the glycerol/ zinc mixture monitored the temperature of the 
preparation.
After heating the mixture was allowed to cool to room temperature and then 
filtered through Whatman’s coarse filter. The precipitate was then washed with 
copious amounts of methanol and allowed to air dry. A sample was then 
collected into a sample vial and sent for microanalysis to a commercial analytical 
company, Medac LTD.
The synthesis was repeated exactly as described above, with ten times more 
glycerol, (92g, 1mole) in order to examine the effect of increasing the excess 
glycerol level on product recovery efficiency. This sample was not sent for 
further microanalysis.
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ZMG synthesis using Zinc Chloride
This method was taken from the one published method for ZMG synthesis (Fairlie 
et al., 1992). In a polypropylene centrifuge tube zinc chloride (219mg) was 
dissolved in 160ml distilled water. The solution was adjusted to pH7.5 with 1M 
sodium hydroxide, at which point a precipitate formed. The precipitate was spun 
in a centrifuge at l5oo^ for 5 minutes and the supernatant liquid poured off. 
The pellet was washed in distilled water and methanol by resuspension and 
centrifugation as described above. The resulting gelatinous pellet was finally 
resuspended in 10ml methanol and then mixed with 20ml glycerol.
The mixture was heated very gradually to 180°C, the methanol and water visibly 
boiling off at 110°C and below. Gradual heating was continued until 248-250°C 
was reached and continued for a total of 90 minutes from the start of heating. A 
flocculent precipitate formed during the heating after which it was allowed to cool 
to 30°C, a temperature cool enough to filter but still warm enough to lower the 
viscosity of the glycerol, allowing easier pouring and washing of the sample from 
the flask. The precipitate was filtered off under reduced pressure, washed with 
copious amounts of distilled water and methanol and allowed to air dry. The 
product was then sent for microanalysis.
ZMG synthesis using zinc acetate
In a round bottomed flask zinc acetate, 447.6mg, was dissolved in 20ml distilled 
water. To this was added 39ml glycerol, which was mixed manually. This 
mixture was heated gradually to 190°C and maintained at this temperature for 15 
minutes until a flocculent precipitate formed. The sample was then allowed to 
cool and the precipitate filtered off, washed with a large amount of water and 
absolute ethanol before drying in an oven at 65°C. The dry product was then 
sent for microanalysis.
One change was made to this protocol in the light of the synthesis of radiolabelled 
ZMG and that was to repeat the above method but with the inclusion of ZnCI2> the 
form in which 65Zn was purchased. For this ZnCI2, 10pl of a 10mM solution, was
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added prior to the addition of the glycerol. The sample was processed exactly as 
described above for the ZMG synthesis from zinc acetate alone. The resulting 
product was also sent for microanalysis.
Synthesis of radiolabelled ZMG from zinc acetate and 65ZnCI2
The basic method for synthesis of ZMG from zinc acetate and glycerol was used 
as it required lower temperatures and had least handling stages. In a round 
bottomed flask zinc acetate, 455.1 mg, was dissolved in 20m! distilled water and 
into this was mixed 39ml glycerol (Ultrapure grade). To this mixture 65ZnCI2> 2pl, 
was added and mixed by gently swirling the flask. The mixture was heated on a 
sand bath to between 170C°-185°C and kept at this temperature for 20min. The 
preparation was then allowed to cool to 40°C at which point it was mixed with 
200ml distilled water and the precipitate was filtered off. The resulting product 
was then used for in vitro studies of ZMG uptake by cells in culture.
Synthesis of a ZMG Fluorescein isothiocyanate (FITC) conjugate
Two methods were used to try and conjugate ZMG to FITC, short periods of 
heating or long term incubation with constant agitation. In the first method, ZMG, 
(30mg) and (FITC), 10mg, were mixed with DMSO, (6ml). The mixture was 
heated until almost boiling and then allowed to cool. The suspended material 
was recovered by filtration and washing in water and methanol.
The process was difficult to work up, as the mixture was highly viscous and 
filtration took a long time, even under reduced pressure from a vacuum pump. In 
addition, although the heating process was slow and boiling was avoided, 
charring still appeared to occur during the heating process where the mixture was 
in contact with the glass of the flask. A red powder was recovered but 
experimentation with this method was not continued.
As the first results had been obtained from the MALDI-ToF analysis of ZMG in 
DMSO it was seen that ZMG in this preparation appeared to exist as individual
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polymeric chains. The hydroxyl residues should thus be readily available for 
reaction.
It was decided to try incubation without heating. ZMG (1.7mg) and FITC (17mg) 
were mixed by brief vortex in DMSO and 5 minute incubation at room temperature 
in a sonicating waterbath. The preparation was incubated at room temperature 
on a rotating mixer for 24 hours. The preparation was then compared with an 
equal amount of ZMG in DMSO without FITC for apparent dissolution. The ZMG 
FITC preparation was clear with apparently effective dissolution whilst the ZMG 
alone was completely opaque. After several attempts, it was discovered that a 
roughly 1:10 or 1:20 ratio of ZMG to FITC allowed greatest dissolution. Whilst, 
after the first experiment, dissolution with this technique was never complete, it 
was always clearly greater than controls without FITC.
Preparations were then vortexed to remove undissolved material and the 
supernate was analysed by ICP-AES in order to determine zinc concentration. 
Results from the ICP-AES were obtained as parts per million and presented 
graphically.
Some preparations were also analysed by thin layer chromatography (TLC). 
Typically, methanol or acetonitrile/water in varying concentrations were used as a 
mobile phase for the TLC analysis. ZMG FITC preparations were spotted onto 
plastic backed silica TLC plates and the plates were placed in a TLC jar 
containing mobile phase solvent either methanol or acetonitrile/water. The plates 
were left in the TLC jars until the mobile phase had risen to within 1cm from the 
top of the plate then they were removed from the jar, air dried and exposed to UV 
light. The fluorescent spots were marked with a pencil for later analysis without 
UV light.
As the products should be fluorescent and TLC was a rapid and relatively low cost 
procedure this was thought to be the most suitable analytical method. In addition 
to this, it was thought that TLC might prove a useful method to separate FITC- 
conjugated ZMG from the free FITC that was in great excess in the preparations.
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2.1.5 ZMG Dissolution
ZMG is an unusual compound in that it is almost completely insoluble in most 
common solvents and only dissolves completely, in aqueous solution, in direct 
proportion to the free hydrogen ion concentration. In practice then, ZMG will only 
dissolve in acid but this is suspected to result in the degradation of ZMG to 
glycerol and free zinc rather than producing a solution of ZMG. Two papers are 
available on the dissolution of ZMG, in the first, Fairlie et al. (1992) described the 
relative solubility of ZMG in a variety of common solvents and tissue preparations. 
In the second paper Tiekink et al. (1996) described the dissolution of ZMG in acid 
and they formulated a mathematical model for this dissolution.
Of interest in the present investigation into the effects of ZMG for in vitro cell 
culture systems was the preparation of the compound in a vehicle compatible with 
cell culture. The most important consideration was the toxicity of the preparation; 
the pharmacological effects of the vehicle itself had to be taken into account in 
order that any overall effect may be attributed directly to the ZMG. Ease and 
rapidity of formulation was also important, and with very little data on the effect of 
ZMG in suspension or solution it was prudent to keep the preparation time as 
short as possible in order to reduce the probability of molecular degradation. 
Examined were commercial solvents commonly used in cell culture techniques, 
and cyclodextrin carrier molecules. Carrier systems are widely used in 
pharmaceutical preparations and of these systems some, including cyclodextrin 
molecules with various side chains, are particularly suited to encapsulation and 
administration of hydrophobic insoluble material.
Method
Dissolution of ZMG in cell culture compatible solvents
Cell culture media tested were balanced salt solutions, HBSS and RPMI, the 
RPMI was also tested with 10% BSA supplement. Distilled water was also tested 
with or without 10% BSA. PEG300 and TWEEN 20, both detergents were tested
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for ability to dissolve or disperse ZMG as they have been used in cell culture 
preparations. Glycerol, DMSO and ethanol were tested for comparison purposes 
although they had been tested in the literature.
ZMG, (15.5mg), was placed in a 50ml polypropylene centrifuge tube and was 
vortexed in 10 ml of the vehicle to be tested. Results were judged immediately by 
visually comparing black lines on a white background through the diameter of the 
50ml Falcon tube containing the various liquids plus ZMG powder. Results were 
marked by an arbitrary rating system based on the clarity of the lines seen 
through the liquid, as no method was available for direct measurement of 
dissolution at this stage. Dissolution was graded as follows; -* meaning no 
change in clarity, -/+’ as just perceptible increase in clarity, V  as definite increase 
in clarity and *++’ as complete clarity. Increasing dissolution was determined as 
increasing clarity of preparation immediately after mixing.
As no non-acidic solvent was found for ZMG, a rapid preparation for ZMG solution 
in citric acid was used for experiments as required. A fraction of ZMG 
administered orally as described in the literature (Whitehouse et al, 1990, 
Rainsford, 1992) is likely to be dissolved rapidly in the stomach due to the low pH 
as indicated by Fairlie et al (1992). Whilst this group used a variety of solvents 
to dissolve ZMG, a simple and rapid preparation for ZMG was sought that could 
be administered to cells. ZMG was shown to dissolve well in citrate (Fairlie et al., 
1992) and as it is a ligand that is found commonly in biological tissue it seemed a 
good solvent for preparations of ZMG solution. For all ZMG acid solutions 
presented in these studies ZMG (31 mg) was dissolved in citric acid solution 
(10ml, 10mM) and made up to 20mls with water to give a final ZMG concentration 
of 5mM.
ZMG preparations with cyclodextrin carrier systems
Aqueous solutions were made of cyclodextrins at varying concentrations. ZMG 
was then either added directly to the cyclodextrin solution or was first suspended 
in water or DMSO before addition. Sonication was carried out to both reduce 
particle size and aid reaction.
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Results
2.2.1 HPLC analysis of glycerol
The initial results from the experiments on the Waters system, validating the 
glycerol analyses, are shown here for completeness and to show that the method 
was repeatable after transfer between HPLC systems. As may be seen in figure
2.1 there Isa peak that corresponds to glycerol, and which is absent in the profile 
obtained from injection of water alone. The baseline is not level in this particular 
trace but the results were consistent over at least four runs with the glycerol peak 
present at 6 minutes in all.
The method was successfully transferred to the older Gilson HPLC system and 
figure 2.2 shows the dose dependent nature of the area under the curve for the 
increasing glycerol concentrations. This is the standard curve from which 
glycerol release from ZMG was calculated as described in the next section. 
There is a slight decrease in sensitivity on the older system with a minimum 
detection limit, on the linear curve, of 8-1 OmM. These results however, confirmed 
that glycerol could be analysed and quantified using a UV detector despite an 
apparent absence of published protocols for this detector type. The chart 
response scales differ between system as both computer systems used differing 
analytical programs.
It should be noted that in each of the series of traces, of which two are presented 
(Figure 2.1), a peak corresponding with water was visible but it did not increase 
as the glycerol peaks increased. Additionally, it should be noted that there were 
no peaks eluted, other than glycerol and water, up to 35mins after sample 
injection.
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Figure 2.1. HPLC analysis of glycerol: Analysis of glycerol using Waters HPLC with 
a Spherisorb NH2 column and a UV detector at 190nm wavelength. Figure 2.1a shows 
the trace of water alone with a peak around 3 mins. Figure 2.1b shows the trace of 
2.5% glycerol in aqueous solution (342mM). The water peak is apparent at 3 mins and 
a further peak may be seen, at 6 mins after injection, that represents glycerol in solution. 
These traces are representative of two experiments carried out on the Waters HPLC, 
each containing 4-5 concentrations of glycerol displaying a peak eluting at the same time 
point.
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Figure 2.2 Analysis of glycerol on Gilson HPLC: Varying concentrations of glycerol 
were analysed by HPLC using Gilson apparatus and UV detector. As with the previous 
standard curve obtained on the Waters HPLC, the linear nature of the glycerol detection 
system is displayed in this graph. This standard curve of glycerol concentration is 
representative of three separate experiments. Equation of curve: y = 15.099x + 77.24
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2.2.2 HPL C analysis o f ZMG degradation by detection o f glycerol release
Glycerol release into solution, from ZMG incubated in neutral pH aqueous 
suspension, was quantified by HPLC. A peak was eluted at 6 minutes after 
injection corresponding to that of glycerol. The area under the curve of the peak 
was analysed by DUO HPLC software. These results were converted to 
equivalent millimolar glycerol by correlation with known glycerol concentrations 
from the standard curve, (Figure 2.2). The results indicated that glycerol is 
gradually released from ZMG 0-240 minutes after suspension in distilled water 
(Figure 2.3, black circles).
From the ZMG in suspension (4g = 12.9mmol/40ml), the maximum theoretical 
mass of glycerol available was 25.8mmol glycerol. The maximum amount of 
glycerol detected in solution, after 240 minutes suspension, was approximately 
19.04mmol per 40ml sample. This indicated that after 4 hours in aqueous 
suspension approximately 74% of the glycerol had been released from the ZMG. 
After filtration of suspensions there was a large amount of white insoluble material 
that, these results indicate, was likely to be predominantly zinc oxide. As syringe 
tip filters were used to obtain the supernate it was not possible to recover the 
insoluble residue for analysis. The results obtained from these glycerol analyses 
are discussed, with relevance to the actions of ZMG in biological systems, in 
chapter 5.
In addition to the expected glycerol and water peaks, a broad peak was eluted 
from 10 to 16 minutes after sample injection (Figure 2.4). Like the glycerol peak, 
the unknown peak increased in size in conjunction with increasing suspension 
time (Figure 2.4 A-E, black arrows). As the glycerol peak eluted consistently at 6 
minutes the only other compounds that might have been in solution could be a 
soluble fraction of ZMG or dissolved zinc oxide. If this represented soluble ZMG 
then over time it might be expected to release more glycerol which would be 
detected as an increase in the glycerol peak. In order to examine this possibility, 
the original filtrate samples were incubated at room temperature and re-analysed 
by HPLC after approximately 24,48, 66 and 168 hours. As may be seen in figure 
2.3, incubation of the filtrates did not result in increase of glycerol release. There
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was no graded increase in glycerol concentration with increasing filtrate 
incubation time from 24-168hrs, any variations from the original Ohr filtrate 
appeared random. So it seemed that the unknown peak did not appear to 
contribute to the total glycerol concentration.
Although no additional glycerol appeared to be released, Figure 2.4 shows that 
the unknown peak partially resolved over time into two peaks. It would seem 
unlikely that putative molecules of soluble zinc oxide would react in this manner, 
eluting as one peak that consisted of two separate peaks. This seems to be a 
more complex component of the solution than zinc oxide or a zinc salt. A 
relatively stable, soluble fraction of ZMG would seem to be the only apparent 
candidate for the unknown filtrate component. Contamination of the original ZMG 
source may be discounted as indicated by the microanalysis of the proprietary 
stock ZMG carried out during the ZMG synthesis experiments (Table 2.1, p.127). 
Contamination of individual suspensions during preparation may be discounted as 
each suspension was made up separately plus the fact that the size of the 
unknown peak increases with time in suspension. Further work was started to 
resolve the two peaks by alteration of the HPLC mobile phase. In addition to the 
new information describing the nature of ZMG in suspension and solution, this 
study also provides a novel, simple and quantitative analytical method for 
examining ZMG degradation.
Some analyses were carried out on the first Waters HPLC system to determine 
glycerol content of ZMG in citric acid solution and pH buffered acid solution. 
Some glycerol was detected without the appearance of an unknown peak but time 
constraints prevented a more thorough examination of these preparations. In the 
light of the MALDI-ToF analyses described later, it is unlikely that the acid 
preparation of ZMG would contain a soluble ZMG component. The MALDI-ToF 
spectrograph shown in Figure 2.14 indicates the presence of a peak 
corresponding only to glycerol in the ZMG acidic solution.
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Figure 2.3 Glycerol released by ZMG in aqueous suspension: ZMG, 1g/ml, was 
incubated from 0 to 240 minutes at room temperature in distilled water with constant, 
gentle mixing. The suspension was filtered and the glycerol concentration of the filtrates 
was determined by HPLC analysis on a Spherisorb NH2 column. Glycerol was released 
into solution with time of incubation (Ohrs, indicated by black circles on graph). 
Samples, 0-240 minutes, were incubated at room temperature a further 24-168 hours 
after filtration, and analysed by HPLC as before. There was no significant difference 
between the glycerol release trend of filtrates incubated 24 (yellow triangle), 48 (pink 
square), 66 (blue diamond) or 168 (red star) hours after filtration and that of the sample 
immediately after filtration, Ohrs. It is clear that variation in glycerol release is random 
with no apparent pattern related to increasing filtrate incubation time from 0-168 hours.
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2.2.3 HPLC analysis of ZMG degradation by detection of zinc release 
from ZMG solution
In the fractions eluted from the Poros column after loading with 1mM zinc 
sulphate solution, zinc is detected in fractions 4-9 (2.9ml/fraction) with a peak 
at fraction 5 (n=5 for each point), (Figure 2.5). The fractions eluted after 
addition of 1mM zinc as ZMG solution, prepared in citric acid, also showed zinc 
eluting between fractions 4-9 with the peak also at fraction 5 (n=4 for each 
point), (Figure 2.5). Statistical analysis of the two sets indicated no significant 
difference in zinc elution between the two samples loaded.
This pattern is mirrored by fractions eluted from the HPLC system after loading 
with zinc sulphate and ZMG solutions at 10mM, (Figure 2.6). No significant 
differences were observed at this concentration between fractions from the two 
preparations. ZMG in citric acid solution therefore appears to act like zinc 
sulphate solution in this system suggesting that both contain zinc in free ionic 
form.
When comparing 1mM and 10mM results it should be noted that elution 
conditions were changed. A faster flow rate was used for elution of the 10mM 
samples and more frequent collection of fractions. This did not affect any 
comparison between results from ZMG and zinc sulphate at each individual 
load concentration.
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Figure 2.5 Elution of zinc in fractions from Poros MC™ column: Zinc, 1mM, 
was loaded as either zinc sulphate solution or ZMG solution (prepared immediately 
before use). Fractions were analysed by HPLC on a Poros MC column (50mmX8mm 
column, 20pm bead size and water as mobile phase), eluted with EDTA/NaCI at 
2.9ml/min and analysed using ICP-AES. Fraction volume was 2.9ml. No significant 
difference was seen between ZMG (n=4) and ZnS04 (n=5) at any point, data 
presented as mean ±SD. Zinc concentration was plotted as parts per million (ppm) 
per fraction. —  = ZMG, —  = ZnS04.
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Figure 2.6 Elution of zinc in fractions from Poros column: Zinc, 10mM, was 
loaded as either zinc sulphate solution or ZMG solution. Fractions were analysed by 
HPLC on a Poros MC column (50mmX8mm column, 20pm bead size and water as 
mobile phase) eluted with EDTA/NaCI at 6ml/min and analysed using ICP-AES. 
Fraction volume was 3ml. No significant difference was seen between ZMG (n=4) 
and ZnS04 (n=5) at any point, data presented as mean ±SD. Zinc concentration was 
plotted as parts per million (ppm) per fraction. —  = ZMG, —  = ZnS04.
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2.2.4 HPLC analysis of ZMG degradation by detection of zinc release 
from ZMG suspension
As may be seen from figure 2.7, when ZMG was suspended in distilled water, 
filtered and analysed by HPLC as described for the zinc solutions, zinc is 
detected in some fractions. No zinc is eluted from filtrates obtained from ZMG 
incubated from 1-15 minutes in water however, zinc appears in the fractions of 
filtrates of longer incubations (50-90 minutes). Of those samples that contain 
zinc the maximum concentration is at fraction 5 as it was with the 1mM zinc 
solutions eluted in an identical manner. ZMG incubated for 50 minutes (n=1) 
produced a peak with maximum of 45.28ppm. At 60 minutes (n=1) a maximum 
of 180.8ppm gives the greatest concentration of zinc released by the ZMG 
filtrate. Filtrates obtained after a 90 minute incubation (n=3) had an average 
maximum of 126.9ppm. Although based on a single experiment, the results 
indicate a time-dependent increase of free zinc, peaking at 60 minutes. This 
would agree, in part, with the results obtained from the analysis of glycerol 
release, which also gradually increased over time.
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Figure 2.7 Elution of zinc in fractions from Poros column: ZMG was incubated 
in water for increasing periods of time then filtered. The filtrate was loaded onto the 
Poros MC column (50mm X 8mm column, 20jum bead size and water as mobile 
phase), fractions were eluted in EDTA/NaCI at 2.9ml/min, and zinc in the fractions was 
measured by ICP-AES. Zinc does not appear to be released into the filtrate by 
15mins but did appear in the filtrate after longer incubations. Zinc concentration 
peaks at fraction 5 for all incubation times. For values n>1 data are presented as 
means, n=3 for 1 and 90 minutes, n=2 for 15 minutes and n=1 for 50 and 60 minutes.
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In addition to measuring the amount of zinc bound to the Poros column after 
loading with the ZMG filtrate, fractions were collected during the load to 
measure any zinc that did not bind to the column. The results obtained from 
this, figure 2.8, show that almost none of the zinc was lost during the loading 
process. The zinc levels detected in these fractions were of concentrations at, 
or near, the threshold of the detection limits for the ICP-AES. Some zinc was 
detected in fractions at 1, 10, 50 and 90 minutes with distinct peaks in the 10 
and 50 minute samples. These results are limited by the detection threshold 
but do indicate that not all zinc in the ZMG filtrate may be in a form that is able 
to bind to the Poros column. Fractions collected after loading with zinc 
sulphate solution did not show any zinc lost from the column (data not shown) 
but due to time constraints only a few of the zinc sulphate ‘load’ fractions were 
tested.
114
Pa
rts
 
pe
r 
m
ill
ion
Figure 2.8 Zinc collected in fraction during loading of Poros MC™ column:
Fractions were collected as the Poros column was loaded with filtrate from filtered 
ZMG suspension. Zinc concentration was measured by ICP-AES. Very low zinc 
concentration was found in most samples tested. The n values are r ^ i-2  ^ r k is ,
F r a c t io n  n u m b e r  10 I n c u b a t io n  t im e  (m in s )
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2.2.5 Analyses of ZMG by Matrix Associated Laser Desorption/Ionisation 
-  Time of Flight (MALDi-ToF)
Analyses of ZMG in HCI solution displayed no peaks that corresponded to an 
apparent breakdown product of ZMG. A representative trace is seen in figure 
2.9. When compared with a profile from the control, HCI alone (not shown), 
the trace from the ZMG in HCI (Fig. 2.9) showed no difference in the peak other 
than the very broad mass band stretching from approximately 135, through the
137.1 matrix peak to the peak at 176.9 which is due to an impurity in the HCI 
solution. Whilst this broad band encompasses the mass of a putative ZMG 
subunit, ~150, the fact that it is so broad plus the lack of a defined peak or 
logical correlation to ZMG breakdown products, suggests that this is an artefact 
of the matrix rather than a true result. For comparison with later results it was 
found that no peak was found of mass larger than 411.3 as shown in figure 2.9.
The focus was turned on ZMG suspensions for the following studies. Figure 
2.10 shows a representative trace of ZMG in DMSO with 2,5-DHB as matrix. 
As seen here there was a series of regular peaks stretching from masses of 
approximately 646 up to 4000 in increments of ~65 and ~220. This was one 
trace from a series of traces showing increasing ZMG concentration from 1- 
100mg/ml and the series of peaks was found in each one down to a ZMG 
concentration of 1 mg/ml below which the regular repeating pattern was not 
seen. This profile was also seen in a sample of ZMG, without DMSO, 
suspended directly into 2,5-DHB (Figure. 2.11). Within the limits of the 
MALDI-ToF system, these results may be considered identical. The peak 
separation became more defined, and peak height increased, with increasing 
ZMG concentration (not shown). This resulted in the sharp and discrete peaks 
of figure 2.10 which were not present in the control matrix alone (Fig. 2.12). 
Analyses of the peak trace in Figure 2.10 is shown in Figure 2.14 and Figure 
2.15 at the end of the MALDI-ToF traces.
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Results obtained from MALDI-ToF analysis of ZMG using non-acidic matrices 
(potassium hexacyanoferrate and cobalt) indicated that, under the conditions 
used, ZMG was not detected as either polymer, monomer or breakdown 
product. ZMG suspended in DMSO and analysed using potassium
hexacyanoferrate is shown in figure 2.13a. The peaks that may be seen in this 
trace were also present in the control sample of matrix without ZMG. This 
experiment was repeated several times without detecting ZMG in any form.
Figure 2.13b shows the analysis of ZMG suspended in DMSO and analysed 
using ultrafine cobalt metal powder as matrix. No peaks representing 
polymeric structures or breakdown products of ZMG were observed using 
cobalt as a matrix. This experiment was repeated without detecting ZMG in 
suspension. Peaks that are present in figure 2.13b were also present in the 
control sample, matrix without ZMG.
These results indicate that cobalt and potassium hexacyanoferrate are 
unsuitable for analysis of ZMG suspension under the conditions used in these 
experiments. The results from the 2,5-DHB experiments show that it is a 
suitable matrix for future MALDI-ToF analysis of ZMG. These results also 
appear to confirm that ZMG in suspension is a polymer with a wide range of 
molecular weight fragments from 646-4000 whilst ZMG in solution does not 
appear to have a higher structure, suggesting that it is completely degraded.
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Figures 2.14 and 2.15 show possible structures of the ZMG polymer range 
based on the MALDI-ToF analysis presented in Figure 2.10. The basic 
molecular structure of the ZMG monomer was taken from that described by 
Hambley and Snow (1984) although the bond lengths and bond angles are not 
drawn to scale here.
When the masses detected by the MALDI-ToF were first analysed they did not 
appear to fit any form of ZMG polymer with any accuracy. However, a very 
common artefact of MALDI-ToF analysis is the association of a sodium ion with 
the molecule being analysed. When the mass of sodium (23) was removed 
from that of each peak shown in Figure 2.10, the resulting masses closely 
matched those of putative ZMG polymers. For example, within the detection 
error limits of the MALDI-ToF, the first peak with a mass of 646, did not easily 
fit with any structure based on the ZMG dimer of approximate mass 620. 
However removing the mass of sodium gave a possible ZMG polymer of mass 
623, which closely matched the expected mass of 620 for the dimer.
The structures in Figures 2.14 and 2.15 were derived by logical addition of 
atoms to the closest whole polymer whether it was the dimer, trimer or higher 
‘n’-mer. The structures were drawn with the aid of lsis™/Draw (version 2.1.1), 
which allowed accurate calculation of molecular mass. This further allowed 
the structures of mass closest to those of the relevant peaks in Figure 2.10 to 
be determined. Structures B and C in Figure 2.14 show two alternative forms 
of ZMG of mass 862 and 1078 respectively however all other structures in 
Figures 2.14 and 2.15 show only the structure of mass nearest to the observed 
mass.
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Figure 2.14 Suggested structure of ZMG polymer range derived from MALDI- 
ToF analysis (Fig. 2.10) mass peaks 646-1293. Structure A1. represents the 
exploded structure of A2. the ZMG monomer, it shows the two glycerol molecules and 
two zinc atoms that form the monomer. A1. also shows the carbon and hydrogen 
atoms hidden in the other structures shown above and in Figure 2.15. Structure A3, 
is the ZMG dimer and corresponds to the 646 mass peak on the MALDI-ToF trace. 
Structure B. represents two possible structures calculated for the 862 peak and 
structure C. represents two possible structures for the 1078 peak. Structure D. 
represents the possible structure for the 1293 peak. For clarity, the carbon and 
hydrogen atoms shown in structure A1 have been omitted in all other structures.
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Figure 2.15 Suggested structure of ZMG polymer range derived from MALDI- 
ToF analysis (Fig. 2.10) mass peaks 1509-2158. Possible structures for ZMG 
polymers of mass peaks 1509, 1725, 1943 and 2158 are shown above in structures 
A-D respectively. Where several structures are possible for a peak within the limits of 
the MALDI-ToF error margin, only the structure providing the closest matching mass to 
the observed MALDI-ToF mass peak has been presented.
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2.2.6 Synthesis of ZMG and ZMG conjugates
Synthesis of ZMG
Results from the microanalyses of the synthesised ZMG preparations are 
presented in table 2.1. The elements analysed were carbon (C), zinc (Zn) and 
hydrogen (H); it was not possible to obtain oxygen content from the 
microanalysis so values for oxygen were calculated by difference. In addition 
to the newly synthesised ZMG preparations, one sample of commercially 
prepared ZMG was analysed in conjunction with the samples. As may be 
seen, most preparations are very similar to both the theoretical proportions for 
ZMG and the proprietary content but the preparations made with zinc acetate 
as zinc source are closest to both the proprietary material and the theoretical 
results. The zinc acetate was also easiest to work with as it required no 
special processing like the zinc chloride and produced the ZMG precipitate at 
lower temperatures than the other zinc sources thus avoiding the possibility of 
over heating. One problem with the synthesis of ZMG was that temperatures 
between approximately 240°C and 260°C were required for reaction but above 
300°C the newly synthesised ZMG decomposes. For this reason good 
temperature control and constant mixing was required. Zinc oxide and zinc 
chloride appeared to require temperatures nearer 260°C for ZMG synthesis. 
However the zinc acetate reacted with the glycerol to form flocculent ZMG 
precipitate at temperatures nearer 240°C. This reduced likelihood of 
breakdown and charring of the product. The product from reaction of zinc 
chloride especially appeared to singe near 260°C instead of near the 
breakdown temperature of 300°C and so was particularly unsuitable for use. 
Additionally, there was a high product yield from the zinc acetate method, the 
product zinc content being 66% of the initial zinc (87.8mg product zinc from 
132.6mg initial zinc). This compared well with the published method for 
synthesis of radiolabelled ZMG using zinc chloride, which achieved 44% yield 
by weight (Fairlie et al., 1992). The zinc acetate method was used for 
synthesis of the radiolabelled ZMG.
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Zinc
Source
Zn% C% H% 0% by 
difference
Comment
Zinc Oxide 43.45 21.01 3.57 31.88 Very low yield 
(<10%)
Zinc
Chloride
43.04 22.50 4.73 29.73 Low yield and
charring
(<10%)
Zinc
Acetate (1)
42.14 23.00 3.84 31.02 High yield 
(66%)
Zinc
Acetate (2)
42.20 23.20 3.89 30.71 Repeat of zinc 
acetate (1)
Proprietary
ZMG
42.26 23.29 3.87 30.58 Commercially
supplied
Theoretical
Proportions
41.94 23.23 3.87 30.97 Calculated
proportions
Table 2.1. Summary of ZMG synthesis results: ZMG was synthesised by 
different methods using different sources of zinc. Products of each method were 
analysed for carbon (C), hydrogen (H) and zinc (Zn) content and results reported as 
percentages. Oxygen content was calculated from the other three percentages. 
The proprietary ZMG was obtained from Bellara Pharmaceuticals.
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Synthesis of ZMG FITC Conjugate
Figure 2.16 shows the dissolution of zinc in the supernatant liquid recovered 
from ZMG incubated with FITC in DMSO as a percentage of zinc in the initial 
preparation. The results represent only one experiment but it indicated a large 
increase of approximately 10 times of dissolved free zinc in the ZMG FITC 
preparation as opposed to intact ZMG suspended alone in DMSO 
(DMSO+ZMG). As a percentage of the total zinc added to the preparation, 
0.713mg zinc (1.7mg ZMG), approximately 16% of that was in the supernatant 
liquid of the ZMG plus FITC sample.
Figure 2.17 shows the separation of constituents in ZMG-FITC DMSO 
preparations. There appeared to be no difference between ZMG FITC 
preparations and FITC alone. In figure 2.17 it is clear that constituent parts of 
the FITC in DMSO were separated by 70% acetonitrile/water (lane 1) but there 
is virtually no difference between the FITC alone and the ZMG FITC 
preparation (lane 2). This was found for all mobile phases used although 
different separation patterns were seen in each case. Lane 2, comprising the 
ZMG plus FITC, appeared more intensely coloured than the FITC alone: this is 
probably due to differences in concentration of FITC. The powder was highly 
electrostatic and, despite washing of spatulas and watchglasses (used in the 
preparation process) in the solvent used to make the sample, some powder 
may have been lost to surfaces in the electronic balance and to the container 
surfaces. Due to the small amounts being used this may have affected the 
concentrations separated to the limited degree visible in the TLC results. As a 
whole, the TLC results appear to indicate that conjugation had not taken place 
and that the zinc in solution is free ionic zinc.
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Figure 2.16 ICP-AES analysis of ZMG and FITC preparations: ZMG, with or 
without FITC, was incubated for 24 hours in DMSO then centrifuged to removed 
remaining particulate matter. The supernatant liquid was analysed by ICP-AES and 
results obtained as parts per million which was converted to mass of dissolved zinc as 
a percentage of the initial mass of zinc in the preparation. The ZMG preparation 
containing FITC had approximately 10 times the amount of zinc than ZMG without 
FITC. Virtually no zinc was present in either FITC aqueous solution or the DMSO 
solvent.
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Figure 2.17 TLC analysis of ZMG FITC preparation: ZMG and FITC were 
incubated in DMSO and centrifuged. The supernatant liquid was analysed by TLC 
(solvent was 70% v/v acetonitrile/water) and visualised under UV light, pencil marks 
indicating fluorescent regions. FITC alone is shown in lane 1 and at least 4 visible 
fractions, indicated by black arrows, appear to have been separated by the 
chromatography with a further far fainter fraction, visible under UV light, indicated by 
the red arrow. The ZMG plus FITC sample run in lane 2 displays an almost identical 
fraction pattern although slightly more intense. These differences may be due to 
variations in the loaded samples.Tk»< tW-ee
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2.2.7 ZMG Dissolution
ZMG preparation for cell culture
Table 2.2 shows a summary of the results from the test of cell culture 
compatible media for solubilization of ZMG. When these experiments were 
initially performed the aim was to find a solvent for ZMG rather than simply a 
carrier medium. Consequently, most media were tested for their ability to 
dissolve ZMG. ZMG was not found to dissolve completely in any of the culture 
media tested. Some media showed a slight apparent dissolution of ZMG, for 
example water or HBSS when bovine serum albumin was present. This is 
supported by published material on ZMG (Fairlie et al 1992) and zinc in 
general (Wellinghausen et al., 1996a). ZMG was shown to dissolve to some 
extent in a BSA saline solution as determined by release of radiolabelled zinc 
into solution (Fairlie et al., 1992). Glycerol also appeared to dissolve the ZMG 
powder fractionally (Table 2.2).
It was observed in the uptake experiments (Chapter 3), that the presence of 
BSA in the medium caused false positive staining of the cells. It was surmised 
that either the BSA itself had a high zinc content, or it was acting as an 
enhancer of ZMG or zinc uptake into the cells. In light of the intensity of the 
stained cells and the ability for media containing BSA to dissolve ZMG, it 
seemed that BSA in the solutions acted as a zinc carrier and would therefore 
be detrimental to examining cell uptake of ZMG itself. In fact, the ability of 
BSA to act as a cell uptake carrier for zinc was later described in the literature 
(Driessen et al., 1995) thus vindicating the exclusion of BSA in all experimental 
cell culture preparations in this thesis. Driessen et al. (1995) made a point of 
emphasising the significant effect of the standard cell culture media 
supplement, BSA, on cell culture experiments examining the actions of zinc.
More media appeared more effective as dispersants than solvents of ZMG, 
especially Tween 20, glycerol and the salt solution containing BSA. DMSO 
gave a poor suspension but a very fine particle size. Water alone also gave a
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relatively fine suspension but again the ZMG was not well suspended and 
instead precipitates to the bottom of the tube. In the absence of a good 
solvent, DMSO or water was used as the vehicle for most experiments requiring 
ZMG suspension. However before use the suspension was always well mixed 
by vortex and then by rapid manual inversion immediately before use. Water 
was preferred, as it was the main component of most experimental media used 
in these studies.
ZMG Cyclodextrin preparations
Previously, no quantitative methods had been devised to determine solubility of 
ZMG and results were determined by eye. Cyclodextrins, especially 
hydroxypropyl p-cyclodextrin, are soluble in both water and DMSO so it was 
assumed that any particulate matter visible was ZMG.
No dissolution was seen for ZMG in the presence of hydroxypropyl p- 
cyclodextrin at relative concentrations from 1:1 ZMG to cyclodextrin to 1:1000. 
Suspension of approximately 1:200 ZMG to hydroxypropyl cyclodextrin in water 
followed by freezing and thawing also had no effect on dissolution of the ZMG.
Suspension of the same preparation in a 50% solution of DMSO/water 
produced an exceedingly fine suspension but no apparent dissolution. 
Addition of 20mg y-cyclodextrin to this preparation resulted in some apparent 
dissolution. Repetition of this with the addition of the 20mg y-cyclodextrin to 
the ZMG (1mg) and hydroxypropyl p-cyclodextrin (200mg) mixture and 
subsequent suspension in 80% DMSO/water (rather than 50% DMSO) gave 
slightly more dissolution. Dissolution was not more than approximately 25%.
ZMG did not appreciably dissolve in any other combination of cyclodextrins.
132
Vehicle Dissolved
ddH20 -
ddH20 + 10% BSA -/+
HBSS -
Glycerol, 100% -/+
TWEEN 20,100% -
PEG 300,100% -
Ethanol, 100% -
DMSO, 100% -
RPMI -
RPMI + 10% BSA -/+
HBSS/glycerol 1:1 -/+
Table 2.2 Dissolution of ZMG powder in cell culture compatible media: ZMG, 
15.5mg was added to 10mls of various media, at room temperature, and vortexed to 
mix. Dissolution was estimated visually, immediately after mixing, by comparing black 
lines on a white background through the diameter of the 50ml Falcon tube containing 
the various liquids plus ZMG powder. Clarity was rated as described previously 
(Methods section, p. 101), starting from complete dissolution, ‘++, +, -/+’ with 
meaning no dissolution.
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Summary
These results have provided information on ZMG that is relevant to both the 
phenomenon of ZMG uptake by cells described later in this thesis and, on a 
wider level, to the study of ZMG in further experimentation and clinical use. 
HPLC analyses reported that ZMG was degraded in aqueous suspension and 
solution whilst MALDI-ToF analyses described the nature of ZMG structure in 
suspension and solution. The dissolution experiments provided information 
that may be useful to future examination of ZMG in cell culture and biological 
systems.
HPLC analysis using the Poros column of ZMG dissolved in citric acid, pH6.6, 
indicated that the zinc in solution appeared to be in the form of ionic free zinc. 
The Poros MC™ matrix works both by binding zinc to imidodiacetate functional 
groups and by allowing non-bound molecules to undergo size exclusion 
through the Poros beads. It would be reasonable to expect that the large ZMG 
polymers would either remain unbound, to pass through the system, or would 
bind to the Poros material and be eluted in different fractions to the free zinc 
salt due to size exclusion. For this reason, the similarity of ZMG solution to 
zinc sulphate solution in this system would seem to favour the idea that ZMG is 
completely and rapidly degraded by mild acidic conditions to give a solution of 
free glycerol and zinc ions.
The complex nature of ZMG as a zinc source is suggested by the results of the 
ZMG suspension studies. These showed that, zinc is released gradually over 
time from a ZMG aqueous suspension. The results obtained from analysis of 
ZMG suspension on the Poros system indicated that maximum zinc released 
occurred after an hour in suspension. Although the results in figure 2.7 
(p. 113) show that zinc release appeared to reach a maximum after 60 minutes 
(Area under the curve=246) and fell again up to 90 minutes (Area under the 
curve=212), this is most likely an artefact that would even out to a plateau with 
increased repetition. An explanation for this is that once the zinc release
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reaches a maximum, in this case after 60 minutes, it must remain in solution as 
there is nowhere for it to be lost and so any variation, after 90 minutes, is not 
likely to be significant. The studies of glycerol release showed that the 
glycerol release from ZMG in suspension was, like zinc, also gradual over time. 
However, a maximum of glycerol release was achieved at the longest time point 
for incubation, 4 hours, not the 2 hour incubation of the ZMG. This would 
initially appear to conflict with the results from the Poros data but no definite 
plateau was observed with the zinc release from ZMG suspension and so 
further repetition may have shown even more zinc release up to 4 hours as 
seen with the glycerol. The zinc analysis was time dependent as the eluent for 
the zinc had a relatively high salt content requiring very lengthy washing after 
each individual run to return the baseline to zero and this limited the number of 
repetitions carried out in the available time.
In addition, the analysis of glycerol release revealed that this was accompanied 
by release of another soluble component. As explained in the Results this 
may only be derived from the ZMG polymer in some form. Precisely what form 
this unknown component took is difficult to determine.
The fact that 74% of the glycerol detected in the longest incubations (4 hours) 
was in the form of glycerol, added to the possibility that the maximum glycerol 
release may not have been achieved, indicates that whatever the unknown 
peak represents, it can only contain a small fraction of the available glycerol. 
This argues in favour of small ZMG subunits being the unknown soluble 
component, as they would represent only a small amount of the total glycerol 
whereas larger ZMG polymers in solution would theoretically sequester a large 
proportion of the glycerol. As the unknown peak resolves over time into two 
peaks this could represent further degradation of, for example, a soluble ZMG 
trimer into a dimer or dimer into a monomer. This area certainly warrants 
further investigation, as it will have direct bearing on the nature of ZMG in 
aqueous experimental media and biological fluids.
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The MALDI-ToF results indicated that ZMG naturally takes the form of a series 
of polymeric molecules from approximately a trimer to a dodecamer, shown by 
analysing ZMG in 2,5-DHB matrix alone. Polymers consisting of more than 12 
subunits may exist but were in such low abundance that the instrument could 
not readily detect them. The suspension of ZMG in DMSO suggested the 
same polymeric structure. Suspension of ZMG in glycerol and water did not 
give as conclusive results but this may have been due to mechanical reasons. 
The MALDI-ToF requires that the ionising laser hit a sample of the compound 
to be analysed. In solution this is not a problem as the compound is equally 
distributed, however in suspension the material is, by its nature, in particulate 
form and not evenly distributed. ZMG forms a very fine suspension in DMSO 
unlike glycerol and water and this may also be the case for the matrix solution
2,5-DHB. If this is so then DMSO and 2,5-DHB may simply distribute ZMG 
more evenly and so provide better targets for the laser to hit.
The MALDI-ToF results are highly interesting as they indicate that ZMG 
polymers of different lengths are probably asymmetrical, having different 
terminal structures at either end. In addition the results indicate not only that 
polymers of one length have two different end structures but that the uneven 
end structures are different for polymers of different lengths.
If ZMG was synthesised by sequential, equal addition of monomeric subunits 
then peak differences would equal the mass of the monomer (C3H603Zn)2l 310 
or possibly the half monomer (C3H603Zn) of mass 155 or even multiples of 
these masses (Figure 2.14 structures A 1-3). However the current results 
indicate that ZMG polymers are separated in size by masses of 65, 150 and 
220. When the mass differences were examined in the context of possible 
molecular structures that could result from addition to the basic ZMG subunit it 
seems clear that consecutive polymeric chains must have distinctly different 
end moieties.
It should be understood that these polymeric chains probably do not represent 
cleavage patterns that would occur during degradation and zinc release but 
rather are an indication of the polymeric structure of the undegraded ZMG
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polymers. This is because the ZMG, particularly when analysed in the 
methanol solution of 2,5-DHB matrix alone, was suspended in the liquid for a 
very brief time before application to the MALDI-ToF target slide after which the 
methanol rapidly evaporated. This left the dry ZMG/2,5-DHB residue on the 
target slide. It is reasonable to assume that degradation cannot readily occur 
after that point therefor the polymeric mass trace obtained from this ZMG 
preparation must be very close to the polymeric mass distribution of the native 
compound. By extension, the polymeric structures deduced from this 
particular preparation (Figures 2.10, 2.14-2.15) are likely to be the same as 
those of the native compound before any degradation occurs. Use of MALDI- 
ToF to determine a degradation or cleavage pattern is discussed in the Future 
Work section.
These polymeric traces were repeatedly obtained several times over a period 
of four years and on two different MALDI-ToF instruments. The polymeric 
trace was found when ZMG was prepared by suspension in DMSO and then in
2,5-DHB matrix or when suspended directly in the matrix without DMSO. For 
these reasons the results are unlikely to be artefactual.
The results from the dissolution and synthesis studies of ZMG relate mainly to 
preparations used in the biological experiments and where relevant with the 
synthesised radiolabelled ZMG for example, are discussed in the following 
chapters. However it should be noted that the synthesis data provides some 
comparison of ZMG synthetic techniques that does not appear at any point in 
the literature.
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Uptake of Zinc into Inflammatory and Gastrointestinal Cells
Chapter Introduction
This chapter discusses the toxicity of ZMG and zinc salts on a variety of cell types 
followed by a description and discussion of zinc uptake into selected cell lines 
using a number of techniques, both qualitative and quantitative.
Background
3.0.1 Effect of zinc compounds on cell viability
In order to investigate and quantify cellular zinc uptake it was first necessary to 
determine the effect of zinc on the cell viability. The cell lines studied included 
the THP-1 monocyte/macrophage cell line (Auwerx, 1991), JurkatT-cell line (Gillis 
and Watson, 1980) and the HGT-1 human intestinal epithelial cell line (Cheret et 
al., 1985, Sandle et al., 1990). As different cells have different tolerances to zinc 
and other micronutrients and as zinc was to be administered in higher than 
physiological concentrations, toxicity was an important consideration. The 
highest non-toxic dose suitable for all cell lines had to be determined before 
comparative uptake experiments could be undertaken. To this end, the cell lines 
that have been used in all the following assays and experiments were tested 
along with other available cell lines for comparison. At the time that these tests 
were carried out, there had been little indication that the ZMG solution might 
contain free zinc ion instead of dissolved molecular ZMG and as a result this 
preparation, as described in the literature, was chosen for the first experiment. 
ZMG suspension was tested on the THP-1 monocyte/macrophage cell line only; 
this experiment is described after the main toxicity experiments. Equimolar zinc 
sulphate solution was used for the purposes of comparison.
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3.0.2 Analysis of cellular zinc uptake by spectrofluorimetry and 
fluorescence photomicrography
The following set of experiments describes the first attempts to quantify zinc in 
cells. The concept was described in a paper by Zalewski et al. (1993) who used 
zinquin to quantify labile zinc within cells. As explained in the introductory 
chapter, the zinquin staining method was originally developed to be used as both 
a qualitative and quantitative method for determining labile zinc content in cells. 
To summarise the published methods, for fluorescent quantification using zinquin 
a calibration curve of ionic zinc, zinc sulphate, in an excess of zinquin was first 
constructed. This was followed in the published study by an estimation of cellular 
zinc ions in cells maximally loaded with zinc in excess zinquin and finally by the 
determination of labile zinc concentration in the unknown sample. In the current 
experiments however, the quantitative study was not repeatable, using identical 
reagents, and the cause was determined. However, the staining procedure 
(Zalewski et al., 1993) proved very effective in the current study for the qualitative 
analysis of zinc uptake. Cells incubated with or without zinc were generally well 
stained by zinquin and this allowed observations to be made on the manner of 
zinc uptake using photomicrographic techniques.
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3.0.3 Analysis of cellular zinc uptake by Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS)
Quantitation of zinc from inorganic and biological samples is well documented in 
many standard techniques differing mainly in sensitivity and specific requirements 
for sample preparation. Analytical chemical techniques are well established for 
analyses of trace metals such as zinc and are selected for use by the nature of 
the sample to be analysed and requirements for sensitivity and speed (Reviewed 
Vallee and Falchuk, 1993, Kruse-Jarres, 1997).
In the present study, as quantification of cellular labile zinc using the fluorescence 
spectrophotometer was not possible, the alternative was to quantify total zinc in 
these cells using, in this case, ICP-MS. ICP-MS was chosen as it is a relatively 
rapid and simple technique that also allows simultaneous measurement of other 
elements, for example copper, if required. The cellular zinc uptake experiments, 
using both fluorescence photomicrography and ICP-MS analysis, share a common 
protocol to begin with and so are incorporated into the same section. The 
fluorescence staining is derived from the method of Zalewski et al. (1993), as 
discussed above and the method for the ICP analysis was constructed for this 
study.
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Experimental
Reagents
Jurkat, THP-1 and U937 cell lines were obtained from the ATCC. The HGT-1 
gastric cell line (Laboisse et al., 1982) was obtained from C. Laboisse (CJF 
INSERM 94-04, Faculte de Medecin, France). Hanks buffered salt solution 
(HBSS), RPMI and DME cell culture media were obtained from GIBCO BRL. Zinc 
sulphate (cell culture grade), zinc oxide, glycerol, 1,4-diazabicyclo[2.2.2]octane 
(DABCO) and trypan blue solution (4%) were obtained from Sigma-Aldrich. 
Zinquin acid and ester were a gift from P. Zalewski (Dept, of Chemistry, University 
of Adelaide, South Australia, Australia). ICP-MS standard solutions (Spectrosol 
1000ppm stock solutions) and Analar grade zinc sulphate (used for 
spectrofluorimetry) were obtained from BDH Chemicals LTD. Analytical grade 
distilled water was used for the spectrofluorimetry, in all other procedures water 
was ultrapure deionised water, obtained from Millipore Milli-QPLUS PF water 
system.
3.1.1 Effect of zinc compounds on cell viability 
Equipment
Cell incubations were carried out using an ICN Flow model 320 Automatic C02 
Incubator and experimental procedures were carried out under a cell culture hood 
(Gelaire Flow Laboratories TC48 model). Haemocytometers were Improved 
Neubauer Haemocytometers. Glass coverslips were obtained from Chance 
Propper LTD.
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Method
Cells incubated with zinc salts or ZMG dissolved in citric acid
Cells were cultured in 96 well microtitre plates in media appropriate to the cell 
line. Jurkat, THP-1 and U937 cell lines were plated out in complete RPMI 
medium (RPMI+ 5% Foetal Calf Serum (FCS)) to a final concentration in the wells 
of 5x105 cells/ml, with a 100pl final volume. HGT-1 cell line was plated out in 
complete DME medium (DME+ 5% FCS) to a final concentration of 5x105 cells/ml, 
with 1 OOjlxI final volume and allowed to adhere overnight at 37°C, 5% C02.
Serial dilutions were made of the ZMG solution (citric acid preparation as 
described in previous chapter) and zinc sulphate solution as follows. ZMG (5mM 
stock solution) was diluted in distilled water to give 1 2 0 0 jl iM , 600pM, 120pM, 
30jxM and 10juM ZMG solutions, with zinc ion concentrations of 2400pM, 1200pM, 
240jiM, 60pM and 20pM respectively as one mole of ZMG contains two moles of 
zinc. Zinc sulphate (100mM stock solution) was diluted in distilled water to give 
solutions of 2400pM, 1200^iM, 240jnM, 60pM and 20pM ionic zinc. To each well 
of every 8 well column of the 96 well plates was added 1 OOjlxI of the appropriate 
dilution. Additions to successive columns were separated by 10 minutes to allow 
time for harvesting and assay by the trypan blue method. The appropriate medium 
alone (100jal) was added as the ‘No Zinc Compound’ control, although as 
indicated on the graphs the media contained approximately 0.5jnM residual zinc. 
The cells’ plates were then incubated either 24 or 48 hours at 37°C in a 5% C02 
humidified incubator.
Cell number and viability was then determined for each cell line used, by trypan 
blue exclusion assay (See Sigma technical notes for trypan blue, product number 
T8154). Routinely, 20-30pl of cells was removed from the cell suspension by 
pipetting up and down 10 times, very gently in order to maintain cell integrity. 
The sample was removed to another clean 96 well plate and carefully mixed with 
an equal volume of 4% trypan blue. The suspension was then pipetted onto a 
haemocytometer, a glass slide accurately etched with gradations within an 
indentation on the slide, to produce a cross hair pattern.
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With a glass coverslip fixed above the indentation by gentle pressure, each major 
etched square has a volume of 0.1mm3 from which may be calculated the number 
of cells within that given volume and hence, by multiplication, the concentration of 
cells in the sample. Cells which excluded trypan blue (viable cells) were counted 
and then cells containing the blue dye (dead cells) allowing a calculation of total 
number and viability as follows:-
1. Cell sample concentration = Celltotx104 cells/ml
2. Cell Viability = (Cell^ / Celltot ) x 100%
( =  viable cells counted, tot = total cells counted)
This assay was also used to determine cell number for all other experiments 
requiring a known concentration of cells. Generally, those cell cultures with less 
than 90% viability were excluded from any experimentation throughout the study 
unless specifically stated.
Percentage viability for the cells incubated in varying zinc concentration were 
plotted as line charts.
Cells incubated with ZMG suspension
THP-1 and U937 cells were washed in serum-free RPMI and prepared as 
described in the previous protocol but were plated out at 1x106 cells/ml, 
500pl/well, into a 24 well plate. ZMG was suspended in complete RPMI by rapid 
vortexing to a final concentration of 2mM (0.62mg/ml) and placed in front of a UV 
lamp in a cell culture hood for ten minutes in order to sterilise the suspension. 
The ZMG stock was then serially diluted 1:10 to a concentration of 200nM. To 
relevant wells containing cells was added 500pl from each ZMG concentration to 
give final concentrations of ZMG suspension from 1mM to 100nM. Cells were 
then incubated for 24, 48 and 72 hours. Viability was determined as described 
above using the trypan blue exclusion method.
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3.1.2 Analyses of cellular zinc uptake by spectrofluorimetry
Equipment
Spectrofluorimetry was performed on a Hitachi Fluorescence Spectrophotometer 
model F-2000.
Methods
An aqueous zinc sulphate stock solution was prepared (6mM), and further diluted 
in HBSS. It was found that concentrations of zinc salt, either sulphate or 
chloride, above approximately 1mM caused visible precipitation of salt out of 
solution. Zinquin acid stock solution was prepared in DMSO to a final 
concentration of 2.5mM (1 mg/ml).
The fluorescence profile of zinquin acid was determined to obtain values of the 
optimum excitation wavelength for induction of fluorescence and the emission 
wavelength for detection of fluorescence. Zinquin acid prepared in HBSS, 5pM 
final concentration, was mixed in an acid washed, clean UV cuvette with zinc 
sulphate solution, 440nM final concentration, and immediately run through a 
fluorescence scan.
A standard curve of zinc sulphate was then constructed by serial dilution in HBSS 
(the medium used to suspend cells for fluorescence analysis) from 22pM to 
1.99pM. The zinc solutions were then diluted 1:2 with zinquin solution, 6pM, 
mixed rapidly in the cuvette, excited in the spectrofluorimeter at 360nm and the 
fluorescence determined at 490nm. Results were obtained as fluorescence units 
and plotted graphically.
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3.1.3 Analyses of cellular zinc uptake by Inductively Coupled Plasma Mass
Spectrometry (ICP-MS) and fluorescence photomicrography
Equipment
Adherent cell culture chamber slides were obtained from Nalgene Nunc 
International. Centrifugation was carried out with an MSE Centaur 2. ICP-MS 
analyses were carried out using a Hewlett Packard 4500 series Shield Torch 
System.
Methods
In order to remove exogenous zinc either secreted from the cells or present as 
protein bound metal, cells were washed and prepared in serum-free media. 
Suspension cell lines, Jurkat and THP-1, were washed twice in serum-free RPMI 
culture medium (sfRPMI) by centrifugation in conical tubes, appropriate to the 
required volume either 15ml or 50ml, at 1000 ref for 5min. Cells were finally 
resuspended to a concentration of 1x106 cells/ml in sfRPMI.
Adherent HGT-1 cells were plated out in DME cell culture medium, with 5% foetal 
bovine serum supplement, to a concentration of 8x106 cells/flask (for ICP-MS 
analysis) or 5x105 - 10 x105 cells/chamber slide (for fluorescence analysis) and 
allowed to adhere overnight. The HGT-1 cells were then washed twice in the 
flask with serum-free DME (sfDME) medium and finally covered with 12 mis 
sfDME.
In some experiments cells were pre-stimulated with lipopolysaccharide, LPS 
(Sigma-Aldrich). If so, after the washing process and before the addition of zinc, 
the cells were allowed to incubate in the presence of LPS (1 jig/ml or 10/ig/ml) 
diluted in culture medium appropriate for the cells. The cells were incubated at 
37°C in a 5% C02 cell incubator.
The following procedure was routinely used to prepare the zinc compounds for 
administration to the cell lines. Prior to their use, aliquots of both zinc oxide and
ZMG were prepared and sterilised by either heating to 120°C for one hour or 
incubated under ultraviolet light for thirty minutes. The zinc compounds and 
glycerol were prepared, immediately prior to addition, in distilled water.
Aqueous standard solutions of zinc sulphate (100mM) and glycerol (1M stock) 
were diluted to 10mM. Zinc sulphate was always prepared first as the zinc was 
already in the free ionic form and not subject to any further degradation. To 
produce zinc sulphate or glycerol solutions each stock solution was diluted in 
distilled water to give final concentrations of 5mM. To give a zinc sulphate and 
glycerol mixture, both stock solutions were diluted to 10mM and mixing in equal 
volumes gave a final solution of zinc sulphate and glycerol (5mM). Zinc oxide 
suspension was prepared in distilled water as follows. Routinely, zinc oxide 
(8mg) was suspended in distilled water (10ml) by briefly vigorously shaking and 
then vortexing for thirty seconds to produce a fine suspension. The suspension 
was then mixed immediately in equal volume with either 10mM glycerol solution or 
distilled water alone to give a molar equivalent of 5mM zinc oxide plus glycerol 
and 5mM zinc oxide suspension. The final zinc oxide preparation, 0.4mg/ml w/v 
with either glycerol or water, was equivalent to 5mM free zinc. ZMG was 
prepared in distilled water immediately before use as follows.
ZMG (31 mg) was suspended by inversion in 20ml distilled water and mixed by 
vortexing for thirty seconds. The ZMG preparation was then immediately added 
to the cells to a final concentration equivalent to 12.5pM (3.9pg/ml w/v). Both 
zinc oxide preparations were then added to a final concentration equivalent to 
25pM (2.1 pg/ml w/v zinc oxide) and then the zinc sulphate preparations were 
added to a final concentration of 25pM. Both ZMG and zinc oxide preparations 
were inverted vigorously immediately before pipetting into the cells.
Controls were run simultaneously as follows, glycerol was run alone to a final 
concentration of 25pM. Vehicle, deionised analytical grade water, was also run 
as a control, in this case an equal volume of deionised water was added when 
administering the zinc samples. The final control consisted of untreated cells, i.e. 
no addition of sample or vehicle.
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The cells were incubated for periods of 2, 4 and 24 hours at 37°C in a 5% C02 
cell incubator. Up to this stage cells for both ICP-MS analysis and fluorescence 
staining were treated identically and after this point the divergent treatments and 
results obtained are described below. Any variations to this protocol are 
described in the appropriate related text and figure in the Results section.
Sample treatment for ICP-MS analyses
Cells to be analysed using ICP-MS were thoroughly washed in serum free media 
and counted as follows. Suspension cells were transferred to 15ml centrifuge 
tubes and centrifuged at isoog for five minutes and the supernatant was 
discarded. The pellets were re-suspended in 10ml sfRPMI medium and inverted 
to mix, and the centrifuge step was repeated. After discarding the supernatant 
and re-suspending in 5ml sfRPMI, each sample was counted and the cell 
concentration noted, in order to normalise the ICP-MS assay values to a given 
cell number. The samples were centrifuged to pellet a final time, after which the 
supernatant was discarded and the pellet air dried by inverting the tubes on paper 
towelling. Adherent cells, HGT-1 cell line in particular, were washed simply by 
removing the medium containing the sample and adding fresh sfDME and 
agitating the flask gently, removing the wash and repeating. After the second 
wash 5mls of sfDME was added to the flask and the cells scraped off the surface 
using a rubber tipped cell scraper, and transferred into a centrifuge tube. The 
flask was washed with a further 5ml of sfDME and the cells were counted as 
described previously. From hereon, the adherent cell lines were treated in the 
same manner as the suspension cell lines.
The pellets were normally either stored overnight at 4°C or immediately processed 
for analysis.
Before analysis each cell pellet was resuspended, in 1ml 63% nitric acid and 
transferred by careful pippeting to acid washed 25ml borosilicate bottles for the 
digestion process. Pellets were then digested for 1-2 hours at 60°C, or until 
complete digestion was observed. The digests were then diluted with 1ml 
distilled water to reduce acidity for the ICP-MS.
148
Cell culture media with and without serum were analysed by ICP-MS to determine 
zinc concentrations before use in the above experiments.
The ICP-MS was always calibrated before use. The instrument itself being 
calibrated against a standard solution of ions as an internal instrument calibration 
and then with zinc and copper at standard concentrations to correct for the 
respective ions being measured. The samples are drawn into the ICP-MS by 
peristaltic pump action, ionized by the argon plasma and a fraction of the ionized 
sample being drawn into the mass spectrometer and the zinc and copper contents 
measured. Values are given as parts-per-billion which are equivalent to 
nanogrammes per millilitre (ng/ml). The values are then corrected for dilution 
and cell number as follows:-
Corrected figure F = (2 X Measured value (ng/ml)) / cell number in
sample
This gives ng of zinc per million cells in that sample. These figures
were then plotted as bar charts.
Sample treatment for fluorescence photomicrography
Fluorescence imaging using zinquin is not well documented and only one 
procedure for quite specific conditions had been published at the beginning of this 
study (Zalewski et al., 1993) and although subsequent studies have been 
published, most use this or very similar methods. This technique was adapted to 
suit the cells and the equipment used in this study as described below.
Suspension cells for analysis by photomicrography were washed after incubation 
with the zinc samples, as described for harvest for ICP-MS analysis. However, 
instead of air drying the pellet at the last stage it was resuspended to a cell 
concentration of 1x106cells/ml in sfRPMI. To the cell suspension was added 
zinquin to a final concentration of 6pM (from 5mM stock in DMSO). The samples 
were then incubated for a further 35-45 minutes at 37°C in a 5% C02 incubator.
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After incubation the cells were washed as described above for the ICP-MS assay 
harvest, but only briefly air-dried to remove most of the liquid without completely 
drying the cell pellet. The cell pellets were then resuspended in mounting 
medium, either glycerol/PBS 3:1 or the commercial proprietary Glycerol/PBS 
mounting medium (Sigma-Aldrich) with either ~2pg DABCO or Immunofluor (ICN) 
proprietary mounting medium added to enhance fluorescence.
Adherent cells, grown on chamber slides, were treated as described above but 
centrifugation was not necessary as the chamber slide allowed washing of the 
cells whilst still adhered. Then sfDME (2ml) was carefully pipetted into the well 
and the slide was gently agitated before returning a fresh 2ml aliquot of sfDME to 
the chamber.
One drop of cell suspension (~10pl volume) was dropped onto a glass coverslip 
which was then carefully placed onto the surface of a glass slide. The coverslip 
was allowed to settle and any air bubbles gently pressed out using a plastic 
pipette tip. The coverslip was then sealed to the slide with either black or 
colourless rapid drying.(<1 min) commercial nail varnish.
Slides prepared for photomicrography were kept out of direct light. If not 
immediately photographed, slides were stored at 4°C for short periods as unfixed 
cells will, it was found, swell over long periods, lose morphology and even 
perhaps continue some low level metabolism.
Slides were examined using an Olympus BX60 fluorescence microscope. 
Fluorescence was observed with a UV dichroic mirror and photomicrographs were 
taken either from computer images, or directly with a still camera. Video­
captured photomicrographs were printed on a Kodak colour printer, whilst still 
camera photomicrographs were captured on 35mm colour film ASA 100 with an 
exposure time of 1 min.
A procedure that was employed for all photomicrographs, was that of selecting 
areas to be photographed, by observation under white light but not ultraviolet. 
This meant that cells were not selected for photographing by any measure of 
fluorescence. Selection under these non-fluorescent conditions was intentionally
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biased to some degree by cell number, in that fields were selected that contained 
as large a number of cells as possible. However, as this was done without any 
indication of the fluorescence level of these cells, the selection was therefore 
random from the standpoint of fluorescence.
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Results
3.2.1 Effect of zinc compounds on cell viability
Three separate statistical comparisons were made for cell viabilities;
1) Comparison of differences in cell viability between cells incubated without zinc 
and those with increasing zinc concentration, calculated by one-way ANOVA 
and Dunnett’s post-test comparison with a control. This describes 
concentration effects of zinc, (Figures 3.1-3.6 and Table 3.1).
2) Comparison of differences between ZMG or zinc sulphate on cell viability in 
different cell types, calculated by two-way ANOVA. This describes the 
effects of zinc source (Figures 3.1-3.6).
3) Comparison between viabilities of different cell lines at each time point with 
each zinc source, calculated by ANOVA and Tukey-Kramer Multiple 
Comparisons post-test. This describes the variation in the sensitivity to zinc 
of different cell types (Figures 3.7-3.10).
Figure 3.1 shows the effects of increasing zinc concentration on THP-1 cells after 
24 hour incubation with either ZMG or zinc sulphate. Statistics for the effect of 
zinc concentration on cell viability is shown in table 3.1. As indicated in table 3.1, 
there was no significant effect of zinc on viability up to 120pM zinc in the form of 
either ZMG or zinc sulphate solution. At the highest zinc concentration both ZMG 
and zinc sulphate caused a significant decrease in cell viability (p<0.01) whilst at 
600pM zinc, only ZMG solution caused a significant decrease in cell viability 
compared to the zero zinc control (p<0.01) (Figure 3.1, table 3.1). There were no 
significant differences between the effects on cell viability of ZMG solution or of 
zinc sulphate solution.
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Treatments ^ 10pM 30{iM 120pM 600pM 1200(iM
THP-1 24 hours ZMG P<0.01 P<0.01
Fig. 3.1 ZnS04 P<0.01
THP-1 48 hours ZMG P<0.01 P<0.01
Fig. 3.2 ZnS04 P<0.01 P<0.01
Jurkat 24 hours ZMG P<0.01 P<0.01
Fig. 3.3 ZnS04 P<0.01 P<0.01
Jurkat 48 hours ZMG P<0.01 P<0.01
Fig. 3.4 ZnS04 P<0.01 P<0.01
HGT-1 24 hours ZMG P<0.01 P<0.01
Fig. 3.5 ZnS04 P<0.05 P<0.01 P<0.01 P<0.01
HGT-1 48 hours ZMG P<0.05 P<0.05 P<0.01 P<0.01
Fig. 3.6 ZnS04 P<0.01 P<0.01 P<0.01 P<0.01 P<0.01
Table 3.1 Statistics for effect of zinc concentration in Figures 3.1-3.6:
Comparison of the effect of culture media zinc concentration (compared to zinc free 
controls) on viabilities of three different cell lines incubated with either ZMG solution or 
zinc sulphate solution. The figure numbers indicate the figures to which each set of 
statistics corresponds. Statistics were obtained using ANOVA and Dunnet’s 
comparisons of values versus control (cells with no exogenous zinc in culture medium). 
Green squares indicate viability significantly greater than the “no zinc” control (See Fig 
3.6). Red squares indicate viability significantly lower than the “no zinc” control (See Figs 
3.1-3.6).
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After 48 hours incubation with varying zinc concentrations (Figure 3.2) both ZMG 
solution and zinc sulphate solution caused a significant decrease in THP-1 cell 
viability at 600 pM and 1200pM zinc ion when compared with zero zinc control 
(p<0,01). There was no significant difference between the overall effect on 
viability of ZMG solution and that of zinc sulphate solution. There was no 
significant difference between cells incubated for 24 hours compared with those 
cells incubated for 48 hours.
Viability of Jurkat T-cells incubated 24 and 48 hours in the presence of increasing 
concentrations of zinc is shown in figures 3.3 and 3.4. Significant reduction in 
viability was seen in Jurkat cells after 24 and 48 hours for both ZMG and zinc 
sulphate solutions at zinc concentrations of 600 pM and 1200pM when compared 
to zero zinc controls, p<0.01 for all (Figures 3.3-3.4 and table 3.1). There was no 
significant difference between the overall effect on viability of ZMG solution and 
that of zinc sulphate solution. As with the THP-1 cells, there is no significant 
difference between cells incubated 24 hours and 48 hours with either zinc 
compound.
Thus for both THP-1 cells and Jurkat T-cells there was no toxicity displayed by 
any zinc compound up to a zinc concentration of 120pM. Additionally, there 
appeared no difference in either cell line whether the zinc source was ZMG 
solution or whether it was zinc sulphate solution.
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Zinc ion concentration (jiM)
Figure 3.1. Change in viability of THP-1 monocytic cells: Cells were incubated for 24 
hours with either ZMG solution (square) or zinc sulphate solution (triangle) of increasing 
zinc ion concentration. There is no significant difference between the effects of ZMG and 
zinc sulphate (ANOVA, p>0.05). Values shown as mean and standard deviation, n=4 
for each point. In this and subsequent graphs, x-axis title ‘Percentage viability’ is taken 
to mean ‘Viable cells as percentage of total cell number in each sample’.
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Figure 3.2. Change in viability of THP-1 monocytic cells: Cells were incubated for 48 
hours with either ZMG solution (square) or zinc sulphate solution (triangle) of increasing 
zinc ion concentration. There is no significant difference between the effects of ZMG and 
zinc sulphate (ANOVA, p>0.05). Values shown as mean and standard deviation, n=4 
for each point.
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Figure 3.3. Change in viability of Jurkat T-cells: Cells were incubated for 24 hours 
with either ZMG solution (square) or zinc sulphate solution (triangle) of increasing zinc 
ion concentration. There is no significant difference between the effects of ZMG and zinc 
sulphate (ANOVA, p>0.05). Values shown as mean and standard deviation, n=4 for 
each point.
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Figure 3.4. Change in viability of Jurkat T-cells: Cells were incubated for 48 hours 
with either ZMG solution (square) or zinc sulphate solution (triangle) of increasing zinc 
ion concentration. There is no significant difference between the effects of ZMG and zinc 
sulphate (ANOVA, p>0.05). Values shown as mean and standard deviation, n=4 for 
each point.
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The viability of HGT-1 human gastric cells incubated 24 and 48 hours in the 
presence of increasing concentrations of zinc is shown in figures 3.5 and 3.6. 
The HGT-1 cells appear to have a very narrow window for zinc toxicity as no 
significant cell death is seen for either zinc compound on the gastric cells up to 
120pM, after which complete cell death was seen at zinc concentrations of 600pM 
and 1200pM. The sensitivity of HGT-1 cells to zinc was emphasised by the 
significant increase in viability from zero zinc to 10pM, 3 0 j iM  and 120pM zinc as 
both ZMG and zinc sulphate solution after 48 hours incubation (Figure 3.6 and 
Table 3.1). So HGT-1 cells appeared to die without zinc over time periods that 
do not appear to affect the viabilities of THP-1 and Jurkat cells. In addition, there 
was no significant difference in overall HGT-1 viabilities whether ZMG or zinc 
sulphate solution was used as zinc source. There was also no significant 
difference over time between HGT-1 cells at 24 hours and 48 hours for either zinc 
source.
Figures 3.7-3.10 figures show a statistical comparison of the effects of zinc 
concentrations between cell types. In figure 3.7 it can be seen that there is no 
significant difference between the effect of ZMG on THP-1, Jurkat or HGT-1 cell 
lines from 0-120pM zinc. At 600pM zinc, Jurkat and HGT-1 cells have 
significantly lower viabilities than THP-1 cells (p<0.001). At this concentration 
HGT-1 cell viability is also significantly lower than that of the Jurkat cells 
(p<0.001). At the highest zinc concentration, 1200pM zinc, there is no significant 
difference between HGT-1 and Jurkat viabilities, but both lines had significantly 
lower viabilities than THP-1 cells. Figure 3.8 shows that 24-hour incubation with 
zinc sulphate instead of ZMG solution gives an identical difference in viabilities 
between cell lines.
Incubation of the three cell lines with or without zinc for 48 hours shows that the 
cell viability in the zinc free HGT-1 cells is significantly lower than that of the zinc 
free THP-1 (p<0.001 for figure 3.9 and 3.10) or Jurkat T-cells (p<0.05 for figure 
3.9 and p<0.001 for figure 3.10). The zero zinc points for figures 3.9 and 3.10 
are effectively the same conditions but repeated for the two separate sets of 
experiments.
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There was no significant difference between the viabilities of cells incubated 24 
hours with either ZMG suspension or zinc sulphate solution at any concentration 
from 100% viability to 0% viability (Figure 3.11). Figure 3.12 shows the viabilities 
of THP-1 cells incubated 48 hours with either ZMG suspension or zinc sulphate 
solution of equivalent zinc ion concentration. There is no significant difference 
between zinc compounds for the effect on cell viability as determined by two-way 
ANOVA.
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Figure 3.5. Change in viability of HGT-1 epithelial cells: Cells were incubated for 24 
hours with either ZMG solution (square) or zinc sulphate solution (triangle) of increasing 
zinc ion concentration. There is no significant difference between the effects of ZMG 
and zinc sulphate (ANOVA, p>0.05). Values shown as mean and standard deviation, 
n=4 for each point.
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Figure 3.6. Change in viability of HGT-1 epithelial cells: Cells were incubated for 48 
hours with either ZMG solution (square) or zinc sulphate solution (triangle) of increasing 
zinc ion concentration. There is no significant difference between the effects of ZMG and 
zinc sulphate (ANOVA, p>0.05). Values shown as mean and standard deviation, n=4 
for each point.
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Figure 3.7. Comparison of viabilities of various cell lines: Compiled from 
previous figures, cells incubated 24 hours with ZMG solution. Cell lines were 
compared for variations in response to ZMG solution. HGT-1 cells (diamond) at 
600pM had significantly lower viability than THP-1 cells (triangle) or Jurkat T-cells
(square) (+++=p<0.001 and ***=p<0.001 respectively) and had significantly lower
viability than THP-1 cells at 1200pM (+++=p<0.001). A t both 600pM and 1200pM 
Jurkat cells had lower viability than THP-1 cells (###=p<0.001). First point on 
each graph is 0.5pM zinc, which represents the residual zinc in the complete 
media before addition of zinc compounds.
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Figure 3.8. Comparison of viabilities of various cell lines: Compiled from 
previous figures, cells incubated 24 hours with zinc sulphate solution. Cell lines 
were compared for variations in response to zinc sulphate solution. HGT-1 cells 
(diamond) at 600jaM had significantly lower viability than THP-1 cells (triangle) or
Jurkat T-cells (square) (+++=p<0.001 and ***=p<0.001 respectively) and had
significantly lower viability than THP-1 cells at 1200juM (+++=p<0.001). A t both 
600pM and 1200juM Jurkat cells had lower viability than THP-1 cells 
(###=p<0.001). First point on each graph is 0.5pM zinc, which represents the 
residual zinc in the complete media before addition of zinc compounds.
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Figure 3.9. Comparison of viabilities of various cell lines: Compiled from 
previous figures, cells incubated 48 hours with ZMG solution. Cell lines were 
compared for variations in response to ZMG solution. HGT-1 cells (diamond) in 
zinc free medium, 600pM zinc and 1200pM zinc had significantly lower viability 
than THP-1 cells (triangle) (+++=p<0.001) and significantly lower viability than 
Jurkat T-cells (square) in zinc free medium (*=p<0.05). At both 600pM and 
1200pM Jurkat cells had lower viability than THP-1 cells (###=p<0.001). First 
point on each graph is 0.5pM zinc, which represents the residual zinc in the 
complete media before addition of zinc compounds.
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Figure 3.10. Comparison of viabilities of various cell lines: Compiled from 
previous figures, cells incubated 48 hours with zinc sulphate solution. Cell lines 
were compared for variations in response to zinc sulphate solution. HGT-1 cells 
(diamond) in zinc free medium, 600pM zinc and 1200pM zinc had significantly 
lower viability than THP-1 cells (triangle) (+++=p<0.001) and significantly lower 
viability than Jurkat T-cells (square) in zinc free medium and 600pM zinc 
(***=p<0.001). At both 600pM and 1200]aM Jurkat cells had significantly lower 
viability than THP-1 cells (###=p<0.001 and #=p<0.05 respectively). First point on 
each graph is 0.5pM zinc, which represents the residual zinc in the complete 
media before addition of zinc compounds.
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Figure 3.11. Change in viability of THP-1 monocytic cells incubated 24 hours with 
either ZMG suspension (square) or zinc sulphate solution (tnv^k) of increasing zinc 
ion concentration: Zinc concentration given as available ion concentration from zinc 
sulphate or an equivalent amount of ZMG suspension. There is no significant difference 
between the effects of ZMG and zinc sulphate (ANOVA, p>0.05). Values shown as 
mean and standard deviation, n=6 for each point.
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Figure 3.12. Change in viability of THP-1 monocytic cells incubated 48 hours with 
either ZMG suspension (square) or zinc sulphate solution (triangle) of increasing 
zinc ion concentration: Cell viabilities of cells incubated with ZMG suspension are not 
significantly different from those of cells incubated with zinc sulphate (ANOVA, p>0.05). 
Values are shown as mean and standard deviation, n=6 for each point.
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3.2.2 Analyses of zinc uptake by spectrofluorimetry
Figure 3.13 shows a signature trace of zinquin as a fluorescence wavelength 
scan. This showed that zinquin acid was maximally excited to fluorescence at 
360nm (Fig. 3.13a) as opposed to 370nm which was indicated in the published 
protocol. This may be due to batch differences in the zinquin acid production or 
mechanical error with instrumentation differences. The emission wavelength of 
488nm determined by this test agreed very closely with the published data at 
490nm (Fig. 3.13b). These observations have significance only in 
spectrofluorimeter studies and not the fluorescence photomicrographic studies 
where broad band wavelength filters covering the UV spectrum are used to excite 
to fluorescence the zinquin localised within the cells.
Figure 3.14 shows increasing zinquin acid fluorescence with increasing zinc 
concentration as zinc sulphate or ZMG solution. The functional portion of the 
curve lies between pM-mM zinc ion concentration.
It was observed as these experiments were carried out, that the fluorescence of 
zinquin acid in the cuvette started high but was reduced very rapidly when 
exposed to the excitation beam in the fluorescence spectrometer.
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Figure 3.13. Determination of excitation and emission wavelengths for zinquin acid 
(5pM) in the presence of zinc sulphate (440nM) in HBSS: Zinc sulphate was dissolved 
in distilled water and, immediately prior to measurement, zinquin in aqueous solution was 
added. The scan was carried out immediately on a Hitachi Fluorescence 
Spectrophotometer. Traces were obtained showing maximum zinquin fluorescence at 
(a) 360nm excitation wavelength and (b) 488nm emission wavelength.
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Figure 3.14 Standard curve of fluorescence of zinquin acid in zinc sulphate 
solution: Zinquin acid 6pM was diluted 1:1 with varying concentrations of zinc sulphate 
solution, inverted thoroughly and immediately placed in a spectrofluorimeter. The 
results were obtained as fluorescence units. This graph is representative of the 
standard curves obtained with zinquin acid and zinc solution using the conditions 
described by Zalewski et al (1993) (data shown as mean ±SD, n=3 for each point).
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3.2.3 Analyses of cellular zinc uptake by Inductively Coupled Plasma Mass
Spectrometry (ICP-MS)
The following series of figures, (Figures 3.15-3.19) show the uptake of zinc into 
the various test cell lines. Some of these figures show comparison of zinc uptake 
over time and others show cross comparison of uptake of a compound in each cell 
line. Statistics have been displayed on the graph or, when space has not been 
available, they have been described in the text.
The statistics used were ANOVA and the Dunnet Multiple Comparison test that 
compares sample values with a control value. Uptake of zinc by THP-1 
monocytic cells is shown in figures 3.15 and 3.16. Figure 3.15 shows the zinc 
uptake by cells after 2 hours incubation with various zinc compounds. Cells 
incubated with ZMG suspension and zinc oxide plus glycerol had a highly 
significant increase in zinc concentration compared with control cells (p<0.01). 
Cells incubated with zinc oxide alone also had a significant increase compared to 
control cells (p<0.05). Cells incubated with zinc sulphate with or without glycerol 
did not show a significant increase in zinc concentration after 2 hours incubation.
After 4 hours incubation with zinc compounds a similar pattern is observed 
compared to the 2 hour incubation (Figure 3.16). However, only cells incubated 
with ZMG contain significantly more zinc than untreated control cells (p<0.05). 
Zinc oxide alone and zinc sulphate alone or zinc sulphate plus glycerol show very 
little apparent difference from controls, although cellular zinc concentrations in 
general are lower than the values from the 2 hour incubations. Values for THP-1 
cells incubated for 24 hours are not shown as no significant increase in zinc 
concentration was seen for cells incubated with any zinc compound.
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Figure 3.15. Zinc uptake by THP-1 monocytic cells, 2 hrs incubation with or without 
zinc compounds, as determined by ICP-MS (mean ±SD): Statistically significant uptake 
was seen in ZMG, zinc oxide and zinc oxide + glycerol suspension when compared to 
untreated cells. All zinc compounds were 25^ M zinc molar equivalent. Values are 
expressed as ng (zinc) per million cells (ng/106 cells). Statistical significance
(Dunnet’s multiple comparison with control): (*) = p<0.05, (**) = p<0.01.
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Figure 3.16. Zinc uptake by THP-1 monocytic cells, 4 hrs incubation with or without 
zinc compounds, as determined by ICP-MS (mean ±SD): Statistically significant uptake 
was seen only in ZMG suspension when compared to untreated cells. Values are 
expressed as ng (zinc) per million cells (ng/106 cells). Statistical significance
(Dunnet’s multiple comparison with control): (*) = Statistical significance of p<0.05.
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Figures 3.17 and 3.18 show zinc uptake over 4 and 24 hours by Jurkat I-ceils 
incubated with different zinc compounds or zinc free controls. Unlike the THP-1 
monocytic cells, the Jurkat T-cells had no significantly increased absorption of 
zinc in the shortest time period (2hrs not shown), but significant uptake was seen 
by cells incubated with both ZMG and zinc oxide suspensions for 4 hours (p<0.01 
and p<0.05 respectively) (Figure 3.17). At 24 hours, cells incubated with ZMG 
suspension contained a significantly higher concentration of zinc than controls 
(p<0.01) (Fig. 3.18) although the overall cellular zinc was far lower than at 2 or 4 
hours.
HGT-1 cells did not absorb zinc at all when incubated at any time point with any 
zinc compound. Data is shown graphically for a 24 hour incubation in Fig. 3.19. 
Compared with the controls there was not even an apparent non-significant 
increase in cellular zinc content in cells incubated with zinc compounds and most 
seem to have mean values below that of the “no treatment” control.
Figures 3.20 and 3.21 show comparisons of cellular zinc concentration trends 
over time in THP-1 cells and Jurkat T-cells respectively where cells were 
incubated with or without zinc. HGT-1 cells are not shown as they did not display 
any level of zinc uptake from the zinc compounds tested and additionally, only two 
time points (2 and 24 hours) were carried out for the uptake from these cells. 
Each point, in figures 3.20 and 3.21, is representative of three experiments. 
Comparisons were made by two-way ANOVA between cellular zinc concentration 
trends of cells incubated with zinc compounds and the ‘No Treatment’ control cells 
for each cell line. In both THP-1 cells and Jurkat T-cells, incubation with ZMG, 
zinc oxide, zinc oxide plus glycerol or zinc sulphate resulted in significantly 
greater zinc concentrations over time than the cells incubated without zinc 
(significance values indicated in Figures 3.20 and 3.21).
It may be seen from figures 3.20 and 3.21 that zinc concentration for both THP-1 
and Jurkat cells have similar overall trends, initially high and decreasing with 
increasing incubation time.
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Figure 3.17. Zinc uptake by Jurkat T-cells, 4 hrs incubation with or without zinc 
compounds, as determined by ICP-MS (mean ±SD): Statistically significant zinc uptake 
was seen in cells incubated with ZMG suspension and zinc oxide when compared to 
untreated cells. Values are expressed as n j (zinc) per million cells (ng/106
cells). Statistical significance (Dunnet’s multiple comparison with control): ** = p<0.01, 
*=p<0.05.
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Figure 3.18. Zinc uptake by Jurkat cells, 24 hrs incubation with or without zinc 
compounds, as determined by ICP-MS (mean ±SD): Statistically significant uptake was 
seen only in cells incubated with ZMG suspension for 24 hrs. Values are expressed as 
ng (zinc) per million cells (ng/106 cells). Statistical significance (Dunnet’s
multiple comparison with control): (**) = p<0.01.
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Figure 3.19. Zinc uptake by HGT-1 cells, 24hr incubation, as determined by ICP-MS 
(mean ±SD): No significant difference from control for any zinc preparation after 24hr or 
after 2hr (not shown). Values are expressed as ng (zinc) per million cells
(ng/106 cells).
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Figure 3.20. Amalgamated time course for cellular zinc concentration of Jurkat 
T-cells incubated with or without zinc compounds over three time points 2, 4 and 24 
hours: This figure shows the trend of cellular zinc concentration for Jurkat T-cells 
incubated with various zinc compounds. Compared to the ‘No treatment’ control, cells 
incubated with ZMG, ZnO, ZnO+glycerol or ZnS04 had significantly higher cellular zinc 
concentration trends over time (By ANOVA: p=0.02, p=0.02, p=0.002 and p=0.01 
respectively). Data represented as means, standard deviations have been omitted for 
clarity, n=3 for each point.
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Figure 3.21. Amalgamated time course for cellular zinc concentration of THP-1 
cells incubated with or without zinc compounds over three time points 2, 4 and 24 
hours: This figure shows the trend of cellular zinc concentration for THP-1 monocytic 
cells incubated with various zinc compounds. Compared to the ‘No treatment’ control, 
cells incubated with ZMG, ZnO, ZnO+glycerol or ZnS04 had significantly higher cellular 
zinc concentration trends over time (By ANOVA: p=0.02, p=0.01, p=0.01 and p=0.05 
respectively). Data represented as means, standard deviations have been omitted for 
clarity, n=3 for each point.
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Further studies were carried out to examine the effect, if any, of external 
stimulation or intervention on the uptake of the various cell lines. THP-1 cells, 
Jurkat T-cells and HGT-1 human gastric carcinoma cells were independently 
stimulated with LPS to simulate an inflammatory response and zinc uptake was 
determined as before. HGT-1 cells were incubated with a mucolytic agent to 
determine whether the lack of zinc uptake was a mechanical effect of a mucus 
barrier.
The effect of LPS appears to be to reduce zinc uptake in THP-1 cells. However 
under these conditions the decrease is not significant when comparison is made 
between cells with and without LPS (Figure 3.22). The trend to lower zinc 
content with increasing LPS concentration is not significant either. However the 
trend appears to be decreasing and it is possible that with more repetition and a 
wider range of LPS concentration that a clearer picture would be seen of the 
effects of LPS on zinc uptake. This is reflected by the results from the effect of 
LPS on Jurkat T-cells (Figure 3.23). The trend appears to be that increasing LPS 
concentration results in an increase in cellular zinc concentration although 
whether this is a real affect can only be determined with greater ’n’ values for 
each sample.
It should be noted that due to lack of cell counts for one set of the Jurkat results 
(Figure 3.23) the overall results were not corrected for cell number and so are 
presented as parts per billion. This does not invalidate the results, as correction 
for cell number is not integral to interpretation of results. Correction of cellular 
zinc concentration for sample cell number was used to increase the probability of 
obtaining an accurate result. However the correction did not tend to change the 
general pattern of uptake, rather it corrected individual points that might be skew 
due to harvesting inaccuracies.
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Figure 3.22 Zinc analysis of THP-1 cells incubated with or without LPS and zinc 
compounds: Cells were incubated 24 hours with 0, 1 and 10ng/ml LPS ( □  , □  and 
□  respectively) and then incubated a further 24 hours with or without zinc compounds 
(25^iM molar equivalent). Zinc content was quantified by ICP-MS. No significant 
difference was seen with increasing LPS concentration when compared to LPS free zinc 
controls. No significant trend towards increasing or decreasing cellular zinc content, 
with increasing LPS concentration, was observed for any zinc compound. Data 
presented as mean±SEM, n=4 for all except<A’ where n=3 and where n=2.
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Figure 3.23 Zinc analysis of Jurkat T-cells incubated with or without LPS and zinc 
compounds: Cells were incubated 24 hours with 0, 1 and 10ng/ml LPS ( □  ,□  and 
□  respectively) and then incubated a further 24 hours with or without zinc compounds 
(25jnM molar equivalent). Zinc content was quantified by ICP-MS. No significant 
trend was seen in any sample. Data presented as mean±SEM, n=4 for all except data 
marked lA’ where n=3.
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HGT-1 cells were incubated with a variety of substances to try and induce any 
level of zinc uptake beyond control levels (Figure 3.24). Initially it was thought 
that, being a gastric derived epithelial cell line, HGT-1 cells might have been 
secreting mucus that could interfere with zinc uptake. This was supported by 
zinquin (zinc specific fluorophore) staining of HGT-1 cells that indicated highly 
fluorescent areas on the slides that seemed associated with but not part of areas 
of HGT-1 cell growth. It is known that mucus is able to bind zinc in vivo and in 
vitro (Coleman and Young, 1979, Seal and Heaton, 1987) so HGT-1 cells were 
incubated with a mucolytic compound to remove any mucus. HGT-1 cells were 
also incubated with cytokines IL-1 p (Figure 3.24), TNF-a and the mitogen LPS 
(not shown). These were used in an attempt to activate the HGT-1 cells in a 
manner that might result in zinc uptake; normally cells react to cytokines or 
mitogens by producing more soluble mediators. This sudden upregulation of 
protein production absolutely requires zinc and might be expected to result in an 
influx of available exogenous zinc.
The results indicated that no external stimulus caused healthy HGT-1 cells to take 
up exogenous zinc. It was not possible to carry out repeated experiments of the 
HGT-1 cell analyses due to a lack of availability of the ICP-MS instrument and 
n=2 for each point except ZMG where n=3. However, it is clear from figure 3.24 
that cells incubated with ZMG contain less zinc than the control cells incubated in 
zinc free media, indicating that zinc levels are in fact at baseline level. 
Comparison with figure 3.19 indicates that there is no difference between the 
HGT-1 cells incubated with ZMG and either n-acetyl cysteine (a mucolytic agent) 
of varying concentration or IL-1 p at 20 units/ml (Figure 3.24) or in fact, 2 units/ml 
(Not shown). These results are similar to those for cells incubated with LPS or 
TNF-a, none of which displayed increase in zinc uptake compared to “no zinc” 
controls (Not shown). In fact no chemical treatment resulted in an increase of 
cellular zinc content in HGT-1 cells. Significantly, zinquin studies showed that 
HGT-1 cells grown on commercial cell culture materials did not display any zinc- 
related fluorescence but cells grown on glass cover slips displayed high levels of 
zinc-related fluorescence and also high levels of cell death. This observation is 
discussed later in the following section of photomicrographic results.
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Figure 3.24 Cellular zinc concentration of HGT-1 gastric carcinoma cell line 
incubated under various conditions: HGT-1 cells were incubated with or without zinc 
(25pM molar equivalent) after pre-incubation with mucolytic agent n-acetyl cysteine (n- 
AC). Alternatively the cells were incubated with inflammatory cytokine IL-1 p in the 
presence or absence of zinc. Data presented as mean, standard deviations not shown 
as n=2 for all points except ZMG alone where n=3.
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3.2.4 Analysis of cellular zinc uptake by fluorescence photomicrography
These results are comprised of photomicrographs taken either by still camera on 
an Olympus fluorescent microscope under which cells fluoresce green/yellow or 
by still camera and computer controlled video image capture where cells fluoresce 
blue/white. The difference in colour is attributable to the differing excitation filters 
used and is not a function of either the zinc specific fluorophore zinquin or of cell 
function.
Figure 3.25 indicates the localisation of zinquin fluorescence to the cytoplasm and 
its exclusion from the nucleus in two different cell types. In figure 3.25a Jurkat T- 
cells were incubated with ZMG suspension for 2 hours then stained with zinquin 
ester and recorded by video capture. In figure 3.25b THP-1 cells were incubated 
with zinc sulphate and sodium pyrithione (a zinc ionophore), then co-incubated 
with zinquin and ethidium bromide. The ionophore allows zinc to bypass the 
normal uptake mechanisms of zinc uptake and was used to show that zinquin 
does not pass into the nucleus. These results agreed with the only publication at 
the time that had used zinquin (Zalewski et al., 1993) and confirmed that the 
fluorescence seen in this set of results was extranuclear, either cytoplasmic or 
membrane bound.
Occasionally, in highly fluorescing cells, the unstained nucleus is not clearly 
visible. However, this appeared to be attributable to the very high fluorescence 
itself, in that the cytoplasm surrounding the nucleus and particularly cytoplasm 
directly above the nucleus fluoresces brightly enough to mask the unstained 
nucleus. This is clear in figure 3.25b, especially in cells marked with a yellow 
arrow, where the highly fluorescent granules of cytoplasmic or membrane bound 
zinc are able to mask even the intense red stain of the ethidium bromide in the 
nucleus. Thus, the dark nuclei of the very bright fluorescing cells in figure 3.25a 
are masked.
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Figure 3.25 Jurkat T-cells (Fig. 3.25a) and THP-1 monocytic cells (Fig. 3.25b) 
incubated with zinc then zinquin: The Jurkat T-cells, incubated with ZMG suspension 
display a distinctive ‘all-or-nothing’ staining pattern of zinc uptake. THP-1 cells were 
incubated with zinc sulphate and sodium pyrithione and then ethidium bromide to stain 
cell nuclei. Yellow (open) arrows indicate ‘positive for uptake’, brightly fluorescing cells 
of both cell lines. Red arrows indicate ‘negative for uptake’ cells with little granular or 
diffuse zinc specific staining. White arrows indicate cell nuclei, unstained in the Jurkat 
cells and stained red with ethidium bromide in the THP-1 cells. Some cells clearly 
contain large amounts of granular fluorescence whilst the other cells remain relatively 
unstained. 0 »  «uW\ ^ T
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Figure 3.25a is a typical example of the all or nothing staining found in all cell 
types investigated. It is clear that some cells fluoresce brightly (marked by yellow 
arrow) whilst some display little more than background fluorescence (marked by 
red arrow). This pattern was displayed by all cell lines examined and appears to 
be an important function in cellular zinc control. The ‘negative for uptake’ cells 
that exclude zinc appear otherwise healthy with an intact nucleus and a visibly 
intact, relatively smooth cell membrane. These observations would argue that 
the cells were not dead from apoptosis, which is typified by nuclear blebbing, or 
necrosis, which is normally typified by outer membrane crenelation. The all-or- 
nothing uptake pattern is apparent even in the very low fluorescing HGT-1 cells 
(Figure 3.35, page 201).
Figures 3.26-3.29 respectively show zinc uptake of ZMG suspension, ZMG 
solution, zinc sulphate solution and no zinc vehicle control by THP-1 monocytic 
cells. The first point to note is that the all-or-nothing staining pattern was present 
to some degree in all figures except the zinc free vehicle control. However, 
compared to zinquin stained Jurkat T-cells in general, there was a far higher 
degree of cytoplasmic staining in all cells, not just the brighter stained ones. In 
the THP-1 cells, there appears little discernible difference in uptake patterns 
between cells incubated with different zinc preparations. Additionally, all zinc 
preparations give distinctly brighter fluorescence than the vehicle control.
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Figure 3.26 Zinc content of THP-1 cells as shown by zinquin fluorescence: THP-1
cells incubated 2 hours with ZMG dissolved in citric acid (25pM zinc) and then 30 
minutes with zinquin (3pM), all appear to have some level of rather diffuse fluorescence. 
One strongly stained cell (yellow open arrow) that appears ‘positive for uptake’ is distinct 
from the less intensely stained cells. ic.«Ctu9A x  <+oo
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Figure 3.27 Zinc content of THP-1 cells as shown by zinquin fluorescence: THP-1 
cells incubated 2 hours with ZMG suspension (25|uM equivalent zinc) and then 30 
minutes with zinquin (3pM). Yellow (open) arrows indicate brightly stained positive cells. 
Although the diffuse stain of all cells appears greater than in figure 3.26 the distinction 
between the individual brightly stained cells is still apparent, x^oo.
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Figure 3.28 Zinc content of THP-1 cells as shown by zinquin fluorescence: THP-1 
cells incubated 2 hours with zinc sulphate solution (25pM zinc) and then 30 minutes with 
zinquin (3pM). Yellow (open) arrows indicate individual cells with positive zinc uptake, 
displaying more intense fluorescence than other cells. Oruu*A.l x ^ c o .
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Figure 3.29 Zinc content of THP-1 cells as shown by zinquin fluorescence: THP-1 
cells incubated 2 hours with zinc free vehicle and 30 minutes with zinquin (3^iM). 
Endogenous zinc levels cause very low background fluorescence in cells incubated 
without zinc. x  <+g o
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These photomicrographs do not make it immediately clear why ZMG suspension 
should provide a significantly greater cellular zinc concentration (Figure 3.15, 
page 173). However, it is possible that the ZMG suspension gave a larger 
number of the positively stained cells overall. It is also possible that the diffuse 
cytoplasmic staining was generally more intense in cells incubated with ZMG 
suspension compared to solutions of ZMG or zinc sulphate but without image 
analysis software this would be difficult to determine accurately. Figure 3.30 is a 
good example of this; THP-1 cells were incubated for 1 hour with either ZMG 
suspension or zinc sulphate (plus glycerol in this example) and photographed at a 
low magnification to acquire a larger field of cells than figures 3.26-3.29.
Figure 3.30a, cells plus ZMG, clearly shows a greater number of fluorescent cells 
than figure 3.30b, cells with zinc sulphate. However the positive cells in Figure 
3.30b appear as intense as the positive cells in figure 3.30a. Thus supporting the 
argument that cells incubated with ZMG have a higher general diffuse 
fluorescence than cells incubated with zinc sulphate. The possibility that ZMG 
suspension might increase the number of highly fluorescent ‘positive’ cells cannot 
be discounted. However, without a densitometric analysis programme it would be 
difficult to say more than that the general fluorescence is apparently increased 
over fields of cells incubated with zinc sulphate. For reasons examined in the 
chapter summary both factors probably account for the significant difference in 
zinc uptake.
193
a.
J'2
X mA
b.
Figure 3.30 Zinc content of THP-1 cells as shown by zinquin fluorescence: THP-1 
cells were incubated for 1 hour with ZMG in suspension or zinc sulphate + glycerol 
solution both providing an equivalent of 25pM zinc, then a further 30 minutes with zinquin 
(3pM). Images were captured by still camera. Cells with ZMG showed a high level of 
general fluorescence (Fig. 3.30a) as opposed to cells with zinc sulphate (Fig. 3.30b).i
Some high fluorescing cells are indicated in each image by yellow arrows.
vcov\ ^  X  IO O .
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Fluorescence in Jurkat T-cells incubated for 24 hours with ZMG solution and 
suspension, zinc sulphate solution or vehicle control is shown in Figures 3.31- 
3.34 respectively. It is not readily apparent that background staining is 
exceedingly low in the Jurkat T-cells as indicated in cells marked with a white 
arrow in the vehicle control cells (Figure 3.34). It meant that zinc negative cells 
were often too dim to register on the video capture system. Two such very faint 
cells, also indicated by white arrows, are shown in Figure 3.32 in cells incubated 
with ZMG suspension. Emphasised by this very low background fluorescence, 
the all-or-nothing staining pattern is quite marked with ‘positively’ stained cells far 
brighter than the low fluorescing cells.
Again, as with the THP-1 cells, the fluorescence profile appears similar for each 
zinc compound. However, unlike the THP-1 cells, there is an observable level of 
prominent punctate fluorescence (in the positive cells indicated with yellow 
arrows) especially in the ZMG suspension (Figure 3.32) but also in the ZMG 
solution (Figure 3.31) and the zinc sulphate solution (Figure 3.33). When filters 
were introduced to reduce fluorescence it was clear that these masses of 
fluorescence were distinct, highly fluorescent granules and, by correlation, 
granules of high zinc concentration. It should be noted that no filters, either on 
the microscope or by software manipulation, were used to clean up the 
photomicrographs presented here. The results for all cell lines are shown as 
taken under identical conditions and are shown as near to the original 
microscopic image as possible.
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Figure 3.31 Zinc content of Jurkat T-cells as shown by zinquin fluorescence:
Jurkat T-cells were incubated 24 hours with ZMG (25pM equivalent zinc) dissolved in 
citric acid and then 30 minutes with zinquin (3|uM). The large contrast between the 
Jurkat positive uptake and less intensely stained cells is shown here. Yellow (open) 
arrow indicates the strongly fluorescing cell, the low fluorescing cell being indicated by a 
white arrow. xt*oo,
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Figure 3.32 Zinc content of Jurkat T-cells as shown by zinquin fluorescence:
Jurkat T-cells incubated 24 hours with ZMG suspension (25pM equivalent zinc) and then 
30 minutes with zinquin (3jiM). Yellow (open) arrows indicate the strongly fluorescing 
cells, the low fluorescing cells being indicated by a white arrow. Some punctate 
fluorescence is visible in the brightly fluorescing cells, indicating the presence of 
vesicular zinc. x<+oo.
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Figure 3.33 Zinc content of Jurkat T-cells as shown by zinquin fluorescence:
Jurkat T-cells incubated 24 hours with zinc sulphate solution (25pM zinc) and then 30 
minutes with zinquin (3pM). Yellow (open) arrows indicate the strongly fluorescing cells, 
the low fluorescing cell being indicated by a white arrow. 0t*uy«/v.al
x  4*Oo
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Figure 3.34 Zinc content of Jurkat T-cells as shown by zinquin fluorescence:
Jurkat T-cells incubated 24 hours with zinc free vehicle and then 30 minutes with zinquin 
(3|uM). A white arrow indicates the low fluorescing cells. It is clear that the Jurkat T-cells 
have low levels of endogenous zinc as indicated by the very low background 
fluorescence in cells incubated without zinc. xuoo
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HGT-1 cells did not appear to appreciably take up zinc from any source; a 
representative photomicrograph of cells incubated 2 hours with ZMG solution is 
shown in Figure 3.35. The background fluorescence was higher than normal due 
to autofluorescence from the plastic of chamber slides used to culture the 
adherent HGT-1 cells. In experiments using coated glass slides or glass 
coverslips to culture HGT-1 cells cellular zinc/zinquin fluorescence was barely 
visible to the eye and practically invisible by photographic or video capture. This 
was also seen in the rat intestinal cell line IEC6 (Figure 3.36). It should be noted 
that the glass surfaces were not used to culture HGT-1 cells for general 
experimentation for reasons explained below and in Figure 3.37. However, as 
indicated by the yellow arrows, the all or nothing pattern is apparent even with this 
very low level of fluorescence, which would seem to indicate a level of zinc 
absorption. HGT-1 cells were also incubated with n-acetyl cysteine the mucolytic 
agent used in the ICP analyses of zinc uptake, to see if the gastric epithelial 
carcinoma cells were secreting mucus that might affect zinc uptake. It had no 
effect and cells still displayed fluorescence lower than the detectable limit for 
video capture.
Experiments using glass coverslips as a culture surface led to an observation that 
was not followed up due to lack of time, but it was noteworthy in itself. Cells 
grown on the coverslips grew normally and, when stained with zinquin, displayed 
exceedingly low fluorescence as observed previously (Figure 3.37a and 3.37b). 
However, when these cells were incubated with either zinc sulphate or ZMG to a 
final zinc concentration of 25pM (the standard concentration used for zinc uptake 
in all cell lines) the HGT-1 cells appeared to be killed without exception. The 
cells were highly crenelated and fragmented and no longer adhered to the 
coverslip. In addition to this they were highly fluorescent after staining with 
zinquin which indicated very high cellular zinc content (Figure 3.37c and 3.37d). 
Cell death was seen in both ZMG and zinc sulphate containing slides but not zinc- 
negative controls.
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Figure 3.35 Zinc content of HGT-1 cells as shown by zinquin fluorescence: HGT-1 
cells were incubated with ZMG dissolved in citric acid (25 jiM  zinc) for 2 hours then 
washed and stained with zinquin (3pM). Fluorescence was observed under UV light.
This is a representative result for zinc uptake in HGT-1 cells. It shows considerably 
more fluorescence than many HGT-1 incubations with zinc but it has been selected as it 
clearly shows that, despite very low overall fluorescence, the all-or-nothing uptake 
appears to be present in HGT-1 cells. Positive cells (yellow arrow) are the only cells 
with any level of zinquin staining above background levels. ^  zoo.
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Figure 3.36 Zinc content of IEC6 cells as shown by zinquin fluorescence: Rat
intestinal epithelial cells were incubated with ZMG dissolved in citric acid (25jJVI zinc) for 
2 hours then washed and stained with zinquin (3pM). Clearly, there are no brightly 
fluorescing cells, the cells being barely brighter than the background fluorescence of the
plastic culture slide. U ^ ^ a / vV X 2 ^ 0  .
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Figure 3.37 HGT-1 cells grown on glass coverslips in the presence or absence of 
zinc: HGT-1 cells were grown to confluence on glass coverslips and then incubated a 
further 24hr in the presence or absence of zinc (25juM zinc) and then stained with zinquin 
(3juM). Images were captured by video imaging. Figure shows two fields, a field of 
cells without zinc under white and UV light (a/b) and a field of cells with zinc under white 
and UV light (c/d). As may be seen control cells are flattened and adherent, healthy 
looking cells (Fig 3.37a) with low fluorescence (Fig 3.37b). However, those cells 
incubated with zinc were small and crenelated, were not adherent and were surrounded 
by fragments of cell membrane (Fig. 3.37c). All remaining intact cell bodies displayed 
high fluorescence compared to the cells without zinc and also compared with figure 3.35, 
HGT-1 cells grown in plastic chamber slides with zinc. O ru y *\# \ K <i6o
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The rat intestinal epithelial cell line, IEC-6, became available and was briefly 
investigated in some experiments in order to compare the fluorescence in a 
gastric cell line other than HGT-1, the human gastric epithelial cell line. These 
cells also displayed fluorescence close to that of background when incubated with 
ZMG solution and zinquin (Figure 3.36).
As zinc was taken up in both punctate and diffuse manner, the vesicular uptake of 
zinc was investigated. THP-1 and Jurkat T-cells were incubated with zinc 
compounds and either co-incubated with FITC-dextran or stained with acridine 
orange. FITC-dextran was used to investigate vesicular transport as the long 
chain polymer is endocytosed in vesicles and the fluorescent FITC, which is most 
intense at neutral pH, allows the transport to be visually tracked under UV light. 
Acridine orange is a stain used to label a number of cellular compartments but 
has particular affinity for acidic compartments. It stained the cell cytoplasm 
orange (mainly staining mRNA) and the nuclear material and cytoplasmic vesicles 
green. It was thought that co-localisation of zinquin fluorescence with the FITC- 
dextran or acridine orange would indicate which compartment the zinc was 
occupying. The FITC-dextran was extensively tested but no FITC fluorescence 
was ever detected and certainly none that co-localised with zinquin fluorescence. 
It is conceivable that bright zinquin fluorescence may have masked the dimmer 
FITC fluorescence. Acridine orange staining was only tested twice and was very 
much a preliminary result. However, it did provide some indication that at least 
some of the punctate zinc staining is not localised to acidic vesicles. Figure 3.38 
shows THP-1 cells incubated with ZMG solution and stained with zinquin alone for 
comparison (Figure 3.38a) or zinquin and acridine orange together (Figure 3.38b). 
Two granules appeared bright blue similar to the normal zinquin stain but three 
granules, apparently closer to the nucleus, are blue/green. The blue/green 
granules may represent a co-stain of the zinquin and acridine orange thus 
indicating the presence of zinc in an acidic vesicle. It further suggests that the 
two blue granules represent zinc in non acidic vesicles. Similar results were 
obtained with Jurkat T-cells (Figure 3.39), the quality of the image was not very 
good due to high levels of acridine orange fluorescence.
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Figure 3.38 Co-stain of THP-1 cells with zinquin and acridine orange: THP-1 cells 
were incubated with ZMG solution and then stained with either zinquin (Fig 3.38a) alone 
or zinquin + acridine orange (Fig 3.38b). The zinquin stain in figure 3.38a highlights the 
distinct granular punctate zinc uptake. The acridine orange stain marks the nuclear 
material clearly green and the cytoplasm a cloudy orange colour. Five definite granules 
are visible, two displaying the fluorescent blue of zinquin (white arrow) and three staining 
a blue green (purple arrow). The blue vesicle appears nearer the outer membrane 
whilst the blue green vesicles appear to be predominantly nearer the nucleus.
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Figure 3.39 Co-stain of Jurkat T- cells with zinquin and acridine orange: Jurkat T- 
cells were incubated with ZMG solution and then stained with alone or zinquin + acridine 
orange. The higher level of acridine orange fluorescence meant that cell structures 
were not as readily visible as they were in the THP-1 cells (Figure 3.38). However, the 
blue punctate fluorescence in one ‘positive for uptake’ cell was clearly visible (white 
arrows). The high level of acridine orange fluorescence combined with the large number 
of granules visible in this particular cell made it difficult to distinguish between vesicles 
with a blue fluorescence and those with a blue/green fluorescence, 
vC&iho''V X iQOOi
Summary
The results from the viability experiments indicate that there is no differential 
effect on viability whether zinc salt or ZMG suspension or ZMG in acid solution is 
used as zinc source. They also provided information that indicated the viability of 
almost all cell lines was unaffected by increasing zinc concentration up to 120pM, 
zinc concentrations higher than 120pM resulting in increasing cell death in all cell 
lines. The exception to this was the HGT-1 cell line that displayed a decrease in 
viability after 48 hours in the absence of additional zinc; the zinc concentration in 
complete medium was 4nM as determined by ICP-MS.
There is a difference seen between cell lines in the reaction to increasing zinc 
concentration. The THP-1 cells appeared to be most resistant to high zinc 
concentration with Jurkat T-cells less resistant and HGT-1 cells appearing least 
resistant of all with no graduation of viability between no cell death, at 120pM 
zinc, and complete cell death at 600pM zinc.
Thus the viability experiments collectively suggest that the different cell lines may 
have different mechanisms for dealing with zinc. This was emphasised by the 
cellular zinc uptake data, which showed that the three cell lines dealt with different 
zinc compounds in distinctly different manners.
At all time points, 2, 4 and 24 hours, only incubation with ZMG suspension or zinc 
oxide suspension (with or without glycerol) resulted in cells with cellular zinc 
concentrations greater than control cells without exogenous zinc. In addition, 
only THP-1 cells and Jurkat T-cells appeared to take up zinc in amounts 
statistically significantly greater than controls. HGT-1 cells did not appear to take 
in exogenous zinc above control levels. THP-1 cells only appeared to display 
statistically significant levels of cellular zinc compared to control cells at early time 
points, 2 and 4 hours incubation with zinc compounds. Jurkat T-cells differed 
from the THP-1 cells in that they displayed statistically significant cellular zinc 
levels compared to controls at 4 and 24 hours but not 2 hours incubation with zinc 
compounds. So it appears that all three cells lines deal with exogenous zinc in 
distinctive fashions. As discussed in Chapter 1, this may be expected as zinc 
transport mechanisms are differentially displayed in the cells of various tissues.
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When uptake results were looked at cumulatively over time, THP-1 and Jurkat T- 
cells appeared to start with high cellular zinc concentrations, when incubated with 
ZMG or zinc oxide suspensions, which decreased over the 24 hour period. 
Overall the trends for cellular zinc content, when incubated with either ZMG 
suspension or either of the zinc oxide suspensions, were significantly different 
from that of the control cells, as determined by ANOVA. Interestingly both THP-1 
and Jurkat cells incubated with zinc sulphate solution had cellular zinc contents 
that were not greater than control levels at 2, 4 or 24 hours individually but 
cumulatively the trend for cellular zinc levels over time was greater than that of 
control cells, as determined by ANOVA. This would seem to indicate that, whilst 
the zinc salt was not as good a source of bioavailable zinc as either ZMG or zinc 
oxide, it was nonetheless causing an increase in cellular zinc as distinct from 
control cells.
Zinc uptake was also examined under conditions that model some aspects of 
inflammation by stimulating the cells with the bacterial mitogen, LPS. None of the 
cell lines displayed a statistically significant increase or decrease in cellular zinc, 
at any single LPS concentration, when compared to cells incubated with zinc but 
without LPS. However, Jurkat T-cells appeared to display trends towards 
increasing cellular zinc with increasing LPS concentration when incubated with 
zinc compounds, whilst THP-1 cells appeared to tend towards decreasing cellular 
zinc with increasing LPS concentrations. The HGT-1 gastric cells did not appear 
to take in significant amounts of zinc under any conditions of stimulation. Even in 
the presence of cytokines, that might have been expected to stimulate secretion of 
other cytokines, failed to cause a noticeable increase in cellular zinc. As protein 
synthesis and secretion absolutely requires zinc and as many proteins use zinc as 
a structural component it seems strange that the HGT-1 cells did not appear to 
have measurable increases in zinc. It may be that the zinc levels in this cell line 
are very efficiently regulated and that they simply maintain sufficient zinc for 
homeostasis and no more.
The results from the zinquin stain of labile zinc in cells showed that, of the labile 
zinc that is available for zinquin binding, the patterns appear quite similar whether 
cells were incubated with ZMG suspension, ZMG dissolved in citric acid or zinc 
sulphate. However, there was a distinct difference between cell lines. THP-1
monocytic cells appeared to display a generally higher level of fluorescence than 
either Jurkat T-cells or the HGT-1 gastric cell line. This was manifested by a 
brighter diffuse fluorescence in the cells although the particularly bright ‘positive 
for uptake’ cells did not seem to be in any more abundance than in the Jurkat 
cells under the same conditions. The diffuse fluorescence was lower in the 
Jurkat cells which resulted in a very marked difference between ‘positive for 
uptake’ cells and all other cells. The HGT-1 cells were barely fluorescent after 
incubation with zinc compounds and then staining with zinquin. This observation 
of zinquin stained labile zinc was in agreement with the ICP-MS results that 
showed no increase in total zinc under similar conditions.
Interestingly, the comparison of large fields of cellular fluorescence after 
incubation with either ZMG suspension or zinc sulphate solution would seem to 
suggest, despite apparent similarity fluorescence patterns in THP-1 cells, in this 
case, that zinc sulphate was providing less labile zinc to the cells. The cells 
incubated with ZMG were generally much brighter than the cells incubated with 
zinc sulphate. This would seem to indicate that the higher level of total cellular 
zinc in THP-1 cells, incubated with ZMG as opposed to zinc sulphate, was 
probably due to an increase in the general diffuse fluorescence of the whole 
population rather than a larger number of ‘positive for uptake’ cells.
In light of the lack of zinquin fluorescence in HGT-1 cells under conditions that 
increased labile zinc fluorescence in THP-1 and Jurkat cells, the effect of growth 
surface on HGT-1 fluorescence was unexpected. HGT-1 cells grown on glass 
coverslips as opposed to plastic culture flasks or slides, in the presence of 
exogenous zinc appeared to display high levels of labile zinc as indicated by high 
zinquin fluorescence. The cells also appeared unhealthy and fragmented. As 
control cells were unaffected it would appear to indicate either that adhesion to 
the glass surface caused a change in the cells that allowed zinc influx and/or 
prevented excess zinc excretion.
The final set of results, the vesicular sequestration of zinc into zinquin stained or 
acridine orange stained granules hints at the route zinc may follow as it is taken 
up by cells. Although preliminary investigations, the results appear to indicate
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that zinc may exist in both non acidic vesicles (fluorescing with zinquin alone) and 
acidic vesicles (fluorescing with zinquin and acridine orange).
As a whole, the results indicate that the three cell lines investigated treat 
exogenous zinc in quite distinctly different manner which would seem to indicate 
the presence of different mechanisms for zinc transport in each line. It may also 
be that they all share the same mechanisms but specific mechanisms 
predominate in different cell lines. This would fit in with the published 
observations of zinc transport mechanisms in freshly isolated cells, which are 
tissue and cell specific.
210
EFFECTS OF ZINC ON CYTOKINE PRODUCTION AND SIGNAL TRANSDUCTION IN 
INFLAMMATORY CELLS........................................................................................................ 212
BACKGROUND..................................................................................................................................................... 212
4.1.1 Uptake of radiolabelled zinc -  investigation into molecular-zinc associations....................... 212
4.1.2 Cytokine bioassay analyses...................................................................................................... 213
4.1.3 Enzyme Linked Immunoassay (ELISA).....................................................................................216
4.1.4 Investigation into the effect of exogenous zinc on NFkB .........................................................216
Experim enta l ...................................................................................................................................................219
Reagents..................................................................................................................................................... 219
4.2.1 Uptake of radiolabelled zinc -  investigation into molecular-zinc associations....................... 219
4.2.2 Cytokine bioassay analyses -  the effect of zinc on cytokine production and on bioassay
activity.........................................................................................................................................222
4.2.3 Enzyme Linked Immunoassay (ELISA) - Effect of zinc on IL-1 p production.........................224
4.2.4 Investigation into the effect of exogenous zinc on NFkB..........................................................224
Results............................................................................................................................................................... 227
4.3.1 Uptake of radiolabelled zinc -  Investigation into molecular-zinc associations.......................227
4.3.2 Cytokine bioassay analyses -  the effect of zinc on cytokine production and on bioassay
activity.........................................................................................................................................233
4.3.4 Enzyme Linked Immunoassay (ELISA) - Effect of zinc on IL-1 p production.........................243
4.3.5 Investigation into the effect of exogenous zinc on NFkB ......................................................... 245
Su m m a r y ............................................................................................................................................................253
211
Effects of zinc on cytokine production and signal transduction in 
inflammatory cells
Background
These experiments were carried out in order to try and relate some cell functions 
with endogenously administered zinc. When this study was initiated very little 
was known about the activity of endogenous zinc in cells and even less was 
known specifically about the effect of endogenous zinc on cytokine function. As 
has been discussed in Chapter 1 the scientific literature contained under ten 
studies looking at the effects of endogenous zinc on cytokine activity in freshly 
isolated cells and none looking at the same effects on cultured cell lines such as 
Jurkat T-cells and THP-1 cells. This led to different lines of enquiry, specifically, 
which proteins endogenous zinc associated with, whether endogenous zinc had 
any effect on transcription factors controlling cytokine production and what effect 
endogenous zinc had on cytokine release by inflammatory cells.
4.1.1 Uptake of radiolabelled zinc -  investigation into molecular-zinc 
associations
This was, in part, a continuation of the investigation of zinc uptake into cells. It 
was known that zinc absorbed by cells is rapidly associated with a number of 
proteins such as metallothionein and CRIP (See Chapter 1). However it was also 
known that zinc modulates cytokine levels in vivo and one of the major cytokine 
control points is the transcription factor NFkB, zinc finger protein. The labile zinc 
pool is increasingly being understood as a ‘store’ of zinc for metalloproteins. It 
was therefore decided to investigate the possibility that exogenous zinc, especially 
when administered as ZMG, may rapidly associate with proteins other than 
metallothionein and CRIP. These two zinc-binding proteins have low molecular 
weights, 6-7kDa for metallothionein and 8.5kDa for CRIP whilst NFkB has a 
molecular weight of between 50 and 130kDa depending on the subunit type and
whether it forms a dimer. It was decided to use a non-denaturing polyacrylamide
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gel to separate the proteins. This non-denaturing method does not affect the 
native protein characteristics and so any bound zinc should be retained in the 
molecules that bind it. Radiolabelled zinc could then be detected by exposure of 
the gel to autoradiographic film.
There is a complex procedure for determining molecular weight of an unknown 
protein in non-denaturing PAGE analysis. As distance run on the gel is not based 
solely on molecular size due to the intact secondary and tertiary protein structures, 
standard size markers must be recorded on a series of non-denaturing gels of 
different gel concentrations (Sigma Chemical Co. Technical bulletin no. MKR-137, 
1986). The migration distance of markers and samples are measured on each 
percentage gel and plotted. The slopes of each graph can then be calculated and 
these slopes plotted against the log of the molecular weights of the marker and 
sample proteins to produce a Ferguson. In the experiments presented here, cell 
lysates were separated along with the markers but additionally, the bands 
displayed on the autoradiograph of the cells with labelled zinc were recorded 
separately and the figures incorporated into the final results.
4.1.2 Cytokine bioassay analyses
Bioassays were the mainstay of cytokine analysis until ELISA kits were 
commercially available (See section 4.1.3 for explanation of ELISA). Cells 
sensitive to specific cytokines provided a measure of the cytokine levels in their 
surrounding media. This meant that culture media could be recovered from cell 
lines of interest, after an intervention such as stimulation with a test compound. If 
the compound changed cytokine secretion by the test cells, this could be detected 
and quantified by incubation of the supernate from these cells with indicator cells. 
For example, T-cells incubated with LPS might produce increased levels of the 
cytokine IL-1 and IL-6. The supernatant medium would be harvested and added 
to indicator cells such as B9 cells that are sensitive to IL-6. The cell death or cell 
proliferation may be quantified in several ways but the most common methods use 
relatively colourless substrates, as MTT or XTT, which are metabolised within the 
cell mitochondrion to produce a dark insoluble product. These crystalline 
products must be solubilized by lysing the cells with detergent and dissolving the 
crystals with acidic solution in order to equalise the colour throughout the well.
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The homogeneous solution can then be measured in a spectrophotometer at a 
specific wavelength. Another common method for measuring cell proliferation is 
to measure the uptake of a radiolabelled molecule. A molecule such as thymidine 
is readily taken up into cell nucleic acids and can be synthesised with tritium (an 
isotope of hydrogen). This uptake can be measured by scintillation counting, the 
levels of tritium being directly proportional to the cell proliferation. These 
techniques are normally carried out in 96 well microplates, suitable for cell culture, 
for which specific spectrophotometers have been designed for the co 16 rimetric 
methods and specific cell harvesters have been designed for the tritium assay.
The bioassay provides information on the activity of the protein as well as its 
concentration in the test medium whilst ELISA simply quantifies protein. In the 
experiments presented here the cytokines TNFa and IL-2 are investigated using 
the L929 (Shahan et al., 1994, Levesque et al., 1995) and CTLL (Gillis et al., 1978, 
Heeg et al., 1985, Russell and Vindelov, 1998) assays respectively. In addition, 
MTT was replaced as an indicator by WST-1 (4-[3-(4-iodophenyl)-2-(4- 
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate), an almost colourless 
mitochondrial substrate that provided a dark water-soluble product. As it was 
water-soluble it removed the need to disrupt the cells and solubilize the 
mitochondrial product as is required for MTT or XTT (Boehringer Mannheim 
technical sheet for product Cat. No. 1644807).
TNFa is a major inflammatory cytokine and is released both in an autocrine 
fashion and as a result of external stimulation. The L929 mouse fibroblast cell 
line is a very well characterised cell line that is sensitive to the cytokine TNFa 
specifically and for which an assay exists (Shahan et al., 1994). L929 cell death 
is directly proportional to the concentration of TNFa present within the surrounding 
medium. These experiments utilise the L929 cell line to determine changes in 
TNFa levels secreted into supernatant media taken from THP-1 monocytic cells.
IL-2 is the major control cytokine for Jurkat proliferation and function. It acts on 
and is released by T-cells and implements itself in an autocrine and paracrine 
manner. The most commonly used standard bioassay for IL-2 uses the CTLL 
murine lymphocyte cell line (Gillis et al., 1978). Supernatants are standardly 
harvested from the test cell line and are then added to the CTLL cells grown in 96 
well microplates. Any increase in IL-2 level in the test culture media causes the
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CTLL cells to proliterate proportionally. cellular incorporation or trmatea 
thymidine is routinely used to determine cell proliferation, in the CTLL assay, 
instead of a col o rimetric method. In the experiments presented here the WST-1 
col o  rimetric detection system was used instead of thymidine uptake.
In both bioassay techniques a standard curve of cell killing or proliferation is 
constructed on each plate with known concentrations of TNFa or IL-2 respectively. 
When absorbance is measured on the microplate spectrophotometer, the 
unknown samples can be examined by comparison with the standard curve.
As a result of some of the studies described in previous chapters it was realised 
that if exogenous zinc can have such profound effects on THP-1 and Jurkat T- 
cells, then it is likely to have an effect on the bioassay cells. An extensive search 
of the literature revealed one paper which presented one figure indicating that zinc 
might inhibit TNFa mediated cell death in L929 cells (Fady et al., 1995). Only one 
concentration was examined, 75pM, and the thrust of the research was towards 
apoptosis rather than the bioassay specifically. This observation was backed up 
by subsequent studies by Wellinghausen et al., (1996) as described in Chapter 1, 
where the zinc content and zinc ligand concentration in culture media were shown 
to alter significantly cellular zinc content and activity. Although these workers did 
not directly examine bioassay function their results strongly suggested that the 
effects of exogenous zinc must be investigated if bioassays were to be used in this 
particular study.
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4.1.3 Enzyme Linked Immunoassay (ELISA)
In this set of experiments the effect of zinc on cytokine release by THP-1 or Jurkat 
T-cells were analysed by ELISA. ELISA is a technique in which a protein is 
detected by a specific antibody, which is in turn bound by a secondary labelled 
antibody or biotinylated antibody. The detection systems are normally fluorescent 
or chromogenic reactions similar to those described above for visualisation of 
protein bands on Western blot membranes. The difference is that ELISA 
measures soluble protein in a fully quantitative manner. A 96-well microplate is 
coated with a capture antibody that can be the same as the primary detection 
antibody. When a culture medium containing the test protein is added to the well 
the protein will bind to the capture antibody and remain in the well after the well 
has been washed. The primary antibody is then added followe4^the secondary 
antibody and the detection system, either chromogenic or fluorescent. A 
microplate spectrophotometer is used to measure the reaction, and test samples 
can be compared to a standard curve of the test protein at known concentrations, 
so allowing quantitation of the protein in the test samples.
The benefit of ELISA over bioassay is that it is rapid, usually around 3-5 hours in 
total and it is convenient as ELISA kits are readily available for most proteins. 
Bioassays can take up to 48 hours to complete and have a limited number of 
applications. ELISA kits are also very expensive whereas bioassays are relatively 
inexpensive. As they are usually commercial kits, ELISAs generally tend to be 
more consistent as all reagents are pre-tested and concentrations are guaranteed 
to be accurate.
4.1.4 Investigation into the effect of exogenous zinc on NFkB
As discussed previously, zinc can modulate cytokine production and NFkB is a 
central control point for many molecules including many cytokines. The possibility 
that endogenous zinc could influence the activity of the nuclear factor in cell lines 
was investigated by Western analysis. The technique starts by separation of 
proteins after boiling in the detergent SDS and running on a denaturing gel (SDS- 
PAGE), this unravels tertiary and secondary structure of proteins and allows 
sample separation by size. As distance migrated is inversely proportional to
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protein size, a series of size markers are run on the same gel ana tne moiecuiar 
weight of the protein can be determined by direct comparison or by correlation 
from a plot of marker migration distance versus marker protein size. The Western 
blot continues with the proteins being transferred from the gel onto a solid 
membrane by passing a weak current through the gel and membrane in the 
direction of transfer. The proteins are then fixed onto the membrane. A specific 
antibody, monoclonal or polyclonal can then be used to probe the membrane for 
the protein of interest (monoclonal recognising one site on the protein and 
polyclonal recognising many sites) (Roitt, 1991). The band on the membrane 
corresponding to the band on the original gel may be visualised by a number of 
methods utilising antibodies specific to the original probe antibody. These 
secondary antibodies can be conjugated to fluorescein for example, which would 
allow it to be observed under UV light or may be conjugated to biotin (Haugland, 
1996). The protein streptavidin has a high affinity for biotin and may be 
conjugated to a large number of different detection reagents. For example, the 
streptavidin could be linked to a fluorescent dye such as phycoerythryn or may be 
linked to an enzyme such as horseradish peroxidase (Haugland, 1996). The 
fluorescent dye may be directly viewed under UV light but the enzyme requires a 
final step in which a chromogenic substrate is exposed to the membrane bound 
enzyme that converts it to an insoluble product. This product precipitates out of 
solution but remains closely associated with the site of the enzyme reaction on the 
membrane. The reason for so many layers of detection is that each successive 
layer is an amplification of the previous layer; for example, two secondary 
antibodies conjugated to several biotin molecules may each bind one primary 
antibody. Each biotin molecule may be bound by streptavidin with further 
amplification possible depending on the detection system used. The result is that 
very small amounts of protein can be detected in this manner.
In these experiments nuclear extracts were prepared from THP-1 and Jurkat T- 
cells. This is a preparation that isolates the cell nuclei from the cell cytoplasm and 
membrane (Andrews and Faller, 1991). The reason for doing this was because 
N Fk B is normally bound to a control protein, IkB and is located in the cytoplasm. 
Upon activation, it dissociates from IkB and translocates to the nucleus. These 
sets of experiments were carried out in order to detect any increases of N F k B in 
the nuclei of THP-1 and Jurkat T-cells, incubated with zinc and stimulated with 
LPS.
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Antibody detection can also be applied to the visualisation of proteins in cells. 
Cells are fixed to a slide and incubated with the antibody and secondary 
antibodies as described above. The fluorescent or chromogenic detection 
molecules are then seen localised to specific areas in the cell depending on the 
protein being detected.
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Experimental
Reagents
Non-denaturing molecular markers, HEPES-KOH, MgCb, KCI, dithiothreitol, 
PMSF, EDTA, Tris-HCI, SDS, glycine, goat anti-mouse antibody, glycerol 
(Sigmallltra grade), p-mercaptoethanol, BCIP/NBT, Actinomycin-C and zinc 
sulphate (cell culture grade) were all molecular grade unless otherwise stated. 
65ZnCl2 was obtained from Amersham International. Mouse anti-human NFkB p50 
antibody was obtained from Serotec. WST-1 cell proliferation indicator was 
obtained from Boeringer Mannheim. Human interleukin-2, human interferon-y and 
human tumour necrosis factor-a were obtained from the National Institute of 
Biological Standards and Control. ELISA kits were obtained from Quantikine R&D.
4.2.1 Uptake of radiolabelled zinc -  investigation into molecular-zinc 
associations
Equipment
Electrophoresis equipment was obtained from Biorad.
Method
Preparation of gel
Molecular markers were obtained in kit form and reconstituted in 1mM sodium 
phosphate buffer or distilled water as indicated. Polyacrylamide gels were 
prepared at different gel concentrations; the method described below is for 
preparation of a 7.5% gel. For gels of different concentrations the acrylamide and 
water volumes were altered as appropriate, all other concentrations were 
unchanged. Acrylamide (1.875 ml of a 30% stock solution), and distilled water 
(3.625ml) were inverted briefly to mix. Gel buffer (1.94ml of 181.5g/l Tris-HCI
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solution), was added and mixed by inversion. Immediately prior to pouring, 
ammonium persulphate (75jnl), and TEMED (7.5pl), were added as gel 
polymerisation initiator and accelerant respectively. The gel was inverted rapidly 
and poured between clean glass plates, a gel well forming comb was inserted at 
the top of the plates and the gel was left to set for a minimum of an hour. The gel 
was either used immediately or wrapped in clingfilm for storage at 4°C overnight. 
Gels were not used if stored for longer than 24 hours.
Prior to use the gels were incubated in an electrophoresis tank containing 
electrophoresis buffer, 30g/l Tris-HCI, 140g/l glycine in aqueous solution.
Preparation of samples and standards
For analysis on the PAGE system the cells were prepared as follows. THP-1, 
Jurkat or HGT-1 cells were incubated with radiolabelled or non-labelled zinc 
compounds as follows. For the radioisotope analysis 65Zn-ZMG (1mg) was 
dissolved in 2.5mM citric acid to a ZMG concentration of 978pM. The unlabelled 
or labelled ZMG solution was added to cells to a final concentration of 12.5pM. 
To other cells was added ZnS0 4  solution to a final concentration of 25pM. As a 
radioactive comparison for the radiolabelled ZMG in the autoradiographic 
analyses, 1pl of ^ZnCfe (10mM in 0.1M HCI solution), was added to 2ml zinc 
sulphate solution (2.5mM), and the resulting solution was added to the cells to a 
final concentration of 25pM. The small volume of radioactive zinc chloride was 
used as the isotope had high specific activity (2.28mCi/ml). All cells were then 
incubated for 24 hours at 37°C, 5% C02, before harvesting and washing twice in 
serum free media. Cells were pelleted and stored at-20°C until required.
PAGE analysis of samples and standards
When ready for use the cells, radioactive or non-radioactive, were thawed and 
prepared as follows. Cell pellets were resuspended in 100pl Tris-HCI (10mM, 
pH8.8) and to each cell suspension was added a protease inhibitor cocktail, 6.4pl, 
to prevent breakdown of proteins. (Protease inhibitor cocktail: PMSF 1Mm, 
leustatin 10pg/ml, E64 20pg/ml, pepstatin A 10pg/ml).
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ine protein content or eacn sample was tnen determined by bUA assay 
(described and reviewed Stoscheck, 1990) so that equal protein amounts could be 
loaded onto the acrylamide gel. The BCA assay uses a colorimetric method to 
determine protein concentration in samples and compares them to soluble bovine 
albumin at known concentrations. Samples or standards were dissolved in 1M 
HCI, 25pl in 225pl respectively. To each sample or standard was then added 
250pl NaOH (1M). Samples or standards were added to a 96 well microplate, 
20pl of each solution per well. BCA reagent (200pl) was added to each well and 
the plate was incubated at room temperature for 20 minutes or until colour reaction 
had occurred. Absorbances were then read on a microplate spectrophotometer at 
570nm and the standard curve of albumin concentrations was plotted. Sample 
absorbances were correlated with standards and sample concentrations were 
determined from the standard curve.
With the sample protein concentrations known, aliquots of each sample were 
diluted to give equal concentrations. Samples (18pl) were then mixed with gel 
loading buffer (2pl) (Tris-HCI, 25% glycerol, 0.5% bromophenol blue) and applied 
to the gel. The gel was run at between 50-80V until the dye front reached 1cm- 
0.5cm from the base of the gel. At this point the method for the PAGE analysis of 
the radiolabelled cells diverges and is described below. The gel was then 
removed and placed in a protein stain and fixative solution for 12-24 hours or until 
the gel was stained darkly. (Stain solution: 45% methanol, 45% distilled water, 
10% acetic acid, 0.25% Coomassie blue).
The gel was then destained with the stain solution minus Coomassie blue. The 
gel was left in the destain solution until all background stain was washed out of the 
gel leaving the protein bands stained and visible. The gel was then dried onto a 
backing of Whatman’s filter paper under vacuum pressure and heat.
The dried gel was then ready for analysis of protein bands. Molecular weight is 
determined by plotting the migration distance (Rf) of a protein in PAGE gels of 
different concentrations. The slopes of these lines are determined for a number 
of standard proteins, in this case, a-lactalbumin, carbonic anhydrase, ovalbumin, 
bovine serum albumin (monomer and dimer) and urease (trimer and hexamer). 
These slopes are then plotted against the log of the molecular weights of the
standards to produce a Ferguson plot. The varying gel concentrations and plots
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must be repeated for the unknown samples to obtain the slope values which may 
then be read off the Ferguson plot to determine the corresponding log of the 
molecular weight and which may then be converted to molecular weight by 
inversion. The proteins from the radiolabelled cell lysates were separated on gels 
of concentration 4%, 7.5% and 12.5% and relative mobilities obtained by marking 
the well positions and dye front position on the autoradiographic film lightly with a 
pencil. The bands detected by autoradiography could then be treated like the 
normal coomassie stained proteins and the molecular weights determined as 
described above.
4.2.2 Cytokine bioassay analyses -  the effect of zinc on cytokine 
production and on bioassay activity
Method
Bioassay sample preparation
For examination of cytokine production, cells were incubated in 24 well plates 
normally for 24 hours, with or without zinc at varying concentrations, in the 
presence of phorbol myristic acetate (PMA) (50nM) or LPS (1-10pg/ml) depending 
on the experiment. For this cytokine stimulation Jurkat T-cells were incubated at 
2.5x106 cells/ml and THP-1 cells were incubated at 1x106/ml. Supernatant media 
were removed, centrifuged to remove cells and then stored at-70°C until required.
TNFa bioassay
L929 murine fibroblast cells (100pl) were plated out into 96 well microplates at a 
density of 5x104 cells/ml. They were allowed to adhere to the plate overnight at 
37°C, 10%CO2. To the plate was then added a standard curve of TNFa (100pl), 
usually from 5000U/ml to 0.001 U/ml, and also the sample supernatant media 
(100pl). U/ml is used for description of cytokine concentrations as the cytokine 
stocks are obtained from the National Institute for Biological Standards and 
Control as International Units per vial which are made up to a specific volume with 
solvent buffer. The concentration unit U/ml or lU/ml is routinely used in the
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literature. Actinomycin-A (10pl) was then added to all wells to a final 
concentration of 1pg/ml. The cells were then incubated 24 hours at 37°C, 
10%CO2. To each well was then added 10yul WST-1 reagent and the cells were 
incubated until the colour developed. The absorbance of the plate was then read 
on a microplate spectrophotometer at 450nm. Cell death was inversely 
proportional to absorbance with no cell death displaying highest absorbance and 
complete cell death displaying the lowest absorbances.
In some experiments, to test specificity of the assay, an anti human 
TNFa antibody was added to the standard curve in concentrations indicated in the 
Results section.
IL-2 bioassay
This experiment was carried out in order to investigate the effect of zinc on the 
CTLL proliferation assay for IL-2. CTLL murine lymphocytic cells, 100pl, were 
plated out in RPMI, with or without foetal calf serum, at various cell densities as 
indicated on the figures in Results section. IL-2 diluted in RPMI was then added 
in concentrations from 2000U/ml-0.02U/ml. In some experiments zinc 
compounds, 1pM-100pM, were added to the IL-2 standard curves. Cells were 
then incubated 24 hours and treated with WST-1 as described for the L929 
bioassay.
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4.2.3 Enzyme Linked Immunoassay (ELISA) - Effect of zinc on IL-ip 
production
Method
THP-1 cells were incubated for 48 hours in serum-free medium in the presence or 
absence of zinc compounds (25pM free ion), LPS (1 jig/ml), or LPS plus IFN-y 
(100U/ml). Cell supernatant media were then collected from the incubates and 
centrifuged to remove particulate material then stored at -70°C until required or 
used immediately. Samples were then analysed using commercial ELISA kits 
according to the instructions provided with the kits. Samples (100^1) were added 
to wells in a microtitre plate pre-coated with anti IL1-p antibody and incubated 
before washing and addition of a second anti IL1-p antibody. The samples were 
incubated and then washed a second time before addition of a detection antibody 
conjugated to the detection system incorporated by the kit. The substrate for the 
detection system was finally added and the colour reaction allowed to develop 
before reading at 450nm on a microplate spectrophotometer. Concentration of 
IL1-p in samples was calculated by comparison of sample absorbance with that of 
a standard curve of known IL1-p concentration.
4.2.4 Investigation into the effect of exogenous zinc on NFkB 
Materials and equipment
Electrophoresis and western transfer equipment were obtained from Biorad or 
LKB.
Method
THP-1 cells and Jurkat T-cells were incubated with or without zinc as ZMG or zinc 
sulphate at 25pM zinc ion concentration, for 24hrs then with LPS for varying times. 
Cell nuclei were then isolated and DNA binding proteins isolated after the method 
of Andrews and Faller (1991).
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Nuclear extraction
For nuclear extraction, cells were harvested, washed in serum free medium and 
pelleted in microfuge tubes. Cell pellets were resuspended, by flicking gently, in 
400pl buffer A (10mM HEPES-KOH pH7.9 at 4°C, 1.5mM MgCI2, 10mM KCI, 
0.5mM dithiothreitol, 0.2mM PMSF). The cells were allowed to swell on ice for 10 
minutes before being vortexed for 10 seconds. Samples were centrifuged for 10 
seconds to pellet and the supernatant, containing cell membrane and cytoplasmic 
contents, was decanted for storage or discarded. The nuclear pellet was 
resuspended in 20-1 OOpI of cold Buffer B (20mM HEPES-KOH pH7.9, 25% 
glycerol, 420mM NaCI, 1.5mM MgCh, 0.25mM EDTA, 0.5mM dithiothreitol. 0.2mM 
PMSF) and incubated 20 minutes on ice for the high salt extraction. Cell debris 
was removed by centrifugation for 2 minutes at 4°C. The resulting supernatant 
containing the DNA binding proteins was decanted and stored at -70°C until 
required.
Analysis of nuclear extracts by Western blot of SDS-PAGE
Polyacrylamide gels, normally 12%, were cast as described previously although 
the gel was not poured to the top of the gel cassette. Gels were prepared as 
previously described (p219-220) with the inclusion of 0.1% SDS in all solutions. 
Once set, a second gel, 4% acrylamide, was cast on top of the first gel taking up 
the remaining space and the wells created in this lower percentage gel. The 
second gel was a stacking gel and allowed all the proteins in the sample to travel 
rapidly through it so that when they reached the interface with the second gel they 
were compacted into a discrete band. The 12% gel was where the proteins were 
separated or resolved according to size, for this reason it was called the resolving 
gel. The tank buffer used for the denaturing gels contained SDS for denaturing 
conditions (in distilled water; Tris-HCI 30.3g/l, SDS 10g/l, glycine 144g/l).
Protein contents of samples were determined by BCA assay, as previously 
described, and equal protein amounts were aliquoted into microfuge tubes. To 
each tube was added 5x loading buffer (in distilled water; SDS 100mg/ml, Tris-HCI 
75mg/ml, glycerol 250mg/ml, bromophenol blue 0.5mg/ml, 25% p-
mercaptoethanol) and samples were then boiled for 1 minute to denature proteins.
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The samples were then immediately loaded onto the gel, which was run at 80-130 
volts until the dye front was near the bottom of the gel.
After electrophoresis the stacking gel was cut from the resolving gel and 
discarded. The resolving gel was then incubated for 15 minutes in transfer buffer 
(in distilled water; glycine 14.4g/l, Tris-base 3g/l, SDS 0.75g/l, methanol 20%). 
PVDF membrane was then cut to the size of the gel, pre-wet in methanol and then 
transfer buffer and placed onto the gel. The gel and membrane were placed in a 
Western blot cassette, which was in turn placed into a transfer tank containing 
transfer buffer. The proteins in the gel were then transferred onto the membrane 
at 60-90 volts for at least an hour. After this the membrane was dried and stored 
at 4°C or probed immediately.
Detection of NFkB in nuclear extracts on Western blot
The membrane was re-wet briefly in methanol and then Tris buffered saline (TBS, 
in distilled water; Tris-base 1.21g/l, NaCI 8.8g/l) and then incubated for 1 hr in 
blocking solution, commercial milk powder (50g/l) in TBST (0.05% Tween-20 in 
TBS). The membrane was next washed in TBST and incubated, with gentle 
agitation, for 2hrs with rabbit anti-human NFkB p50 antibody (Serotec) diluted 
1:1000 in 2g/l milk powder TBS solution. The wash was repeated and the 
membrane incubated with the secondary antibody at 1:5000 dilution for 1.5-2hrs. 
The secondary antibody was goat anti-mouse antibody conjugated to alkaline 
phosphatase (Sigma/Aldrich). The membrane was washed again and incubated 
with an alkaline phosphatase substrate, BCIP/NBT, a chromogenic substrate, 
leaving a dark purple insoluble end product at the site of reaction with the alkaline 
phosphatase. The NFkB p50 bands visualised on the membrane by the antibody 
probe were photographed by still camera. Molecular weights of the bands were 
calculated by plotting the standard marker weights against relative mobility and 
correlating the unknown band relative mobilities with the standard graph to obtain 
unknown band molecular weights.
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Results
4.3.1 Uptake of radiolabelled zinc -  Investigation into molecular-zinc 
associations
These results are divided up into two sections, the analysis of marker proteins and 
unlabelled cell lysates (Figure 4.1 and table 4.1) and the presentation of 
autoradiographic results from cell lysates labelled with 65Zn isotope, (Figures 4.2- 
4.3). The comparison of autoradiographic results with marker proteins and 
unlabelled cell proteins is then examined. Figure 4.1 shows the Ferguson plot 
derived from running standard marker proteins on gels of varying concentration. 
In essence it represents the trends of protein migration on the non-denaturing gels 
of different concentration compared to the molecular weight of the proteins. The 
molecular size of NFkB is between approximately 50kDa and 130kDa depending 
on subunit dimerization and so the gel concentrations selected are suitable for the 
PAGE separation of proteins of these sizes.
From the Ferguson plot the molecular weights of the major protein bands in THP-1 
and Jurkat cells may be calculated and these are presented in Table 4.1. Treated 
like the standard proteins, the relative migration distances were calculated for 
bands in each lysate and plotted against gel concentration. The slope of each 
graph was read off the Ferguson plot (Figure 4.1) to obtain the molecular weight of 
the band (Table 4.1). It may be seen from table 4.1 that molecular weights of four 
or five bands have been calculated for each lysate. They were representative of 
the range of major protein bands found in the lysates although many more were 
present. It was not necessary to determine the sizes of all constituent proteins in 
the cell lysates as the reference ranges were required for approximate comparison 
of protein bands within the autoradiograph of the radiolabelled lysates.
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Figure 4.1 Ferguson plot of molecular weights against slope of graphs derived 
from relative mobilities of proteins in gels of varying concentration: This calibration 
curve was constructed to determine the molecular weights of unknown proteins. Each 
point represents the graph slope of the relative mobilities of a standard protein on 6 
different concentrations of acrylamide gel.
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Protein band number 
in order of mobility
Jurkat T-cell lysate 
protein band molecular 
weight (Da)
THP-1 cell lysate protein 
band molecular weight 
(Da)
1 (lowest mobility) 550000 485000
2 156000 123000
3 114000 73000
4 130000 57000
5 (highest mobility) 27000
Table 4.1 Molecular weights of selected major protein bands from PAGE 
analysis of cell lysates: Cells were incubated with zinc and analysed by PAGE. Protein 
bands were visualised by Coomassie staining and molecular weights were determined for 
selected major protein bands spanning the molecular weight reference standard range as 
described in figure 4.1. The slopes for graphs of relative mobilities for each protein were 
determined as described previously for standard proteins. The slope values of the 
unknown proteins were correlated with molecular weights using the Ferguson plot to give 
the size of each protein band. The bands selected were the prominent protein bands 
within the range of the molecules of interest (NFkB molecular family, 48-63kDa 
monomers, 100-115kDa dimers and larger multimeric complexes).
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The reason for such elaborate calibration of molecular sizes is illustrated in table 
4.1. The protein bands are numbered in order of mobility with 1 being least 
mobile and 5 being most mobile. It may be seen that protein band 4 from the 
Jurkat T-cell lysate is larger than protein band 3 but that it appears to have greater 
mobility than the smaller protein in band 3. This is due to the non-denaturing 
conditions of the PAGE analyses in which the secondary and tertiary protein 
structure is maintained. This means that proteins are not necessarily separated 
by size alone but also by molecular shape and charge.
Cell lysates labelled with radioactive zinc in the form of ZMG or free zinc salt 
(ZnSCV^ZnCfe) were analysed by PAGE and gels were then exposed to 
autoradiographic film shown in figures 4.2-4.3. These lysates were fractionated 
on 4.5%, 7.5% and 12.5% gels. Bands were present on the autoradiograph of the 
4% gel but they were too faint to be detected without a light box and so the gel is 
not shown as a figure. The bands ran in two wells apparently at the same 
distance as the dye front. Figures 4.2 and 4.3 show autoradiographs of the 7.5% 
and 12.5% gels. Again the bands apparently correspond to proteins running with 
or immediately behind the dye front and certainly they would appear to be small by 
their relative mobilities. The molecular weight from the relative mobility was 
calculated from the Ferguson plot. However the molecular weights were well 
below the limits of the calibration graph standard proteins. The results indicate 
that the radiolabelled zinc from both 65Zn-ZMG and ZnSCV^ZnCfe was not 
associated with proteins of molecular weights corresponding to any NFkB subunit 
or any dimer combination of the nuclear factor. The low molecular weights 
calculated for the 65Zn-labelled proteins were approximately 3kDa as determined 
from relative mobilities on the 7.5% and 12.5% gels. Whilst there may be low 
accuracy of the plot for low molecular weights these results suggest that 
exogenous labelled zinc was bound to metallothionein or CRIP, the two main zinc 
storage proteins in cells.
230
THP-1 Jurkat Jurkat HGT-1 HGT-1
ZnSO 4/ ZMG ZnSO^ ZMG ZnSCV
65ZnCI2 65ZnCI2 65ZnCI2
Figure 4.2 Autoradiograph of cell lysates labelled with 65Zn and run on a 7.5% 
acrylamide gel: Cells were incubated 24 hours with either 65Zn-ZMG or ZnS04/65ZnCI2. 
Lysates were analysed by PAGE followed by exposure to autoradiographic film for 39 
days. Bands are visible for Jurkat lysates within the dye front region (blue dotted line) 
and are more weakly visible in the THP-1 lysate (orange arrows). Bands are not 
apparent in the HGT-1 lysates. No bands appear above the dye front. White arrows 
indicate start point for PAGE (well position) and blue dotted line indicates dye front 
position at end of PAGE run. THP-1 cell lysate with ZMG is not shown due to severe 
marking on the autoradiographic film. Close examination of this lane suggested the 
presence of an autoradiographic band but of lower intensity than that of THP-1 +ZnS04/ 
65ZnCI2.
231
HGT-1
ZMG
Jurkat
ZnS 04/
65ZnCI2
THP-1
ZnS 04/
65ZnCI2
THP-1
ZMG
Jurkat
ZMG
Figure 4.3 Autoradiograph of cell lysates labelled with 65Zn and run on a 12.5% 
acrylamide gel: Samples were run as described in figure 4.2, but sample lane order is 
reversed. Again the bands are present in the Jurkat lysates with both zinc compounds 
and more weakly in the THP-1 + ZnS04/65ZnCI2 cell lysate (orange arrows). In this 
concentration of gel the bands appear to be running slightly behind the body of the dye 
front. No bands are apparent in the HGT-1 lysates and HGT-1 + ZnS04/65ZnCI2 lysate is 
clipped due to severe marking on the autoradiographic film. White arrows indicate start 
point for PAGE (well position) and blue dotted line indicates dye front position at end of 
PAGE run.
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4.3.2 uytOKine Dioassay analyses — uie eneui ui ^mu um uyiumn^ 
production and on bioassay activity
L929 bioassay for TNFa
This assay is specific for TNFa and is a standard bioassay for the cytokine. 
However, there is normally an anti human TNFa antibody control on each assay 
plate to show that any cell death is TNFa specific. It was not possible to obtain a 
control antibody however an antibody was taken from a TNFa detection ELISA kit, 
normally used as the primary antibody which was specific for human TNFa. 
There was not enough antibody to use for each bioassay but a validation 
experiment was carried out using the small amount of antibody available to block a 
standard curve of TNFa induced cell death (Figure 4.4). This showed that the cell 
death caused by TNF could be blocked by anti-TNFa antibody in a dose 
dependent manner and provided a limited validation for the bioassay for the 
following set of experiments.
Figure 4.4 shows death of L929 cells incubated with a concentration of TNFa 
known to induce high levels of cytotoxicity (10U/ml) and which is blocked by 
increasing concentrations of anti human-TNFa antibody. This figure shows that a 
1/400 dilution of antibody caused a significant decrease in TNFa induced cell 
death (p<0.01). However higher concentrations of antibody did not prevent cell 
death. It is likely that the anti-bacterial agent (sodium azide) in the antibody 
preparation caused cell death independently, as there was cell death at high 
antibody concentrations where TNFa cytotoxic activity should have been inhibited. 
It then seems likely that as the antibody preparation was diluted down to 1/400 the 
sodium azide was also diluted and so the protective effects of the antibody were 
seen. As the antibody was diluted further, down to 1/2000, its protective ability 
was reduced and TNFa mediated cell death increased. This is another reason 
that the antibody could not be used as a control for the bioassay but these results 
do show that the 1/400 dilution of antibody can specifically significantly inhibit 
TNFa induced cytotoxicity of L929 cells.
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Figure 4.4 L929 cell death by TNFa inhibited by anti-hTNF antibody: L929 cells
were incubated with TNFa (lOU/ml), a high concentration causing a large quantity of cell 
death. The antibody, at a dilution of 1/400, significantly blocked the cytotoxicity
(**=p<0.01) and this was the only significant protection observed. At higher
concentrations the antibody itself appeared cytotoxic with a % dilution of antibody 
displaying significantly higher cytotoxicity than 1/100, 1/400 or 1/2000 (+=p<0.05, 
++=p<0.01, +++=p<0.001). Increasing absorbance indicates decreasing ceil death with 
results presented as mean ±SD.
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with values for cell death calculated as a percentage of absorbance of cells 
incubated in complete medium alone (taken as zero cytotoxicity). The zinc ion 
concentrations tested spanned a range of experimental concentrations of zinc 
used in the studies described here, and also within the general literature. Higher 
concentrations, 100pM and above, were found in publications where freshly 
isolated cells were used for examination of the effects of zinc. It is clear that the 
zinc concentration had a complex effect on the standard curves of TNFa induced 
cytotoxicity. Zinc sulphate at 25jnM reduced cell death very significantly (p<0.001) 
in the mid-range of TNFa concentrations, but had no effect at either end of the 
standard curve. Zinc sulphate at 50pM appeared both to enhance the TNFa 
cytotoxicity at lower cytokine concentrations (p<0.001) and also to inhibit the 
cytotoxicity at higher cytokine concentrations (p<0.001-p<0.05). The effects of 
zinc ions up to 50pM were not significant at TNFa concentrations higher than 
50U/ml (not shown) as cell death increased from 70%-100%.
Figure 4.6 shows the effect of increasing zinc concentration, as ZMG in citric acid 
solution, on the CTLL proliferation assay. The data are presented as percentage 
proliferation from the control of unstimulated cells, incubated without zinc or IL-2. 
It was clear that zinc had an effect on the bioassay standard curve of IL-2 induced 
proliferation, showing that it was significantly toxic to the CTLL cells at 
concentrations 60pM and above causing complete cell death. The lower zinc 
concentrations had no significant effect on the proliferation. There was no 
gradual concentration response of zinc action; 10-30pM zinc had no significant 
effect on the proliferation assay standard curve whilst 60pM zinc ion concentration, 
and above, caused complete cell death at every concentration of IL-2.
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Figure 4.5 Effect of zinc on TNFa induced cytotoxicity in L929 cells: L929 cells 
were incubated with increasing concentrations of TNFa in the presence or absence of 
different concentrations of zinc (ZnS04). It is clear that zinc significantly affects the TNFa 
induced cytotoxicity of L929 cells in this bioassay. Compared with those cells without 
zinc (diamond), cells with zinc at 12.5pM (square) did not alter the TNFa cytotoxicity 
however at 25.5pM (triangle) zinc ion appeared to significantly protect L929 cells from 
TNFa induced cell death at concentrations of 0.05-0.5 U/ml cytokine (p<0.001). Zinc ion 
50pM (cross) caused a significant increase in cell death at lower cytokine concentrations 
(p<0.001) but significant protection from TNFa induced cytotoxicity at cytokine 
concentrations of 0.5, 5 and 50 U/ml (by ANOVA: p<0.001, p<0.01 and p<0.05 
respectively). Data presented as mean ±SD, n=3 for all points.
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Figure 4.6 Effect of zinc on IL-2 induced cell proliferation in CTLL cells: CTLL 
cells were incubated with increasing concentrations of IL-2 in the presence or absence of 
different zinc concentrations (ZMG solution in citric acid). Zinc at concentrations of 10pM 
(square) and 30pM (triangle) had no significant effect on the IL-2 induced CTLL 
proliferation when compared with control cells (diamond). Zinc concentrations of 60pM 
(circle) and 90pM (cross) significantly inhibited the cell proliferation (p<0.01 for all points in 
both data sets). Data presented as mean ±SD, n=3.
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The effect of zinc compounds on TNFa production by THP-1 monocytic cells is 
shown in figure 4.7. Values were calculated as percentage cell death in control 
cells without zinc or TNFa (taken as zero cell death). Data were analysed 
statistically by One way ANOVA and Dunnett Multiple Comparison to a control 
value, in this case cells with LPS alone as the effect of zinc on LPS stimulated 
cells was being investigated. It is clear that zinc had a significant effect on TNFa- 
mediated cell death in CTLL cells but no significant difference was observed 
between zinc compounds (analysed by Tukey-Kramer Multiple comparisons test). 
These experiments were carried out before the test of zinc concentrations on the 
bioassay itself as described in figure 4.5 and were, in part, the reason for those 
experiments.
Zinc appears to have a dual effect on TNFa release by THP-1 cells as shown in 
figure 4.7. At higher concentrations in the presence of LPS, 25pM and 50pM, it 
appears to enhance the cytotoxicity of the THP-1 supernatant media compared to 
media from THP-1 cells incubated with LPS alone. The levels of cell death 
corresponded to the concentrations of TNFa as indicated above each bar in figure 
4.7. Zinc concentrations in the figure (6.25pM, 12.5pM, 25jnM and 50jliM) refer to 
zinc added to THP-1 cells to stimulate cytokine release. As the THP-1 
supernatant media are diluted 1:2 on the L929 assay plate the effective zinc 
concentrations in the bioassay are half that of the THP-1 supernatant media, and 
are therefore 3.125pM, 6.25pM, 12.5pM and 25jliM. The effect of these 
concentrations on the L929 assay were described previously in figure 4-5 and it is 
clear that zinc up to and including 12.5pM has no significant effect on the L929 
assay. It may therefore be assumed that any change in levels of L929 cell death 
with zinc concentrations up to 12.5pM is due to the actions of zinc on the THP-1 
cells rather than on the assay. The effect, on the bioassay results, of the samples 
with 25pM zinc is discussed later.
At lower zinc concentrations, 6.25pM and 12.5pM, the THP-1 supernatant media 
appeared to have significantly less cytotoxicity in L929 cells than media from THP- 
1 cells with LPS alone (p<0.01 in all cases). It was shown in figure 4.5 that a zinc 
concentration of up to 12.5pM had no effect on the L929 bioassay. Therefore the 
significant decrease in cell death seen at 6.25pM and 12.5pM in figure 4.7
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supernatants.
Shown in figure 4.7, the cell death of L929 cells incubated with supernatant media 
from THP-1 cells stimulated with LPS and incubated with 25pM and 50pM zinc 
was significantly greater than that from THP-1 cells incubated with LPS alone 
(p<0.01 in all cases). The media containing 25pM zinc from the THP-1 cell 
stimulation resulted in 12.5pM zinc in the L929 assay plate. This concentration of 
zinc was shown not to effect the bioassay (Figure 4.5). Thus changes in L929 cell 
death at this concentration were a result of zinc modulating of the THP-1 cell 
cytokine secretion and was not an effect of zinc directly on the bioassay. 
Therefore, stimulating THP-1 cells with 25pM zinc, produced media with 
significantly more cytotoxic activity than THP-1 cell media from cells incubated 
with LPS alone.
THP-1 media from cells incubated with LPS plus 50pM zinc also caused 
significantly more cell death in L929 cells than media from THP-1 cells incubated 
with LPS alone. It may be seen from figure 4.5 that 50pM zinc in the THP-1 
media, corresponding to 25pM zinc in the L929 plate, significantly inhibited TNFa 
induced cell death. However, zinc only affected cytotoxicity of up to and including 
0.5U/ml TNFa; from figure 4.7 it may be seen that 50pM zinc as ZMG solution or 
zinc sulphate solution produced 410U/m! and 580U/ml TNFa respectively from 
THP-1 cells. At these concentrations of TNFa, 25pM zinc had no effect on TNFa 
cytotoxicity and so the L929 assay results for THP-1 cells incubated with 50pM 
zinc can be assumed to be unaffected by zinc activity directly on the assay.
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Figure 4.7 Cytotoxic activity of THP-1 cell supernatant media after stimulation 
with LPS with or without zinc compounds, as determined by L929 bioassay: THP-1 
cells were incubated 24 hours with 5pg/ml LPS and zinc compounds (ZMG citrate solution 
or ZnS04) from 6.25-50pM zinc ion. Supernatant media were recovered and assayed for 
TNFa activity by L929 bioassay. Results presented as cell death calculated as a 
percentage of unstimulated control cells (cells without LPS or zinc). Displayed above 
each bar is the TNFa concentration (U/ml), calculated from the standard curve, 
corresponding to percentage cell death as derived from a standard curve of TNFa 
cytotoxicity. Zinc concentrations of 25pM-50pM significantly increased the cytotoxic 
activity of the THP-1 supernatant media (p<0.01) indicating an increase in TNFa 
concentration. Zinc concentrations of 6.25pM-12.5pM significantly decreased the 
cytotoxic activity of THP-1 supernatant media (p<0.01) indicating a decrease in TNFa 
concentration. Values presented as mean ±SD (error bars present on all data columns) 
and n=3 for all points except 12.5piM ZMG where n=2; **=p<0.01.
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media was determined by L929 assay (Figure 4.8). Almost no cytotoxicity was 
observed in the Jurkat supernatants and no significant difference in cytotoxicity 
was seen in cell supernatants from stimulated Jurkat T-cells incubated with or 
without zinc compounds at any concentration tested.
Both THP-1 cells and Jurkat T-cells were incubated with PMA with similar results 
to those in figure 4.8. Very little cytotoxicity was seen in the L929 assay for any of 
these cell supernatants. No significant difference was seen in supernatant 
samples from cells incubated with zinc compounds compared to the supernatant 
media of cells incubated with PMA alone.
The lack of stimulation of cytokine secretion in some of the experiments looking at 
LPS and PMA stimulation of cells was probably due to the batch of LPS or PMA 
used however time did not allow for further examination of this fact.
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Figure 4.8 Cytotoxic activity of Jurkat T-cell supernatant media after 
stimulation with LPS with or without zinc compounds, as determined by L929:
Jurkat T-cells were incubated 24 hours with 5|ug/ml LPS and zinc compounds (ZMG 
solution or ZnS04 solution) from 0.39-50pM zinc ion. Supernatant media were 
recovered and assayed for TNFa activity by L929 bioassay. Results are presented as 
cell death calculated as a percentage of unstimulated control cells (cells without LPS or 
zinc). When calculated from the standard curve of TNFa cytotoxicity (0.05-5000U/ml) 
TNFa levels were very low and the highest concentration, the LPS control, induced a 
percentage cell death below the limits of the standard curve. No significant cytotoxicity 
was observed in any media (ANOVA and Dunnet’s multiple comparison to control).
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4.3.4 Enzyme Linked Immunoassay (ELISA) - Effect of zinc on IL-1p 
production
Results for the IL-1p ELISA are shown in figure 4.9, the data were presented as 
means of two observations. Statistics have not been applied as samples were 
only run in duplicate as the results were intended as a preliminary examination 
of cytokine release.
It is clear from figure 4.9 that THP-1 cells appear to have a low level of IL-ip 
secretion in the unstimulated state. When cells were stimulated with LPS they 
secreted approximately ten times more IL-1 p than without the mitogen and 
when stimulated with LPS plus PMA the THP-1 cells produced roughly 100 
times more IL-1 p than those stimulated with LPS alone. As samples were 
tested in duplicate it is only possible to say that none of the zinc compounds 
had a dramatic effect on the cytokine secretion of stimulated THP-1 cells. As a 
general observation, cells stimulated with LPS with or without PMA and 
incubated with ZMG suspension appeared to secrete less IL-p than stimulated 
cells incubated with vehicle control. As a preliminary study this may indicate an 
effect that should be examined further.
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Figure 4.9 Analysis of IL-1 p secretion by THP-1 cells stimulated with LPS or 
PMA and incubated with zinc compounds: THP-1 cells were incubated with either 
ZMG suspension (1), zinc sulphate solution (2), zinc sulphate solution plus glycerol (3), 
zinc oxide suspension (4), zinc oxide suspension plus glycerol (5) or vehicle control, 
distilled water (6). All zinc compounds provided 25pM final zinc concentration. Cells 
were concomitantly stimulated with LPS (1pg/ml) alone, LPS plus IFN-y (100U/ml) or 
left unstimulated. Cells stimulated with LPS secreted approximately 10 times more IL- 
1p than unstimulated cells. Cells stimulated with LPS + PMA secreted approximately 
1000 times more IL-1 p than unstimulated cells and 100 times more of the cytokine than 
cells stimulated with LPS alone. Values are presented as mean, n=2 for all points.
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4.3.5 Investigation into the effect o f exogenous zinc on NFkB
Although some preliminary work was carried out involving both THP-1 and 
Jurkat cells, time limitations meant that work had to be focussed on one cell line 
at a time. Figure 4.10 shows a comparison of lysates from THP-1 and Jurkat 
cells. The following two figures (Figures 4.11 and 4.12) describe tests carried 
out to determine conditions for the main assay, namely LPS concentration and 
incubation time. The final figure, figure 4.13, shows analyses of Jurkat cells 
incubated with zinc and LPS. The anti human NFkB antibody was indicated in 
the commercial literature as being specific to the p50 subunit and its p105 
precursor protein. The Serotec data sheet, accompanying the antibody, further 
stated that in some gel assays it showed activity against p50:p50 and p50:p65 
NFkB dimers. This should mean that only these bands were seen on 
membranes probed with this specific antibody, in fact in several cases extra 
bands were observed and so the molecular weights of all major bands were 
calculated. However, small differences in lane length due to gel shrinkage or 
slight skewing of the gel on the membrane during Western transfer could have 
affected the molecular weight calculations from relative mobilities. Thus in 
figures 4.10-4.13 the theoretical molecular weights, as expected from the 
information on the data sheet, were shown along with the calculated molecular 
weights where relevant.
Figure 4.10 shows unstimulated THP-1 and Jurkat whole cell lysates indicating 
that identical bands were detected in each case. It should also have given an 
indication of all the bands available for antibody binding and in fact five distinct 
bands are visible, the most intense corresponding to p50 (calculated mw = 
56.4kDa). The top band corresponds to a calculated molecular weight of 
110.96kDa, this may be the p50:p50 homodimer but is more likely to be the p50 
precursor protein (105kDa). However, as can be seen from the THP-1 lane 
there is a suggestion that the 110.96kDa band may in fact be two poorly 
resolved bands. Given that samples were boiled with SDS it seems unlikely 
that these bands could represent either the p50:p50 homodimer or the p50:p65 
heterodimer as these should not survive the SDS treatment.
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Figure 4.10 Cell lysates analysed by Western blot and probe by anti NFkB p50 
antibody: Two major bands are apparent in each cell line sample, one of 56.4kDa and 
one of 110kDa as determined by comparison with relative mobilities of molecular 
marker proteins. These bands are assumed to correspond to the p50 monomer and 
the p105 precursor allowing for some error and gel shrinkage during gel processing.
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Results from later experiments looking at LPS and zinc stimulation of Jurkat 
cells would appear to agree with this observation (Figure 4.13) with two or three 
bands being observed in the high molecular weight range proteins of the 
nuclear extracts.
Figure 4.11 shows the effect of increasing time of incubation of Jurkat cell with 
LPS (1 pig/ml). This was done to determine whether incubation time effected 
the levels of NFkB in nuclear extracts. The control lane is slightly occluded by 
incomplete transfer from gel to membrane during Western blot however the 
probe indicates apparently no difference between 30 minutes incubation and 
120 minutes incubation. This incomplete transfer also affected the marker 
lane on the membrane so that relative mobilities of the molecular weight marker 
proteins were determined from both the membrane and the gel and the 
molecular weights of the unknown bands were determined from both the 
Coomassie stained gel and the membrane markers. There was no difference in 
molecular weights, the smallest protein detected corresponded to 55kDa. It 
must be assumed, unless antibody specificity is questioned, that this is the p50 
subunit and that the corresponding 110kDa bands in figure 4.11 are likely to be 
the precursor protein, perhaps cytoplasmic contaminants from the nuclear 
extraction. Increasing incubation time of cells in LPS apparently makes no 
difference to the nuclear concentration of NFkB p50 monomer or dimer as 
detected by Western blot and probe. Image analysis would be required to 
confirm this quantitatively.
In addition to the p50 monomer and the 110kDa protein there appear two 
protein bands of 60.5kDa and 82.0kDa. These are not expected to be detected 
with the antibody according to the commercial literature. It seems unlikely that 
the antibody is detecting the p65 subunit of NFkB as the sizes are not correct 
for any combination of the molecule. If the p50 protein corresponds to a band 
of 55kDa then the same correction for the smaller unknown protein of 60.5kDa 
on the blot would make it in reality 55.5kDa.
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110kDa (p105)
60.46kDa 
55.5kDa (p50)
81,64kDa
Control
Figure 4.11 Nuclear extract of Jurkat T-cells incubated for different times:
Jurkat T-cells were incubated for 30 and 120 minutes with LPS (1 pg/ml) and nuclear 
extracts were prepared and analysed by Western blot and probe with anti NFkB p50 
antibody.
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Figure 4.12 shows Jurkat cell nuclear and cytoplasmic extracts from cells 
incubated with high and low concentrations of LPS (1 and 10 pg/ml 
respectively). The calculated molecular weight for the smaller major protein 
band was 60.1kDa. As with the previous figure, Figure 4.11, the specificity of 
the antibody indicates that this is p50. However, the broad nature of the band 
may conceal two bands larger and smaller than 60.1kDa that produce the 
average band of a size that corresponds to 60.1kDa. If this is the case antibody 
could possibly be detecting the p65 NFkB subunit. This would not matter in 
practice for interpretation of results as both the p50 and p65 monomers can 
constitute the dimer that translocates to the nucleus on stimulation with LPS or 
cytokines. There appears to be no great difference between intensity of bands 
of cytoplasmic 60.1 kDa protein. There does appear to be slight increase in 
band intensity of the nuclear 60.1 kDa protein with increasing LPS 
concentration, although this would require computer image analysis to confirm. 
Certainly this observation would be made clearer by repetition of this 
experiment with a larger range of LPS concentrations.
Two minor protein bands of 44.5kDa and 39.1 kDa were also visible and 
appeared more intense in the high LPS than the control. Significantly, the 
NFkB inhibitory protein, IkB, has two isoforms IkB-a (37kDa) and kB-p (45kDa) 
and these dissociate from NFkB when the nuclear factor is activated. An 
increase in NFkB activity should thus lead to an increase in IkB dissociation and 
to an increase in the concentration of IkB in the cytoplasm where it is mainly 
situated. Figure 4.12 shows 39.1 and 44.5kDa bands more intense than the 
control. Certainly this cannot be used as a measure of NFkB activity as it 
cannot be proved from these results that IkB was detected in addition to the 
NFkB specificity claimed by the supplier. It does however further bring into 
question the specificity of the antibody.
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Figure 4.12 Nuclear and cytoplasmic extracts of Jurkat T-cells incubated for 90 
minutes with different concentrations of LPS: The cells were incubated with LPS at 
1 and 10pg/ml then nuclear and cytoplasmic extracts were analysed by Western blot 
and probed with an anti NFkB p50 antibody.
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As there did seem to be a slight graduation of increasing NFkB band intensity in 
figure 4.12, the concentration of 1pg/ml was selected for examination of effect 
of zinc on the nuclear factor activation. This would allow zinc mediated 
increases or decreases in band intensity to be observed. Nuclear extracts from 
Jurkat cells incubated with zinc (ZMG and ZnS0 4  at either 12.5pM or 25pM) 
and LPS (1 jag/ml) are shown in figure 4.13. There were two protein bands 
around the p50 area and they were calculated to be 54.7kDa and 58.5kDa in 
size. The larger 110kDa band is present as before and the bands in the 
nuclear extracts from cells incubated with zinc do appear to be less intense than 
the zinc free controls. As with figure 4.12, two bands at 39.2kDa and 44.8kDa 
are strongly present in all extracts.
There appeared to be a slight decrease in the intensity of the 54.7kDa and 
58kDa bands in extracts from cells incubated with increasing ZMG solution. 
The control plus LPS 54.8kDa and 58kDa bands appear darker than the same 
protein bands from cells incubated with 12.5mM zinc (as ZMG solution) which in 
turn was darker than the same bands in the 25mM zinc (as ZMG solution) lane. 
This pattern of decrease in intensity was not seen in all the bands of these three 
lanes suggesting that it was not as a result of unequal sample load 
concentrations. The pattern was not visible at all in the lanes derived from cells 
incubated with equivalent concentrations of zinc sulphate instead of ZMG.
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Figure 4.13 Nuclear extracts of Jurkat cells incubated with zinc compounds 
and LPS: Jurkat cells were incubated 24 hours with ZMG or zinc sulphate solution, 
12.5|uM and 25pM zinc ion concentration then for 90 minutes with LPS (1 fig/ml). 
Nuclear extracts were prepared and analysed by Western blot and probe with anti 
NFkB p50 antibody.
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Summary
The inhibition and activation of cytokine secretion by zinc in vivo and in vitro has 
been discussed previously in Chapter 1 along with studies carried out on the 
control of cytokine levels by activation of the zinc finger nuclear factor protein 
NFkB. The experiments described in this chapter were conducted to 
investigate any possible links between zinc levels and NFkB control of cytokine 
activity. In addition, the studies examined, generally, the zinc control of 
cytokine secretion by cultured cell lines in vitro. In doing so questions arose 
and answers derived regarding the action of zinc on the cytokine assays 
themselves.
The results obtained from the PAGE analyses of radiolabelled zinc in Jurkat and 
THP-1 cells appeared to agree with the major part of the literature which 
indicated that zinc is absorbed by the cells and is rapidly bound by small 
storage molecules. Either metallothionein or CRIP appear to bind the rapidly 
exchangeable labile zinc component of cells. These may transport the ion 
back out of the cell or may act as a transfer point for zinc to other proteins. In 
the time period studied, 24 hours, it appears that none of the exogenous zinc is 
transferred to larger proteins such as NFkB in amounts detectable by 
autoradiography. It would also appear from these results that ZMG citrate 
solution is no different from zinc sulphate solution in this respect. It is possible 
that incubating cells with the radiolabelled zinc compounds for a longer period 
or co-stimulating the cells with the labelled zinc compounds and NFkB 
activators might result in incorporation of the radioactive zinc by NFkB in 
amounts detectable by the autoradiographic techniques used in this study. 
Time restrictions precluded further study of these possibilities, however 
increasing incubation time may not have been relevant to NFkB activation and 
subsequent cytokine stimulation, as discussed in the Discussion chapter.
As exogenous labelled zinc, examined by autoradiographs, did not seem to bind 
directly to the zinc-binding site of NFkB to activate it then it may have acted 
indirectly on NFkB resulting in its translocation to the nucleus. The SDS-PAGE 
analyses by Western blot were carried out to investigate this possibility.
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The first figure in the Western analysis study of NFkB (Figure 4.10) indicated 
that NFkB p50 was expressed and detectable in both THP-1 and Jurkat T-cells. 
The following studies focussed on Jurkat T-cells and showed that the anti NFkB 
p50 antibody was not at all specific. The analyses did not show a distinct 
difference in nuclear or cytoplasmic NFkB p50 levels in LPS stimulated cells 
incubated with or without zinc. It may be that the method is not sensitive 
enough to detect these changes but it is highly likely that the lack of specificity 
affected the sensitivity of the detection system. The study indicated that the 
antibody detected major protein bands of sizes that corresponded to, variously, 
NFkB p65 monomer, c-Rel (an 85kDa member of the Rel family to which NFkB 
belongs) but also all combinations of NFkB homo- and heterodimers. As there 
are proteins in this family at 49kDa, 50kDa (NFkB p50), 52kDa, 55kDa and 
even the 65kDa NFkB subunit (p65) the lack of specificity of the antibody must 
be assumed to affect the observed results. If strongly detected by the antibody 
or if in high enough concentration proteins of similar size are unlikely to be 
resolved into discrete bands by SDS-PAGE or equally by immunoblot of 
proteins, transferred by Western blot, from the acrylamide gel. For this reason 
the results obtained cannot be conclusively explained. However as the 
antibody was primarily raised against NFkB p50 subunit it is reasonable to 
assume that it would be detected more than the other proteins in that family. 
Taking this into consideration there still does not seem to be any visible 
variation in the intensity of stain between nuclear extracts from cells incubated 
with or without zinc compounds thus indicating that p50 does not seem to have 
been activated and translocated to the nucleus. An antibody probe of Western 
blot membrane is not the best way to examine nuclear factor levels but it was 
chosen as best for the study in view of cost and speed of assay. Ideally 
electrophoretic mobility shift assay (EMSA) would be the method of choice for 
analysing NFkB activity.
As NFkB is a major control point for cytokine activity, the action of zinc on 
cytokine production was investigated. It was clear from the literature, as 
discussed in chapter 1, that zinc can modulate cytokine secretion but a search 
of the literature revealed no studies carried out on the effect of zinc on cultured
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cell lines. As many such lines, including THP-1 cells and Jurkat T-cells, are 
very commonly used as models for cells of the same lineage in vivo it was of 
particular interest to examine the effect of zinc on cytokine production by these 
cell lines.
From the results obtained it is clear that zinc modulates cytokine secretion in 
the model cell lines but that it additionally has a significant effect on the 
bioassays used to measure the cytokine levels. This is an important 
observation and perhaps a logical one, but one that had apparently not been 
approached in the literature in any depth. The L929 bioassay for TNFa 
(Shahan et al., 1994) and the CTLL bioassay for IL-2 (Gillis et al., 1978) are two 
very common bioassays used for measurement of cytokine activity. However 
the results presented here indicate that levels of zinc used in experimental zinc 
studies could very easily affect the sensitivity of the assay. Concentrations of 
zinc of up to 50pM in the test samples caused a significant enhancement of 
L929 cell death in the assay. As the actions of zinc in peripheral blood 
mononuclear cells have been examined using zinc concentrations in excess of 
200pM and often routinely at 100pM, the results presented here are highly 
relevant. Examination of cytokine production by bioassay would, under these 
conditions, be significantly affected by the presence of the high zinc 
concentrations. More generally, these results indicate the problems associated 
with studying a substance as ubiquitous and as active as zinc. The effect of 
the ion on all assay types should be taken into consideration.
Having tested the assay it seemed that most of the results obtained for the zinc 
modulation of cytokine secretion were carried out at zinc concentrations that 
had no effect on the assay. Thus it appears that zinc modulation of TNFa is 
bimodal in LPS stimulated THP-1 cells, increasing its secretion at higher ion 
concentrations, 25pM and 50pM whilst reducing it at lower concentrations, 
12.5pM and 6.25pM. Why this might occur is not clear but the highly complex 
nature of cytokine secretion, the autocrine activity and paracrine activity of 
cytokines and the control of these mechanisms by zinc is only very recently 
being understood. The potentiation of LPS stimulated TNFa release by higher 
exogenous zinc concentrations and the inhibition of LPS stimulated release at
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lower exogenous zinc concentrations (Figure 4.7) agrees with the available 
literature. These are discussed in greater detail in Chapter 5.
The IL-1 p ELISA was carried out as a preliminary investigation and all that was 
being looked for was a result that would warrant further study. Although there 
was no definite effect of zinc on cytokine secretion by the stimulated cells, those 
that were incubated with ZMG suspension appeared to produce lower levels of 
IL-1 p than control cells under both stimulatory conditions tested. This would 
appear to be a result worthy of further investigation.
Knowledge of how zinc affects cytokine production by most of the commonly 
used cell lines is scant. However, as the ion is found associated with many 
compounds, sample zinc concentration may have a significant effect on any cell 
investigation especially in the study of cytokines. This is reinforced by the 
results from the L929 study (Figure 4.7) that showed not only that zinc 
concentration significantly altered the assay parameters but also that well within 
normal experimental concentrations of zinc there was a bimodal effect of zinc 
on the TNFa secretion by THP-1 cells. These results suggest that it is highly 
important to continue the examination of zinc on cytokine release in cultured cell 
lines and extend it to encompass a greater number of cytokines.
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Discussion
The results presented in this thesis have extended the knowledge of ZMG in 
particular and have continued and extended the general understanding of the 
actions of zinc in biological systems. This discussion aims to present and 
comment on the findings of the thesis in the context of the known literature.
The chemical analyses of ZMG were carried out in order to understand better 
the action on cultured cells of either the ZMG suspension or ZMG dissolved in 
acid solution. It became clear from the results that the acid preparation of 
ZMG resulted in degradation of ZMG to give a solution of free zinc ions and 
glycerol. Thus no true dissolution of ZMG molecules occurred at acid pH. 
Where the term ‘ZMG solution’ or ‘dissolved ZMG’ has been used in relation to 
acid preparations both in this thesis and in the available literature (Fairlie et al., 
1992, Tiekink et al., 1996), these results show the solutions contained mainly 
free zinc ion and glycerol. Whilst it was not explicitly concluded by Fairlie et 
al. (1992) that free ionic zinc was released, they carried out solubility 
experiments that produced a solubility profile for ZMG consistent with 
degradation of ZMG to release zinc and glycerol in direct proportion to the 
hydrogen ion concentration. The results presented here agree with this 
observation in that zinc from ZMG dissolved in citric acid solution had zinc 
elution profile identical to that of zinc sulphate solution. In addition to the 
HPLC analyses, the MALDI-ToF analysis of ZMG dissolved in dilute 
hydrochloric or citric acid showed that there was no peak of mass equivalent to 
the ZMG polymer of any substitution number. Together with the HPLC data, 
for both zinc and glycerol release, this indicated that in acid solution, the higher 
structure of ZMG was probably entirely degraded to give zinc and glycerol. 
This has important implications for ZMG administered orally for therapeutic 
purposes, in that initially it might be thought that ZMG solid, suddenly 
suspended in gastric juice would react very rapidly with stomach acid and 
degrade to release zinc and glycerol. ZMG would then be expected to react 
like any other soluble zinc salt, binding to ligands in digesta or secreted ligands 
from the mucosa. There can be little doubt that this does happen to some 
degree but the present study suggests that this reaction is only one of several
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possible fates for ZMG in the stomach, and is probably the least important of 
them from a biological and therapeutic standpoint. To understand why this is 
true, the results relating to the physical nature of ZMG are examined below in 
greater detail.
The results presented in this thesis agree in part with a study by Tiekink et al. 
(1996), who used spectrophotometric techniques to measure dissolution of 
ZMG in aqueous suspension by its decrease in turbidity under varying 
conditions. Before the two sets of results may be compared, the method 
employed by Tiekink et al. (1996) should be looked at. Tiekink et al. (1996) 
carried out this analysis by adding the ZMG to the vehicle and shaking the 
cuvette containing the suspension before placing it in the spectrophotometer. 
It was observed during the course of the experiments in this thesis, that ZMG, 
when suspended in water or in fact most non-viscous media, settled very 
rapidly even when particle size was very fine. If this sedimentation factor of 
ZMG had been taken into account by Tiekink et al. (1996) is not made clear in 
the published study and presumably must affect the results obtained using this 
method of analysis. What they showed was that ZMG ‘dissolution’ in a variety 
of buffered aqueous media was dependent on the concentration of the solid 
particle dispersion and also probably to the square root of the hydrogen ion 
concentration. The results presented in this thesis indicate that in very mildly 
acidic water (>pH6.6), ZMG is not entirely degraded to release zinc and 
glycerol but releases something into solution that appears to be a soluble 
component of the ZMG molecule. This does not conflict with Tiekink et al. 
(1996), as release of the soluble fraction of ZMG from ZMG particles in 
suspension would simply appear as a decrease in turbidity in their results, 
which do not specify the fate of ZMG once dissolved. It should also be noted 
that Tiekink et al. (1996) use a lower concentration of ZMG than used in the 
current study, 1 mg/ml maximum concentration as opposed to 100mg/ml used in 
the ZMG suspension studies presented here. It would be interesting to 
observe, using the HPLC analysis of glycerol, the effect of lower ZMG 
concentration on the soluble fraction of ZMG. This is discussed further in the 
Future Work section.
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Where the results presented here do not entirely agree with those of Tiekink et 
al. (1996) is on the subject of polymer size. They observe, using fast atom 
bombardment analysis, a spectrum that showed the major fragment of ZMG to 
be [(C3H60 3 )Zn]4 followed in decreasing abundance by [(C3H60 3 )Zn]3, 
[(C3H603)Zn]2 and [(C3H60 3)Zn] (Tiekink et al., 1996). This is presented as a 
statement without data and seems odd, since fast atom bombardment normally 
requires that the target compound be dissolved in a solvent suitable to that 
compound (Cotter, 1997). Tiekink et al. (1996) used 3-nitrobenzyl alcohol as 
matrix without any indication as to the solubility of ZMG in that solvent and 
without description of the method employed, so it is difficult to determine what 
is being analysed in their preparation. Assuming that no dissolution or 
degradation occurred, only simple suspension, then the experiment appears 
similar to the MALDI-ToF analyses presented here, in which ZMG was 
prepared in 2,5-DHB matrix solution. The present results indicate that ZMG 
exists in polymeric form with a wide range of sizes approximately extending 
from [(C3H60 3 )Zn]4 to [(C3H60 3)Zn] 24.subunits. These results are not in 
complete disagreement with those of Tiekink et al., (1996) but suggest that the 
MALDI-ToF method was more sensitive than fast atom bombardment.
MALDI-ToF has not been used quantitatively in this thesis but it seems 
possible, by comparison of relative peak intensities, that [(C3H603 )Zn]4 (620Da) 
and a larger fragment (840Da) may have been the most abundant fragments. 
Smaller fragments may be present in limited quantities but the MALDI-ToF 
matrix appeared to cause interference at lower masses, which made it difficult 
to distinguish lower mass peaks. The MALDI-ToF data add to the known 
structural information relating to ZMG as they provide a basis to determine 
molecular structure. Chapter 2 showed that ZMG polymers of different lengths 
have different end moieties as determined by examining mass differences (See 
Figures 2.14-2.15). These were derived by addition to and subtraction from 
the structures determined by X-ray crystallography of ZMG (Hambley and 
Snow, 1983). As the MALDI-ToF has an error margin between approximately 
4-5 mass units it is possible that these are not the correct or only structures but 
the structures presented here are those that seemed to best fit the available 
data within that error margin.
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It should be understood that the MALDI-ToF traces did not provide a picture of 
ZMG degradation, instead they are a picture of the range ZMG polymers in that 
one commercial preparation as supplied. As the results from HPLC analysis of 
glycerol release and zinc release both indicate, virtually no ZMG is degraded in 
aqueous suspension (>pH6.6) up to 15 minutes after suspension. In the 
MALDI-ToF analyses the ZMG was suspended in the matrix methanol solution 
for a very brief time, several seconds, before it evaporated to leave the dry 
ZMG/matrix residue. It is thus reasonable to assume that little, if any, ZMG 
degradation was likely to occur. The polymeric trace obtained for ZMG in the 
MALDI-ToF results is therefore likely to be very close to the true polymeric size 
range for the compound before any degradation and zinc release occurs. 
Thus, in aqueous suspension, different length polymers could be degraded at 
different rates as different end moieties might be more or less susceptible to 
attack. This could result in different release rates of zinc from polymers of 
varying lengths. The variation in polymer terminal structures could also affect 
the way that the ZMG polymer interacts with cell membranes. A chain with an 
exposed terminal zinc atom may have greater affinity for membrane-bound 
peptide zinc ligands than would a chain with a terminal hydroxyl or methyl 
group. In both cases, the different terminal structures could account for the 
slow release of zinc from ZMG preparations observed in the current study 
(Chapters 2 and 3) and in previous investigations (Whitehouse et al., 1990, 
Rainsford and Whitehouse, 1992, Fairlie et al., 1992). Use of the MALDI-ToF 
could determine the change in each polymer over time if ZMG were to be 
incubated in suspension prior to testing by this method. In this manner traces 
of the polymer mass range could be obtained at various points after 
degradation had started and could give an indication of the cleavage points on 
the ZMG chains.
That ZMG in suspension was shown in this present study to release zinc and 
glycerol over time is in agreement with the published data (Fairlie et al., 1992, 
Tiekink et al., 1996). However, the methods employed here have not been 
employed previously for this purpose. The analyses, with the Poros HPLC 
column, of zinc in solution provide a novel method for further study of ZMG
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dissolution and degradation, but may also provide the basis for the analysis or 
purification of other zinc compounds. In addition, this is the first presentation 
of a simple quantitative HPLC method for directly analysing glycerol release 
from ZMG in suspension where previously an indirect quantitative iodometric 
method had been used (Fairlie et al., 1992). Together they may comprise a 
relatively simple HPLC based tool for further analysis of ZMG preparations, 
although it would probably require further refinement for use with the various 
media that may be used to suspend or dissolve ZMG.
The observation mentioned above, that ZMG may release both ionic zinc and a 
possible ZMG molecular component into solution, is a novel one. It has 
relevance for the action of ZMG in vivo, as a molecule of ZMG would be treated 
differently from released ionic zinc by most cells that have specific zinc uptake 
channels and transporters. Even if the dissolved ZMG molecule consisted 
simply of one zinc atom and one glycerol molecule i.e. one ZMG subunit, it is 
unlikely that it would have access to the normal zinc ion transporter 
mechanisms due to size and steric hindrance.
From the chemical studies of ZMG it was possible to relate properties of the 
compound to its action in cell culture systems as displayed in the various 
biological assays carried out in the present study. ZMG has been tested in 
vivo in rodent models of both arthritis and ulcer (Whitehouse et al., 1990, 
Rainsford and Whitehouse, 1992, Rainsford, 1992), its solubility had also been 
examined in various tissue homogenates (Fairlie et al., 1992). It was clear 
from these studies that various tissues including skin and probably gastric 
mucosa readily absorbed ZMG. ZMG was also variously shown to be less 
irritant than zinc sulphate in the gastric mucosa (Rainsford, 1992) and when 
injected subcutaneously (Whitehouse et al., 1990). This latter study also 
noted that in rats the skin readily absorbed 65Zn-ZMG powder (radiolabelled) 
more efficiently than zinc oxide when rubbed on and that the label (65Zn) from 
the ZMG was excreted in the faeces. This indicated that dermal application of 
ZMG resulted in the ready absorption, presumably by the epidermal cells, and 
ready processing to excretion of the exogenous zinc. In addition, dermally 
applied or subcutaneously injected ZMG suspensions (in glycerol or water)
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were far more effective than other zinc preparations of equivalent zinc 
concentration, including zinc sulphate and zinc oxide, at reducing inflammation 
in rat models of arthritis (Whitehouse et al., 1990). Together these results 
suggested that ZMG reacted with cells in vivo, particularly epidermal cells and 
cells mediating inflammation, in a manner different to that of other zinc 
compounds. The results presented currently are in agreement with the 
published literature and describe the uptake profile of ZMG in cell lines of 
different lineage.
The ICP-MS analyses of zinc uptake by THP-1, Jurkat or HGT-1 cells were 
designed to compare the bioavailability of zinc as ZMG suspension with that of 
an insoluble and soluble zinc control, zinc oxide and zinc sulphate respectively. 
In the cell lines where uptake occurred, THP-1 and Jurkat, the results were 
clear that ZMG and zinc oxide provided approximately 5 to 10 times more 
bioavailable zinc than zinc sulphate over short, 2-4hr time periods. However, 
over a 24hr period the difference diminished such that cells incubated with 
ZMG or zinc oxide contained almost the same amounts of zinc as those 
incubated with zinc sulphate. This would appear to indicate that the physical 
nature of ZMG caused it to be taken up by cells in a manner similar to zinc 
oxide and quite distinct from that of soluble ionic zinc.
As the uptake experiments were carried out in serum free media it is unlikely 
that ZMG or zinc oxide interactions with soluble proteins could account for the 
high levels of cellular zinc provided by these compounds. It is possible that 
proteins and peptides with zinc binding regions, secreted by the cells, could 
acquire the exogenous zinc and increase cellular uptake (Rowe and Bobilya, 
2000, Prasad and Oberleas, 1970). In fact, this should positively favour the 
soluble, unbound zinc provided by zinc sulphate solution as it provided a more 
ready source of the ion than either ZMG or zinc oxide suspensions. The free 
ion would be more likely to be acquired by the ligand-binding route and so this 
cannot account for the higher levels of cellular zinc provided by ZMG or zinc 
oxide suspension. It would seem therefore to be a function of the particulate 
nature of both ZMG and zinc oxide suspensions that caused this rapid uptake 
after 2 and 4 hours, with resultant high cellular zinc concentrations. It may be
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that whole particles are simply ingested by cells via an endocytic mechanism or 
that the particles, in close physical proximity to the cell membrane, release zinc 
in a concentrated ‘bolus’, stimulating uptake in a localised area of membrane 
via an endocytic mechanism such as potocytosis. It is not certain which of 
these two possibilities is most likely. For instance, exogenous zinc has been 
shown to stimulate phagocytosis in some cell types (Peretz et al., 1994). 
Certainly this is a possibility with the THP-1 cells, which are derived from the 
monocyte macrophage lineage, but it may also occur in a more limited fashion 
with the Jurkat T-cells. This process has been shown to occur in neutrophils 
where phagocytosed particles of zinc hydroxide were observed by 
electronmicroscopy (Ogino et al., 1994). This study further suggested that the 
zinc hydroxide itself stimulated the phagocytic uptake of the particles by these 
cells (Ogino et al., 1994). Also there is a commonly used technique known as 
‘glycerol shock’ used to aid the uptake of DNA into cells during transfection, the 
mechanism of which does not appear to be recorded in the current literature 
(See Rottingen et al., 1995 for example of the method). However, the method 
involves DNA being precipitated onto cell surfaces often by addition of calcium 
phosphate. Glycerol is then added at as high a concentration as the cells will 
bear (this is ascertained empirically) for a brief time before being washed off. 
It may be that the sudden osmotic potential created by the high glycerol 
concentration causes a transient increase in cell membrane permeability. If 
so, a granule of ZMG could act in similar fashion at a highly localised point on 
the cell membrane. It would release glycerol at a single locus as it degrades, 
thus causing a transient increase in permeability at that point on the membrane 
resulting in increased uptake of the granule or of released ionic zinc.
The possibility, at the time intervals over which ZMG uptake was determined, 
that vesicular uptake of zinc from ZMG may have occurred, does not exclude 
the possibility of other mechanisms acting concurrently. In fact the degradation 
analyses of ZMG suggest that it is almost certain that, whilst particulate ZMG 
may be endocytosed by cells, ZMG is also releasing free ionic zinc over the 2- 
4hr time period which would be taken up by the same mechanisms as zinc from 
zinc sulphate. These would almost certainly include cation channels, zinc 
specific channels (McMahon and Cousins, 1998) and passive diffusion but
263
could also include protein ligand binding by cellular secreted proteins (Rowe 
and Bobilya, 2000) or uptake via anion channels if zinc was associated with an 
anion (Chang et al., 1998). The contribution of these other mechanisms to 
zinc uptake has not been quantified here, but as it would be equal to or less 
than the cellular concentrations provided by zinc sulphate solution, it may be 
assumed to be negligible compared to the zinc taken up by vesicular transport. 
However, the alternative mechanisms may account for the fact that incubation 
with ZMG suspension resulted in a generally higher mean cellular zinc content 
after 2hr and 4hr, than incubation with zinc oxide with or without glycerol. As 
zinc oxide is virtually insoluble in neutral aqueous suspension, it should not 
release free zinc to participate in the secondary uptake mechanisms in the 
same amounts as ZMG. The statistical significance of the apparently higher 
cellular levels of zinc from ZMG may or may not become clearer with more 
repetitions of the uptake experiment.
By 24 hours the normal mechanisms for processing zinc seem to take effect, as 
the zinc content of cells incubated with ZMG, zinc oxide or zinc sulphate gave 
approximately the same levels of total cellular zinc. The question must then be 
asked, why use ZMG or even zinc oxide when after 24 hours the cells in vitro 
have generally the same zinc content? The zinc uptake must be examined in 
the in vivo application of a tablet or suspension of ZMG.
The mechanisms for cellular zinc homeostasis appeared to remove a large 
amount of the zinc present in the cells, after 2 and 4 hour incubation with ZMG 
or zinc oxide, by the 24 hour time point. In cell culture the excess zinc could 
only be excreted back into the culture medium by zinc transport mechanisms 
such as the ion channels ZNT-1 and ZNT-2 or DCT1. However in vivo, the 
excess zinc can be transferred to adjoining cells or transferred into the 
circulation and also excreted back into the gastrointestinal tract or the surface 
of the skin, depending on where it was applied. Thus applied, ZMG would be 
well absorbed by a larger area of tissue than an equivalent concentration of 
free ionic zinc as the high zinc levels would distribute out between cells 
adjoining those that actually absorbed the initial dose of ZMG. So in addition 
to the lower gastric irritancy and better absorption through skin when compared
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to zinc sulphate or zinc oxide respectively, the cellular uptake characteristics of 
ZMG could favour whole tissue uptake of zinc from ZMG over zinc oxide or 
sulphate.
It should be noted that even prior to contact with the mucosal cells, the 
chemical and physical properties of ZMG might provide greater bioavailability 
of zinc by enhanced binding to the gastric mucus. Free ionic zinc from zinc 
salts may well bind to ligands in the gastric milieu, such as phytate that inhibits 
zinc uptake (Lonnerdal et al., 1988), and thus be poorly absorbed across the 
gastric mucus to the mucosa. It is known that gastrointestinal mucus binds 
zinc (Coleman and Young, 1979, Davies, 1980) and that this binding by the 
mucus layer is the rapid initial phase of zinc uptake into the mucosal cells 
(Davies, 1980). A bolus of ZMG would physically lie on the mucus and release 
zinc onto the mucosa in a concentrated area, which a solution of zinc salt could 
not do. As the initial binding of ionic zinc to the mucus was only 1 % of the total 
zinc in the study by Davies (1980), it seems reasonable to expect that between 
physical settling onto the mucus, and possible affinity for the mucus the ZMG 
particles could provide greater than 1% zinc in that initial uptake. In the case 
of an ulcerated lesion the zinc particles might come into direct contact with 
mucosal cells but also T-cells and macrophages in the mucosa that could 
infiltrate the wound (Shigeta et al., 1998). The ZMG could then be expected to 
be taken up by those cells in a similar fashion to the uptake seen in the Jurkat 
T-cells and THP-1 monocytic cells of the present study.
The zinquin fluorescence and cell viability studies complemented the total zinc 
uptake experiments. The distinction between the ICP-MS analyses and the 
fluorescence analyses was that ICP measured total cell content of zinc whilst 
zinquin bound only to freely available labile zinc. This labile pool of zinc was 
shown to be important in prevention of apoptosis in cultured thymocytes, where 
it represented a freely available source of the ion for cellular processes that 
require a rapidly available source of zinc for molecular function (Zalewski et al., 
1993). Zinquin allowed this zinc pool to be directly observed by microscopy 
but in addition to this, the fluorophore allowed observation of the effects of 
exogenously applied zinc on this labile pool. As an extension of this method
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zinquin was used in the present study to follow the progress of exogenous zinc 
uptake into cells from various different zinc sources. The results presented 
here are supported by the observations obtained from the ICP-MS experiments 
particularly in the manner of cellular zinc uptake from ZMG suspensions. In 
particular the fluorescence studies indicated specific differences in treatment of 
exogenous zinc, between the THP-1 cell line and the Jurkat T-cell line, which 
were not apparent from the ICP-MS studies. In addition the fluorescence 
photomicrographs suggested reasons for the apparent lack of zinc uptake by 
that HGT-1 gastric cell line and acute sensitivity to high concentrations of zinc. 
These reasons are discussed later.
As mentioned above there could be a number of possible mechanisms for zinc 
uptake either from zinc solution or from particles of zinc compounds. These 
mechanisms could differ between cell lines. Before looking at differences 
between cell lines, a point of interest is that there was an observation common 
to all three cell lines. Some cells in each population appeared to be distinctly 
more able to take up exogenous zinc than others, regardless of zinc source. 
This ‘all or nothing’ uptake pattern was detectable in the Jurkat cell line and to 
a lesser degree in the HGT-1, due to generally low cellular fluorescence and 
THP-1 cell line due to generally high cellular fluorescence. The ‘uptake- 
positive’ cells did not generally appear to be physically different from other 
cells, which tended to rule out zinc entering after loss of membrane integrity 
due to apoptosis or necrosis. The viability experiments supported this 
observation as no significant cell death was shown for the zinc concentrations 
used in the uptake studies. It seems then that there may be a zinc uptake 
mechanism that can be switched on in one particular cell and that allows 
tolerance of higher than normal zinc concentrations. Whether or not this 
mechanism is active in some cells all the time or in all cells at specific times 
cannot be determined from these results, but it is an observation from which 
further investigation might provide an insight into cellular zinc regulation. 
Certainly, measurement of the zinc concentration by image analysis of zinquin 
fluorescence levels in such cells could determine the contribution made by 
‘uptake-positive ’ cells to the total zinc in any given population of cells. The 
photomicrographs presented here indicate that this contribution might be
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important in the Jurkat T-cell line with its distinctly high and low fluorescing 
cells and perhaps less important in the THP-1 cell line where all cells had a 
relatively high level of fluorescence after incubation with zinc compounds.
The treatment of exogenous zinc, and ZMG suspension in particular, was 
distinctly different in all three cell lines. The HGT-1 cell line, which did not 
take up measurable amounts of zinc in the uptake experiments, will be 
discussed later as it had a particularly unusual response to exogenous zinc. 
Considering then the two remaining cell lines, it may be reasonable to assume 
that it was the physical properties of ZMG or shared zinc uptake mechanisms 
that caused the ion to be taken up in similar amounts by THP-1 cells and Jurkat 
cells. However, the manner in which zinc was treated after the first initial 
uptake differed between the monocytic and T-cell lines. This might be 
expected as, for example, cells from different lineages may display differential 
expression of zinc specific transport molecules such as the ion channels ZNT- 
1, -2, -3 and -4  as discussed in chapter 1.
In light of the various known mechanisms for zinc transport and processing, it is 
possible to suggest reasons for the differences observed between the THP-1 
and Jurkat cell lines. All THP-1 cells appeared to have relatively uniform 
diffuse zinquin fluorescence, some with a number of brightly fluorescing 
vesicles, after incubation with zinc compounds over 2-4 hours. Jurkat T-cells 
appeared to have a larger number of cells containing brightly fluorescing 
vesicles and some diffuse fluorescence although this was not uniform. There 
were a number of Jurkat cells that had little or no diffuse fluorescence. With 
the microscopy techniques employed to examine the zinquin fluorescence it 
was not possible to determine definitely whether the diffuse fluorescence, that 
was so marked in the THP-1 cells, was in the cytoplasm or on the outer cell 
membrane. It would be very important for an understanding of the response of 
the cells to high levels of zinc, to know whether the zinc levels were increased 
in the cytoplasm or whether the excess zinc had been rapidly localised to the 
outer membrane ready for excretion. If the excess zinc were rapidly removed 
from the cytoplasmic compartment to the membrane, then that would suggest a 
cell line with a rapid and efficient zinc removal mechanism. If, however, the
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zinc remained in the cytoplasm then this would seem to suggest a cell line with 
a higher tolerance for zinc which was able to protect itself from zinc toxicity by 
binding the ion into storage molecules such as metallothionein. For several 
reasons discussed below it seems likely, but not certain, that the zinc was 
localised to the membrane.
The ICP-MS data revealed that in THP-1 total cellular zinc fell rapidly between 
2 and 4 hours incubation with zinc compounds and levelled off over the 
subsequent 24 hours. The early rapid fall in cellular zinc levels would tend to 
indicate that the cells had started to remove the excess zinc almost as soon as 
it was taken into the cells. It would seem logical then, that by that time the zinc 
was less likely to be still situated within the cytoplasm and more likely to be 
situated towards the outside of the cells. This could occur in a number of ways 
but given the nature of vesicular processing by cells of the monocyte 
macrophage lineage and the fact that zinc has been shown to be required for 
phagocytosis in macrophages (Wirth et al., 1989), the excretion of zinc could 
well involve the endocytic/exocytic mechanism. It is also possible that the 
THP-1 cells could have the additional facility of sequestration of any free 
cytoplasmic zinc into vesicles as was shown in BHK cells with the ZNT-2 zinc 
transporter (Palmiter et al., 1996). This would mean that both zinc in endocytic 
vesicles and free cytoplasmic zinc subsequently were sequestrated into 
vesicles and could be removed from the cells by the relatively rapid method of 
exocytosis. Vesicular exocytosis would account for several of the features 
seen in the photomicrographs of the THP-1 cells. First there were few 
punctate, highly fluorescent vesicles, second there was a generally high level 
of diffuse fluorescence that could be situated at membrane level and third, total 
cellular zinc rapidly fell after only 2 to 4 hours incubation with exogenous zinc. 
Added to this proposed mechanism could be zinc excretion by membrane 
bound zinc transporters such as ZNT-1 and ZNT-4. These molecules are 
thought to remove zinc from the cytoplasm through the basolateral membrane 
of enterocytes and into the microcirculation or into adjoining cells (Palmiter and 
Findley, 1995, Murgia et al., 1999). These would also tend to cause zinc to be 
concentrated at the outer cellular membrane as it was pumped out of the cell.
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The results obtained from the Jurkat T-cells could also fit the zinc control 
mechanism proposed above although they may be more similar to the BHK 
cells examined by Palmiter and co-workers (1996). They showed that the 
ZNT-2 transporter molecule could be expressed in vesicles and lead to 
vesicular sequestration of zinc from the cytoplasm. Once in the vesicles, the 
cytoplasmic zinc was no longer at toxic or near toxic concentration. What 
Palmiter et al., also showed was that the BHK cells did not appear to remove 
the zinc filled vesicles from the cell. In fact, the cells reduced the total zinc 
load by distributing half the zinc filled vesicles into either daughter cell during 
cell division (Palmiter et al., 1996). Thus the zinc filled vesicles remained in 
the cells but the total zinc in the cell population was reduced relative to the 
number of cells. They showed that there was some leakage of zinc from the 
vesicles and proposed that this acted as a pool of zinc should the cells require 
it (Palmiter et al., 1996). It may be similar with Jurkat T-cells, in that excess 
cytoplasmic zinc, obtained from the exogenous zinc sources, could be either 
pumped into vesicles where it would remain, or directly pumped out of the cell 
as discussed for THP-1 cells. This would account for the lower levels of 
generalised diffuse fluorescence and higher levels of vesicular fluorescence 
than the THP-1 cells. The ICP-MS data would tend to suggest that the Jurkat 
cells did not act exactly like BHK cells in that over 24 hours the total cellular 
zinc levels did fall dramatically. This would suggest that although zinc was 
highly localised to the vesicles, the Jurkat cells did indeed have a mechanism 
for removing the vesicular zinc, albeit far more gradually than the THP-1 cells.
Unlike the THP-1 cells or the Jurkat T-cells, the HGT-1 cells did not seem able 
to take up zinc in measurable amounts as determined by ICP-MS or by zinquin 
fluorescence. Obviously HGT-1 cells have some level of cellular zinc flux, as 
they would not survive without it, however these cells provide evidence that 
mechanisms for zinc processing can vary, sometimes dramatically, between 
cell lines. The lack of zinc uptake may or may not have been an aspect of the 
original gastric carcinoma cell from which this particular clone was derived, it is 
not currently possible to determine this. However, when grown on glass 
coverslips and subsequently incubated with a normally non-toxic concentration 
of zinc, the HGT-1 cells appeared both zinc rich and dead. This suggested
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that contact with the glass surface had triggered a zinc uptake mechanism in 
the cells as cells grown in plastic culture flasks, with the same concentration of 
zinc, were healthy and contained no zinc. At first, it does seem unlikely that a 
gastric cell should be resistant to zinc uptake and so sensitive to zinc toxicity 
given that in vivo the cells of gastrointestinal tract must act as a highly selective 
barrier for zinc uptake. The protective barrier action of the gastric cells is 
thought to act at least in part, by capture of the zinc probably by 
metallothionein, and subsequent release back into the digestive tract (Davis et 
al., 1998, Albergoni and Piccinni, 1998), either by excretion though pathways 
as discussed above, or by cell death and sloughing. If the effect of excess 
zinc is to cause the cells to die and slough off into the gastrointestinal tract 
then the responses of the HGT-1 cell line to zinc can be explained as a 
defensive mechanism against high levels of zinc in the digesta.
As discussed previously, it has been observed in almost all in vivo studies, that 
orally administered zinc has little effect on disease state where circulating zinc 
levels are adequate (Remarque et al., 1993). Additionally, dietary 
supplementation with large doses of zinc does not seem to result in plasma 
zinc levels being elevated greater than normal (Coppen and Davies, 1987). 
Given the normally rapid turnover of gastric epithelial cells, the reaction of 
HGT-1 cells to zinc may indeed be part of the normal function of this cell type. 
That external stimuli, in this case the growth surface, are able to apparently to 
switch on zinc uptake, provides an interesting area for future research. It is 
not inconceivable that cell surface receptors in contact with glass instead of 
plastic, could be activated to send a signal resulting in upregulation of a zinc 
uptake mechanism. The different responses obtained by changing the growth 
surface could be a starting point to determine the pathways involved in HGT-1 
zinc uptake and subsequent cell death.
The aspect of zinc processing that appeared common to both THP-1 and Jurkat 
T-cells, the zinc rich vesicles, was examined in a little more detail by co­
incubation with either acridine orange or FITC-Dextran. The cells take up the 
large dextran molecules into vesicles where, under neutral conditions, the 
fluorescein label fluoresces under ultraviolet light. The experiments carried
270
out in this area gave very poor FITC-dextran labelling of the cells and little or 
no vesicular association with the FITC fluorescence. The acridine orange 
associates preferentially with acidic compartments of cells, not necessarily with 
vesicles alone (Palmiter et al. 1996). Some vesicles, especially lysosomes, do 
have a lower pH and it would be interesting to know whether zinc from ZMG 
suspension was associated with these low pH vesicles. In terms of zinc 
release, if a particle of ZMG was taken up into a vesicle with a high H+ content 
then, according to the chemical analyses, it would be more likely to rapidly 
degrade and release the zinc. If the vesicle containing a putative ZMG particle 
were neutral pH, then the zinc release would be expected to occur more slowly. 
In these preliminary co-incubation experiments, THP-1 cells and Jurkat T-cells 
were examined for vesicles that appeared to fluoresce either blue from the 
zinquin, red from the acridine orange or a mixture of both. The results again 
were not conclusive but did seem to indicate that some of the zinc from ZMG 
suspensions was associated with non-acridine orange stained vesicles as 
indicated by normal blue zinquin vesicular fluorescence. There were other 
vesicles however that appeared blue/green in colour, which may have indicated 
vesicles fluorescing both blue and red. From this it seemed reasonable to 
conclude that zinc taken up from a ZMG suspension by THP1 cells and Jurkat 
cells was found definitely in non-acidic vesicles but also possibly in acidic 
vesicles. Using the techniques described in this thesis it was not possible to 
determine whether these vesicles contained ionic zinc or particulate ZMG but 
cytoplasmic ionic zinc has been shown to accumulate in acidic vesicles 
(Palmiter et al., 1996).
Subsequent experiments were carried out in order to determine the eventual 
destination of zinc taken up by cells incubated with radiolabelled zinc. This 
was done specifically to see if the zinc associated with any of the cell signalling 
molecules or nuclear factors. Zinc of course is required for cell function as 
discussed in detail in this chapter and Chapter 1, and exogenous zinc is 
acquired by molecules that require it for function, NFkB for example. It was 
also known that much of the loosely bound zinc in cells is to be found 
associated with the metallothionein molecule or the CRIP molecule, depending 
on cell type. The aim of the current study was, in part, to examine the effect of
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zinc on cellular processes involved in the inflammatory response. Zinc can 
mediate relatively rapid changes in secreted cytokine levels (Scuderi, 1990) in 
many cases promoting increased levels of these inflammatory mediators. This 
suggested that the ion might control cytokine expression pathways either by 
direct association with a transcription factor or a metal responsive element on 
the cytokine gene or indirectly by controlling the activation of a nuclear factor.
NFkB is a zinc finger bearing transcription factor that is involved in the 
activation of a large number of cytokines including the inflammatory cytokines 
such as IL-1 p and TNFa (Chen et al., 1999). NFkB was shown in the literature 
to have transcriptional enhancement activity independent of its own protein 
synthesis (Sen and Baltimore, 1986) indicating post-translational mobilisation 
of the protein as the control point for its activity. Later it was shown that NFkB 
is found inactivated in the cytoplasm and bound to IkB, a control protein 
(Reviewed Grimm and Baeuerle, 1993). From these initial studies and a large 
number of later publications it was clear that the control of cytokine activity by 
NFkB, being rapid, was most likely to occur through this post-translational 
activation of the nuclear factor. This was shown specifically in T-cells (Sen 
and Baltimore, 1986) and monocytes (Hass et al., 1992). If exogenous zinc 
was to have a direct effect on the nuclear factor activity under inflammatory 
conditions it would have to act on the post-translational NFkB molecule and not 
by stimulation of NFkB synthesis. As NFkB requires the zinc atom to co­
ordinate DNA binding it seemed reasonable to determine whether zinc could 
exert its cytokine modulating effect by direct association with the active or 
inactive transcription factor. This possible mechanism was supported in the 
literature by the in vitro inhibition of NFkB DNA binding by zinc chelators and 
reconstitution of NFkB DNA binding ability by addition of zinc (Otsuka et al., 
1995). The results obtained in the present study of cellular zinc uptake 
indicated that exogenous zinc was not directly associated with the NFkB 
molecule or with any other molecule of similar size over the time period 
required for cytokine activation. It is possible that the detection methods were 
not sensitive enough to detect low levels of NFkB or similar proteins that may 
have associated with the exogenous labelled zinc. Instead, the results implied 
that, as expected for zinc recently entering into a cell, the radiolabelled zinc
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was associated with low molecular weight proteins. The assay was optimised 
for detection of proteins between approximately 20kDa and 150kDa so it was 
not possible to accurately determine the size of the bands detected which were 
smaller than 10kDa. However, this size range would encompass 
metallothionein and CRIP, the two important intracellular zinc storage and 
transport molecules.
As the analysis of cellular uptake of radiolabelled zinc indicated that 
exogenous zinc did not appear to associate and activate NFkB directly, indirect 
stimulation by zinc, of the nuclear factor, was examined. These experiments 
were carried out to investigate whether application of exogenous zinc could 
increase levels of NFkB in the nucleus. The technique applied to determine 
NFkB levels was the probe of Western blots of nuclear extracts by an antibody 
specific to the p50 NFkB molecule. Ideally, the antibody should have detected 
one major protein band however, although the antibody was sold as 
monoclonal with little or no cross reactivity with other related proteins, in this 
study the antibody appeared to recognise proteins from a wide range of sizes. 
Proteins that are much larger or smaller than the p50 protein of interest were 
unlikely to interfere with analysis of the p50 NFkB molecule levels but there are 
components of the NFkB system that were of similar size, 49-65kDa. If these 
molecules ran close to the p50 molecule in the Western blot and were also 
recognised by the antibody, then they could interfere with observations of 
changes in band intensity. Even if this occurred, it may not have altered the 
eventual result as these proteins may have been unaffected by the zinc or LPS 
used to stimulate NFkB. In addition, p50 can act as a homogeneous but also a 
heterogeneous dimer, p50 binding to p65 or possibly to other sized monomers 
(Grimm and Baeuerle, 1993). Therefore these other subunits would also act 
as indicators of NFkB translocation to the nucleus.
The cells were activated with LPS, which is known to cause the translocation of 
the nuclear factor (Sen and Baltimore, 1986) and also with zinc to determine 
whether endogenous zinc had any effect on this translocation. Therefore, LPS 
should have increased the levels of NFkB in the nuclear extracts and hence the 
intensity of the detected protein band. The effect of zinc on the intensity of
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that band was observed. The data obtained did appear to indicate a slight 
increase in nuclear NFkB p50, however definite conclusions could not be made 
without quantitation requiring image analysis. Whilst not conclusive, the 
immunoblot results do agree with the published literature which has recently 
shown a level of control over NFkB activation by zinc. This topic is discussed 
below in relation to cytokine activity as the cytokine experiments carried out in 
this study indicate that in vitro, zinc is able to modulate cytokine secretion. It 
seems likely from the recent literature and the indication obtained from the 
current immunoblot experiments that this ability of zinc to modulate cytokine 
production and secretion is based on its ability to control the activity of NFkB.
The cytokine experiments led in two directions, the first examined the effect of 
zinc on the cell based bioassays used to measure cytokine production and the 
second direction investigated the effect of zinc on cytokine production by the 
THP-1 and Jurkat T-cells cells. In only one publication found in a search of 
the relevant literature was there a mention of the effect of zinc on the commonly 
used bioassays for cytokine secretion. This seemed strange, in that zinc is 
such a ubiquitous ion and is required by cells for so many functions, that zinc 
levels could vary significantly depending on the indicator cell line and the test 
cell line. Cell bioassays are generally similar in methodology. Briefly, a test 
cell line is stimulated in order to secrete a specific substance into the culture 
medium, for example THP-1 cells stimulated by LPS to secrete TNFa. That 
medium is then sampled and either centrifuged or filtered to remove particulate 
matter. The sample of medium containing the secreted substance is then 
place into a well containing indicator cells which are sensitive to the effects of 
this substance, for example murine L929 fibroblast cells which are sensitive to 
the cytotoxic effects of TNFa. The indicator cells are either killed, as in the 
above example, or proliferate in the presence of the secreted substance, for 
example murine CTLL T-cells in the presence of IL-2. These two examples, 
the L929 assay and CTLL assay, were used in the present study and it seemed 
very strange that they had apparently not previously been tested for the effects 
of zinc. Zinc is known to protect against cell death, which could possibly affect 
TNFa cytotoxicity, and zinc is well known to modulate many aspects of IL-2
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activity in T-cells, which could affect the CTLL assay. In fact zinc was shown 
in this study to have significant effects on both assays.
When the standard concentration-effect curve of TNFa-induced L929 cell death 
was carried out in the presence of either 25pM or 50jiM  zinc, there was found 
to be a change in the levels of cell death. This change was present most 
importantly along the linear part of the curve for both concentrations, but in the 
case of the higher concentration, along the whole curve. The higher 
concentration of zinc increased cell death at lower TNFa concentrations and 
protected against cell death at higher concentrations. Therefore, if the zinc 
concentration of a sample were to be around 25pM then these results indicate 
that the L929 assay could show the TNFa concentration in the sample to be 
lower than it truly was. If the sample zinc concentration was above 50pM, then 
the cytotoxicity of low TNFa levels in the sample may be masked in the L929 
assay by the cytotoxic effect of the high sample zinc concentration. Both 
concentrations are well within the ranges of zinc concentration used to study 
the effect of zinc on cytokine production in vitro (for examples see Fady et al., 
1995, Dreissen et al., 1995). For the TNFa bioassay it appears that zinc 
levels can have quite a wide range of effects, the CTLL assay was also 
affected by zinc concentrations similar to those used in many experiments. No 
alteration in IL-2-induced CTLL cell proliferation was seen up to 30pM zinc, but 
at 60pM and 90pM zinc no cell proliferation was seen. In fact, on visual 
examination the majority of cells appeared dead. As samples are diluted 1:1 
when added to the wells in the bioassay, 60pM and 90pM would correspond to 
120pM and 180pM zinc in the original samples. Although the latter 
concentration is probably near the top range of zinc concentrations used for in 
vitro study, the former is well within commonly used test levels for zinc 
stimulation of cells. Whilst the study of the effects of zinc on cytokine 
stimulation in vitro is still relatively new with few publications, especially relating 
to the common cell culture models such as THP-1 or Jurkat T-cells, bioassays 
will be used in conjunction with ELISA analyses. The results presented here 
indicate that not only must the zinc concentration of samples be taken into 
account but also they strongly suggest that the effects of zinc on the indicator 
cell lines, L929 and CTLL, should be studied more closely. In addition, these
275
results strongly indicate that other bioassays should be examined for the 
effects of zinc concentration. These would include, for example, the WEHI 
assay for TNFa (Espevik and Nissen-Meyer, 1986), the B9 assay for IL-6 and 
D10 assay for IL-1 (Helle et al., 1988) and the HT-2 assay for IL-2 (Gieni et al., 
1995).
After sample content of zinc was taken into account, the L929 assay results 
obtained from the zinc and LPS stimulation of the THP-1 monocyte cell line 
were particularly interesting. A bimodal effect was observed for increasing 
zinc concentration. The L929 assay indicated that supernatants of LPS- 
stimulated THP-1 cells incubated with zinc (6.25-12.5pM) contained 
significantly less TNFa than supernatants from cells incubated with LPS alone. 
In apparent contradiction, supernatants from LPS-stimulated cells incubated 
with higher concentrations of zinc (25-50pM) contained significantly more 
TNFa than cells incubated with LPS alone. The recent literature examining 
the effects of zinc on NFkB activation and function appear to support the 
observation of bimodal effects by zinc on cytokine secretion.
Wellinghausen etal. (1996a) showed that higher zinc levels, 50pM and 100pM, 
significantly increased TNFa and IL-1 p production in LPS stimulated freshly 
isolated PBM cells. They showed that this increase in cytokine secretion might 
be due to alteration of the LPS molecular structure by zinc. This could account 
for the increase in TNF* production seen in the current study of the effects of 
zinc on TNFc* production by the THP-1 monocytic cell line. However, they 
only showed this effect to be directional i.e. zinc cannot make LPS less 
effective, only more effective at inducing cytokine secretion therefore the 
bimodal effect of zinc must be through an unrelated mechanism.
It is possible that the decrease in TNFa secretion observed in the results from 
the present work was due to a membrane stabilising effect of zinc (Bettger and 
O’Dell, 1993) or possibly through alteration of some cytoplasmic signalling 
cascade involving NFkB (Shumilla et al., 1998, Kim et al., 1999). While both 
mechanisms are possible, as mentioned previously zinc has recently been
276
shown to mediate NFkB function as suggested by the results of the 
immunoprobe for NFkB presented in Chapter 4 .
NFkB exists as the inactive IkB/NFkB complex in the cell cytoplasm until it is 
degraded by phosphorylation of IkB by the IkB kinase (IKK). Exogenous zinc 
influx has recently been shown to inhibit NFkB activation (Connel et al., 1997). 
More specifically, zinc has recently been shown to inhibit IKK in LPS-stimulated 
monocytes, and so prevent the degradation of the IkB/NFkB complex (Jeon et 
al., 2000). This would in turn inhibit NFkB translocation to the nucleus and 
any subsequent promotion of cytokine synthesis. Zinc has also been shown 
by electrophoretic mobility shift assay (EMSA), to inhibit NFkB binding to DNA 
in nuclear extracts, albeit at high concentrations, >100pM (Shumilla et al., 
1998). As the samples in this study were nuclear extracts, the NFkB in the 
EMSA was not associated with the cytoplasmic inhibitory molecule IkB (found 
in the cytoplasm not the nucleus), thus indicating a secondary point for zinc 
inhibition of NFkB activation.
In light of these publications (Wellinghausen et al. 1996a, Connel et al., 1997, 
Jeon et al., 2000, Shumilla et al., 1998) the TNFa bioassay results presented in 
Chapter 4 would seem to indicate that the synergistic effect of zinc on LPS 
activity is able to overcome the inhibitory effects of zinc on NFkB activity and 
that this effect is dose dependent. The effect of this interaction is seen in the 
inhibition or stimulation of TNFa production detected by the cytokine study. It 
is becoming increasingly clear that the role of free ionic zinc or zinc in the labile 
cellular pool is as important to cell function as enzymatic and structural zinc. 
Whether the zinc is free ionic zinc or whether it acts in a readily exchangeable 
state bound to metallothionein or CRIP remains to be determined. In either 
case the effects of supplementing this labile pool with exogenous zinc, in the 
form of ZMG or soluble zinc salts, are only beginning to be understood. New 
zinc-specific fluorescent indicators such as zinquin (Zalewski et al, 1993) or N- 
(6-methoxy-8-quinolyl)-p-toluenesulfonamide, TSQ (Fredrickson et al., 1987) 
will be useful tools in investigating this pool.
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As the active role of zinc in cell function is studied more widely the effects of 
ionic zinc and zinc metalloproteins, other than nuclear factors, on signal 
transduction and nuclear transcription will become clearer. An example of this 
role can be found when comparing the actions of zinc and metallothionein on 
control of apoptosis, programmed cell death. Zinc can inhibit apoptosis as 
shown by addition of exogenous zinc (Mathieu et al., 1996) or chelation of 
endogenous zinc (Ho et al., 2000) and as discussed above it can modulate 
NFkB activity (Otsuka et al., 1995). Similarly it has been reported that 
increasing cellular metallothionein levels will inhibit apoptosis (Kondo et al., 
1997, Deng et al., 1999). In addition to this, metallothionein interacts with the 
p50 NFkB subunit and in doing so activates NFkB and possibly mediates DNA 
binding of the nuclear factor (Abdel-Mageed and Agrawal, 1998). 
Metallothionein and zinc have been shown to translocate to the nucleus at the 
same time during differentiation (Schmidt and Beyersmann, 1999, Apostolova 
et al., 1999) with cell lines containing higher levels of metallothionein 
displaying lower levels of apoptosis (Apostolova et al., 1999). It has also been 
shown that NFkB activation can, depending on stimuli, suppress apoptosis 
(Natoli et al., 1998, Mustapha et al., 2000). In light of these studies the 
question remains as to whether zinc can, for example, translocate to the 
nucleus and directly modulate NFkB to inhibit apoptosis, or whether it acts as 
part of the metallothionein molecule to the same end. This distinction is of 
importance to the action of novel zinc compounds. If the novel zinc compound 
directed zinc to a compartment where it is less likely to bind to metallothionein 
for instance, then the normal processing of exogenous zinc may be altered. 
This could result in the control by zinc of NFkB activation and subsequent 
cellular effects, being different depending on whether ZMG or free ionic zinc 
salts were used as the exogenous zinc source.
Use of the new zinc indicators for labile zinc will increasingly elucidate the 
cellular processing of labile zinc not only from common zinc salts but especially 
from novel zinc compounds such as ZMG or polaprezinc. This rapidly 
exchangeable and transportable fraction of zinc will almost certainly prove to 
be of utmost interest in relation to the novel zinc compounds. To continue the 
apoptosis and metallothionein example, metallothionein itself is inducible by
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zinc through a metal responsive element on the metallothionein gene (Pulido et 
al., 1966). Cultured cells in the studies of Pulido et al., (1966) show an 
upregulation of metallothionein synthesis when incubated with zinc salts. As 
shown in this thesis soluble zinc salts provide a low level of cellular zinc whilst 
ZMG can provide a far higher level of zinc. This alone should be expected to 
cause a difference in levels of metallothionein gene induction with more zinc 
likely to reach the nucleus from ZMG. However the cellular activity should not 
be seen as unchanging. In fact ZMG provides a higher level of zinc that 
gradually falls over at least the 24 hour period examined in this study while 
soluble zinc salts maintain the low zinc concentrations over the same period. 
Thus ZMG could be expected to maintain metallothionein gene induction for 
longer and possibly at a higher level than simple zinc salts. This might result 
in greater protection by ZMG against apoptosis through the mechanisms 
described previously, than would be afforded by simple zinc salts. The 
importance of this labile pool is really only now beginning to be understood with 
the apoptotic control mechanisms discussed above representing just one facet 
of labile zinc activity. If ZMG provides different levels of labile zinc, then it is 
reasonable to assume that not only might the apoptotic response be different 
but, due to the ubiquitous roles of zinc (especially those relating to nuclear 
factor activation), the inflammatory and immune responses would be different. 
It then becomes particularly interesting to examine the relative effects of ZMG 
compared to zinc salts on the inflammatory and immune responses of cells in 
vivo.
Despite the generalised functions of zinc in the body as a whole, it is the 
surprising capacity for zinc to target and modulate specific cell activation 
pathways that makes the construction and function of novel zinc compounds 
particularly interesting. Whilst the unique properties of ZMG, that provide a 
higher bioavailability of zinc to cells, may be somewhat masked by dissolution 
in the extreme conditions of the stomach, there is perhaps a good argument for 
enteric coating of ZMG in a tablet form to act further down the digestive tract. 
The stomach is an important part of the overall digestive system although less 
involved in nutrient absorption and it may be that the truly interesting actions of 
ZMG may occur in the less acidic portions of the intestine where ZMG may be
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better able to maintain its unique polymeric structure. Although ZMG almost 
certainly maintains enough structural integrity to bind to the mucus and 
mucosal cells in the stomach as discussed previously, a bolus of the compound 
might be expected to last far longer without the hydrogen ion levels found in the 
gastric juice. This would leave any ZMG particles free for longer to interact 
with the intestinal mucosa. This is interesting in general because the mucosa 
is a rapidly changing barrier for the highly dynamic and responsive intestinal 
tissue and zinc participates in rapid changes of cell function.
Of particular relevance to the present study would be the effect of intact ZMG 
particles on the immune cells of the gut-associated lymphoid tissue (GALT). 
The GALT is a discrete immune ‘organ’ in different species and acts as the 
interface with, and main line of defence against, infection from pathogens in the 
digestive tract (Hall, 1979, Ermak et al., 1990). It is organised into a network 
of lymph ducts linking external nodes such as the tonsils, adenoids, appendix 
and Peyer’s patches to the lamina propria (Parham, 2000, King et al., 1997). 
Briefly, the nodes, such as the Peyer’s patches, contain discrete T-cell and B- 
cell areas, and a germinal centre. Pathogens are transported across the 
mucosa and are processed by lymphocytes that enter the Peyer’s patches from 
the general circulation (Parham, 2000). A search of the literature for 
publications on zinc in relation to GALT or Peyer’s patches revealed nothing, 
however the evidence for zinc modulation of lymphocyte activity and T-cell 
function in particular is strong and has been presented above and in Chapter 1. 
It has also been shown that there is a subset of T-cells, intestinal intra- 
epithelial lymphocytes (IEL), which develop and mature outside of the thymus 
(Poussier and Julius, 1994). The site of lymphopoeisis for these cells is, as 
their name suggests, in the intestinal GALT. It was found that adult mice, 
irradiated or thymectomized and then irradiated, still recovered IEL T-cell 
numbers despite the lack of a working thymus (Yoshikai et al., 1991, Poussier 
and Julius, 1994).
V
Zinc is intimately linked with T-cell maturation and differentiation in the thymus 
and changes in body zinc levels can result in changes in T-cell subset 
production (Prasad et al., 1997, Oksel and Tanell, 1996, Mocchegiani et al.,
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1999, Coto et al., 1992, Savino et al., 1984). For this reason alone it would be 
of interest to observe the effect of general zinc compounds on the maturation 
and differentiation of IEL. However, the results obtained for cellular zinc 
uptake from ZMG suspension in the present study, and the possibility that this 
uptake could lead to a localised increase in tissular zinc concentration, indicate 
that the compound might act as a particularly efficient zinc delivery system to 
immune cells beyond the mucosa. A search of the current literature for any 
relation of zinc levels to IEL revealed only one publication, in Portuguese (de 
Amorim et al., 1984). The abstract stated that the IEL population was 
decreased after a four week zinc deficient diet when compared to rats fed a 
normal diet with zinc supplements (de Amorim et al., 1984). So it seems that 
zinc levels may modulate IEL in the GALT, which seems a reasonable 
assumption given the body of evidence relating to zinc and thymic T-cell 
activity. The evidence that ZMG may bypass some of the normal cellular zinc 
uptake mechanisms suggests that it might be more effective than common zinc 
salts in upregulating IEL activity during zinc deficiency.
Although the IEL in GALT have been described here as a possible target for 
exogenous zinc control they are only one of several areas that have yet to be 
investigated but which would be worthy of examination in relation to ZMG and 
other zinc compounds. Recent evidence has indicated that the innate immune 
response of intestinal epithelial cells to bacterial infection in vitro is centrally 
mediated by NFkB which controls the expression of pro-inflammatory genes in 
these cells (Elewaut et al., 1999). The complex control of NFkB activation by 
both exogenous zinc and metallothionein suggests that this may be another 
specific target for exogenous zinc compounds to exert control over the gastric 
immune and inflammatory response. Again, a study of the relative effects of 
ZMG and other zinc compounds on prophylactic and acute zinc treatment of 
such infected cells would seem to be a worthwhile investigation.
The study of zinc and its involvement in the development and function of the 
immune system response to inflammatory insult and host defence is still in its 
relative infancy. Even more generally, cellular zinc specific transport 
mechanisms have been described, and the importance of the labile zinc pool
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has been understood, really only in the last ten years. During this time it has 
become clear that zinc in structural and catalytic roles, but especially as the 
rapidly translocated and exchangeable labile zinc pool, is intimately involved in 
the response of immune cells to inflammatory insult. Zinc compounds such as 
ZMG, polaprezinc and zinc acexamate, which are able to bypass normal zinc 
transport and control mechanisms, might be expected to affect immune cells in 
ways that ionic zinc salts could not, due to the strict control of cellular ionic zinc 
flux. It may well be that the difference between the effects of ZMG 
administration compared to zinc salt administration in vivo is, as this thesis 
supports, the delivery by ZMG of zinc in higher concentration to cells than is 
possible with zinc sulphate for example. This does not exclude the possibility, 
as suggested, that in bypassing normal zinc uptake mechanisms ZMG may 
specifically direct ionic zinc to cytoplasmic compartments that simple zinc salts 
could not. The presence of a putative soluble fraction of ZMG as indicated in 
this thesis would increase this likelihood. The most important aspect of ZMG 
may well be seen in whole tissue studies of zinc uptake where the highly 
efficient cellular zinc delivery by the polymer could lead to far higher tissue zinc 
levels beyond the mucosa than would be achievable with zinc salts. This 
would certainly have an impact on the local cellular environment of the 
gastrointestinal tract whether or not the increased zinc levels were transferred 
into the general circulation.
The results presented in this thesis provide new information about the chemical 
structure of ZMG and the release of ionic zinc or a possible soluble ZMG 
component from the ZMG polymer that is in support and continuance of 
published data. The biological studies described in this thesis have shown 
that ZMG provides a greater level of bioavailable zinc without increased toxicity 
to the THP-1 monocyte or Jurkat T-cell lines when compared to common zinc 
salt. Aside from the actions of ZMG the data presented currently provides 
information on the action of ionic zinc in the THP-1 monocyte, Jurkat T-cell and 
HGT-1 gastric epithelial cell lines and also on the function of cell bioassays. 
In particular, the observation that the HGT-1 cell line is resistant to zinc uptake 
and is particularly sensitive to increased zinc levels may be of great relevance 
to the use of this line as a gastric cell model. The results from the cytokine
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studies showed in detail for the first time that sample zinc levels may alter the 
sensitivity of the commonly used L929 bioassay for TNFa and the CTLL 
bioassay for IL-2. The cytokine studies also revealed a possible bimodal 
action of exogenous zinc on TNFa secretion in THP-1 cells. This observation 
is supported by the data published on the differential control of NFkB activation 
by zinc in LPS stimulated cells and the resulting modulation of cytokine 
production. As a whole, the data presented in this thesis expand on and agree 
with the current knowledge of zinc in general and ZMG in particular.
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Future work
• HPLC analyses of ZMG in suspension. Release of both zinc and glycerol 
by ZMG in suspension should be examined over longer periods until, in both 
cases, maximum release is determined. In addition, more time points 
between Omin and 240mins should be taken to more accurately show the 
linear phase of both zinc and glycerol release.
• Analysis o f unknown soluble component of ZMG. The unknown peak 
observed in the analysis of glycerol release by ZMG should be identified. 
The fractions containing the unknown element could be collected and dried. 
The sample could then be analysed by MALDI-ToF and ICP-MS to 
determine mass and composition. The release of this component by ZMG 
in aqueous suspension could then be quantified.
• Analysis of ZMG degradation by MALDI-ToF. MALDI-ToF could be used 
to determine the changes in ZMG polymer length over time. ZMG would be 
incubated in aqueous suspension and filtered, as for the HPLC analyses, 
and the residue analysed. The mass peaks in the polymeric traces 
presented in this study would be expected to shift to the left as they released 
zinc and glycerol.
• Cellular uptake of zinc -  total zinc analyses. It would be desirable to 
confirm cellular zinc uptake results obtained by ICP-MS by increasing 
experiment repetition number. This may show differences between zinc 
compounds that may have been masked by low ‘n’ values, especially the 
difference between ZMG, zinc oxide and zinc oxide plus glycerol.
• Cellular uptake of zinc -  labile zinc analyses. A closer analysis of ZMG, 
zinc oxide and zinc salt by cell lines between 0min-120mins, the initial zinc 
uptake period, would provide useful information. Of particular interest 
would be observation of zinc uptake into the vesicles, whether this develops 
at the cell membrane or within the cytoplasm. The former would support 
endocytosis as a probable uptake mechanism, the latter would indicate 
vesicular zinc sequestration prior to excretion of the excess zinc.
• Cellular uptake of ZMG -  zinquin analysis. The localisation of putative 
ZMG particles into vesicles was preliminarily examined in the present study 
using ethidium bromide and FITC-dextran. The continuation of this would
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expand on the fate of zinc from ZMG once inside the cell. As discussed 
previously, an acidic vesicular environment might encourage zinc release 
from a ZMG particle, whilst in a neutral vesicle the zinc release may be 
slower. An uptake marker such as FITC-dextran would also indicate 
whether the vesicular zinc was derived from external endocytosed zinc or 
cytoplasmic zinc. Zinc and dextran rapidly co-localised to vesicles would 
suggest that they were entering the cell at the same time. The initial 
presence of FITC-dextran alone followed by increasing zinquin fluorescence 
in vesicles would indicate that zinc was not being taken up at the same time 
but instead that it were entering from the cytoplasm.
• Cellular uptake of ZMG -  radiolabel analysis. As a direct continuation of 
the radiolabelled ZMG analysis, it had been intended to label ZMG with 14C- 
glycerol to examine the fate of glycerol released from ZMG during cellular 
uptake. Using scintillation counting of cells it could be possible to quantify 
the labelled glycerol content of cells and compare with cells incubated with 
the 65Zn labelled ZMG. It may then be possible to determine whether 
glycerol uptake equalled zinc uptake from ZMG, which would indicate 
cellular uptake of ZMG particles as opposed to free zinc and free glycerol.
• Tissue uptake of ZMG. It is important that the cell uptake profile of ZMG be 
studied with tissue and in vivo experiments. Whilst the in vitro cell studies 
can suggest mechanisms for ZMG uptake, the variable conditions of cells in 
whole tissue cannot be easily recreated in culture. The difference between 
gastric absorption of ZMG compared to intestinal absorption of the 
compound is likely to be quite different given the effect of hydrogen ion 
concentration on ZMG zinc release. Given the increased bioavailability of 
zinc from ZMG it would be interesting to compare the uptake rates of zinc 
from the compound or from zinc salts using in vivo models of zinc deficiency. 
The present cellular zinc uptake results suggest that ZMG would be more 
efficient than zinc salts at providing zinc as a dietary supplement however 
correlation between cell culture and in vivo treatment may not be exact. 
This would support the need for analysis of ZMG uptake in gastric tissue 
preparations or in vivo uptake experiments.
• Cellular treatment of exogenous zinc. Both THP-1 cells and Jurkat T- 
cells reduced the high levels of zinc from ZMG over a 24hr period. Recently 
it has been suggested that metallothionein may act as a barrier to zinc
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uptake in gastric cells (Davis et al., 1998). CRIP, expressed in immune 
cells may interact with metallothionein and has been suggested to 
participate in modulation of immune and inflammatory response (Fernandez 
et al., 1997, Hempe and Cousins, 1992). If the excess exogenous 
cytoplasmic zinc is bound or actively transported from immune cells in 
particular then it is probable that one of these two proteins is involved. 
Antibody labelling of metallothionein or CRIP could determine whether there 
is directed translocation of either molecule during the reduction of zinc 
levels.
• Effect of exogenous zinc on NFkB activation. The antibody probe of 
Western blots in the current study indicated that NFkB activation and 
translocation to the nucleus after stimulation by LPS, could be modulated by 
exogenous zinc. The results were inconclusive due in part to the possibility 
of cross reactivity. The same experiments should be carried out using 
EMSA as indicated in the Discussion section. This relies on the binding of 
specific labelled nucleotide sequences to the activated nuclear factor and is 
highly specific.
• Analysis of HGT1 cells. The lack of quantifiable zinc uptake by this cell 
line suggests that it is not the best model cell line for analysis of all gastric 
cell functions. As gastric epithelial cells, however, this line may provide an 
interesting model for the analysis of zinc control mechanisms. Determining 
the metallothionein, CRIP and zinc transporter expression in these cells may 
elucidate novel zinc control mechanisms for this zinc sensitive cell line.
• Zinc modulation of cytokine stimulation. Zinc was shown to modulate 
bimodally the secretion of TNFa in the THP-1 cell line in agreement with 
what is know about the effect of zinc on NFkB activation by LPS. These 
results support further study of this differential effect.
• Zinc modulation of cell bioassays. Zinc was shown in the present study 
to affect bioassay results at concentrations used for the in vitro study of zinc. 
It likewise has the potential to interfere in the study of other zinc bearing 
molecules such as insulin. If zinc or zinc bearing molecules are tested on a 
cell line for effect on secreted cytokine, and the medium is then tested on a 
bioassay specific for that cytokine then the zinc content remaining in the 
media sample could affect the result obtained. This suggests that the effect
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of zinc ion should be tested on every cell bioassay commonly used, 
especially for the study of the action of zinc on cytokine secretion.
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